Patients on supraphysiologic doses of steroids or use of such within the previous six weeksXx_NEWLINE_xXPrior therapy for metastatic disease permitted; at least 4 weeks must have elapsed since prior chemotherapy or biological therapy, 6 weeks if the regimen included carmustine (BCNU) or mitomycin C; radiotherapy must be completed at least 4 weeks prior to registrationXx_NEWLINE_xXMyelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this studyXx_NEWLINE_xXReceived chemotherapy or radiotherapy within 3 weeks prior to randomization or those who have not recovered to =< grade 1 adverse events (other than alopecia) due to agents administered more than 3 weeks earlier; herbal therapy intended as anticancer therapy must be discontinued at least 1 week prior to randomization; for patients who received prior immunotherapy (eg anti-CTLA-4), at least five drug half-lives must have passed before the patient may enroll on this study; however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Palliative radiotherapy for bone metastases >= 2 weeks prior to randomizationXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to randomizationXx_NEWLINE_xXFull recovery from nephrectomy or metastasectomy within 12 weeks from randomization following surgeryXx_NEWLINE_xXAt least 4 weeks must have elapsed since completion of antibody-directed therapyXx_NEWLINE_xXSubjects must be at least 4 weeks post last dose of temozolomideXx_NEWLINE_xXThe subject received cytotoxic chemotherapy within the past 4 weeks (6 weeks for nitrosoureas) of the planned surgery dateXx_NEWLINE_xXThe subject has received systemic dexamethasone continuously at a dose > 8 mg/day for 8 weeks prior to the date of the screening assessmentXx_NEWLINE_xXPatients who have had chemotherapy, immunotherapy, or investigational therapy, within 4 weeks (6 weeks for nitrosoureas or mitomycin C), or palliative radiotherapy within 2 weeks prior to the first dose of the study drugXx_NEWLINE_xXWithin 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration: Leukocytes >= 3,000/mcLXx_NEWLINE_xXWithin 2 weeks prior to screening step registration and within 4 weeks prior to treatment step registration: Platelets >= 100,000/mcLXx_NEWLINE_xXUse of any investigational product within 4 weeks prior to randomizationXx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): No specific timeframe between registration and randomization needs to be observed, as long as:\r\n* Patients randomized to the chemotherapy arms have their cycle 1/ day 1 (platinum based or capecitabine) start within 3 weeks (15 working days) following randomization date\r\n* Randomization occurs no more than 24 weeks from surgery dateXx_NEWLINE_xXPatients must have completed a minimum of 10 weeks of single agent nivolumab on arm 1 of A091401 to be eligible for re-registrationXx_NEWLINE_xXPatients must be at least 2 weeks and within 12 weeks from documented progressive disease (PD) on Step 1 of current study; all sites of disease must be evaluated within 4 weeks prior to registrationXx_NEWLINE_xXAny prior surgeries must have been completed at least 4 weeks prior to randomizationXx_NEWLINE_xXPatient should be randomized in the trial ideally within a maximum of 8 weeks of completion of their last treatment (surgery, chemotherapy or radiotherapy), but in no case longer than 12 weeksXx_NEWLINE_xXPatients may or may not have been treated previously with a nonsteroidal antiandrogen, such as flutamide, bicalutamide or nilutamide; for patients previously treated with an antiandrogen, they must be off treatment for at least 4 weeks (for flutamide) or 6 weeks (for bicalutamide or nilutamide) prior to registration and must have shown PSA progression after discontinuing the anti-androgenXx_NEWLINE_xXGroup B and C patients who do not enroll on ANBL1232 within 4 weeks of definitive diagnostic procedureXx_NEWLINE_xXInfants must be > 36 weeks gestational age at the time of enrollmentXx_NEWLINE_xXParticipation in any investigational drug study (excluding non-oncology and/or symptom management studies) within 4 weeks prior to registration.Xx_NEWLINE_xXAll patients must have a Medical Oncology evaluation within 4 weeks prior to registrationXx_NEWLINE_xXPatients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)Xx_NEWLINE_xXComorbid conditions\r\n* No evidence of active bleeding, bleeding diathesis, or hemoptysis (>= 1/2 teaspoon of red blood) =< 8 weeks prior to registration\r\n* No evidence of intracranial hemorrhage =< 4 weeks prior to registration\r\n* Patients who have experienced thromboembolic event within 6 months prior to registration must be on stable therapeutic anticoagulation for at least 4 weeks prior to registration\r\n* No symptomatic congestive heart failure (New York Heart Association class II, III, or IV) within 6 months prior to registration\r\n* No current unstable angina or uncontrolled arrhythmia\r\n* No uncontrolled hypertension at time of registration (blood pressure [BP] > 150/95 despite antihypertensive therapy)\r\n* No known history of prolonged QT syndrome\r\n* No known history of ventricular arrhythmia within 6 months of registration\r\n* No known history of uveitis or iritis =< 4 weeks prior to registration\r\n* No known history of or evidence of retinal pathology that is considered a risk factor for neurosensory retinal detachment, retinal vein occlusion (RVO), or neovascular macular degeneration within 12 months of registrationXx_NEWLINE_xXPatients who are receiving any other chemotherapy or investigational agents; radiation treatment will not be permitted during study treatment; patients can receive radiation therapy (XRT) 4 weeks prior to study drug administration or 4 weeks post study completion or discontinuation; steroids equivalent to prednisone 60 mg daily are permitted prior to study drug administration, but needs to be discontinued 1 day prior to BV administration; patients receiving steroids for lymphoma symptoms should have measurable disease as mentioned above on baseline scansXx_NEWLINE_xXPrior radiotherapy (RT): At least four weeks since completion of whole-brain irradiation, at least two weeks since completion of prophylactic cranial irradiation, and to any other site.Xx_NEWLINE_xXImmunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drugXx_NEWLINE_xXPrior isotope therapy with strontium-89, samarium or radium-223 within 12 weeks of treatment startXx_NEWLINE_xXAdministration of antifungal agents (itraconazole, fluconazole, etc) within 4 weeks of treatment start or unrecovered adverse events (AEs) due to agents administered more than 4 weeks of treatment startXx_NEWLINE_xXMust be on a stable dose of the same oral hormonal contraceptive product for at least 4 weeks before dosing with study drug and for the duration of the studyXx_NEWLINE_xXActive hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drugXx_NEWLINE_xXPatient has received any of the following treatments within the specified timeframes: a. Surgery, radiotherapy, chemotherapy (including molecular-targeted drugs): 4 weeks (28 days), b. Immunosuppressants or cytokine formulations (excluding G-CSF): 4 weeks (28 days), c. Endocrine therapy or immunotherapy (including biological response modifier therapy): 2 weeks (14 days)Xx_NEWLINE_xXPrior IL-15 treatment or cytotoxic therapy, immunotherapy, radiotherapy, major surgery, antitumor vaccines or monoclonal antibodies in the 4 weeks prior or for checkpoint inhibitors such as anti-CTLA-4 or anti PD1/PD-L1 or nitrosoureas or mitomycin C for 6 weeks prior to C1D1.Xx_NEWLINE_xXParticipants receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 2 weeks from the last dose prior to study treatment (or a longer period depending on the defined characteristics of the agents used); the patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment with olaparib and temozolomideXx_NEWLINE_xXSystemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, 4 weeks washout period. For patients receiving anticancer immunotherapies such as CTLA-4 antagonists, 6 weeks is indicated as the washout period.Xx_NEWLINE_xXUse of any vaccines against infectious diseases (e.g. influenza, varicella, pneumococcus) within 4 weeks of initiation of study treatment.Xx_NEWLINE_xXParticipants who have had anti-cancer therapy within 2 weeks prior to entering the study or those who have not recovered from acute adverse events due to agents administered more than 2 weeks earlier; palliative radiation to bony metastases >= 2 weeks prior to study entry is allowed; chronic use (defined as starting at least 3 months prior to registration) of GnRH agonist therapy, such as leuprorelin, at the time of study entry is not exclusionary and participants can continue the GnRH agonist therapy while on studyXx_NEWLINE_xXPatients must have discontinued active immunotherapy (interleukin [IL]-2, interferon, cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], etc.) or chemotherapy at least 4 weeks prior to entering the study and oral targeted therapy at least 2 weeks prior to entering the study; patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entryXx_NEWLINE_xXPhase I/II: Patients must have received ? 2 units of RBCs for hemoglobin ? 9.0 g/dL within 8 weeks prior to start of treatment.Xx_NEWLINE_xX-  Treatment with an immunomodulatory agent within 4 weeks prior to first administration of BI 836858.Xx_NEWLINE_xXRadio- or toxin-immunoconjugates within 10 weeksXx_NEWLINE_xXNitrosourea or mitomycin C within 6 weeksXx_NEWLINE_xXPatients may have had 0-4 prior therapies\r\n* Prior chemoembolization or local ablative therapies are permitted if completed >= 6 weeks prior to study enrollment\r\n* Prior temozolomide is permittedXx_NEWLINE_xXPatients who have had recent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of study drug) are NOT eligible for participationXx_NEWLINE_xXThe patients' last dose of chemotherapy must be at least 3 weeks prior to initiation of study therapyXx_NEWLINE_xXAt least 4 weeks for focal radiation therapy (RT) or >= 6 weeks for craniospinal RT must have elapsed prior to study entryXx_NEWLINE_xXThe subject may have had other systemic chemotherapy for PCNSL during the 90 days since PCNSL diagnosis; prior systemic chemotherapy must have been given at least 4 weeks prior to study entry (6 weeks for nitrosourea agents), with the exceptions of methotrexate and rituximab which may have been given at least 10 days prior; ocular lymphoma treatment may have been given any time prior to study entry; if the subject has undergone treatment for parenchymal disease and the parenchymal disease has progressed on a stable or increasing dose of steroids, the subject is not eligible for enrollmentXx_NEWLINE_xXPrior therapy with intravesical Bacillus Calmette-Guerin (BCG) within 6 weeks of treatment.Xx_NEWLINE_xX3. Receipt of any investigational anti-cancer therapy within 4 weeks prior to first dose of TAB001;Xx_NEWLINE_xXSevere infection within 4 weeks prior to randomizationXx_NEWLINE_xXPrior therapy with BRAF/MEK agents within 3 weeks prior to first day of study treatment (for treatment phase)Xx_NEWLINE_xXPatients must have had their last fraction of: \r\n* Craniospinal irradiation (> 24 GRAY [Gy]) or total body irradiation > 12 weeks prior to enrollment\r\n* Focal irradiation > 2 weeks prior to enrollment\r\n* >= 3 months since autologous bone marrow/stem cell transplant prior to enrollmentXx_NEWLINE_xXStable (without evidence of progression by imaging [using same imaging modality for each assessment] for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline)Xx_NEWLINE_xXReceipt of cytotoxic chemotherapy within 3 weeks (6 weeks for nitrosoureas and mitomycin C) of scheduled C1D1 dosing.Xx_NEWLINE_xXReceipt of treatment with immunotherapy, biological therapies, targeted small molecules, hormonal therapies within 3 weeks of scheduled C1D1 dosing.Xx_NEWLINE_xXReceived small molecule targeted therapy such as TKIs within 2 weeks prior to study enrollmentXx_NEWLINE_xXTreatment with anti-myeloma monoclonal antibodies within 6 weeks prior first dose.Xx_NEWLINE_xXTreatment with any of the following:\r\n* Any investigational agents or study drugs from a previous clinical study within 30 days of the first dose of study treatment\r\n* Any other chemotherapy, immunotherapy or anticancer agents within 3 weeks or 5 half lives, whichever is shorter, of the first dose of study treatment, except fulvestrant, enzalutamide or hormonal therapy with LHRH analogues for medical castration in patients with breast or prostate cancer, which are permitted\r\n* Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John's wort)\r\n* Major surgery (excluding placement of vascular access) within 4 weeks of the first dose of study treatment\r\n* Radiotherapy with a wide field of radiation within 4 weeks of the first dose of study treatment\r\n* AKT inhibitorsXx_NEWLINE_xXCytotoxic chemotherapy or prior azacitidine or decitabine within 4 weeks of first dose of study treatment.Xx_NEWLINE_xXSystemic anti-cancer therapy within 2 weeks of the first dose of study treatment; for cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, 4 weeks is indicated as washout period; for patients receiving anticancer immunotherapies such as CTLA-4 antagonists, 3 weeks is indicated as the washout periodXx_NEWLINE_xXSevere infection within 4 weeks prior to initiation of study treatment;Xx_NEWLINE_xXPrior use of any monoclonal antibody, radioimmunoconjugate, or antibody-drug conjugate within 4 weeks before first infusionXx_NEWLINE_xXRBC transfusion of either 2-4 pRBC units over the 8 weeks prior to randomization or 1 pRBC in two consecutive periods of 8 weeks within the 16 weeks prior to randomizationXx_NEWLINE_xXCarmustine (BCNU): 42 days/6 weeksXx_NEWLINE_xXReceived 3-bis(2-chloroethyl)-1nitrosourea (BCNU or Carmustine) within 6 weeks prior to anticipated first dose of G-CSF.Xx_NEWLINE_xXAutologous HSCT within six weeks prior to start of AMG 673 treatment.Xx_NEWLINE_xXPatients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n* 12 weeks from the completion of radiation\r\n* 6 weeks from a nitrosourea chemotherapy\r\n* 3 weeks from a non-nitrosourea chemotherapy\r\n* 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n* 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., erlotinib, hydroxychloroquine, etc.)Xx_NEWLINE_xXAny of the following therapies prior to registration:\r\n* Chemotherapy =< 3 weeks\r\n* Immunotherapy =< 3 weeks\r\n* Biologic therapy =< 3 weeks\r\n* Hormonal therapy =< 2 weeks\r\n* Monoclonal antibodies =< 3 weeks\r\n* Radiation therapy =< 2 weeks\r\n* CDK 4/6 inhibitors =< 4 weeks\r\n* mTOR inhibitors =< 4 weeksXx_NEWLINE_xXSevere infection within 4 weeks before initiation of study treatmentXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks before initiation of study treatmentXx_NEWLINE_xXPrevious cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to randomization. IMiDs, PIs and or corticosteroids within 2 weeks prior to randomization. Other investigational therapies and monoclonal antibodies within 4 weeks of randomization. Prednisone up to but no more than 10 mg orally q.d. or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least 7 days prior to randomizationXx_NEWLINE_xXParticipants must meet the following windows from procedures (there is no window required for port placement since there is no anticipated impact on wound healing with bavituximab):\r\n* Major surgery (ex. craniotomy) within 3 weeks of initiation of treatment\r\n* Brain biopsy within 2 weeksXx_NEWLINE_xXPatients must not have received myelosuppressive therapy within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea)Xx_NEWLINE_xXPatients who require thyroid replacement therapy are not eligible if they have not been receiving a stable replacement dose for at least 4 weeks prior to study enrollmentXx_NEWLINE_xXCytotoxic chemotherapy or immunotherapy within 3 weeks of study entryXx_NEWLINE_xXCytotoxic chemotherapy, surgery, immunotherapy, radiotherapy or other targeted therapies within 4 weeks (6 weeks in cases of ramucirumab, mitomycin C, nitrosourea, lomustine; 2 weeks in case of biopsy) prior to randomization (Adjuvant radiotherapy given to local area for non-curative symptom relief is allowed until 2 weeks before randomization.).Xx_NEWLINE_xXMyelosuppressive chemotherapy: must not have received within 4 weeks of registration onto this study (6 weeks if prior nitrosourea)Xx_NEWLINE_xXAt least 6 weeks must have elapsed since prior therapy that includes a monoclonal antibody prior to registrationXx_NEWLINE_xXAt least 4 weeks after the last dose of chemotherapy or radiation therapy; 6 weeks for mitoxantrone or mitomycin therapyXx_NEWLINE_xXFinasteride, bicalutamide and nilutamide discontinued at least 4 weeks prior to registrationXx_NEWLINE_xXAt least 4 weeks must have elapsed from the use of palliative radiation, strontium-89, radium-223, or approved immunotherapy prior to registrationXx_NEWLINE_xXReceipt of a stable ART regimen for at least 3 weeks prior to start of trialXx_NEWLINE_xXSevere infection within 4 weeks prior to randomizationXx_NEWLINE_xXPatients who have had chemotherapy (e.g., purine analogues, alkylating agents), radiation therapy, or participation in any investigational drug treatment within 4 weeks of initiation of DMF or at any time during the studyXx_NEWLINE_xXPatients must not have received systemic therapy within 2 weeks of initiating palbociclib; NOTE: For the HER2-positive cohort, patients on trastuzumab can remain on the drug; no break or washout period required; however, lapatinib, ado-trastuzumab-emtansine, and pertuzumab are prohibited and a minimum wash out period of 2 weeks is requiredXx_NEWLINE_xXPatients who are on any prohibited medication; a wash-out period of minimum 2 weeks prior to registration is mandatory for the patient to be eligible for the studyXx_NEWLINE_xXMinimum interval since last drug therapy:\r\n* 3 weeks since last non-cytotoxic therapy\r\n* 3 weeks must have elapsed since the completion of non-nitrosourea-containing chemotherapy regimen\r\n* 6 weeks since the completion of a nitrosourea-containing therapy regimenXx_NEWLINE_xXPatients must be able to travel to one of the study-designated exercise facilities up to three days per week for four weeks during cycle 0, two days per week for cycles 1-8 (32 weeks) and once per week for cycles 9-11 (12 weeks). In addition, patients must be able to attend exercise testing visits as outlined in the Table 1.Required Initial Laboratory Values:Xx_NEWLINE_xXChemotherapy within 2 weeks of initiating study treatment; there is no maximum allowable number of previous therapiesXx_NEWLINE_xXWithin 3 weeks prior to study registration: \r\nTotal bilirubin =< 1.5 x the upper limits of normal (ULN) within 3 weeks prior to study registrationXx_NEWLINE_xXWithin 3 weeks prior to study registration: \r\nAlkaline phosphatase limit =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) within 3 weeks prior to study registrationXx_NEWLINE_xXWithin 3 weeks prior to study registration: \r\nSerum creatinine =< 1.5 x the ULN within 3 weeks prior to study registrationXx_NEWLINE_xXWithin 3 weeks prior to study registration: \r\nPlatelet count > 100000 /mm^3 within 3 weeks prior to study registrationXx_NEWLINE_xXPatients must have received their last dose of known myelosuppressive anticancer chemotherapy at least 21 days prior to study registration or at least six weeks if nitrosourea; at least two weeks must have lapsed if patients received lower dose oral etoposide (50 mg/2) without experiencing evidence of myelosuppression (i.e. neutropenia or requiring transfusion with blood products)Xx_NEWLINE_xXCurrent use of systemic immunosuppressant(s), or prior anti-cancer therapy to include: lenalidomide, fludarabine, or alemtuzumab within 12 months; radioimmunoconjugate within 12 weeks; mAb or antibody-drug conjugate within 4 weeks; or radiotherapy/chemotherapy/hormone therapy/targeted small-molecule therapy within 2 weeks prior to Day 1 of Cycle 1Xx_NEWLINE_xXGreater than 5 weeks from doxorubicin at the time of consent, with radiation to be initiated no less than 6 weeks from doxorubicinXx_NEWLINE_xXDiscontinuation of previous cancer therapies at least four (4) weeks prior to treatment in this study.Xx_NEWLINE_xXPrior definitive radiation therapy must have been completed at least 6 weeks before study drug administration and the irradiated lesions should show evidence of progression if they are intended to be considered target lesions. Prior palliative radiotherapy must be completed at least 2 weeks before study drug administration. The radiotherapy-related side effects must have resolved before the study entry. No radiopharmaceuticals (strontium, samarium) will be allowed within 8 weeks before study drug administration.Xx_NEWLINE_xXPrior ablative, radiation, resection, or transplant therapies less than 4 weeks before study registrationXx_NEWLINE_xXThe following time periods must have elapsed prior to the planned start date of study treatment:\r\n* >= 2 weeks or 6 half-lives from any approved tyrosine kinase inhibitors (TKIs) or investigational agent, whichever is shorter\r\n* >= 4 weeks from prior cytotoxic therapy, except >= 3 weeks from last dose of temozolomide and >= 6 weeks from nitrosoureas or mitomycin C\r\n* >= 2 weeks from non-cytotoxic agents\r\n* >= 3 weeks from bevacizumabXx_NEWLINE_xXRecent initiation of bone modifying therapy with a bisphosphonate or denosumab unless it has been started more than 4 weeks prior to the first dose of the study regimen; patients who are already enrolled in this study can initiate bone modifying therapy after the first set of re-staging scans (>= 8 weeks from cycle 1, day 1)Xx_NEWLINE_xXReceived chemotherapy, targeted therapies, definitive radiotherapy, or treatment with an investigational anticancer agent within 2 weeks (in the case of nitrosoureas and mitomycin C, within 6 weeks; in the case of immunotherapy, within 4 weeks) before the first administration of study drug. Localized palliative radiation therapy (but should not include radiation to target lesions) and ongoing bisphosphonates and denosumab, are permittedXx_NEWLINE_xXLess than 4 weeks since any therapy for MDSXx_NEWLINE_xXSystemic anticancer therapy within three weeks of study entry, except for nitrosoureas or mitomycin C within six weeks.Xx_NEWLINE_xXAny chemotherapy, sipuleucel-T, or investigational drug in prior 4 weeks, or abiraterone or enzalutamide in prior 2 weekXx_NEWLINE_xXMore than 2 seizures over the last 4 weeks prior to study entryXx_NEWLINE_xXChemotherapy less than or equal to 4 weeks prior to registrationXx_NEWLINE_xXMitomycin C/nitrosoureas less than or equal to 6 weeks prior to registrationXx_NEWLINE_xXImmunotherapy less than or equal to 4 weeks prior to registrationXx_NEWLINE_xXBiologic therapy less than or equal to 4 weeks prior to registrationXx_NEWLINE_xXExposure to any other anti-leukemic therapy (except hydroxyurea) within 2 weeks before the first dose of study treatment (including investigational chemotherapy regimens involving approved agents)Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, and radiotherapy prior to participating in this trial\r\n* No prior myelosuppressive chemotherapy for at least 21 days prior to study enrollment\r\n* Must not have received craniospinal radiation therapy within 24 weeks prior to study entry and no involved field radiation therapy for 12 weeks prior to study enrollment\r\n* If patients received prior monoclonal antibody treatment, at least three half-lives must be elapsed by the time of treatment initiation\r\n* No investigational drugs for 4 weeks prior to study enrollment\r\n* No prior therapy with mTOR inhibitors (including sirolimus, temsirolimus or everolimus)Xx_NEWLINE_xXChemotherapy, radioactive, or biological cancer therapy within 4 weeks prior to the first dose of study drug, or not recovered from clinically significant adverse events due to cancer therapeutics administered more than 4 weeks prior to the first dose of study drugXx_NEWLINE_xXUntreated disease EXCEPT for corticosteroids, hydroxyurea, leukapheresis, and/or tyrosine kinase inhibitors for up to 2 weeks prior to initiation of study therapyXx_NEWLINE_xXNo addition or subtraction of other immunosuppressive medications for at least 4 weeks prior to starting treatmentXx_NEWLINE_xXOn stable immunosuppressive regimen for 2 weeks prior to enrollment; adjustment of immunosuppressive medications to maintain a therapeutic level is permittedXx_NEWLINE_xXUse of tumor necrosis factor (TNF) alpha inhibitors within four weeks prior to study entryXx_NEWLINE_xXHad systemic treatment with anticancer therapy, antibody-based therapy, retinoid therapy, or hormonal therapy within 3 weeks before study drug treatment; or treatment with nitrosoureas or mitomycin C within 6 weeks before study drug treatment; or treatment with small-molecule targeted agents within 2 weeks before study drug treatment. Previous and concurrent use of hormone replacement therapy, the use of gonadotropin releasing hormone modulators for prostate cancer, and the use of somatostatin analogs for neuroendocrine tumors are permitted if such therapy has not been changed within 8 weeks before study drug treatment.Xx_NEWLINE_xXPatients who have received chemotherapy (including monoclonal antibodies) or radiotherapy, administered for any condition, within 4 weeks prior to registration are not eligible\r\n* NOTE: Patients may have received one dose of rituximab prior to enrollment; in such cases, patients will only continue with 3 doses of rituximab during induction (4 total doses)Xx_NEWLINE_xXPrior treatment including chemoembolization or other ablative therapy, any cytotoxic, biologic or other investigational agents must have been completed at least 4 weeks prior to study entryXx_NEWLINE_xXAny major surgery must be completed at least 4 weeks prior to study entry; minor surgical procedures (except insertion of vascular access device) must have been completed at least 2 weeks prior to study entryXx_NEWLINE_xXNo other investigational, biologic or chemotherapy agents, localized ablation or chemoembolization for 4 weeks prior to study entryXx_NEWLINE_xX>= 4 weeks from protocol tissue procurement since resolution of all immune related toxicities and off systemic steroids >= 4 weeks; prophylactic use of steroids in preparation for radiologic exams are acceptableXx_NEWLINE_xXRadiation therapy, chemotherapy, and other investigational agents within 3 weeks (6 weeks for nitrosourea or mitomycin C) prior to starting fenretinide + safingol; patients must have recovered from toxicities of prior therapyXx_NEWLINE_xXMyelosuppressive chemotherapy: Must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea)Xx_NEWLINE_xXMyelosuppressive chemotherapy: Must not have received within 4 weeks of enrollment onto this study (6 weeks if prior nitrosourea)Xx_NEWLINE_xXPatients taking a cholesterol lowering agent must be on a single medication and on a stable dose for at least 4 weeksXx_NEWLINE_xXCurrently receiving any investigational agents within the previous six weeks or received any tumor vaccines within the previous 6 weeksXx_NEWLINE_xXPrior investigational therapy (medications or devices) within 6 weeks of treatment.Xx_NEWLINE_xXThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXPatients who have had chemotherapy or biological therapy within 4 weeks of registrationXx_NEWLINE_xXLast anti-cancer treatment within 2 weeks prior to study entryXx_NEWLINE_xXParticipation in other studies involving investigational drug(s) within 4 weeks prior to study entryXx_NEWLINE_xXTreatment with any CTLA4 antibody within 6 weeks of the start of study drug.Xx_NEWLINE_xXTreatment with nivolumab or any PDL1 or PDL2-directed antibody within 4 weeks of the start of study drug.Xx_NEWLINE_xXTreatment with pembrolizumab within 4 - 12 weeks of the start of study drug (cohort dependent).Xx_NEWLINE_xXAny prior therapy must have been completed >= 4 weeks (6 weeks for nitrosoureas and mitomycin C) or, if known, >= 5 half-lives of the prior agent (whichever is shorter) prior to enrollment on protocol (minimum of 1 week between prior therapy and study enrollment), and the participant must have recovered to eligibility levels from prior toxicity; prior definitive radiation should have been completed >= 4 weeks or palliative radiation should have been completed >= 2 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (where a sub-therapeutic dose of drug is administered) at the principal investigator's (PIâ€™s) discretion, and should have recovered to grade 1 or baseline from any toxicitiesXx_NEWLINE_xXParticipants who have had chemotherapy, immune therapy, or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C; five-half lives for any investigational or Food and Drug Administration [FDA]-approved kinase inhibitors) prior to entering the study. Patients who have received prior CHK1 inhibitor therapy are excluded. Exposure to prior PD-L1 antibody will be allowed as long as this was not the most recent treatment prior to enrollment.Xx_NEWLINE_xXParticipants who have had chemotherapy, radiotherapy, biologic therapy, major surgery, or another investigational agent within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study. Previous BRAF/MEK inhibitor use is allowed with no washout period for the phase I and II portionsXx_NEWLINE_xXCytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapyXx_NEWLINE_xXMajor surgery within 4 weeks of the first dose of BVD-523; tumor embolization procedure or ablation procedure within 2 weeks of first dose of BVD-523Xx_NEWLINE_xXHas received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study startXx_NEWLINE_xXPrior antitumor therapy that is not completed at least 4 weeks prior to first dose of study drug, or at least 2 weeks if progressing. Prior CAR T-cell therapy must be completed 8 weeks before first dose of study drug.Xx_NEWLINE_xXBlood transfusion within 4 weeks prior to screeningXx_NEWLINE_xXMitomycin C or a nitrosourea: 6 weeksXx_NEWLINE_xXExpected survival of ? 12 weeks.Xx_NEWLINE_xXAny investigational agents, anti-cancer monoclonal antibody, anti-cancer therapeutic vaccine, immunostimulant (e.g. IL-2) or study drugs from a previous clinical study within 4 weeks of the first dose of mRNA-4157 or pembrolizumab (note only a 2 week wash out is required from prior pembrolizumab treatment)Xx_NEWLINE_xXTreatment with chemotherapy (not including tyrosine kinase inhibitors) or radiotherapy within 4 weeks (6 weeks from nitrosoureas or mitomycin C), or treatment with monoclonal antibody therapy within 4 weeks prior to start of study treatment\r\n* Note: no minimum washout period is required for tyrosine kinase inhibitor therapy (eg, imatinib or sunitinib)Xx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on study.Xx_NEWLINE_xXAt least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half-lives\r\n* Exceptions:\r\n** There is no time restriction with regard to prior intrathecal chemotherapy (including [incl.] steroids) provided there is complete recovery from any acute toxic effects of such\r\n** Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis\r\n** Subjects who are on standard ALL maintenance type chemotherapy (vincristine, 6-mercaptopurine or oral methotrexate) may be enrolled provided that chemotherapy is discontinued at least 1 week prior to apheresis\r\n** Subjects receiving steroid therapy at physiologic replacement doses (=< 5 mg/day of prednisone or equivalent doses of other corticosteroids) only are allowed provided there has been no increase in dose for at least 2 weeks prior to starting apheresis\r\n** For radiation therapy: radiation therapy must have been completed at least 3 weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable/evaluable disease outside the radiation portXx_NEWLINE_xXInterferon, everolimus (mTOR-inhibitors), sunitinib or other systemic therapies within 4 weeks prior to enrollment; bevacizumab within 6 weeks prior to enrollmentXx_NEWLINE_xXAny liver directed treatment (surgery, radioembolization, chemoembolization, chemotherapy and radiofrequency ablation) within 12 weeks prior to enrollmentXx_NEWLINE_xXENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Participants who have had chemotherapy, radiotherapy, or major surgery within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the studyXx_NEWLINE_xXreceived cytotoxic chemotherapy for either metastatic HSPC or CRPC within the last 12 weeks or other investigational agents within 4 weeksXx_NEWLINE_xXTime since the last prior therapy to treat underlying malignancy to start of drug:\r\n* Cytotoxic chemotherapy: greater than the duration of the most recent cycle of the previous regimen (with a minimum of two weeks for all)\r\n* Biologic therapy (e.g., antibodies): >= four weeks\r\n* >= 5 x t1/2 of a small molecule therapeutic, not otherwise defined above, with a minimum of 2 weeks (including aromatase inhibitors and tamoxifen)Xx_NEWLINE_xXCytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapyXx_NEWLINE_xXSubjects on treatment with chemotherapy or any investigational therapeutic agent will need to discontinue therapy 4 weeks prior to registration (wash out period)Xx_NEWLINE_xXTreatment with any systemic anti-neoplastic therapy, or investigational therapy within the 4 weeks prior to the initiation of study drug administration.Xx_NEWLINE_xXRadiation therapy within 2 weeks prior to randomization, including stereotactic or partial brain irradiation. Whole brain irradiation within 4 weeks prior to randomizationXx_NEWLINE_xXPrior Therapies:\r\n* There is no maximum number of prior medical therapies\r\n* There must be no curative or life prolonging treatments available\r\n* Patients who have received other IGF-1R antibodies or inhibitors are eligible, as long as an appropriate washout period has elapsed \r\n* Participants must have had their last fraction of external beam radiation therapy that is local and palliative at least 2 weeks prior to enrollment, and had their last substantial bone marrow radiation at least 6 weeks prior to enrollment\r\n* Participants must have had their last dose of temozolomide at least 4 weeks prior to enrollment; their last dose of other cytotoxic chemotherapy at least 3 weeks prior to enrollment; their last dose of biological therapy, such as biological response modifiers (e.g., cytokines), immunomodulatory agents, vaccines, differentiating agents, used to treat their cancer at least 7 days prior to enrollment, their last dose of a monoclonal antibody at least 3 half-lives prior to enrollment, and their last dose of any investigational agent at least 4 weeks prior to enrollment\r\n* Participants must have recovered from the acute toxic effects of prior therapy to a grade 1 (Common Terminology Criteria for Adverse Events [CTCAE] version [v.]4.0) level prior to enrollment (does not apply to alopecia)Xx_NEWLINE_xXThe subject must have completed RT with concurrent TMZ at least 12 weeks prior to the planned start of treatment on this study UNLESS there is pathological verification of recurrent tumor and at least 4 weeks have elapsed since the end of RT with concurrent TMZ.Xx_NEWLINE_xXthey are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline),Xx_NEWLINE_xXPatients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea).Xx_NEWLINE_xXPatients who require thyroid replacement therapy are not eligible if they have not been receiving a stable replacement dose for at least 4 weeks prior to study enrollment.Xx_NEWLINE_xXAny approved anti-cancer therapy within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXSevere infection within 4 weeks prior to initiation of study treatmentXx_NEWLINE_xXParticipants must have known HIV infection and histologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; any number of prior cancer therapies will be permitted; at least 4 weeks must have elapsed since prior chemotherapy or biological therapy, 6 weeks if the regimen included carmustine (BCNU) or mitomycin C; prior radiation therapy to the thoracic cavity, abdomen, or pelvis must be completed at least 3 months prior to registration; radiotherapy to any other site (including bone or brain metastases) must be completed at least 28 days prior to registrationXx_NEWLINE_xXA cluster of differentiation (CD)4+ lymphocyte count > 50/mcL will be required within 2 weeks of study participationXx_NEWLINE_xXPatients may have had treatment (chemotherapy and/or radiotherapy) or no treatment for any number of relapses prior to this recurrence\r\n* Patients must have received their last dose of myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration or at least six (6) weeks of nitrosourea\r\n* Patients must have received their last dose of other investigational or biological agent > 7 days prior to study entry\r\n** For agents that have known adverse events occurring beyond 7 days after administration, this period should be extended beyond the time during which adverse events are known to occur; this should be discussed with the study chair\r\n* If patients received prior monoclonal antibody treatment, at least three half-lives must be elapsed by the time of treatment initiation; these patients should also be discussed with the study chair\r\n* Patients must have received their last fraction of craniospinal or focal radiation to primary tumor or other sites > 12 weeks (3 months) prior to registrationXx_NEWLINE_xXPatients who are receiving any other investigational agents; all investigational agents other than ibrutinib must have been discontinued at least 4 weeks prior to beginning treatment; prior ibrutinib therapy must have been discontinued at least 2 weeks prior to beginning therapyXx_NEWLINE_xXMyelosuppressive chemotherapy: patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to study registration or at least six weeks if nitrosoureaXx_NEWLINE_xXRadiation: patients must have:\r\n* Had their last fraction of local irradiation to primary tumor >= 12 weeks prior to registration; investigators are reminded to review potentially eligible cases to avoid confusion with pseudo-progression\r\n* Had their last fraction of craniospinal irradiation or total body irradiation >= 12 weeks prior to registrationXx_NEWLINE_xXPrior treatment with Provenge vaccine and 223 radium (Xofigo) is allowed if > 4 weeks from last doseXx_NEWLINE_xXParticipant has used investigational agents within 4 weeks of randomization.Xx_NEWLINE_xXPatients who have had chemotherapy (including investigational cytotoxic chemotherapy), biologic agents (e.g., cytokines or antibodies) within 3 weeks (6 weeks for nitrosoureas or mitomycin C) before the first dose of study treatmentXx_NEWLINE_xXPatients must evidence of disease progression, either clinically or radiographically, within the 12 weeks prior to study enrollment, as determined by the investigator enrolling the patient on the studyXx_NEWLINE_xXINCLUSION - INFUSION: Patients should have been off other investigational therapy for 4 weeks prior to entry in this studyXx_NEWLINE_xXPatients who have had radiotherapy (except for palliative reasons), immunotherapy or chemotherapy during the previous 4 weeks (6 weeks for nitrosoureas or mitomycin) before treatment, or those who have ongoing toxic manifestations of previous treatments, with the exception of alopecia, of grade higher than 1Xx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.Xx_NEWLINE_xXAt least 2 weeks post any treatments/therapies at the time of first dose.Xx_NEWLINE_xXAlemtuzumab or ATG within 2 weeks of enrollment.Xx_NEWLINE_xXTREATMENT EXCLUSION: Received anti-CD30 antibody-based therapy within the previous 4 weeksXx_NEWLINE_xXExperimental therapies within 4 weeks before first ZW25 dosingXx_NEWLINE_xXParticipants who have had chemotherapy, other investigational or biologic therapy, major surgery, or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the planned first dose of prexasertib (LY2606368) therapy.Xx_NEWLINE_xXEstimated survival of at least 12 weeks;Xx_NEWLINE_xXStable or decreasing steroid dose within 2 weeks of first dose of study drug if patient is taking steroids. No steroid use is also acceptable.Xx_NEWLINE_xXPatients with HGG: Have received anticancer therapies including: radiation therapy to current site of disease within 12 weeks of dose assignment, targeted agent therapy within 2 weeks of dose assignment, nitrosoureas within 6 weeks of dose assignment, procarbazine within 3 weeks of dose assignment, or other cytotoxic agents within 4 weeks of dose assignmentXx_NEWLINE_xXHave received prior treatment with any investigational drug within 4 weeks prior to dose assignmentXx_NEWLINE_xXPatient Received neoadjuvant chemoradiation (4-10 weeks prior to surgery)Xx_NEWLINE_xXUse of any vaccines against infectious diseases within 4 weeks of initiation of study treatment.Xx_NEWLINE_xXCompletion of any prior treatment with radiation, chemotherapy, biologics, and/or other investigational agents at least 4 weeks prior to the first dose of ibrutinib; patients must have completed any prior immunotherapy (e.g., rituximab or PD-1 inhibition) or antibody drug conjugate therapy (e.g. brentuximab vedotin) at least 4 weeks prior to the first dose of ibrutinib in the absence of clear disease progressionXx_NEWLINE_xXCholangitis that required treatment or intervention within 4 weeks of study enrollmentXx_NEWLINE_xXmAb (including rituximab) within 2 weeks of enrollmentXx_NEWLINE_xXother lymphotoxic chemotherapy (including steroids except as below) within 2 weeks of enrollmentXx_NEWLINE_xXBlood cell count (CBC)/differential obtained within 8 weeks prior to registration on studyXx_NEWLINE_xXActive gastrointestinal bleed within 2 weeks of study enrollmentXx_NEWLINE_xXNitrosourea or mitomycin C within 6 weeks of the first doseXx_NEWLINE_xXAny investigational medicinal product or other systemic chemotherapy, or antibody therapy within 4 weeks prior to the first dose of study treatment, or within 8 weeks after immunotherapy, whichever is the most appropriate and as judged by the Investigator. Note: androgen-deprivation therapy is permitted for patients with prostate cancer.Xx_NEWLINE_xXRx or non-Rx drugs or other products known to be sensitive BCRP or OAT1 substrates or to be potent inhibitors/inducers of CYP1A2, which cannot be discontinued 2 weeks prior to Day 1 of dosing and withheld throughout the study until 2 weeks after the last dose of AZD4635.Xx_NEWLINE_xXSmall pox vaccination for 4 weeks before study therapy and during study treatmentXx_NEWLINE_xXPrior chemotherapy within 3 weeks, targeted small molecule therapy or radiation therapy within 2 weeks prior to enrollment, or who has not recovered (i.e., ?Grade 1 at enrollment) from AEs due to a previously administered agent.Xx_NEWLINE_xXHas had prior chemoembolization, bland embolization, radioembolization, local ablative therapies, radiation to liver tumors, or major surgery such as liver resection within 4 weeks prior to study enrollment or who has not recovered (i.e., =< grade 1 or at baseline) from adverse events due to intervention more than 4 weeks earlierXx_NEWLINE_xXThe patient has received chemotherapy or radiotherapy within 4 weeks or has received nitrosoureas or mitomycin C within 6 weeks prior to the first dose of study drug.Xx_NEWLINE_xXMyelosuppressive chemotherapy: Must not have received within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea).Xx_NEWLINE_xXSubjects who have taken 5a-reductase inhibitors (finasteride or dutasteride), saw palmetto, or PC-SPES within the last 6 weeks are ineligible; subjects will be eligible for the study after the wash out period of 6 weeksXx_NEWLINE_xXSevere infection within 4 weeks prior to enrollmentXx_NEWLINE_xXPatients must be off corticosteroid for at least for 2 weeks before the first neoadjuvant vaccine and for at least 2 weeks prior to the first adjuvant vaccineXx_NEWLINE_xXAutologous HSCT within six weeks prior to start of AMG 330 treatmentXx_NEWLINE_xXTreatment with systemic immune modulators 2 weeks before enrollment (day 1)Xx_NEWLINE_xXMolecular targeted agents including monoclonal antibodies and tyrosine kinase inhibitors: at least two weeks since last therapyXx_NEWLINE_xXUse of experimental drug within 4 weeks of treatmentXx_NEWLINE_xXDisease-related platelet transfusion within 8 weeks of registrationXx_NEWLINE_xXReceipt of any chemotherapy, biological therapy or investigational agents within 3 weeks prior to study registrationXx_NEWLINE_xXRadiotherapy within 4 weeks prior to therapy except palliative radiation to target organs other than primary tumor may be allowed up to 2 weeks prior to registrationXx_NEWLINE_xXIntravesical chemo- or biologic therapy within 6 weeks of first treatmentXx_NEWLINE_xXPatients must have completed any chemotherapy, radiation therapy, or biologic therapy >= 4 weeks or 5 half-lives (whichever is shorter) (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study and be >= 2 weeks since any prior palliative radiation or cyberknife therapy; patients must have recovered to grade 1 from prior toxicity or adverse events; patients with bone metastases or hypercalcemia on intravenous bisphosphonate treatment prior to study entry may continue this treatmentXx_NEWLINE_xXBiologic therapy (eg, antibodies), other than ADCs: ?4 weeksXx_NEWLINE_xXNon-cytotoxic small molecule therapeutics: ?5 T1/2 or ?2 weeks (whichever is longer)Xx_NEWLINE_xXAny of the following prior therapies:\r\n* Chemotherapy =< 3 weeks prior to study entry\r\n* Immunotherapy =< 4 weeks prior to study entry\r\n* Biologic therapy =< 4 weeks prior to study entry\r\n* Extensive abdominal surgery if it includes enterotomy(ies) =< 3 weeks prior to study entry; (NOTE: this criterion does not apply to placement of the peritoneal Port-A-Cath or lysis of adhesions at the time of study entry)\r\n* Any viral or gene therapy prior to study entryXx_NEWLINE_xXNo use of investigational agents within 4 weeks of study enrollment or use of immunosuppressive or immunomodulating agents within 8 weeks of study entryXx_NEWLINE_xXPatients cannot have experienced a significant (CTCAE Grade 3 or 4 with or without neutropenia) infection within 2 weeks of their first dose of MT-3724.Xx_NEWLINE_xXPatients must have received their last dose of known myelosuppressive anticancer therapy at least three (3) weeks prior to study enrollment or at least six (6) weeks if prior nitrosoureaXx_NEWLINE_xXPatients must have had their last fraction of:\r\n* Craniospinal irradiation >= 3 months prior to enrollment\r\n* Other substantial bone marrow irradiation >= 6 weeks prior to enrollment\r\n* Local palliative radiation therapy (XRT) (small port) >= 2 weeksXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Patients must have received their last dose of known myelosuppressive anticancer therapy at least three (3) weeks prior to study enrollment or at least six (6) weeks if prior nitrosoureaXx_NEWLINE_xXINCLUSION CRITERIA FOR STRATUM C: Patients must have had their last fraction of:\r\n* Craniospinal irradiation >= 3 months prior to enrollment\r\n* Other substantial bone marrow irradiation >= 6 weeks prior to enrollment\r\n* Local palliative radiation therapy (XRT) (small port) >= 2 weeksXx_NEWLINE_xXInclusion Criteria:\n\n        Adult participants (greater than or equal to 18 years old):\n\n          -  Histologically confirmed de novo (primary) Glioblastoma Multiforme with unequivocal\n             tumor progression or recurrence.\n\n          -  In case of testing at the time of first progression: either at least 3 months after\n             the end of radiotherapy or have tumor progression that is clearly outside the\n             radiation field or have tumor progression unequivocally proven by surgery/biopsy\n\n          -  Absence of any psychological, familial, sociological or geographical factors\n             potentially hampering compliance with the study protocol and follow-up schedule; such\n             conditions should be assessed with the patient before registration in the trial.\n\n          -  Availability of adequate biological material (formalin-fixed paraffin embedded [FFPE]\n             tumor) for central testing of Epithelial Growth Factor Receptor (EGFR) amplification\n\n          -  Presence of EGFR amplification confirmed by central assessment; participants with\n             undetermined EGFR status are excluded\n\n          -  World Health Organization (WHO) Performance status 0 - 2\n\n          -  No more than one line of chemotherapy (concurrent and adjuvant Temozolomide based\n             chemotherapy including in combination with another investigational agent is considered\n             one line of chemotherapy). Chemotherapy must have been completed at least 4 weeks\n             prior to randomization.\n\n          -  Post surgery MRI within 48 hours following surgery, however an MRI scan has to be done\n             within 2 weeks prior to randomization.\n\n          -  Surgery completed at least 2 weeks before randomization and patients should have fully\n             recovered as assessed by investigators.\n\n        Pediatric sub-study participants (less than 18 years old):\n\n          -  The study will only include patients under 3 years of age when results of a juvenile\n             repeated mouse toxicity study become available and are favorable to support use in\n             patients aged under 3 years.\n\n          -  Histologically proven high grade glioma (HGG: WHO grade III glioma [e.g anaplastic\n             astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma], grade IV\n             glioma [e.g glioblastoma, gliosarcoma] or diffuse intrinsic pontine glioma [DIPG]).\n\n          -  Must either have recurrent/progressive tumor or, if newly diagnosed, have completed\n             any planned radiation therapy at least 4 weeks prior to first dose of ABT-414.\n\n          -  The tumor tissue must have been determined to have EGFR amplification, (by local or\n             other testing service).\n\n          -  Availability of adequate biological material for retrospective confirmatory central\n             testing of EGFR amplification\n\n          -  Participant has sufficiently recovered from previous therapy. The investigator\n             believes that benefit of treating the pediatric subject with ABT-414 outweighs the\n             expected risks and that this treatment is in the best interests of the pediatric\n             subject.\n\n        Exclusion Criteria:\n\n        Adult population (greater than or equal to 18 years old):\n\n          -  Prior treatment with nitrosoureas\n\n          -  Prior treatment with bevacizumab\n\n          -  Previous exposure to Epithelial Growth Factor Receptor (EGFR) targeted agents,\n             including EGFRvIII targeting agents\n\n          -  Prior discontinuation of temozolomide chemotherapy for toxicity reasons\n\n          -  Prior Radiation Therapy (RT) with a dose over 65 Gy, stereotactic radiosurgery or\n             brachytherapy unless the recurrence is histologically proven\n\n          -  Previous other malignancies, except for any previous malignancy which was treated with\n             curative intent more than 5 years prior to randomization, and except for adequately\n             controlled limited basal cell carcinoma of the skin, squamous carcinoma of the skin or\n             carcinoma in situ of the cervix\n\n          -  Women of childbearing potential must have a negative serum or urine pregnancy test\n             (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to\n             randomization.\n\n          -  No history of wheat allergies and Coeliac disease.\n\n          -  No EIAED, patients who require anti-convulsant therapy must be taking non-enzyme\n             inducing antiepileptic drugs (non-EIAED). Patients previously on EIAED must be fully\n             switched to non-EIAED at least 2 weeks prior to randomization.\n\n        Pediatric sub-study (less than 18 years old):\n\n          -  (For recurrent disease) No prior RT with a dose over 65Gy to the brain, stereotactic\n             radiosurgery or brachytherapy unless the recurrence is histologically proven\n\n          -  No current or recent (within 4 weeks or 5 half-lives (whichever is shorter) before\n             enrollment) treatment with another investigational drug\n\n          -  Female participants of childbearing potential must have a negative serum or urine\n             pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72\n             hours prior to randomization.Xx_NEWLINE_xXAt least 4 weeks post-surgery prior to first dosing of study agentXx_NEWLINE_xXAny therapeutic antibody within 4 weeks of first dose of study drugs.Xx_NEWLINE_xXOther anti-neoplastic investigational agents currently or within 2 weeks prior to apheresis (i.e. start of protocol therapy)Xx_NEWLINE_xXMust be off all immunosuppressive medications (except steroids) for graft versus host disease (GVHD) for at least 2 weeks prior to study entryXx_NEWLINE_xXAll previous cancer therapy (with the exception of hydroxyurea) including donor lymphocyte infusions must have been discontinued at least 2 weeks prior to treatment in this studyXx_NEWLINE_xXPrevious systemic anti-cancer therapy must have been discontinued at least 3 weeks prior to treatment in this study; if there is progression of disease on that therapy and all adverse effects have resolved to grade 1 or baseline, in which case 2 weeks is acceptableXx_NEWLINE_xXPrevious radiation, hormonal therapy, and surgery must have been discontinued at least 2 weeks prior to treatment in this study and adverse effects must have resolved; lymph node or other diagnostic biopsy within 2 weeks is not considered exclusionaryXx_NEWLINE_xXChemotherapy: patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study enrollment in the study or at least six (6) weeks for those receiving nitrosoureaXx_NEWLINE_xXBiologic therapy: patients should have received their last dose of biologic agent >= 7 days prior to enrollment; in the event the patient has received another biologic agent and has experienced >= grade 2 myelosuppression, then at least three (3) weeks must have elapsed prior to enrollment; if the investigational or biologic agent has a prolonged half-life then at least three (3) weeks interval is requiredXx_NEWLINE_xXPatients who have had chemotherapy (e.g., purine analogues, alkylating agents), immunotherapy, radiation therapy, or participation in any investigational drug treatment within 4 weeks of initiation of UC-961, or at any time during the studyXx_NEWLINE_xXChemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study drug (6 weeks for nitrosoureas); concomitant hormonal therapies for breast cancers are allowedXx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen, and patientsâ€™ toxicities must have recovered to a grade 1 or less; patients may have undergone minor surgical procedures or local radiotherapy within the past 4 weeksXx_NEWLINE_xXPatients who are currently receiving systemic cytotoxic chemotherapy, radiation, targeted molecular therapy (e.g. vemurafenib, other inhibitor of mutant BRAF, MEK, or cKit), or other experimental therapy, or who have received this therapy within the preceding 4 weeks (except as specified). Gamma knife or stereotactic radiosurgery may be administered within the prior 4 weeks, but must not be administered less than one week prior to study registration. Patients who are currently receiving nitrosoureas or who have received this therapy within the preceding 6 weeks are excluded.Xx_NEWLINE_xXA minimum of 4 weeks from prior systemic anti-cancer therapies or 3 weeks for radiation treatment prior to enrollment is requiredXx_NEWLINE_xXGranulocyte > 1500/ul within four weeks of enrollmentXx_NEWLINE_xX< 24 days from prior temozolomide, < 6 weeks from nitrosourea, < 4 weeks from other chemotherapy or investigational agents prior to start of treatment within study.Xx_NEWLINE_xXConcomitant therapies that cannot be discontinued or switched to a different medication prior to study entry that are known to increase serum phosphate levels are not permitted within 4 weeks prior to start of study treatment)Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior anti-cancer therapy\r\n* Patients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment\r\n* Patients must be > 7 days since treatment with hematopoetic growth factors (> 14 days for Neulasta)\r\n* Patients must be > 7 days since therapy with a biologic agent and beyond the period for which adverse events of the biologic agent are known to occur if longer\r\n* Patients must be > 3 half-lives since therapy with a monoclonal antibody\r\n* Patients must be > 42 days since completion of any immunotherapy (i.e. tumor vaccines)\r\n* Patients must be greater than 2 weeks since most recent palliative XRT and greater than 6 weeks since substantial bone marrow irradiation\r\n* Patients must be greater than 8 weeks since prior stem cell transplant or infusion and without evidence of active graft versus (vs.) host diseaseXx_NEWLINE_xXMinimum interval since last drug therapy:\r\n* 3 weeks since last non-cytotoxic therapy\r\n* 3 weeks must have elapsed since the completion of a non-nitrosourea-containing chemotherapy regimen\r\n* 6 weeks since the completion of a nitrosourea-containing chemotherapy regimenXx_NEWLINE_xXPatients must have completed any chemotherapy, radiation therapy, or biologic therapy >= 4 weeks (or 5 half-lives, whichever is shorter) prior to entering the study (6 weeks for nitrosoureas or mitomycin C); patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study and >= 1 week from palliative radiation therapy; patients must have recovered to eligibility levels from prior toxicity or adverse events; treatment with bisphosphonates is permittedXx_NEWLINE_xXBevacizumab within the last 3 weeks before enrollment on trialXx_NEWLINE_xXPrior radiation therapy must be completed >= 2 weeks prior to enrollment and the patient must have recovered from all toxicity; prior radiopharmaceuticals (strontium, samarium, alpharadin) must be completed >= 4 weeks prior to enrollmentXx_NEWLINE_xXLab results per the following within 4 weeks prior to study registration:Xx_NEWLINE_xXPFT (pulmonary function test) with a FEV1 > 0.75 liters/second within 16 weeks prior to study registration.Xx_NEWLINE_xXUnintentional weight loss >10% within 4 weeks prior to study registration.Xx_NEWLINE_xXPatients who have received any cytotoxic therapy, immunotherapy, antitumor vaccines or monoclonal antibodies in the 4 weeks prior to the start of the studyXx_NEWLINE_xXIf on corticosteroids for mass effect and/or edema related to the tumor, patient must be on a stable or decreasing dose for at least 2 weeks prior to study entryXx_NEWLINE_xXWithin 4 weeks prior to study enrollment: Shortening fraction of >= 27% by echocardiogram ORXx_NEWLINE_xXWithin 4 weeks prior to study enrollment: Pulse oximetry > 94% on room air or oxygen (O2) by nasal cannulaXx_NEWLINE_xXWithin 4 weeks prior to study enrollment: No evidence of dyspnea at restXx_NEWLINE_xXtreatment with cytotoxic agents, or treatment with biologic agents within 4 weeks prior to treatment with APS001F (6 weeks for mitomycin C or nitrosoureas).Xx_NEWLINE_xXAt least 2 weeks must have elapsed from any prior surgery or hormonal therapy.Xx_NEWLINE_xXThe following required Initial Laboratory Values should be obtained within 4 weeks of the start of treatment:Xx_NEWLINE_xXPatients must have recovered from effects of prior therapy; at least 2 weeks should have elapsed since the last dose of high dose chemotherapy; hydroxyurea, steroids and vincristine are allowed to control counts until eligibility is confirmed and study treatment can be initiatedXx_NEWLINE_xXSubjects must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and meet time restrictions from end of prior therapy as stated below: \r\n* Myelosuppressive chemotherapy: Subjects must have received the last dose of myelosuppressive therapy at least 3 weeks prior to study registration or at least 6 weeks if therapy included nitrosourea\r\n* Investigational/biological agent: Subjects must have received the last dose of other investigational or biological agent > 7 days prior to study registration; subjects must not have received poly-ICLC in the past\r\n* Radiation therapy (XRT): Subjects must be >= 8 weeks since the completion of radiation therapy\r\n* Study specific limitations on prior therapy: There is no limit on the number of prior treatment regimens or received doses of radiation therapy\r\n* Growth factor(s): Subjects must not have received any hematopoietic growth factors within 7 days of study entry or 21 days for pegfilgrastim\r\n* Prior surgery: Subjects must be >= 2 weeks from prior surgery\r\n* Steroids: Subjects must be on a stable steroid dose for 7 days prior to study entry if they are on steroid treatmentXx_NEWLINE_xXTreatment indicated based on demonstration of at least one of the following no more than 4 weeks from the time of enrollment, and no less than 6 months after prior purine analog and no less than 4 weeks after other prior treatment, if applicableXx_NEWLINE_xXNo other therapy (i.e. chemotherapy, interferon) for 4 weeks prior to study entry, or cladribine for 6 months prior to study entryXx_NEWLINE_xXAt the investigatorâ€™s discretion, receipt of a live vaccine within 4 weeks prior to randomization; efficacy and/or safety of immunization during periods of B-cell depletion have not been adequately studied; it is recommended that a patientâ€™s vaccination record and possible requirements be reviewed; per the investigatorâ€™s discretion, the patient may have any required vaccination/booster administered at least 4 weeks prior to the initiation of study treatment; review of the patientâ€™s immunization status for the following vaccinations is recommended: tetanus; diphtheria; influenza; pneumococcal polysaccharide; varicella; measles, mumps and rubella (MMR); and hepatitis B; patients who are considered to be at high risk for hepatitis B virus (HBV) infection and for whom the investigator has determined that immunization is indicated should complete the entire HBV vaccine series at least 4 weeks prior to participation in the studyXx_NEWLINE_xXReceiving another experimental drug within 4 weeks of initiation of conditioning (day -6) unless approved by the PIXx_NEWLINE_xXTreatment must begin at a minimum of 4 weeks after, but no later than 14 weeks after, the date of completion of radiotherapy.Xx_NEWLINE_xXPrior surgery that required general anesthesia must be completed at least 4 weeks before study drug administration; surgery requiring local/epidural anesthesia must be completed at least 72 hours before study drug administrationXx_NEWLINE_xXTime from prior therapy:\r\n* Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter (6 weeks for nitrosoureas or mitomycin C)\r\n* Hormonal therapy is not considered anti-neoplastic therapy\r\n* Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatmentXx_NEWLINE_xXAt time of registration and within 4 weeks prior to initiating on-protocol treatment: Platelets >= 100 x 10^9 /LXx_NEWLINE_xXPatients who have received antiandrogens such as flutamide, bicalutamide, or nilutamide for > 6 months immediately before enrollment on this study must be off treatment for 4 weeks (6 weeks for bicalutamide) and demonstrate a continued rise in PSA. Patients on antiandrogens for < 6 months must be off medication for 2 weeks.Xx_NEWLINE_xXAt least 2 weeks must have elapsed since local radiation therapy (XRT) (small port); ? 3 months must have elapsed if prior cranial or craniospinal XRT was received, if ? 50% of the pelvis was irradiated, or if total body irradiation (TBI) was received; ? 6 weeks must have elapsed if other substantial bone marrow irradiation was givenXx_NEWLINE_xXRadionuclide treatment within 6 weeks of the first dose of study drug in this studyXx_NEWLINE_xXTreatment with therapeutic doses of metaiodobenzylguanidine (MIBG) ?6 weeks before first dose of study drugXx_NEWLINE_xXChemotherapy within 3 weeks of starting study drug (6 weeks if prior nitrosourea)Xx_NEWLINE_xXAdministration of chemotherapy, biological, immunotherapy, or investigational agent (therapeutic or diagnostic) within 3 weeks before enrollment (14 days for non-myelosuppressive therapy). Subjects should be 6 weeks from last dose of nitrosourea, nitrogen mustards or monoclonal antibody, 12 weeks from autologous stem cell transplantation (SCT), and 16 weeks from allogeneic SCTXx_NEWLINE_xXTreatment with plasmapheresis within 4 weeks before enrollmentXx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXHas received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to study enrollmentXx_NEWLINE_xXAny prior PSA, MUC1, and/or brachyury-targeted immunotherapy (e.g., vaccine) must have been discontinued at least 12 weeks before initiation of study treatment; subjects must have recovered from all acute toxicities from prior treatment prior to screening for this studyXx_NEWLINE_xXPrevious cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to initiation of therapy. The use of live vaccines within 30 days before initiation of therapy. IMiDs, PIs and or corticosteroids within 2 weeks prior to initiation of therapy. Other investigational therapies and monoclonal antibodies (mAb) within 4 weeks of initiation of therapy Prednisone up to but no more than 10 mg orally once daily (q.d.) or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least 7 days prior to initiation of therapyXx_NEWLINE_xXInvestigational drug therapy outside of this trial during or within 3 weeks prior to C1D1.Xx_NEWLINE_xXGrade >= 3 hemorrhage within 4 weeks of patient randomizationXx_NEWLINE_xXThe patient has taken a medication known to be a potent inducer of CYP1A2, CYP2C8, or CYP3A4 within 4 weeks prior to the first dose of study drugXx_NEWLINE_xXPrior therapeutic intervention with any of the following:\r\n* Nitrosoureas or mitomycin C within 6 weeks\r\n* Therapeutic anticancer antibodies (including rituximab) within 4 weeks\r\n* Radio- or toxin-immunoconjugates within 10 weeks\r\n* All other chemotherapy, radiation therapy within 3 weeks prior to initiation of therapyXx_NEWLINE_xXAn interval of >= 4 weeks after the last administration of any other treatment for GBM.Xx_NEWLINE_xXSystemic chemotherapy ? 2 weeks (6 weeks for clofarabine or nitrosoureas) or radiation therapy ? 3 weeks prior to apheresis; exceptions:\r\n* There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such\r\n* Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis\r\n* Patients who are on standard ALL maintenance type chemotherapy (vincristine, 6-mercaptopurine, oral methotrexate or tyrosine kinase inhibitors in patients with Philadelphia [Ph]+ ALL) may be enrolled provided that chemotherapy is discontinued at least 1 week prior to apheresis\r\n* Subjects receiving steroid therapy are allowed provided there has been no increase in dose for at least 1 week prior to starting apheresis; patients on physiologic steroids will not be excluded\r\n* For radiation therapy: Radiation therapy must have been completed at least 3 weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable / evaluable disease outside the radiation portXx_NEWLINE_xXMonoclonal antibodies therapy within 2 weeks before study entryXx_NEWLINE_xXRadiotherapy or cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids) or any investigational drug within 2 weeks before study entryXx_NEWLINE_xXMost recent laboratory values within 2 weeks prior to Week 1 Day 1 (W1D1) meet the following standards:Xx_NEWLINE_xXThe subject is neurologically stable for at least 2 weeks prior to Screening.Xx_NEWLINE_xXThe last dose of previous therapy must have occurred at least 3 weeks prior to the start of study therapy; palliative radiotherapy is allowed up to 2 weeks before the first LMB-100 infusionXx_NEWLINE_xXPatients who have had chemotherapy within 2 weeks prior to first dose of study drug.Xx_NEWLINE_xXThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 4 weeks, or intravesical Bacillus Calmette-Guerin (BCG) within 6 weeks of the first dose of study treatmentXx_NEWLINE_xXHepatic intra-arterial embolization or peptide receptor radionuclide therapy (PRRT) within 4-8 weeks; cryoablation, radiofrequency ablation or trans-arterial chemoembolization of hepatic metastases within ? 4 weeks of study enrollmentXx_NEWLINE_xXPrior anti-ROR1 therapy within 12 weeks prior to the start of study therapy.Xx_NEWLINE_xXFour weeks must have elapsed since any prior antibody therapies to allow antibody levels to declineXx_NEWLINE_xXFor cohort 4, patients must be at least 4 weeks from radiation therapy; additionally, patients must be at least 6 weeks from nitrosoureas, 4 weeks from temozolomide, 3 weeks from procarbazine, 2 weeks from vincristine and 4 weeks from last bevacizumab administration; patients must be at least 4 weeks from other cytotoxic therapies not listed above and 2 weeks for non-cytotoxic agents (e.g., interferon) including investigative agentsXx_NEWLINE_xXHas received prior RT within 2 weeks of start of study treatmentXx_NEWLINE_xXCytotoxic agents, unless at least 4 weeks have elapsed from last dose of prior anti-cancer therapy and initiation of study therapyXx_NEWLINE_xXPatients should be off any prior treatment or line of therapy for 2 weeks prior to start study with the exception of hydrea (hydroxyurea)Xx_NEWLINE_xXCOHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Patients who have received chemotherapy in the previous 3 weeks (6 weeks for nitrosoureas or mitomycin); other investigational agents within 3 weeks or a PD1/PDL1 agent within 4 weeks prior to first dose of study treatmentXx_NEWLINE_xXCOHORT 2: TRIPLE NEGATIVE BREAST CANCER: Patients who have received chemotherapy in the previous 3 weeks (6 weeks for nitrosoureas or mitomycin); other investigational agents within 3 weeks or a PD1/PDL1 agent within 4 weeks prior to study enrollmentXx_NEWLINE_xXCOHORT 3: ENDOMETRIAL CANCER: Patients who have received chemotherapy in the previous 3 weeks (6 weeks for nitrosoureas or mitomycin); other investigational agents within 3 weeks or a PD1/PDL1 agent within 4 weeks prior to study enrollmentXx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccines.Xx_NEWLINE_xXWash-out requirements (standard or investigational):\r\n* At least 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen; and\r\n* At least 23 days must have passed since the completion of Temodar and/or 4 weeks for any other non-nitrosourea-containing cytotoxic chemotherapy regimen; if a participantâ€™s most recent treatment was with a targeted agent only, and s/he has recovered from any toxicity of this targeted agent, then a waiting period of only 2 weeks is needed from the last dose and the start of CAR T cell infusion with the exception of bevacizumab where a wash out period of at least 4 weeks is required before starting CAR T cell therapyXx_NEWLINE_xXAny drug used for GVHD within 4 weeks prior to enrollmentXx_NEWLINE_xXAny prior therapy must have been completed at least 4 weeks prior to entry into the studyXx_NEWLINE_xXCytotoxic chemotherapy within 4 weeks of investigational product (6 weeks for mitomycin C or nitrosoureas) if immediate prior regimen was administered on an every 3 4 week schedule or 2 weeks of investigational product if immediate prior regimen consisted of weekly therapy.Xx_NEWLINE_xXAt least 3 weeks between last systemic chemotherapy and planned start of study treatment (4 weeks for prior investigational drugs, immunotherapy, radiotherapy, or biologics) for ovarian cancerXx_NEWLINE_xXPatients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugsXx_NEWLINE_xXPHASE II: At the time of enrollment, at least 6 weeks must have elapsed since the last dose of any nitrosourea, and the longer of 2 weeks or 3 half-lives must have elapsed since the last dose of any other tumor-directed medication, or biologic therapyXx_NEWLINE_xXAny major surgery, radiotherapy, or immunotherapy within the last 21 days (focal radiation does not require a washout period; ?4 weeks for WBRT). Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks.Xx_NEWLINE_xXImaging evaluations necessary to establish eligibility for study entry must be done within three (3) weeks prior to registrationXx_NEWLINE_xXAll other evaluations necessary to establish eligibility for study entry must be done within two (2) weeks prior to registrationXx_NEWLINE_xXPatients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to study registration or at least six weeks if nitrosoureaXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, biologic therapy or radiotherapy prior to study entry\r\n* Myelosuppressive chemotherapy: Patients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three weeks prior to registration on the Re-treatment Study or at least six weeks if a nitrosourea\r\n* Biologic agent: Patient must have received their last dose of the biologic agent >= 7 days prior to study registration; for biologic agents and monoclonal antibody treatment, at least three half-lives must have elapsed prior to registration\r\n* Other investigational agents (not fitting into one of the above specified categories): patients must have received their last dose of any other investigational agent greater than 28 days prior to enrollment\r\n* Radiation: Patients must have:\r\n** Had their last fraction of local irradiation to the primary tumor >= 12 months prior to registration; investigators are reminded to review potentially eligible cases to avoid confusion with pseudo-progression;\r\n** Had their last fraction of craniospinal irradiation (> 24Gy) > 3 months prior to registration\r\n* Corticosteroids: Patients who are receiving dexamethasone must be on a stable or decreasing dose for at least 1 week prior to registration\r\n* Growth factors: Patients must be off all colony-forming growth factor(s) for at least 1 week prior to registration (filgrastim, sargramostim, erythropoietin) and at least 2 weeks for long-acting formulationsXx_NEWLINE_xXChemo-, or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 2 weeks prior to treatment with the trial drugXx_NEWLINE_xXSubjects must start study agent within 6 weeks from the first diagnostic surgery for glioblastomaXx_NEWLINE_xXChemotherapy or immunotherapy within 3 weeks prior to start of hu3F8Xx_NEWLINE_xXTreatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide), 5-alpha reductase inhibitors (finasteride, dutasteride), estrogens, chemotherapy, or biologic therapy within 4 weeks of enrollment (day 1 visit)Xx_NEWLINE_xXRadiation therapy within 3 weeks (if single fraction of radiotherapy within 2 weeks) of enrollment (day 1 visit)Xx_NEWLINE_xXNo prior investigational therapy within 2 weeks prior to study enrollmentXx_NEWLINE_xXCompletion of most recent salvage therapy within 8 weeks of enrollmentXx_NEWLINE_xXPrior therapies\r\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy\r\n* Myelosuppressive chemotherapy: Must not have received within 3 weeks (6 weeks if prior nitrosourea)\r\n* Hematopoietic growth factors: At least 7 days since the completion of therapy with a growth factor, 14 days for long- acting (e.g. PEG-filgrastim)\r\n* Biologic (anti-neoplastic agent): At least 7 days or 3 half-lives (whichever is longer) since the completion of therapy with a biologic agent\r\n* Radiation therapy: >= 12 weeks must have elapsed from craniospinal radiation; >= 2 weeks must have elapsed from focal radiation\r\n* Surgery: > 3 weeks from major surgery; if recent craniotomy, adequate wound healing must be determined by neurosurgical team\r\n* Autologous stem cell transplant or rescue: No evidence of active graft versus (vs.) host disease and >= 4 weeks must have elapsedXx_NEWLINE_xXSubject who have received ferumoxytol within 3 weeks of study entryXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to start of study treatment.Xx_NEWLINE_xXSevere infection within 4 weeks prior to initiation of study treatmentXx_NEWLINE_xXHormonal therapy during the study or within 2 weeks of first study enrollmentXx_NEWLINE_xXCompletion of phase 1 lymphedema care in the past 8 weeks;Xx_NEWLINE_xXSubjects must be free from active GVHD and off immunosuppressive GVHD therapy for 4 weeks prior to enrollmentXx_NEWLINE_xXThere is no need for steroids and patients have not had steroids at least 2 weeksXx_NEWLINE_xXConcurrent or recent chemotherapy, radiotherapy, or general anesthesia/major surgery within 3 weeks. Patients must have recovered from all known or expected toxicities from previous treatment and passed a treatment-free \washout\ period of 3 weeks before starting this program (8 weeks for persons receiving nitrosourea or mitomycin).Xx_NEWLINE_xXSubject who have received ferumoxytol within 3 weeks of study entryXx_NEWLINE_xXSevere infection that in the opinion of the investigator would interfere with the patients safety or compliance on trial within 2 weeks prior to enrollment. Oral or IV antibiotics within 2 weeks or 5 half-lives prior to enrollmentXx_NEWLINE_xXHas had prior chemotherapy or targeted small molecule therapy within 2 weeks before administration of study treatment.Xx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXNo concomitant therapy with any of the following: IL2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; or other investigational therapies; all such therapies must have been discontinued > 4 weeks prior to registrationXx_NEWLINE_xXPatients must be off cancer-directed therapy for at least 3 weeks (2 weeks for oral agents) prior to day 1 of the studyXx_NEWLINE_xXSubjects who received non-oncology vaccine therapies for prevention of infectious disease within 4 weeks of study drug administrationXx_NEWLINE_xXNon-oncology vaccine therapy used for prevention of infectious disease within 4 weeks of trial enrollment.Xx_NEWLINE_xXPatients with neurological deficits should have deficits that are stable for a minimum of 2 weeks prior to registrationXx_NEWLINE_xXExposure to any investigational drug or placebo within 4 weeks of enrollmentXx_NEWLINE_xXChange in chemotherapy or hormone therapy within 8 weeks of the start of the studyXx_NEWLINE_xXSubjects who have had chemotherapy or radiotherapy within 3 weeks (4 weeks for immunotherapy; 6 weeks for nitrosoureas or mitomycin C) prior to starting the study agent.Xx_NEWLINE_xXAt least 2 weeks (or 5 half-lives, whichever is longer) wash-out since the end of previously administered experimental therapy (6 weeks if previous nitrosourea containing regimen) or 2 weeks for standard-of-care regimens. Concurrent corticosteroids are allowed provided they are administered at an equivalent prednisone dose of ? 10 mg/day, as prediction or blood products only;Xx_NEWLINE_xXAny other prior therapy directed at the malignant tumor, including biological and immunologic agents, must be discontinued at least three weeks prior to registrationXx_NEWLINE_xXAndrogens such as testosterone, dehydroepiandrosterone (DHEA), etc. unless discontinued at least two weeks prior to randomization.Xx_NEWLINE_xXHerbal products that may decrease PSA levels (e.g., saw palmetto) unless discontinued two weeks prior to randomization.Xx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXAll prior chemotherapy must be at least 4 weeks prior to TATE and free from treatment-related toxicity. No gap is needed for prior PD-1 checkpoint inhibitors in NSCLC patients.Xx_NEWLINE_xXNon-oncology vaccine therapies for prevention of infectious disease within 4 weeks of study drug administrationXx_NEWLINE_xXPrior chemotherapy, monoclonal antibody therapy, must have been completed at least 4 weeks prior to start. Radiotherapy or radiosurgery must have been completed at least 2 weeks prior to start.Xx_NEWLINE_xXSubjects unable or unwilling to have their first randomized treatment within three weeks of the post induction imaging and within five weeks of their last induction treatmentXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to the first study treatmentXx_NEWLINE_xXPrevious cytotoxic therapies, including cytotoxic investigational agents, within 3 weeks (6 weeks nitrosoureas) prior to start of study treatment; previous corticosteroids used with intent to treat amyloidosis within three weeks; (prednisone up to but no more than 10 mg orally once a day [q.d.] or its equivalent for symptom management of comorbid conditions is permitted but dose should be stable for at least 7 days prior to study treatment)Xx_NEWLINE_xXPegvisomant, within 24 weeksXx_NEWLINE_xXDopamine agonists, within 12 weeksXx_NEWLINE_xXPasireotide, within 24 weeksXx_NEWLINE_xXInclusion Criteria:\n\n          1. Fully understand the study and voluntarily sign the informed consent form;\n\n          2. 18-75 years of age\n\n          3. Body weight ? 45kg\n\n          4. Histologically or cytologically documented, locally advanced or metastatic solid\n             malignancy (except squamous NSCLC) that has progressed on approved systemic therapy,\n             the last dose of prior systemic anti-cancer therapy must have been administered ? 4\n             weeks prior to initiation of study treatment, and for whom no effective therapy or\n             standard of care exists.\n\n          5. Have measurable disease per RECIST Version 1.1 (expansion phase only)\n\n          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n\n          7. Expected survival of more than 12 weeks;\n\n          8. For female patients of childbearing potential and male patients with partners of\n             childbearing potential, agreement (by patient and partner) to use a highly effective\n             form(s) of contraception that results in a low failure rate ( < 1% per year) when used\n             consistently and correctly, and to continue its use for 90 days after the last dose of\n             fruquintinib.\n\n        Exclusion Criteria:\n\n        Patients will be excluded from the study, if any of the following criteria is met:\n\n          1. Absolute neutrophil count (ANC) < 1.5Ã—109/L, platelet count < 100 Ã—109/L, or\n             hemoglobin < 90 g/L;\n\n          2. Serum total bilirubin > 1.5 times the upper limit of normal (ULN);\n\n          3. Alanine aminotransferase (ALT) aspartate aminotransferase (AST) > 1.5 ULN in patients\n             without hepatic metastases or ALT, AST > 3 ULN in patients with hepatic metastases;\n\n          4. Serum potassium, calcium, or magnesium levels out of the normal laboratory reference\n             range, and clinically significant in the investigator's judgment.\n\n          5. Serum creatinine clearance < 60 mL/min;\n\n          6. Urine dipstick for proteinuria > 2 +. Patients discovered to have ? 1 + proteinuria on\n             dipstick urinalysis at baseline should undergo a 24-hour urine collection and must\n             demonstrate ? 1 g of protein in 24 hours;\n\n          7. Uncontrolled hypertension, defined as: systolic blood pressure ? 140 mmHg and/or\n             diastolic blood pressure ? 90mmHg;\n\n          8. International Normalized Ratio (INR) > 2 or activated partial thromboplastin time\n             (aPTT) > 1.5 ULN, except if the patient is currently receiving or intending to receive\n             anti-coagulants for therapeutic purposes (prophylactic use is allowed).\n\n          9. Risk of, or active hemorrhage: history or presence of active gastric/duodenal ulcer or\n             ulcerative colitis, active hemorrhage of an unresected gastrointestinal tumor, or any\n             other condition that could possibly result in gastrointestinal tract hemorrhage or\n             perforation;\n\n         10. History or presence of hemorrhage from any other site (e.g., hemoptysis or\n             hematemesis) within 2 months prior to screening\n\n         11. History of a thromboembolic event (including DVT, pulmonary embolism, stroke and/or\n             transient ischemic attack) within 12 months prior to screening;\n\n         12. Patients with squamous non-small-cell lung cancer (NSCLC);\n\n         13. Clinically significant cardiovascular disease, including but not limited to acute\n             myocardial infarction or coronary artery bypass surgery within 6 months prior to\n             enrollment, severe or unstable angina pectoris, New York Heart Association Class\n             III/IV congestive heart failure, ventricular arrhythmias requiring treatment, or left\n             ventricular ejection fraction (LVEF) < 50%;\n\n         14. Mean corrected QT interval using the Fredericia method (QTcF) > 480 msec or any\n             factors that increase the risk of QTc prolongation or risk of arrhythmic events such\n             as hypokalemia, congenital long QT syndrome, family history of long QT syndrome, or\n             unexplained sudden death under 40 years of age in a next of kin relative.\n\n         15. Concomitant medications with a known risk of causing QT prolongation and/or Torsades\n             de Pointes (See list in Appendix E; source list is continuously updated online at\n             www.qtdrugs.org ).\n\n         16. Systemic anti-neoplastic therapies within 4 weeks prior to the initiation of\n             investigational treatment, including chemotherapy, radical radiotherapy,\n             hormonotherapy, bio-therapy and immunotherapy;\n\n         17. Palliative radiotherapy for bone metastasis/lesion within 2 weeks prior to the\n             initiation of study treatment;\n\n         18. Use of strong inducers or inhibitors of CYP3A4 within 2 weeks before the first dose of\n             study treatment (3 weeks for St John's Wort). See Appendix F for a list of such\n             medications.\n\n         19. Surgery prior to enrollment within 28 days prior to the initiation of study treatment\n             or unhealed surgical incision;\n\n         20. Toxicity from a previous anti-tumor treatment that does not return to Grade 0 or 1\n             (except for alopecia);\n\n         21. Known human immunodeficiency virus (HIV), hepatitis A, B or C infection except for\n             fully recovered Hepatitis A. Previous medical history of hepatitis B virus (HBV)\n             infection regardless of drug control, HBV DNA ?104 Ã—copy number or ?2000 IU/mL;\n\n         22. Known clinically significant history of liver disease, including hepatitis or\n             cirrhosis; current alcohol abuse.,\n\n         23. Evidence of ongoing or active infection requiring intravenous antibiotics;\n\n         24. Women who are pregnant or lactating;\n\n         25. Central nervous system (CNS) metastatic disease or prior cerebral metastasis;\n\n         26. Inability to take medication orally, dysphagia or an active gastric ulcer resulting\n             from previous surgery (e.g., gastric bypass) or a severe gastrointestinal disease, or\n             any other condition that investigators believe may affect absorption of the\n             investigational product;\n\n         27. Received investigational treatment in another clinical study within 4 weeks prior to\n             the initiation of investigational treatment;\n\n         28. Other disease, metabolic disorder, physical examination anomaly, abnormal laboratory\n             result, or any other condition that investigators suspect may prohibit use of the\n             investigational product, affect interpretation of study results, or put the patient at\n             undue risk of harm.Xx_NEWLINE_xXRadiation treatment must begin >= 3 weeks and =< 8 weeks after surgeryXx_NEWLINE_xXPatients must discontinue antiandrogen therapy (i.e. bicalutamide, flutamide, nilutamide) at least 4-6 weeks prior to registration with no evidence of PSA decline after washout\r\n* Bicalutamide: Washout period at least 6 weeks\r\n* Flutamide and nilutamide: Washout period at least 4 weeksXx_NEWLINE_xXAt least 2 weeks or 5 half-lives, whichever is shorter, must have elapsed since any prior systemic therapy at the time the subject is planned for leukapheresis, except for systemic inhibitory/stimulatory immune checkpoint therapy, which requires 5 half-lives\r\n* Exceptions:\r\n** There is no time restriction with regard to prior intrathecal chemotherapy (including [incl.] steroids) provided there is complete recovery from any acute toxic effects\r\n** Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis\r\n** Subjects who are on standard ALL maintenance type chemotherapy (vincristine, 6-mercaptopurine or oral methotrexate) may be enrolled provided that chemotherapy is discontinued at least 1 week prior to apheresis\r\n** Subjects receiving steroid therapy at physiologic replacement doses (>= 5 mg/day of prednisone or equivalent doses of other corticosteroids) only are allowed provided there has been no increase in dose for at least 2 weeks prior to starting apheresis\r\n** For radiation therapy: Radiation therapy must have been completed at least 3 weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable/evaluable disease outside the radiation portXx_NEWLINE_xXThe following restrictions apply to current or prior anti-cancer treatment, prior to the first dose of study drug:\r\n* Patients who are actively receiving any other investigational agents\r\n* Any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2 weeks prior to the first dose of study drug\r\n* Radio- or toxin-immunoconjugates within 10 weeks prior to the first dose of study drug\r\n* Previous treatment with greater than one of the study agents (i.e., venetoclax, ibrutinib, obinutuzumab or Revlimid), excluding prior prednisone or rituximab treatment\r\n* Prior allogeneic stem cell (or other organ) transplant within 6 months or any evidence of active graft-versus-host disease or requirement for immunosuppressants within 28 days prior to first dose of study drug\r\n* Not recovered (i.e., =< grade 1 or baseline) from adverse events due to previously administered anti-cancer treatment, surgery, or procedure; NOTE: exceptions to this include events not considered to place the subject at unacceptable risk of participation in the opinion of the principal investigator (PI) (e.g., alopecia)Xx_NEWLINE_xXPatients who have had chemotherapy, radiotherapy, immunotherapy or anticancer agents within 4 weeks (6 weeks for nitrosoureas or mitomycin C) of the first dose of study treatment, except hormonal therapy with luteinizing hormone-releasing hormone (LHRH) analogues for medical castration in patients with prostate cancer and breast cancer, which are permittedXx_NEWLINE_xXGeneral history and physical examination within 8 weeks prior to registrationXx_NEWLINE_xXThe subject has received cytotoxic chemotherapy or biologic agents (e.g., cytokines or antibodies) within 14 days, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXPlanning to relocate within the next 4-5 weeksXx_NEWLINE_xXPatients may not be taking any corticosteroid for any reason while on study and all corticosteroids must be stopped two weeks prior to initiation of study drugXx_NEWLINE_xXChemotherapy must not have been received within 2 weeks of entry onto this studyXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to study treatmentXx_NEWLINE_xXPatients must have completed their most recent drug therapy directed at multiple myeloma in the following timeframes:\r\n* Chemotherapy, biological therapy, immunotherapy, or an investigational therapy at least 3 weeks prior to starting cabozantinib\r\n* Corticosteroids at least 3 weeks prior to starting cabozantinib, except for a dose equivalent to dexamethasone of =< 4 mg/day\r\n* Nitrosoureas, nitrogen mustards, mitomycin C, or monoclonal antibodies at least 6 weeks prior to starting cabozantinib\r\n* Autologous stem cell transplantation at least 12 weeks prior to starting cabozantinib\r\n* Allogeneic stem cell transplantation at least 24 weeks prior to starting cabozantinib, and these patients must also not have moderate to severe active acute or chronic graft versus host diseaseXx_NEWLINE_xXPatients who have undergone any recent major surgery must have done so at least 4 weeks prior to starting therapy with cabozantinib, with the following exceptions:\r\n* Vertebroplasty and/or kyphoplasty, which must have been performed at least 1 week prior to starting cabozantinib\r\n* Planned elective surgery unrelated to the patientâ€™s diagnosis of multiple myeloma, such as hernia repair, may be allowed, at the discretion of the principle investigator, as long as it was performed at least 2 weeks prior to starting cabozantinib, and patients have\r\nrecovered fully from this procedureXx_NEWLINE_xXPatients who have required plasmapheresis and exchange less than 2 weeks prior to initiation of therapy with cabozantinibXx_NEWLINE_xXActive and inactive vaccinations within 4 weeks of the first dose of avelumab and while on trial is prohibitedXx_NEWLINE_xXPrior therapy for lymphoma including chemotherapy or immunotherapy including ibrutinib/anti-CD20 agents; patient may have received corticosteroids, but should be off them 2 weeks prior to study entry; known prior significant hypersensitivity to obinutuzumab (not including infusion reactions) or ibrutinibXx_NEWLINE_xXA 4 weeks interval from any investigational agents or cytotoxic chemotherapy to start of study is requiredXx_NEWLINE_xXPatients who have received chemotherapy in the previous 3 weeks (6 weeks for nitrosoureas or mitomycin)Xx_NEWLINE_xXPatients who have had administration of chemotherapy, target therapy, and/or immunotherapy within the last 4 weeks before the first OBP-301 administration.Xx_NEWLINE_xXmAb (including rituximab) within 2 weeks of enrollmentXx_NEWLINE_xXother lymphotoxic chemotherapy (including steroids except as below) within 2 weeks of enrollmentXx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXRadiation therapy within 3 weeks (within 2 weeks, if single fraction of radiotherapy) before day 1.Xx_NEWLINE_xXGrade 3 or 4 hemorrhage within the past 3 weeksXx_NEWLINE_xXPatients who have received any monoclonal antibody therapy within 4 weeks prior to entering the studyXx_NEWLINE_xXAt least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureasXx_NEWLINE_xXPrior systemic chemotherapy or other investigational therapy must have been completed at least two weeks prior to administration of nivolumabXx_NEWLINE_xXPatients who have received monoclonal anti-cancer antibody within 4 weeks of first dose of study drugsXx_NEWLINE_xXAny of the following prior therapies:\r\n* Chemotherapy =< 4 weeks prior to registration\r\n* Targeted biologic therapy =< 4 weeks prior to registration\r\n* Immunotherapy =< 4 weeks prior to registration\r\n* Any viral or gene therapy prior to registration\r\n* External beam radiotherapy =< 4 weeks prior to registration\r\n** NOTE: Vaginal brachytherapy may be performed at any time prior to registrationXx_NEWLINE_xXPrevious anticancer treatment must be discontinued at least 3 weeks prior to the initiation of study treatment (6 weeks for mitomycin C; 6 weeks for anti-androgen therapy if discontinued prior to treatment initiation, except 8 weeks for bicalutamide);Xx_NEWLINE_xXFor patients with refractory disease they must be at least 4 weeks out from most recent therapeutic interventionXx_NEWLINE_xXAt least 4 weeks must have elapsed since any surgeries, with evidence of good wound healingXx_NEWLINE_xXHas had a prior systemic anti-cancer treatment within the last 8 weeksXx_NEWLINE_xX(For cohort B only): Patients must have at least 3 and no more than 5 weeks between anthracycline-based therapy and start of treatment with mirvetuximab soravtansineXx_NEWLINE_xXCRITERIA FOR LEUKAPHERESIS AND PRE-THERAPY EVALUATION: Use of any of the following:\r\n* Cytotoxic or lymphotoxic agents (including prednisone > 5 mg/day or equivalent corticosteroid) within 1 week prior to leukapheresis; physiologic corticosteroid replacement, and topical or inhaled corticosteroids are not excluded\r\n* GVHD therapies within 4 weeks prior to leukapheresis (e.g., calcineurin inhibitors, methotrexate or other chemotherapeutics, mycophenolate, rapamycin, thalidomide, immunosuppressive antibodies such as anti-TNF, anti-IL-6, or anti-IL-6R)\r\n* Experimental agents within 4 weeks prior to leukapheresis unless progression is documented on therapy and at least 3 half-lives have elapsed prior to leukapheresis\r\n* Radiation within 6 weeks prior to leukapheresis unless there is progressive disease in irradiated lesions or there are additional non-irradiated, positron emission tomography (PET)-positive lesions \r\n* Allo-HSCT within 60 days prior to leukapheresis or donor lymphocyte infusion (DLI) within 6 weeks prior to leukapheresis\r\n* Treatment with cladribine within 3 months prior to leukapheresis\r\n* Treatment with alemtuzumab within 3 months prior to leukapheresisXx_NEWLINE_xXPatients previously treated with regorafenib, lonsurf or capecitabine as the last prior regimen can start on this study as long as there is at least 1 week of period between the last dose of previous treatment and day 1 in this study provided the patients are eligible; patients who were on FOLFOX or FOLFIRI regimens must have at least 2 weeks period between the last dose and the first dose in this clinical study; patients previously treated with Avastin, Zaltrap, cetuximab, pembrolizumab, panitumumab, nivolumab Erbitux, and Vectibix must have at least 4 weeks period between the last dose of previous chemotherapy and the first dose in this clinical studyXx_NEWLINE_xX131I therapy not allowed within 24 weeks before entry (4 weeks if negative post-treatment scan)Xx_NEWLINE_xX131I therapy within 24 weeks before entry (4 weeks if negative post-treatment scan)Xx_NEWLINE_xXMust have an anticipated survival of at least 12 weeks.Xx_NEWLINE_xXMust be recovered from any reversible side effects of prior therapy (e.g. no major surgery, no antineoplastic or experimental therapy, or no significant radiation therapy to hematopoietic sites within 4 weeks of Baseline/C1D1, and no nitrosoureas or nitrogen mustards within 6 weeks of Baseline/C1D1)Xx_NEWLINE_xXHistory of use of another IP within the last 4 weeks prior to enrollment.Xx_NEWLINE_xXMonoclonal antibodies therapy within 2 weeks before study entryXx_NEWLINE_xXParticipants receiving any other investigational agents within 2 weeks of the start of this trial and throughout the duration of this trial; participants receiving anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) within 3 weeks prior to first dose of dabrafenib or trametinib; participants receiving proteasome inhibitors or immunomodulatory drugs (â€“imid), or chemotherapy without delayed toxicity within 2 weeks prior to first dose of dabrafenib or trametinib; treatment by localized radiotherapy is not an exclusion criterion if an interval of at least two weeks between the end of radiotherapy and initiation of protocol therapy is observedXx_NEWLINE_xXHematocrit >= 28% obtained < 4 weeks prior to starting treatmentXx_NEWLINE_xXTreatment must begin at a minimum of 4 weeks after, but no later than 14 weeks after, the date of the completion of radiotherapyXx_NEWLINE_xXDiscontinued all previous treatments for cancer ?4 weeks prior.Xx_NEWLINE_xXProhibited treatments and or therapies\r\n* Autologous stem cell transplant (ASCT) =< 12 weeks prior to first dose of the study drug\r\n* Prior treatments (window prior to registration): \r\n** Chemotherapy =< 2 weeks\r\n** Nitrosureas =< 6 weeks\r\n** Therapeutic anticancer antibodies =< 4 weeks\r\n** Radio- or toxin immunoconjugates =< 10 weeks\r\n** Radiation therapy =< 3 weeks\r\n** Or major surgery =< 2 weeks\r\n* Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways\r\n* Prior allogeneic stem cell transplant (SCT)\r\n* Chest radiation =< 24 weeks prior to registrationXx_NEWLINE_xXPatients may not be receiving or have received Zometa during/or within 3 weeks prior to treatment with ZometaXx_NEWLINE_xXPrior surgery that required general anesthesia must be completed at least 4 weeks before study drug administration; surgery requiring local/epidural anesthesia must be completed at least 72 hours before study drug administrationXx_NEWLINE_xXPatients on systemic steroids (except if solely for adrenal replacement) within two weeks of collectionXx_NEWLINE_xXCancer chemotherapy within 2 weeks prior to start of daratumumab treatment (exception hydroxyurea). Use of hydroxyurea to control proliferative disease will be allowed prior to starting therapy on study and for 7 days during cycle 1-3 (maximum daily dose of 7 gm)Xx_NEWLINE_xXThere is no need for steroids and patients have not had steroids at least 2 weeksXx_NEWLINE_xXConcurrent or recent chemotherapy (within 3 weeks), XRT within 3 weeks, may have had immunotherapy in the past (off within 3 weeks), or general anesthesia/major surgery (within 3 weeks). Patients must have recovered from all known or expected toxicities from previous treatment and passed a treatment-free \washout\ period of 3 weeks before starting this program (8 weeks for persons receiving nitrosourea or mitomycin).Xx_NEWLINE_xXBrain metastases or spinal cord compression, unless treatment was completed at least 4 weeks before study entry, and stable without steroid treatment for at least 4 weeksXx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXUse of any prohibited concomitant medications within the prior 2 weeksXx_NEWLINE_xXChemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 4 weeks prior to first administration of study treatmentXx_NEWLINE_xXInvestigational drug within 4 weeks of proposed step 1 start dateXx_NEWLINE_xXPrior somatostatin analogue therapy; (patients should receive the first dose of study drug no sooner than 4 weeks from the last dose of somatostatin analogue)Xx_NEWLINE_xXReceived rituximab within 4 weeks of study start.Xx_NEWLINE_xXAlemtuzumab treatment within 8 weeks of HSCT admissionXx_NEWLINE_xXSubject has started treatment with denosumab < 1 month prior to study entry; subjects are allowed to be on bisphosphonates or denosumab provided they are on a stable dose for >= 4 weeks before administration of study drugXx_NEWLINE_xXUse of non-oncology vaccines containing live virus for prevention of infectious diseases within 12 weeks prior to study drugXx_NEWLINE_xXNote: Treatment with bicalutamide and nilutamide within 6 weeks prior to enrollment is not allowed; treatment with flutamide within 4 weeks prior to enrollment is not allowed; treatment with all other gonadotrophin-releasing hormone (GnRH) analogues or antagonists is allowed\r\n* Chemotherapy\r\n* Biologic therapy\r\n* Investigational therapy\r\n* ImmunotherapyXx_NEWLINE_xXNo use of herbal products that may decrease PSA levels within 4 weeks prior to enrollmentXx_NEWLINE_xXPatients must not be receiving concurrent anti-tumor treatment and must have recovered from toxicity of prior treatment. Minimum interval required: 1) > 6 weeks following nitrosourea chemotherapy; 2) > 4 weeks after recovering from any non-nitrosourea drug or systemic investigational agent; 3) > 2 weeks after receiving any non-cytotoxic anti-tumor drug; 4) > 4 weeks after receiving radiation therapy (> 12 weeks following upfront concurrent chemoradiation); 5) > 2 weeks following Optune device use.Xx_NEWLINE_xXFor MM patients only:\r\n* Prior radiotherapy within 2 weeks prior to the administration of study drug\r\n* Surgery within 4 weeks\r\n* Chemotherapy (Chemo) within 3 weeks (6 weeks for melphalan, or monoclonal antibodies)Xx_NEWLINE_xXAt least 4 weeks since any previous treatment for cancerXx_NEWLINE_xXInclusion Criteria:\n\n        Patients with NSCLC:\n\n          1. Has histologically- or pathologically-confirmed recurrent/metastatic NSCLC.\n\n          2. If has adenocarcinoma, required to have previously been tested for anaplastic lymphoma\n             kinase (ALK) rearrangements and epidermal growth factor receptor (EGFR) mutations,\n             with results available for collection in this study, and, if positive, has been\n             treated with prior EGFR or ALK therapy.\n\n          3. Received at least 1 chemotherapeutic regimen in the advanced/metastatic setting and\n             experienced documented, unequivocal progressive disease by either RECIST 1.1 or\n             clinical assessment.\n\n          4. Patients with NSCLC enrolled in Cohort 1 of the Expansion Phase should not have been\n             previously treated with a PD-1/PD-L1-blocking antibody\n\n             Patients in Expansion Phase, Cohorts 2 and 3\n\n          5. Previously treated with a PD-1/PD-L1-blocking antibody and experienced experienced\n             documented, unequivocal radiographic progression of disease by irRECIST, or similar\n             criteria during or within 12 weeks after last dose of such treatment. Patients must\n             have received at least 6 weeks of PD-1/PD-L1 therapy for Cohort 3.\n\n             Patients with Melanoma:\n\n          6. In addition to having been previously treated with a PD-1/PD-L1-blocking antibody\n             (inclusion #5), has a histologically- or cytologically-confirmed diagnosis of\n             unresectable or metastatic melanoma and experienced unequivocal progressive disease\n             during treatment with a BRAF inhibitor if BRAF V600 mutation-positive. Treatment with\n             BRAF inhibitor may occur AFTER treatment with the checkpoint inhibitor.\n\n             Patients in Expansion Phase, Cohort 4 (Colorectal Cancer)\n\n          7. Received at least 1 chemotherapeutic regimen in the advanced/metastatic setting and\n             experienced documented, unequivocal progressive disease by either RECIST 1.1 or\n             clinical assessment. Must have documented mismatch repair-proficient colon cancer as\n             determined by either immunohistochemistry for mismatch repair proteins or PCR-based\n             functional microsatellite instability. Patients with colorectal cancer enrolled in\n             Cohort 4 should not have been previously treated with a PD-1/PD-L1-blocking antibody\n             (i.e., pembrolizumab, nivolumab, MEDI36MEDI4376, or GNE PDL1 [MPDL3280A])\n\n             All Patients\n\n          8. Aged 18 years or older on the day written informed consent is given.\n\n          9. If has brain metastases, must have stable neurologic status following local therapy\n             for at least 4 weeks without the use of steroids or on stable or decreasing dose of\n             ?10 mg daily prednisone (or equivalent), and must be without neurologic dysfunction\n             that would confound the evaluation of neurologic and other AEs.\n\n         10. Evidence of locally recurrent or metastatic disease based on imaging studies within 28\n             days before the first study drug dose:\n\n               -  At least 1 measurable lesion ?20 mm by conventional techniques or ?10 mm by\n                  spiral CT scan or MRI, with the last imaging performed within 28 days before the\n                  first study drug dose. If there is only 1 measurable lesion and it is located in\n                  previously irradiated field, it must have demonstrated unequivocal progression\n                  according to RECIST, version 1.1.\n\n         11. If receiving radiation therapy, has a 2-week washout period following completion of\n             the treatment prior to receiving the first study drug dose and continues to have at\n             least 1 measureable lesion, per above criterion.\n\n         12. ECOG performance status of 0 or 1.\n\n         13. Has acceptable, applicable laboratory parameters.\n\n         14. Female subjects must not be pregnant.\n\n         15. If male, agrees to use an adequate method of contraception\n\n        15. Experienced resolution of toxic effect(s) of the most recent prior chemotherapy to\n        Grade 1 or less (except alopecia). If patient underwent major surgery or radiation therapy\n        of >30 Gy, they must have recovered from the toxicity and/or complications from the\n        intervention.\n\n        17. Willing to have fresh tumor samples collected during screening and at other time points\n        designated as mandatory, per the Schedule of Study Assessments.\n\n        18. Able to understand and give written informed consent and comply with study procedures.\n\n        Exclusion Criteria:\n\n        Patients meeting any of the following criteria are not eligible for study participation:\n\n          1. Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form\n             of immunosuppressive therapy within 7 days prior to the first dose of study drug. The\n             use of physiologic doses of corticosteroids may be approved after consultation with\n             the Sponsor.\n\n          2. Active autoimmune disease that has required systemic treatment in past 2 years (i.e.,\n             with disease modifying agents, corticosteroids, or immunosuppressive drugs).\n             Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid\n             replacement therapy for adrenal or pituitary insufficiency) is not considered a form\n             of systemic treatment.\n\n          3. History of interstitial lung disease (ILD).\n\n          4. Allergy to benzamide or inactive components of entinostat.\n\n          5. History of allergies to any active or inactive ingredients of pembrolizumab or severe\n             hypersensitivity (>= Grade 3) to pembroluzumab.\n\n          6. History or current evidence of any condition, therapy, or laboratory abnormality that\n             might confound the results of the study, interfere with the patient's participation\n             for the full duration of the study, or is not in the best interest of the patient to\n             participate, in the opinion of the treating Investigator, including, but not limited\n             to:\n\n               -  Myocardial infarction or arterial thromboembolic events within 6 months prior to\n                  baseline or severe or unstable angina, New York Heart Association (NYHA) Class\n                  III or IV disease, or a QTc interval > 470 msec.\n\n               -  Uncontrolled heart failure or hypertension, uncontrolled diabetes mellitus, or\n                  uncontrolled systemic infection.\n\n               -  Another known additional malignancy that is progressing or requires active\n                  treatment (excluding adequately treated basal cell carcinoma, squamous cell of\n                  the skin, cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or\n                  melanoma in situ, or ductal carinoma in situ of the breast). Prior history of\n                  other cancer is allowed, as long as there is no active disease within the prior 5\n                  years.\n\n               -  Has a history of (non-infectious) pneumonitis that required steroids or current\n                  pneumonitis.\n\n               -  Active infection requiring systemic therapy.\n\n               -  Known active central nervous system (CNS) metastases and/or carcinomatous\n                  meningitis.\n\n             Note: Patients with previously treated brain metastases may participate provided they\n             are stable (without evidence of progression by imaging [using the identical imaging\n             modality for each assessment, either MRI or CT scan] for at least 4 weeks prior to the\n             first dose of study drug and any neurologic symptoms have returned to baseline), have\n             no evidence of new or enlarging brain metastases, and are not using steroids for at\n             least 2 weeks prior to the first dose of study drug or are on stable or decreasing\n             dose of ?10 mg daily prednisone (or equivalent). This exception does not include\n             carcinomatous meningitis which is excluded regardless of clinical stability.\n\n          7. Known psychiatric or substance abuse disorders that would interfere with cooperation\n             with the requirements of the study.\n\n          8. Currently participating and receiving study therapy or has participated in a study of\n             an investigational agent and received study therapy or used an investigational device\n             within 4 weeks of the first dose of treatment.\n\n          9. Received a live virus vaccination within 30 days of the first dose of treatment.\n\n         10. Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to baseline or who\n             has not recovered (i.e., ?Grade 1 or at baseline) from AEs due to agents administered\n             more than 4 weeks earlier.\n\n         11. Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2\n             weeks prior to study baseline or who has not recovered (i.e., ?Grade 1 or at baseline)\n             from AEs due to a previously administered agent.\n\n             Note: Patients with ?Grade 2 neuropathy or ?Grade 2 alopecia are an exception to this\n             criterion and may qualify for the study.\n\n             Note: If patient underwent major surgery, they must have recovered adequately from the\n             toxicity and/or complications from the intervention prior to starting therapy.\n\n         12. Received transfusion of blood products (including platelets or red blood cells) or\n             administration of colony stimulating factors (including granulocyte-colony stimulating\n             factor [G-CSF], granulocyte macrophage-colony stimulating factor [GM-CSF], or\n             recombinant erythropoietin) within 4 weeks prior to the first dose of study drug.\n\n         13. Currently receiving treatment with any other agent listed on the prohibited medication\n             list such as valproic acid, or other systemic cancer agents within 14 days of the\n             first dose of treatment.\n\n         14. If female, is pregnant, breastfeeding, or expecting to conceive, or if male, expect to\n             father children within the projected duration of the study, starting with the\n             screening visit through 120 days after the last dose of study drug.\n\n         15. Known history of human immunodeficiency virus (HIV) (HIV 1/2 antibodies).\n\n         16. Known active hepatitis B (e.g., hepatitis B surface antigen-reactive) or hepatitis C\n             (e.g., hepatitis C virus ribonucleic acid [qualitative]).\n\n         17. For CRC expansion cohort, no prior history of malignant bowel obstruction requiring\n             hospitalization in the 6 months prior to enrollment\n\n         18. For the CRC expansion cohort, no history of uncontrolled ascites, defined as\n             symptomatic ascites and/or repeated paracenteses for symptom control in the past 3\n             monthsXx_NEWLINE_xXMyelosuppressive chemotherapy: must not have received within 4 weeks of entry onto this studyXx_NEWLINE_xXMajor surgeries (eg, abdominal laparotomy) within 4 weeks of the first dose of study drug. Following major surgeries, >4 weeks prior to the first dose of study drug, all surgical wounds must be healed and free of infection or dehiscence.Xx_NEWLINE_xXSigns and symptoms of infection within 2 weeks of first study treatment; receipt of therapeutic oral or IV antibiotics within 2 weeks of first study treatment; subjects receiving routine antibiotic prophylaxis (for dental extractions/procedures) are eligibleXx_NEWLINE_xXClinical laboratory values as specified below within 4 weeks before the first dose of study drug:Xx_NEWLINE_xXSubjects who had a thromboembolic event ? 4 weeks of C1D1 must be receiving adequate anticoagulation treatment for at least 2 weeks before C1D1 and must continue as clinically indicated post first doseXx_NEWLINE_xXAny of the following prior therapies:\r\n* Chemotherapy (IMIDs, alkylating agents, proteosome inhibitors) =< 2 weeks prior to registration\r\n* Immunotherapy (monoclonal antibodies) =< 4 weeks prior to registration\r\n* Experimental agent in case of AML or TCL within 4 half-lives of the last dose of the agentXx_NEWLINE_xXLYMPHODEPLETION: Treatment with any investigational drug within 14 days (ie, two weeks) prior to lymphodepletion or has received any tumor vaccines within the previous five weeks prior to lymphodepletionXx_NEWLINE_xXPrior therapeutic intervention with any of the following:\r\n* Therapeutic anticancer antibodies within 4 weeks (rituximab), except within 6 months for obinutuzumab or a similar investigational type II monoclonal antibody;\r\n* Radio- or toxin-immunoconjugates within 10 weeks;\r\n* Inhibitors of BTK (ibrutinib), PI-3K (idelalisib), BH3-mimetic venetoclax, lenalidomide and other â€œtargetedâ€ therapy (including but not limited to investigational BTK and PI-3K inhibitors, etc.) â€“ within 6 half-lives (i.e., 36 hours for ibrutinib)\r\n* All other chemotherapy, radiation therapy within 3 weeks prior to initiation of therapy\r\n* SYK inhibitors at any timeXx_NEWLINE_xXStable dose of corticosteroids for 2 weeks prior to enrollment, i.e. the patientâ€™s steroid dose (mg/kg) will remain unchanged (e.g. 0.5 mg/kg) in the 2 weeks preceding enrollment; allowances will be made for up or down titrating the dose based on changes in body weightXx_NEWLINE_xXExposure to any new immunosuppressive medication in the 4 weeks prior to enrollmentXx_NEWLINE_xXReceipt of the last dose of chemotherapy or tyrosine kinase inhibitors should be at least 3 weeks prior to durvalumab and tremelimumab dosing; monoclonal antibodies such as bevacizumab, ziv-aflibercept, ramucirumab, cetuximab, and panitumumab should be at least 6 weeks prior to durvalumab and tremelimumab therapyXx_NEWLINE_xXPatients may not have received chemotherapy or bevacizumab =< 4 weeks (except for nitrosourea [6 weeks] or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide [1 week]) prior to starting the study drug unless patients have recovered from side effects of such therapyXx_NEWLINE_xXPatients on greater than 4 mg per day of dexamethasone within the 2 weeks prior to admission for PVSRIPO infusionXx_NEWLINE_xXHas a spinal cord compression unless asymptomatic, radiographically stable over the last 4 weeks, and not requiring steroids for at least 4 weeks before the start of study treatmentXx_NEWLINE_xXDefinitive cancer surgery is expected to be performed < 10 days or more than 12 weeks post study enrollment as determined by the enrolling physicianXx_NEWLINE_xXSubjects with controlled brain metastasis (no radiographic progression at least 4 weeks following radiation and/or surgical treatment, off steroids for at least 4 weeks, and have no new or progressing neurological signs or symptoms) will be allowedXx_NEWLINE_xXSubjects must not have had any prior investigational agents or devices within 4 weeks of beginning study drugXx_NEWLINE_xXSubjects must not have received a donor lymphocyte infusion (DLI) within 8 weeks prior to the first dose of study medicationXx_NEWLINE_xXHormonal treatment within 2 weeks prior to start of study treatment (continued use of anti-androgens and/or gonadorelin analogues for treatment of prostate cancer permitted); radiotherapy within 4 weeks prior to enrolment; palliative radiation to target organs may be allowed up to 2 weeks prior to enrolment, as long as there are other target lesions that can be monitored for response to study treatmentXx_NEWLINE_xXWithin 4 weeks since any plasmapheresisXx_NEWLINE_xXA minimum of 2 weeks off of enzalutamide or abiraterone, if applicable, prior to registrationXx_NEWLINE_xXSubjects who have had treatments with anti-cancer agents including rituximab or obinutuzumab and/or other monoclonal antibody or radioimmunotherapy within 6 weeks before the starting IP treatment.Xx_NEWLINE_xXWilling to undergo core biopsies for research at study entry and at ~4 weeksXx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXMust have completed any systemic therapy at least one week prior to planned start of SBRT (two weeks preferred), and must have no plans to initiate systemic therapy for at least one week following end of SBRT (two weeks preferred)Xx_NEWLINE_xXSubjects who have received therapy for HCV =< 4 weeks from the start of pembrolizumab; Note: those with untreated HCV and those who completed HCV therapy >= 4 weeks of study treatment start are eligibleXx_NEWLINE_xXNo major surgeries within 3 weeks of starting chemotherapyXx_NEWLINE_xXMust be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, and 8 weeks since any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatmentXx_NEWLINE_xXThe following minimum intervals are required between prior treatment and initiation of study therapy:\r\n* Cytotoxic chemotherapy: 3 weeks\r\n* Molecularly targeted therapy or immunotherapy: 2 weeks\r\n* Conventional fractionated radiation therapy: 2 weeks\r\n* Stereotactic radiation therapy: 1 week\r\n* Major surgery: 3 weeksXx_NEWLINE_xXPulmonary hemorrhage or hemoptysis > 2.5 mL blood within 6 weeks (or within 2 weeks if source definitively treated [eg, radiation therapy or bronchoscopic procedure])Xx_NEWLINE_xXWashout of 2 weeks is required for aromatase inhibitors; washout of 4 weeks is required for CDK 4/6 inhibitor, everolimus or other biological agentXx_NEWLINE_xXPatients must have the following lab values obtained < 4 weeks prior to starting treatment:Xx_NEWLINE_xXInclusion Criteria:\n\n        Main inclusion criteria all patients, Part 1 and Part 2:\n\n          -  Male or female, at least 18 years of age at the time of informed consent\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1\n\n          -  Life expectancy >3 months assessed during Screening\n\n          -  Documented (histologically- or cytologically-proven) epithelial malignancy that is\n             locally advanced or metastatic, having received all therapy known to confer clinical\n             benefit\n\n        Additional inclusion criteria applicable to Part 2 ONLY:\n\n          -  Epithelial malignancy (tumor types to be determined), measurable according to RECIST\n             v1.1 that has been confirmed by computed tomography (CT) or magnetic resonance imaging\n             (MRI) within 4 weeks prior to C1/D1\n\n          -  Willingness to undergo a pre-and post-dosing biopsy (total of 2 biopsies) from primary\n             or metastatic tumor site(s) considered safe for biopsy\n\n        Exclusion Criteria:\n\n          -  Any antineoplastic agent for the primary malignancy (standard or investigational)\n             without delayed toxicity within 4 weeks or 5 plasma half-lives (whichever is shortest)\n             prior to C1/D1, except nitrosoureas and mitomycin C within 6 weeks prior to C1/D1.\n\n          -  Part 2 ONLY: Radiotherapy against target lesions within 4 weeks prior to C1/D1, unless\n             there is documented progression of the lesion following radiotherapy\n\n          -  Immunosuppressive or systemic hormonal therapy (>10 mg daily prednisone equivalent)\n             within 2 weeks prior to C1/D1 with exceptions\n\n          -  Use of hematopoietic growth factors within 2 weeks prior to C1/D1\n\n          -  Active second malignancy or history of another malignancy within the last 3 years,\n             with allowed exceptions\n\n          -  Central nervous system (CNS) malignancies including:\n\n               1. Primary malignancies of the CNS\n\n               2. Known, untreated CNS or leptomeningeal metastases, or spinal cord compression;\n                  patients with any of these not controlled by prior surgery or radiotherapy, or\n                  symptoms suggesting CNS metastatic involvement for which treatment is required\n\n          -  Inadequate recovery from an acute toxicity associated with any prior antineoplastic\n             therapy\n\n          -  Major surgical procedure within 4 weeks prior to C1/D1 or inadequate recovery from any\n             prior surgical procedure\n\n          -  Non-healing wounds on any part of the body\n\n          -  Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within\n             4 weeks prior to C1/D1, unless adequately treated and stable\n\n          -  Active uncontrolled bleeding or a known bleeding diathesis\n\n          -  Significant gastrointestinal abnormalities\n\n          -  Significant cardiovascular disease or condition\n\n          -  Abnormal hematologic, renal or hepatic functionXx_NEWLINE_xXWomen of child-bearing potential must agree to use 2 reliable methods of contraception beginning 4 weeks prior to the initiation of treatment, during therapy, and for at least 4 weeks after the last drug administration.Xx_NEWLINE_xXCytotoxic chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 4 weeks prior to first administration of study treatment and/or other renal cell carcinoma (RCC)-directed systemic therapy =< 2 weeks prior to first administration of study treatmentXx_NEWLINE_xXHave adequately recovered from second look surgery to be able to start bevacizumab within 7 weeks of this procedureXx_NEWLINE_xXCompletion of at least 3 months, but no more than 12 months of standard induction chemotherapy for LAPC, which may include FOLFIRINOX or gemcitabine and nab-paclitaxel, preferably within 2-4 weeks but no longer than 8 weeksXx_NEWLINE_xXChemotherapy or immunotherapy within 3 weeks prior to the first dose of vaccineXx_NEWLINE_xXPatients receiving any other investigational agents or whom have received recent treatment for colorectal cancer (radiation within the previous two weeks, chemotherapy or investigational therapy within the previous four weeks)Xx_NEWLINE_xXMore than four weeks must have elapsed since any prior systemic therapy at the time the patient receives the E7 TCR cells\r\n* Note: Patients may have undergone minor surgical procedures within the past three weeks, as long as all toxicities have recovered to grade 1 or lessXx_NEWLINE_xXRadiotherapy for extended field within prior 4 weeks or limited field within prior 2 weeks;Xx_NEWLINE_xXPlatelets ? 100 K/mm^3 (transfusion to achieve this level is not permitted within 2 weeks of first study drug administration)Xx_NEWLINE_xXAt least 4 weeks must have elapsed since any surgeries, with evidence of completed wound healingXx_NEWLINE_xXDiscontinuation of bicalutamide or nilutamide less than 6 weeks, and other antiandrogens less than 4 weeks, abiraterone less than 3 weeks, prior to the start of study medication.Xx_NEWLINE_xXPrior chemotherapy, radiation, sipuleucel-T or other experimental immunotherapy less than 4 weeks prior to the start of study medication.Xx_NEWLINE_xXTreatment with trastuzumab, bevacizumab or other targeted therapies within the past 4 weeksXx_NEWLINE_xXThe last dose of previous therapy must have occurred at least 3 weeks prior to the start of study therapy; palliative radiotherapy is allowed up to 2 weeks before the first LMB-100 infusionXx_NEWLINE_xXAdministration of any of the following within the specified timeframe prior to the first dose of study drug:\r\n* 4 weeks from TMZ\r\n* 6 weeks from a nitrosoureas\r\n* 3 weeks from a biologic or targeted agent (i.e. small molecule)\r\n* 4 weeks for a VEGF inhibitor (i.e. bevacizumab)Xx_NEWLINE_xXThe patient has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) within 3 weeks or biologic agents (e.g., cytokines or antibodies) within 4 weeks prior to study enrollmentXx_NEWLINE_xXUROTHELIAL CARCINOMA EXPANSION COHORT: Bisphosphonates and denosumab are permitted if on a stable dose for >= 4 weeksXx_NEWLINE_xXmCRPC EXPANSION COHORT: The patient has received chemotherapy, radiotherapy, biologic agents or enzalutamide within 3 weeks before the first dose of study treatment (nitrosoureas or mitomycin within 6 weeks); however, for patients receiving abiraterone, they must discontinue the medication at least 14 days before the first dose of study treatmentXx_NEWLINE_xXTime interval from last systemic chemotherapy (not including low dose dexamethasone) more than 2 weeks prior to initiation of ABC294640; patients receiving high dose dexamethasone defined as 40 mg dexamethasone a day for 4 days will need 2 weeks washout prior to initiation of ABC294640Xx_NEWLINE_xXPatients must be entered within 12 weeks of diagnosisXx_NEWLINE_xXPrior therapy\r\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: Patients must not have received myelosuppressive chemotherapy within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea)\r\n* Hematopoietic growth factors: At least 14 days must have elapsed after receiving pegfilgrastim and least 7 days must have elapsed since the completion of therapy with a non-pegylated growth factor\r\n* Biologic (anti-neoplastic agent): At least 7 days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibodies: At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy: >= 2 weeks must have elapsed since local palliative external beam radiation therapy (XRT) (small port); >= 6 weeks must have elapsed since treatment with therapeutic doses of metaiodobenzylguanidine (MIBG); >= 3 months must have elapsed if prior craniospinal XRT was received, if >= 50% of the pelvis was irradiated, or if traumatic brain injury (TBI) was received; >= 6 weeks must have elapsed if other substantial bone marrow irradiation was given\r\n* Stem cell transplant or rescue without TBI: No evidence of active graft versus (vs.) host disease and >= 2 months must have elapsed since transplantXx_NEWLINE_xXPatients who have received either immunotherapy within =< 8 weeks; chemotherapy within =< 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapiesXx_NEWLINE_xXThe subject must have no measurable disease at the time of investigational product administration\r\n* The subject must complete all prior surgery requiring general anesthesia at least four (4) weeks before administration of the investigational product; the subject must complete all surgery requiring local/epidural anesthesia at least seventy-two (72) hours prior to administration of the investigational product\r\n* The subject must complete all prior systemic chemotherapy therapy, and all adverse events have either returned to baseline or have stabilized at least four (4) weeks prior to administration of the investigational product\r\n* The subject must complete all prior systemic radiation therapy at least four (4) weeks prior to administration of the investigational product; the subject must complete all prior focal radiation therapy at least two (2) weeks prior to the administration of the investigational agent; the subject must not have received a radiopharmaceutical within eight (8) weeks prior to the administration of the investigational product\r\n* The subject may continue hormonal therapy (i.e. tamoxifen, anastrozole) during the studyXx_NEWLINE_xXPatients who have received experimental agents within 4 weeks of study entryXx_NEWLINE_xXTreatment with any of the following anti-cancer therapies prior to the first dose of BGJ398 within the stated timeframes\r\n* Cyclical chemotherapy (intravenous) within a period of 2 weeks unless there are ongoing side effects > grade 2\r\n* Biological therapy (including small molecules, and/or) within a period of time that is =< 2 weeks prior to starting study drug unless there are ongoing side effects > grade 2\r\n* Any other investigational agents within a period =< 2 weeks prior to starting study drug unless there are ongoing side effects > grade 2\r\n* Wide field radiotherapy (including radioisotopes) =< 2 weeks prior to starting study drug unless there are ongoing side effects > grade 2Xx_NEWLINE_xXINCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients must be off chemotherapy for a minimum of 3 weeks prior to start of treatment; targeted therapies must be stopped at least 3 days prior to start of lymphodepletionXx_NEWLINE_xXTreatment with high dose immune inhibitors including lymphotoxic monoclonal antibodies such as campath, or rapamycin and its analogs or cytotoxic agents less than 2 weeks prior to enrollment.Xx_NEWLINE_xXAny of the following prior therapies:\r\n* Chemotherapy =< 3 weeks prior to registration\r\n* Immunotherapy =< 4 weeks prior to registration\r\n* Biologic therapy =< 4 weeks prior to registration\r\n* Radiation therapy =< 3 weeks prior to registrationXx_NEWLINE_xXPRIOR TO LYMPHODEPLETION: Received any investigational agents or received any tumor vaccines within the previous six weeks prior to cell infusionXx_NEWLINE_xXPRIOR TO LYMPHODEPLETION: Received anti-CD30 antibody-based therapy within the previous 4 weeks prior to cell infusionXx_NEWLINE_xXPRIOR TO INFUSION OF ATLCAR.CD30 CELLS: Received any investigational agents or received any tumor vaccines within the previous six weeks prior to cell infusionXx_NEWLINE_xXPatients who have received any systemic corticosteroid therapy within 4 weeks prior to the start of therapy, or 12 weeks if given to treat graft versus host disease (GVHD), with the exception of physiological replacement doses of cortisone acetate or equivalentXx_NEWLINE_xXPatients must not have received myelosuppressive chemotherapy within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea)Xx_NEWLINE_xXAt least 2 weeks must have elapsed since local palliative radiation therapy (XRT) (small port); at least 6 weeks must have elapsed since treatment with therapeutic doses of metaiodobenzylguanidine (MIBG); at least 3 months must have elapsed if prior craniospinal XRT was received, if more than 50% of the pelvis was irradiated, or if total body irradiation (TBI) was received; at least 6 weeks must have elapsed if other substantial bone marrow irradiation was givenXx_NEWLINE_xXHad alemtuzumab therapy within 12-weeks prior to screening.Xx_NEWLINE_xXPatient who has had systemic therapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study entryXx_NEWLINE_xXPrior anti-lymphoma therapy (chemotherapy, immunotherapy or other investigational agent) within 4 weeks prior to start of study treatment (corticosteroid treatment at doses of ?20 mg/day, G-CSF or GM CSF are permitted up to 2 weeks prior to start of study treatment.). Note: excluding pre-treatment with rituximab as part of this studyXx_NEWLINE_xXknown uncontrolled arrhythmias (except sinus arrhythmia) in the past 24 weeks.Xx_NEWLINE_xXTreatment with plasmapheresis within 4 weeks prior to event 1Xx_NEWLINE_xXPatients who have received chemotherapy and/or radiation therapy within 2 weeks unless there is evidence of rapidly progressive disease; in the event that subjects have received chemotherapy < 2 weeks from the date of enrollment, they may be included provided they have recovered from the associated non-hematological toxicities to less than or equal to grade 1; hydroxyurea is allowed up to 24 hours prior to starting therapy in the setting of rapidly proliferating diseaseXx_NEWLINE_xXNo restriction based on prior treatments but at least 4 weeks from prior immunotherapy, or prior investigational agentsXx_NEWLINE_xXSubject has received any of the following:\r\n* Chemotherapy, biological therapy, or surgery within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks prior to on-study date\r\n* Radiation therapy, within 10 weeks prior to entering the study or those who have not recovered from adverse events due to radiation administered more than 10 weeks prior to on-study date\r\n* Prior therapy with bevacizumab\r\n* Prior therapy with an anti-programed cell death 1 (PD-1), anti-programed cell death 1-ligand (PD-L)1, anti-PD-L2, anti-cluster of differentiation (CD)137, or anti-cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody\r\n* Prior treatment with an HDAC inhibitor, with the exception of prior or current treatment with valproate\r\n* Any investigational agents or have had any investigational agent within the 30 days prior to on-study date\r\n* A live vaccine within 30 days prior to on-study date\r\n* Previous treatment with carmustine wafer except when administered as first line treatment and at least 6 months prior to on-study dateXx_NEWLINE_xXHas received systemic therapy within 4 weeks of the first dose of pembrolizumabXx_NEWLINE_xXSubjects with clinically apparent arrhythmia or arrhythmias who are not stable on medical management within two weeks of enrollmentXx_NEWLINE_xXA minimum of 3 weeks must have elapsed from last intake of prior standard chemotherapy treatment.Xx_NEWLINE_xXA minimum of 6 weeks must have elapsed from the last dose of nitrosoureas.Xx_NEWLINE_xXMore than 12 weeks from completion of chemoradiation, unless RANO criteria for early progression within 12 weeks of chemoradiation are met (See 18.1)Xx_NEWLINE_xXContraindication to antiangiogenic agents, including:\r\n* Serious non-healing wound, non-healing ulcer, or bone fracture\r\n* Major surgical procedure or significant traumatic injury within 4 weeks prior to initiating study treatment\r\n* Pulmonary hemorrhage/bleeding event >= grade 2 (Common Terminology Criteria for Adverse Events [CTCAE] v4.0) within 12 weeks prior to initiating study treatment\r\n* Any other hemorrhage/bleeding event >= grade 3 (CTCAE v4.0) within 12 weeks prior to initiating study treatmentXx_NEWLINE_xXSubjects with clinically apparent arrhythmia, or arrhythmias that are not stable on medical management within 2 weeks of the screening/enrollment visitXx_NEWLINE_xXPrior locoregional therapy is allowed if completed at least 2 weeks prior to enrollmentXx_NEWLINE_xXPrior chemotherapy is allowed if stopped/completed at least 2 weeks prior to enrollmentXx_NEWLINE_xXExperimental therapy within 4 weeks prior to first dose of study drug treatment on Study Day 1 of Period AXx_NEWLINE_xXPrior treated brain or meningeal metastases must be without MRI evidence of progression for at least 8 weeks and off systemic steroids for at least 2 weeks prior to screening/baseline.Xx_NEWLINE_xXUse of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within 4 weeks of initiation of study treatment.Xx_NEWLINE_xXPrevious therapy with antiandrogens within 4 weeksXx_NEWLINE_xXSubjects with clinically apparent arrhythmia or arrhythmias who are not stable on medical management within two weeks of enrollmentXx_NEWLINE_xXReceipt of a prior investigational study agent within 4 weeks prior to enrollment; *Note- patients who have received anti-CD19 CART cells (e.g. CART19/cytotoxic T lymphocyte [CTL] 019) on an investigational study where cell infusion occurred greater than 4 weeks before the screening visit are NOT excludedXx_NEWLINE_xXCAPMATINIB EXCLUSION CRITERIA: Known symptomatic brain metastases requiring increasing doses of steroid to manage CNS symptoms within 2 weeks prior to study entry\r\n* Patients with asymptomatic brain metastases may be enrolled at the discretion of the sponsor as long as the patient is stable and has not required increasing dose of steroids to manage CNS symptoms for at least 2 weeks prior to study enrollment\r\n* Patients requiring seizure prophylaxis must be taking non-enzyme-inducing anti-epileptic drugs (non-EIAED); if patients were previously on EIAEDs and these have been discontinued, they must be discontinued for at least 1 weeks prior to capmatinib administration; if patients require an antiepileptic medication, then a CYP3A4 non-EIAED can be used such as levetiracetam, valproic acid, gabapentin, topiramate or lacosamideXx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Prior treatment with the following anti-neoplastic therapies within the following time frame:\r\n* Any prior treatment with regorafenib\r\n* Radiotherapy within 2 weeks prior to enrollment\r\n* Receipt of any cytotoxic chemotherapy, biologic agent, or investigational agent within 4 weeks prior to the first dose of study drug (within 6 weeks for nitrosoureas, mitomycin C or liposomal doxorubicin)Xx_NEWLINE_xXENTRECTINIB EXCLUSION CRITERIA: Prior treatment with the following anti-neoplastic therapies within the following time frame:\r\n* Any prior treatment with entrectinib\r\n* Any prior treatment with TRK, ROS1, or ALK inhibitors\r\n* Radiotherapy within 2 weeks prior to enrollment\r\n* Whole brain radiotherapy within 2 weeks prior to enrollment, or stereotactic radiation to the brain within 1 week prior to enrollment\r\n* Receipt of any cytotoxic chemotherapy, biologic agent, or investigational agent within 2 weeks prior to the first dose of study drugXx_NEWLINE_xXIf an accessible lesion is present, a biopsy will be performed within 6 weeks of the start of study intervention; the results of the biopsy must be obtained prior to initiation of study interventionXx_NEWLINE_xXSubjects must have completed their most recent drug therapy directed at multiple myeloma in the following timeframes: \r\n* Chemotherapy, biological therapy, immunotherapy, or an investigational therapy at least 2 weeks prior to starting DS3032b\r\n* Corticosteroids at least 2 weeks prior to starting DS3032b, except for a dose equivalent to dexamethasone of >= 4 mg/day\r\n* Nitrosoureas, nitrogen mustards, mitomycin C, or monoclonal antibodies at least 6 weeks prior to starting DS3032b\r\n* Autologous stem cell transplantation at least 12 weeks prior to starting DS3032b\r\n* Allogeneic stem cell transplantation at least 24 weeks prior to starting DS3032b, and these subjects must also NOT have moderate to severe active acute or chronic graft versus host disease (GVHD)\r\n* Previous and concurrent use of hormone replacement therapy, the use of gonadotropin-releasing hormone modulators for prostate cancer, and the use of somatostatin analogs for neuroendocrine tumors are permitted if such therapy has not been changed within 8 weeks before study drug treatmentXx_NEWLINE_xXSubjects who have undergone any recent major surgery must have done so at least 4 weeks prior to starting therapy with DS3032b, with the following exceptions: vertebroplasty and/or kyphoplasty, which must have been performed at least 1 week prior to starting DS3032b; planned elective surgery unrelated to the subjectâ€™s diagnosis of multiple myeloma, such as hernia repair, may be allowed, at the discretion of the principle investigator, as long as it was performed at least 2 weeks prior to starting DS3032b, and subjects have recovered fully from this procedureXx_NEWLINE_xXSubjects who have required plasmapheresis and exchange less than 2 weeks prior to initiation of therapy with DS3032bXx_NEWLINE_xXPatient has or had any active infection requiring antibiotic, antifungal, or antiviral therapy within the 2 weeks prior to administration of Toca 511.Xx_NEWLINE_xXPatient received chemotherapy within 2 weeks prior to initiation of treatment with Toca 511 (6 weeks for nitrosoureas).Xx_NEWLINE_xXAny medication administered within 4 weeks prior to 1st dose of TAS3681 that is known to affect QT interval or arrhythmogenicXx_NEWLINE_xXExpected survival of more than 12 weeks;Xx_NEWLINE_xXRequired washout period for prior therapies Topical therapy: 2 weeksXx_NEWLINE_xXPhototherapy (PUVA): 4 weeksXx_NEWLINE_xXRetinoids: 4 weeksXx_NEWLINE_xXInterferons: 4 weeksXx_NEWLINE_xXLow dose methotrexate: 4 weeksXx_NEWLINE_xXHDAC inhibitors: 8 weeksXx_NEWLINE_xXRadiation therapy must be completed at least 2 weeks prior to study entry; radiated lesions may not serve as measurable disease unless they have been radiated >= 12 months prior to enrollmentXx_NEWLINE_xX2 weeks or more since end of previous systemic or radiation treatment (4 weeks or more for bevacizumab plus interferon-alfa)Xx_NEWLINE_xXPatients who have had prior chemotherapy or any other investigational drug within 30 days of registration or prior radiotherapy to the study treatment volume; prior surgery is allowed; there must be at least 6 weeks between mitomycin or nitrosoureas and any new therapyXx_NEWLINE_xXExposure to other investigational drugs within 4 weeks before enrollmentXx_NEWLINE_xXThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXReceipt of any type of small molecular kinase inhibitor (including investigational kinase inhibitors) within 2 weeks of enrollment or receipt of any anti-cancer therapy (including investigational therapy, monoclonal antibodies, cytokine therapy) within 3 weeks of enrollmentXx_NEWLINE_xXSubjects who are receiving corticosteroids must be on a stable or decreasing dose for at least 4 weeks before first dose of study treatment.Xx_NEWLINE_xXReceiving any other investigational agent which would be considered as a treatment for the primary neoplasm; patients must be >= 2 weeks from prior anti-lymphoma therapy; the use of steroids and/or rituximab up to 1 week prior to registration for management of symptoms is allowedXx_NEWLINE_xXChemotherapy: nitrosoureas (At least 6 weeks since last dose of nitrosoureas prior to first dose of tazemetostat)Xx_NEWLINE_xXLaboratory results within the 2 weeks prior to Randomization must be as follows:Xx_NEWLINE_xXAt least 2 weeks must have elapsed since the administration of previous therapy; six weeks must have elapsed since administration of nitrosoureas or mitomycin C; seven days must have elapsed since the administration of filgrastim (G-CSF) and/or sargramostim (GM-CSF)Xx_NEWLINE_xXPatients should not have received prior systemic therapy for metastatic RCC; prior radiotherapy must have been completed at least 2 weeks prior to the administration of study drug; patients must be 2 weeks from prior major surgery and 1 week from pre-treatment biopsy; prior systemic adjuvant therapy (excluding with PD1 or CTLA4 pathway blockers) is allowed if treatment completed > 12 months previouslyXx_NEWLINE_xXHaving received immunotherapy or chemotherapy within 2 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapiesXx_NEWLINE_xXEntry into the study is limited to no more than 8 weeks from the date of surgery.Xx_NEWLINE_xXWilling to set a quit date within 6 weeksXx_NEWLINE_xXPatients receiving any systemic chemotherapy, radiotherapy (except for palliative reasons), within 4 weeks from the last dose prior to study treatment; the patient can receive a stable dose of bisphosphonates for bone metastases, before and during the study as long as these were started at least 4 weeks prior to treatment with study drugXx_NEWLINE_xXPHASE I STUDY ELIGIBILITY CRITERIA:\r\nPatients who have received chemotherapy, radiotherapy, any other investigational agents within 4 weeks (6 weeks for nitrosoureas or mitomycin) prior to study enrollmentXx_NEWLINE_xXPHASE II STUDY COHORT 1 OVARIAN CANCER ELIGIBILITY CRITERIA (MEDI+O, MEDI+C AND MEDI+O+C):\r\nPatients who have received chemotherapy, radiotherapy, any other investigational agents within 3 weeks (4 weeks for platinum agents and 6 weeks for nitrosoureas or mitomycin) prior to study enrollmentXx_NEWLINE_xXPHASE II STUDY COHORT 5 TRIPLE NEGATIVE BREAST CANCER ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nPatients who have received chemotherapy in the previous 3 weeks (6 weeks for nitrosoureas or mitomycin); or who received radiotherapy or any other investigational agents within 3 weeks prior to study enrollmentXx_NEWLINE_xXPHASE II STUDY NON-SMALL CELL LUNG CANCER (COHORT 2; MEDI+O AND MEDI+C) AND SMALL CELL LUNG CANCER (COHORT 3; MEDI+O ONLY) ELIGIBILITY CRITERIA:\r\nPatients who have received chemotherapy, radiotherapy any other investigational agents within 3 weeks (6 weeks for nitrosoureas or mitomycin) prior to study enrollment are ineligible with the following exceptions:\r\n* SCLC patients who have received radiation therapy within 14 days before the first dose of study treatment\r\n* NSCLC patients who have received erlotinib, afatinib, osimertinib, crizotinib, or ceritinib within 14 days of the first dose of study treatmentXx_NEWLINE_xXPHASE II STUDY METASTATIC CASTRATE-RESISTANT PROSTATE CANCER COHORT 4 ELIGIBILITY CRITERIA (MEDI+O ONLY):\r\nThe patient has received chemotherapy, radiotherapy, biologic agents or enzalutamide within 3 weeks before the first dose of study treatment (nitrosoureas or mitomycin within 6 weeks); however, for patients receiving abiraterone, they must discontinue the medication at least 14 days before the first dose of study treatmentXx_NEWLINE_xXPHASE II COLORECTAL CANCER COHORT 6 (MEDI+C ONLY):\r\nPatients who have received chemotherapy, radiotherapy, any other investigational agents within 3 weeks (6 weeks for nitrosoureas or mitomycin) prior to study enrollmentXx_NEWLINE_xXPatients who have received immunotherapy of any type within the past 4 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXAnti-cancer therapy, such as chemotherapy, immunotherapy, targeted and hormonal/endocrine therapy, or investigational agents within two weeks for oral drugs, four weeks for intravenous drugs, and six weeks for nitrosoureas, mitomycin C, or bevacizumab prior to administration of the first dose of study drugXx_NEWLINE_xXContraindication to antiangiogenic agents, including:\r\n* Serious non-healing wound, non-healing ulcer, or bone fracture\r\n* Major surgical procedure or significant traumatic injury within 4 weeks prior to initiating study treatment\r\n* Pulmonary hemorrhage/bleeding event >= grade 2 within 12 weeks prior to initiating study treatment\r\n* Any other hemorrhage/bleeding event >= grade 3 within 12 weeks prior to initiating study treatmentXx_NEWLINE_xXMonoclonal antibodies therapy within 2 weeks before study entryXx_NEWLINE_xXRadiotherapy and cancer chemotherapy (except for intrathecal prophylaxis and/or low-dose maintenance therapy such as vinca alkaloids, mercaptopurine, methotrexate, steroids) or any investigational drug within 2 weeks before study entryXx_NEWLINE_xXCorticosteroid use within 2 weeks of study treatmentXx_NEWLINE_xXSubject has had at least 4 weeks of postoperative recovery from surgery prior to enrollment to ensure complete wound healingXx_NEWLINE_xXEstimated survival of at least 8 weeksXx_NEWLINE_xXAT THE TIME OF INFUSION: Subjects should have been off other investigational antineoplastic therapy for two weeks prior to entry in this study; temozolomide will be allowed up to 48 hours pre-infusion; dexamethasone up to a total dose of 2 mg per day will be allowed if medically indicatedXx_NEWLINE_xXWashout of 3 weeks in case of prior chemotherapy, 6 weeks if treatment included nitrosoureas; 4 weeks for definitive radiotherapy, and 2 weeks for palliative radiotherapy; 3 months from high-dose chemotherapy and stem cell rescue; 3 weeks from major surgery. Participants must have recovered from the acute toxic effects of all prior anticancer therapy before enrollment into the study.Xx_NEWLINE_xXPatients must not have received myelosuppressive therapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)Xx_NEWLINE_xXPrior treatment with vorinostat is allowed but at least 3 weeks must have elapsed from the last dose and effects of prior therapy have resolvedXx_NEWLINE_xXSevere infection within 4 weeks prior to enrollmentXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of chemotherapy, immunotherapy, surgery, or radiotherapy prior to entering this study:\r\n* Myelosuppressive chemotherapy: patient has not received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)\r\n* Hematopoietic growth factors: at least 7 days must have elapsed since the completion of therapy with a growth factor; at least 14 days must have elapsed after receiving pegfilgrastim\r\n* Biologic (anti-neoplastic agent): at least 7 days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibodies: at least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy: at least 2 weeks must have elapsed since any irradiation; at least 6 weeks must have elapsed since craniospinal radiation therapy (RT) or substantial bone marrow irradiationXx_NEWLINE_xXChemotherapy: \r\n* Must not have received myelosuppressive chemotherapy within 3 weeks of the study entry (6 weeks if prior nitrosourea); prior treatment with either dasatinib or temsirolimus but not both is allowed; at least 3 weeks must have elapsed from the last doseXx_NEWLINE_xXBiologic therapy (anti-neoplastic)\r\n* Must not have received oral tyrosine kinase inhibitors (other than dasatinib) or other similar agents within 3 weeks of the study entry and all toxicities must have resolved to < grade 2 prior to enrollment\r\n* Must not have received bevacizumab or other monoclonal antibody therapy within 4 weeks of study the entryXx_NEWLINE_xXRadiotherapy (XRT): at least 4 weeks for focal XRT or 8 weeks for craniospinal XRT must have elapsed prior to study entryXx_NEWLINE_xXPrior treatment with bevacizumab within 12 weeks of study entryXx_NEWLINE_xXRadiotherapy within 4 weeks prior to enrollment, except as follows:\r\n* Palliative radiation to target organs other than chest may be allowed up to 2 weeks prior to enrollment, and\r\n* Single dose palliative treatment for symptomatic metastasis outside above allowance to be discussed with sponsor-investigator prior to enrollingXx_NEWLINE_xXPatients with lymphoma must ideally have at least stable disease from last therapy, however if the PI or LAI believes there is a high likelihood of response to induction chemotherapy (etoposide, prednisone, vincristine sulfate, cyclophosphamide, doxorubicin hydrochloride-fludarabine phosphate+/-rituximab [EPOCH-F+/-R]), then the patient may be enrolled on the induction phase arm; for enrollment on the research phase arm, the patient must have at least stable disease which is defined as:\r\n* Absence of disease progression for at least 8 weeks after previous therapy or 12 weeks after autologous transplantation\r\n* Patients who are less than 8 weeks from previous therapy or 12 weeks from autologous transplantation may participate in the study at the discretion of the PI or LAI as long as they do not have progressive diseaseXx_NEWLINE_xXHad surgery within 4 weeks prior to study treatment except for minor procedures (hepatic biliary stent placement is allowed)Xx_NEWLINE_xXMay not have received cytotoxic chemotherapy, targeted therapies, biologic response modifiers, chemotherapy, and hormonal therapy within the last 3 weeks, or nitrosureas within the last 6 weeks prior to study treatment.Xx_NEWLINE_xXAble to initiate study treatment no later than 6 weeks from last dose of any antineoplastic component of prior therapy regimenXx_NEWLINE_xXTherapy must begin =< 5 weeks after surgery or biopsyXx_NEWLINE_xXMyelosuppressive chemotherapy: must not have received within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)Xx_NEWLINE_xXReceipt of the following treatment prior to first dose of BGB-3111: corticosteroids given with anti-neoplastic intent within 7 days, chemotherapy or radiotherapy within 2 weeks, monoclonal antibody within 4 weeks.Xx_NEWLINE_xXBilirubin =< 3 x UNL, values =< 2 weeksXx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study; for investigational targeted therapies, patients will need to clear for 5 half-lives (not applicable to standard of care therapies)Xx_NEWLINE_xXCompletion of definitive therapy 4-12 weeks prior to enrollment; there are no specific limitations on which treatment modalities can be used in the definitive setting (e.g. the use of adjuvant chemotherapy is acceptable), but all other treatments must be complete at least 4 weeks prior to enrollmentXx_NEWLINE_xXCompletion of definitive therapy for oligometastatic disease greater than 12 weeks prior to enrollmentXx_NEWLINE_xXPatients on greater than 4 mg per day of dexamethasone within the 2 weeks prior to admission for D2C7-IT infusionXx_NEWLINE_xXTreated with antiangiogenic agents (like bevacizumab) within 4 weeks before biopsyXx_NEWLINE_xXTreated with alkylating agents within 4 weeks before enrollment (6 weeks for nitrosoureas) or treated within 1 week before enrollment with daily or metronomic chemotherapy, unless the patient has recovered from the expected toxic effects of such therapyXx_NEWLINE_xXReceived cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXAny significant systemic infection within 4 weeks prior to dosingXx_NEWLINE_xXPatients receiving bevacizumab within 12 weeks prior to protocol treatmentXx_NEWLINE_xXMust be at least 4 weeks post-operativeXx_NEWLINE_xXPatients must be a minimum of 3 weeks from thoracotomy (if performed) and well-healed before starting treatmentXx_NEWLINE_xXPatients receiving erythropoietin (darbepoetin, epoetin alfa) must be on a stable dose and with stable transfusion requirement or hemoglobin level during the 8 weeks prior to study entryXx_NEWLINE_xXPatients who have received the last administration of nitrosourea or mitomycin-C =< 6 weeks prior to starting study drugXx_NEWLINE_xXPatients who have received targeted therapy (e.g., sunitinib, sorafenib, pazopanib), except ALK inhibitors, =< 2 weeks prior to starting study drugXx_NEWLINE_xXPrevious chemotherapy/immunotherapy within 3 weeks before study entryXx_NEWLINE_xXWash-out requirements (standard or investigational):\r\n* At least 6 weeks since the completion of a nitrosourea-containing chemotherapy regimen\r\n* At least 23 days since the completion of Temodar and/or 4 weeks for any other non-nitrosourea-containing cytotoxic chemotherapy regimen; if a patientâ€™s most recent treatment was with a targeted agent only, and s/he has recovered from any toxicity of this targeted agent, then a waiting period of only 2 weeks is needed from the last dose and the start of study treatment, with the exception of bevacizumab where a wash out period of at least 4 weeks is required before starting study treatmentXx_NEWLINE_xXHistory/physical examination within 4 weeks prior to registration, including assessment of weight and weight loss in past 6 monthsXx_NEWLINE_xXRecent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of pazopanib)Xx_NEWLINE_xXAny number of prior therapies is permitted; from the start of study treatment, the following time periods must have elapsed: 6 weeks from nitrosourea-containing chemotherapy, 4 weeks from non-nitrosourea-containing cytotoxic chemotherapy (except 23 days from last daily dose of temozolomide taken in a 5 of 28 day regimen), and 2 weeks from last dose of a targeted agent (except 4 weeks for bevacizumab); there is no time period requirement for prior radiation therapyXx_NEWLINE_xXUse of drugs known to inhibit UGT1A1, such as atazanir, gemfibrozil, indinavir, or ketoconazole, within 2 weeks prior to start of study treatmentXx_NEWLINE_xXFlucytosine within 2 weeks prior to start of study treatmentXx_NEWLINE_xXPatients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXMust not have received myelosuppressive chemotherapy and/or biologics within 3 weeks of entry onto this study (4 weeks if prior nitrosourea)Xx_NEWLINE_xXMinimum of six weeks is required following prior therapeutic doses of MIBG.Xx_NEWLINE_xXChemotherapy, biologics, immunotherapy, vaccine, cytokine therapy within 4 weeks prior to enrollmentXx_NEWLINE_xXResearch participant must be at least 2 weeks from having received the last dose of immunosuppressant medications (e.g. calcineurin inhibitors, methotrexate, immunosuppressive antibodies, etc)Xx_NEWLINE_xXThe last dose of lymphotoxic chemotherapeutic agents (e.g. cyclophosphamide, ifosofamide, bendamustine, etc) must be at least 2 weeks before the leukapheresis procedureXx_NEWLINE_xXThe last dose of lymphotoxic chemotherapeutic agents (e.g. cyclophosphamide, ifosofamide, bendamustine, etc) must be at least 2 weeks before lymphodepletionXx_NEWLINE_xXPatients who have taken part in an experimental drug study within 4 weeks of initiating study treatment with sonidegibXx_NEWLINE_xXIf research participant is undergoing leukapheresis the last dose of prior chemotherapy, immunotherapy or radiation must be at least 2 weeks before the leukapheresis procedure\r\n* Exception rule: the wash out period for Hydrea is 48 hoursXx_NEWLINE_xXMyelosuppressive chemotherapy: Must not have received within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea).Xx_NEWLINE_xXThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies; including investigational biologic agents) within 3 weeks, or nitrosoureas/ mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXThe subject has received enzyme-inducing anti-epileptic agents within 2 weeks before the first dose of cabozantinib (e.g., carbamazepine, phenytoin, phenobarbital, primidone); other enzyme inducing agents prohibited within 2 weeks before the first dose of cabozantinib include rifampin, rifabutin, rifapentine, and St. Johnâ€™s WortXx_NEWLINE_xXPrior systemic treatment was discontinued for at least 2 weeks prior to the Baseline Visit.Xx_NEWLINE_xXLocoregional treatment within 4 weeks prior to the Baseline Visit.Xx_NEWLINE_xXOccurrence of esophageal or other gastrointestinal hemorrhage requiring transfusion within 4 weeks prior to the Baseline Visit.Xx_NEWLINE_xXAt least 2 weeks from prior MF-directed treatment (till the start of study drug)Xx_NEWLINE_xXPatients must have no clinical evidence of leptomeningeal or brain metastasis causing spinal cord compression that are symptomatic or untreated or not stable for >= 4 weeks (must be documented by imaging) or requiring corticosteroids; subjects on a stable dose of corticosteroids > 1 month or who have been off of corticosteroids for at least 2 weeks can be enrolled with approval of the Cancer Therapy Evaluation Program (CTEP) medical monitor; subjects must also be off of enzyme-inducing anticonvulsants for > 4 weeksXx_NEWLINE_xXPatients who have taken part in an experimental drug study =< 4 weeks prior to registrationXx_NEWLINE_xXAny of the following prior therapies:\r\n* Chemotherapy =< 3 weeks prior to registration\r\n* Immunotherapy =< 4 weeks prior to registration\r\n* Biologic therapy =< 4 weeks prior to registration\r\n* Extensive abdominal surgery if it includes enterotomy(ies) =< 3 weeks prior to registration; this criterion does not apply to placement of the peritoneal Port-A-Cath or lysis of adhesions at the time of registration\r\n* Any viral or gene therapy prior to registration\r\n* Radiation therapy to the abdomen or pelvisXx_NEWLINE_xXTreatment with corticosteroids within 4 weeks prior to enrollmentXx_NEWLINE_xXPatients must have failed external beam radiotherapy >= 5,000 cGy to the brain, and if eligible and tolerated, undergone appropriate treatment with temozolomide chemotherapy; all radiation and additional chemotherapies must have been completed at least 4 weeks prior to enrollment; prior therapy with nitrosoureas must have been completed at least 6 weeks prior to enrollmentXx_NEWLINE_xXPatients who have had chemotherapy, cytotoxic therapy, immunotherapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas), surgical resection within 4 weeks prior to entering the study, or have received experimental viral therapy or gene therapy at any time (e.g., adenovirus, retrovirus or herpes virus protocol); however, this does not preclude re-treatment with M032 at a later dateXx_NEWLINE_xXReceipt of bevacizumab (Avastin) therapy within 4 weeks of scheduled M032 administration; (receipt of bevacizumab [Avastin] greater than 4 weeks of scheduled M032 administration does not exclude patient)Xx_NEWLINE_xXPatients must be ?4 weeks since major surgery, radiotherapy, chemotherapy (6 weeks if they were treated with nitrosureas) or biotherapy/targeted therapies.Xx_NEWLINE_xXParticipation in a prior investigational study within 4 weeks prior to enrollment or longer if required by local regulationXx_NEWLINE_xXExpected survival > 12 weeksXx_NEWLINE_xXRequired wash out periods for prior therapy (for cohort B):\r\n* Topical therapy: 2 weeks \r\n* Chemotherapy: 4 weeks\r\n* Radiotherapy: 4 weeks\r\n* Other investigational therapy: 4 weeks\r\n* Rituximab: 12 weeksXx_NEWLINE_xXChemotherapy within 3 weeks of the first scheduled study treatmentXx_NEWLINE_xXPatients must be entered no more than 12 weeks post operativelyXx_NEWLINE_xXRequire steroid therapy or steroid-containing compounds, or have used systemic steroids in the past 4 weeks, or have used topical or inhalational steroids in the past 2 weeks prior to lymphodepletion; the exception being patients on chronic physiologic dose of steroid (Turnstile II)Xx_NEWLINE_xXHave received radiotherapy, chemotherapy, biological therapy or investigational treatment less than four weeks (six weeks for nitrosourea or mitomycin C) prior to first dose of study medication or have not recovered from all acute toxicities from prior treatments.Xx_NEWLINE_xXMinimum interval since last investigational agent and/or prior cytotoxic drug therapy (patient must have also recovered from the toxic effects of any prior therapy):\r\n* 3 weeks since last non-cytotoxic therapy\r\n* 3 weeks must have elapsed since the completion of a non-nitrosourea-containing chemotherapy regimen\r\n* 6 weeks since the completion of a nitrosourea-containing chemotherapy regimenXx_NEWLINE_xXPatients treated on any other therapeutic clinical protocols within 3 weeks of registrationXx_NEWLINE_xXPatients on alemtuzumab within 6 weeks prior to consentingXx_NEWLINE_xXActive GI ulcer disease within 4 weeks of study enrollmentXx_NEWLINE_xXAdministration of immunosuppressive drugs less than 2 weeks prior to first dose of ERC1671Xx_NEWLINE_xXBilirubin =< 1.5 x UNL obtained =< 2 weeks prior to enrollmentXx_NEWLINE_xXRoutine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatmentXx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): ANC >= 1500/mcL (1.5 x 0^9/L), obtained within 2 weeks prior to registrationXx_NEWLINE_xXRANDOMIZED PHASE II (ARMS K AND L): Routine vaccinations, including seasonal influenza, should be given at least 2 weeks prior to study treatment; vaccines are not prohibited on study, but must be given at least 6 weeks after cycle 1 and not within 7 days of treatmentXx_NEWLINE_xXSubjects who have had chemotherapy within 4 weeks prior to entering the studyXx_NEWLINE_xXRelapsed/refractory MCL: Prior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, major surgery within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drugXx_NEWLINE_xXHormonal therapy within 2 weeks before the first dose of study treatmentXx_NEWLINE_xXBiologic therapy (including antibodies [other than trastuzumab], immune modulators, cytokines) within 4 weeks before the first dose of study treatment; Note: there is no washout period required for trastuzumabXx_NEWLINE_xXDisease must be evaluable by metaiodobenzylguanidine (MIBG) scan; a positive MIBG scan must be present within 8 weeks prior to study entry and subsequent to any intervening therapy; if the patient has only one MIBG positive lesion and that lesion was radiated, a biopsy must be done at least 4 weeks after radiation was completed and must show viable neuroblastomaXx_NEWLINE_xXAt least 2 weeks should have elapsed since any chemotherapy causing myelosuppressionXx_NEWLINE_xXSkin biopsy performed at least 5 days and no longer than 10 weeks from the time of initial entry into the studyXx_NEWLINE_xXPatients must have had at least one prior chemotherapeutic regimen; steroids alone and local radiation do not count as regimens; radiotherapy must have been completed at least 4 weeks prior to entry into the study; Rituxan alone does not count as a regimen; however, Bexxar or Zevalin (ibritumomab tiuxetan) do and patients must have completed radioimmunotherapy (RIT) > 12 months prior to enrollmentXx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy and be at least 3 weeks from the last dose of standard cytotoxic chemotherapy or myelosuppressive biological therapy and at least 1 week from the last dose of non-myelosuppressive biologic therapy; any questions related to the definition of non-cytotoxic agents should be directed to the principal investigators; for those who have received radiation, 4 weeks must have elapsed before beginning vaccinationXx_NEWLINE_xXPatients must have stable topical medication regimen for 2 weeks prior to study initiationXx_NEWLINE_xXHistory of phototherapy within 2 weeks prior to study initiationXx_NEWLINE_xXMust be able to start treatment within 12 weeks of surgery or 8 weeks of finalization of chemotherapy.Xx_NEWLINE_xXPatients who have received immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXPatients who have received alemtuzumab or ATG within 8 weeks of the transplant admissionXx_NEWLINE_xXNo chemotherapy or immunotherapy for a minimum of three weeks prior to start of hu3F8Xx_NEWLINE_xXPatients must not have had a known interruption of TKI therapy of greater than 21 consecutive days or for a total of 6 weeks in the 6 months prior to enrollment.Xx_NEWLINE_xXHas had prior systemic cancer therapy within the past four weeks at the time of the start of the lymphodepletion regimen (Turnstile II)Xx_NEWLINE_xXRequires no steroids within 4 weeks and have not used topical or inhalational steroids in the past 2 weeks prior to lymphodepletion; the exception being patients on chronic physiologic dose of steroid (Turnstile II)Xx_NEWLINE_xXPatients who have completed previous therapies 4-weeks prior to (or within 5 drug half lives) enrollment on study. Radiation therapy wash out period will be 2 weeks. This includes an exception of patients with metastatic GIST tumors who are taking maintenance imatinib mesylate therapy. These patients are allowed to remain on imatinib mesylate therapy up to enrollment in this study.Xx_NEWLINE_xXPatients having received anti-CD20 therapy ? 4 weeks prior to the first study dose.Xx_NEWLINE_xXReceived anti-viral treatment with activity against influenza (for example amantadine, rimantadine, oseltamivir, laninamivir, peramivir, zanamivir, and ribavirin) or probenecid medication within 2 weeks prior to randomizationXx_NEWLINE_xXUse of any MPN-associated myelofibrosis-directed therapy within 2 weeks prior to study day 1Xx_NEWLINE_xXRadioimmunotherapy within 12 weeksXx_NEWLINE_xXExposure to other investigational drugs within 2 weeks before enrollmentXx_NEWLINE_xXGI hemorrhage or obstruction experienced within the previous 6 weeksXx_NEWLINE_xXCOHORT 3: ATOPIC DERMATITIS PATIENTS: Use of systemic antibiotics within 8 weeks, or topical antibiotics on intended sampling sites within 3 weeks, prior to baseline samplingXx_NEWLINE_xXAny other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to first dose of study drug (6 weeks for nitrosoureas or mitomycin C)Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within two weeks, 4 weeks for nitrosoureas, mitomycin C, pegylated-doxorubicin and one half-life for bevacizumab, hormone therapy within one week, trastuzumab within 2 weeks or lapatinib within one week of study day 1Xx_NEWLINE_xXHemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drugXx_NEWLINE_xXSpecific KS therapy, including cytotoxic chemotherapy but not including HAART, within the past 4 weeks (6 weeks if the therapy was bevacizumab)Xx_NEWLINE_xXPatients must be at least 4 weeks from radiation therapy; additionally, patients must be at least 6 weeks from nitrosoureas, 4 weeks from temozolomide, 3 weeks from procarbazine, 2 weeks from vincristine and 4 weeks from last bevacizumab administration; patients must be at least 4 weeks from other cytotoxic therapies not listed above and 2 weeks for non-cytotoxic agents (e.g., interferon, tamoxifen) including investigative agents; all toxicities from prior therapies should be resolved to Common Terminology Criteria for Adverse Events (CTCAE) =< grade 1 (except for toxicities such as alopecia, or vitiligo)Xx_NEWLINE_xXHistory of tocilizumab therapy within prior 6 weeksXx_NEWLINE_xXHistory of rituximab or intravenous bevacizumab therapy within six weeksXx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy: > 3 weeks for biologic therapies or non-cytotoxic therapies, > 4 weeks for cytotoxic therapies, and > 6 weeks for nitrosoureas; any questions related to the definition of non-cytotoxic agents should be directed to the study chair\r\n* NOTE: 13 cis-retinoic acid (Accutane) as biologic therapy has a washout period of 14 daysXx_NEWLINE_xXA minimum of 2 weeks elapsed off of antiandrogen therapy prior to start of study drug (i.e. flutamide, nilutamide, bicalutamide)Xx_NEWLINE_xXThe use of anti-convulsants is allowed, as long as the patient is on a stable dose with no seizure activity for at least 2 weeks prior to initiating trial therapyXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 2 weeks prior to treatment start or those who have not recovered from adverse events due to agents administered more than 2 weeks prior to treatment start; hydroxyurea is allowed for symptomatic leukocytosis during screening, lead in, and cycle 1 only if clinically necessary; a total white blood cell (WBC) count < 25 x 10^9/L prior to first dose of decitabine on trial is required; prior leukapheresis and/or prior or concurrent treatment with hydroxyurea to achieve this level are allowedXx_NEWLINE_xXDonor lymphocyte infusion within 8 weeks prior to treatment start if post-transplantXx_NEWLINE_xXSystemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity and any prior immunotherapy approach, 4 weeks is indicated as washout periodXx_NEWLINE_xX-  Non-tolerable > Grade 2 neuropathy or evidence of unstable neurological symptoms within 4 weeks first doseXx_NEWLINE_xXPrior immune-checkpoint inhibitors within 4 weeks (or 8 weeks, if immuno-oncology doublet used as the prior line of therapy)Xx_NEWLINE_xXPrior monoclonal antibodies, antibody-drug conjugates, or radioimmunoconjugates within 4 weeks (or 2 weeks if patient experienced disease progression on the prior treatment)Xx_NEWLINE_xXPrior T-cell or other cell-based therapies within 12 weeks (or 2 weeks if patient experienced disease progression on the prior treatment)Xx_NEWLINE_xXHave experienced >2 seizures within 4 weeks prior to study entry.Xx_NEWLINE_xXEvidence of recovery from any prior chemotherapy; no myelosuppressive anticancer chemotherapy or biological therapy within 3 weeks (6 weeks if a nitrosourea or mitomycin C agent) prior to registrationXx_NEWLINE_xXPatients must be entered no more than 12 weeks post operativelyXx_NEWLINE_xXAt least 4 weeks for focal radiation therapy (RT) or >= 6 weeks for craniospinal RT must have elapsed prior to study entryXx_NEWLINE_xXReceived anti-CD30 antibody-based therapy within the previous 4 weeksXx_NEWLINE_xXNormal left ventricular function as evaluated by echocardiograph within 4 weeks of start of protocol therapyXx_NEWLINE_xXNo other therapy (i.e. chemotherapy, interferon) for 4 weeks prior to study entry, or cladribine for 6 months prior to study entry, unless progressive disease more than 2 months after cladribine is documentedXx_NEWLINE_xXReceipt of a live vaccine within 4 weeks prior to randomization; efficacy and/or safety of immunization during periods of B-cell depletion have not been adequately studied; it is recommended that a patientâ€™s vaccination record and possible requirements be reviewed; the patient may have any required vaccination/booster administered at least 4 weeks prior to the initiation of study treatment; review of the patientâ€™s immunization status for the following vaccinations is recommended: tetanus; diphtheria; influenza; pneumococcal polysaccharide; varicella; measles, mumps and rubella (MMR); and hepatitis B; patients who are considered to be at high risk for hepatitis B virus (HBV) infection and for whom the investigator has determined that immunization is indicated should complete the entire HBV vaccine series at least 4 weeks prior to participation in the studyXx_NEWLINE_xXChemotherapy: Chemotherapy within 4 weeks of PV-10 administration (6 weeks for nitrosoureas or mitomycin C). Subjects with HCC who have been on a stable dose of sorafenib for at least 4 weeks will be candidates for enrollment in Expansion CohortXx_NEWLINE_xX>= 3 weeks between completion of chemotherapy or immunotherapy and first (1st) vaccinationXx_NEWLINE_xXPrior Therapy: at least 2 weeks should have elapsed since any biologic therapy; three weeks should have elapsed since last dose of chemotherapyXx_NEWLINE_xXINCLUSION CRITERIA FOR CCT: at least 2 weeks should have elapsed since any biologic therapy; three weeks should have elapsed since last dose of chemotherapyXx_NEWLINE_xXPatients who have received cranial or spinal irradiation less than 3 weeks prior to the start of this protocolXx_NEWLINE_xXRecent history of allergen desensitization therapy within 4 weeks of starting study treatment.Xx_NEWLINE_xXAn oral contraceptive (must be on a stable dose of the same oral hormonal contraceptive product for at least 4 weeks before dosing with study drug and for the duration of the study and for 6 months after study drug discontinuation); orXx_NEWLINE_xXHas received autologous SCT within 12 weeks before the date of study treatment.Xx_NEWLINE_xXProhibited treatments and or therapies\r\n* Autologous stem cell transplant (ASCT) =< 12 weeks prior to registration\r\n* Prior chemotherapy =< 2 weeks prior to registration\r\n* Prior treatment with nitrosureas =< 4 weeks prior to registration\r\n* Therapeutic anticancer antibodies =< 2 weeks prior to registration\r\n* Radio- or toxin immunoconjugates =< 4 weeks prior to registration\r\n* Radiation therapy to the injected area =< 2 weeks prior to registration\r\n* Major surgery =< 2 weeks prior to registrationXx_NEWLINE_xXFebrile neutropenia or serious persistent infection within 2 weeks prior to Day 1 of treatmentXx_NEWLINE_xXOngoing or previous anti-cancer treatment within 4 weeks before randomization.Xx_NEWLINE_xXReceived any antibody targeting T-cell check point or co-stimulation pathways within 4 weeks, received any other monoclonal antibody within 4 weeks, and all other immunotherapy (tumor vaccine, cytokine, or growth factor) within 2 weeks prior to study treatment.Xx_NEWLINE_xXReceived any kinase inhibitors within 2 weeks prior to study treatment.Xx_NEWLINE_xXSystemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or radiopharmaceuticals (strontium, samarium) within 8 weeks prior to study treatment.Xx_NEWLINE_xXIs not expected to be available to receive study drug within 16 weeks from the time of baseline biopsy for any reasonXx_NEWLINE_xXIntravenous treatment with anti-infective therapy that has been administered less than two weeks prior to first dose in this trial, orXx_NEWLINE_xXPrior chemotherapy within 3 weeks of study registrationXx_NEWLINE_xXAble to begin study therapy within 3 weeks (+/- 1 week) of final IV/IP chemotherapyXx_NEWLINE_xXCancer chemotherapy within four weeks prior to start of MCLA-117;Xx_NEWLINE_xXPrevious treatment with any other investigational agents within 4 weeks prior to MCLA-117 administration;Xx_NEWLINE_xXUse of immunosuppressant medications within 4 weeks of MCLA-117 administration;Xx_NEWLINE_xXHas been receiving: radiotherapy, chemotherapy, or molecularly-targeted agents or tyrosine kinase inhibitors within 2 weeks or 5 half-lives (whichever is longer) of the start of study treatment; immunotherapy/monoclonal antibodies within 3 weeks of the start of study treatment; nitrosoureas, antibody-drug conjugates, or radioactive isotopes within 6 weeks of the start of study treatment.Xx_NEWLINE_xXTreatment with any of the following medications within 4 weeks before the baseline diagnostic biopsy is taken:Xx_NEWLINE_xX?12 weeks for total skin electron beam irradiation,Xx_NEWLINE_xX?4 weeks for monoclonal antibodies (?8 weeks for alemtuzumab),Xx_NEWLINE_xX?3 weeks for phototherapyXx_NEWLINE_xXInclusion Criteria:\n\n        For Arm A, B, and C: Histologically confirmed World Health Organization Grade IV\n        glioblastoma. WHO Grade IV gliomas will be allowed on protocol.\n\n        For Arm D and E: WHO Grade IV glioma as per above and tumor must harbor a histone H3 K27M\n        mutation as evidenced by testing any tumor sample with a immunohistochemistry or DNA\n        sequencing test.\n\n        Unequivocal evidence of progressive disease on contrast-enhanced brain computerized\n        tomography (CT) or magnetic resonance imaging (MRI) as defined by Response Assessment in\n        Neuro-Oncology Criteria (RANO), or have documented recurrent glioblastoma on diagnostic\n        biopsy.\n\n        Previous first line therapy with at least radiotherapy and temozolomide.\n\n        For Arm A: Any number of recurrences are allowable. For Arm B: First recurrence (only)\n        glioblastoma who had a complete tumor resection at first diagnosis. For Arm C: Patients\n        must have clinical and/or radiographic evidence of first recurrence of glioblastoma (only)\n        and be eligible for salvage surgical resection as deemed by the site Investigator.\n\n        Must be 12 weeks from radiotherapy. If patients are within 12 weeks of radiotherapy, then\n        the progressive lesion must be outside of the high-dose radiation target volume or have\n        unequivocal evidence of progressive tumor on a biopsy specimen.\n\n        From the projected start of scheduled study treatment, the following time periods must have\n        elapsed: 5 half-lives from any investigational agent, 4 weeks from cytotoxic therapy\n        (except 23 days for temozolomide and 6 weeks from nitrosoureas), 6 weeks from antibodies,\n        or 4 weeks (or 5 half-lives, whichever is shorter) from other anti-tumor therapies.\n\n        All adverse events Grade > 1 related to prior therapies (chemotherapy, radiotherapy, and/or\n        surgery) must be resolved, except for alopecia.\n\n        Male or Female age ?18 years.\n\n        Karnofsky Performance Status (KPS) ? 60% (see Appendix A).\n\n        Adequate organ and marrow function as defined below, all screening labs should be performed\n        within 14 days of treatment initiation:\n\n          -  leukocytes ? 3,000/mcL\n\n          -  absolute neutrophil count ? 1,500/mcL\n\n          -  platelets ? 100,000/mcL\n\n          -  hemoglobin > 8.0 mg/dL\n\n          -  total bilirubin < 2.0 x upper limit of normal\n\n          -  AST (SGOT)/ALT (SGPT) ?2.5 Ã— upper limit of normal creatinine OR creatinine clearance\n             ?60 mL/min/1.73 m2 for patients with creatinine levels above normal.\n\n        CT or MRI within 14 days prior to start of study drug.\n\n        Corticosteroid dose must be stable or decreasing for at least 5 days prior to the scan. For\n        Arm B: Corticosteroid dose must be stable or decreasing for at least 2 weeks prior to study\n        entry.\n\n        The effects of ONC201 on the developing human fetus are unknown. For this reason, women of\n        childbearing potential and men must agree to use adequate contraception (hormonal or\n        barrier method of birth control; abstinence) prior to study entry and for the duration of\n        study participation. Should a woman become pregnant or suspect she is pregnant while she or\n        her partner is participating in this study, she should inform her treating physician\n        immediately. Male subjects should agree to use adequate method of contraception starting\n        with the first dose of study therapy through 120 days after the last dose of therapy.\n\n        Archival tissue for evaluation of correlative objectives (if available). Archival tissue is\n        required for Arms B and C.\n\n        Ability to understand and the willingness to sign a written informed consent document.\n\n        Exclusion Criteria:\n\n        History of allergic reactions attributed to compounds of similar chemical or biologic\n        composition to ONC201 or its excipients.\n\n        Current or planned participation in a study of an investigational agent or using an\n        investigational device.\n\n        Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n        infection or psychiatric illness/social situations that would limit compliance with study\n        requirements.\n\n        Active infection requiring systemic therapy.\n\n        Prior stereotactic radiotherapy, convection enhanced delivery (CED) or brachytherapy must\n        have had a biopsy to confirm radiographic progression is consistent with progressive tumor\n        and not treatment-related necrosis. If the recurrent lesion is outside of any prior\n        high-dose radiation target volume or distant from the prior CED or brachytherapy site,\n        subjects will be considered eligible\n\n        Pregnant women because ONC201 is novel agent with unknown potential for teratogenic or\n        abortifacient effects. Because there is an unknown but potential risk for adverse events in\n        nursing infants secondary to treatment of the mother with ONC201, breastfeeding should be\n        discontinued if the mother is treated with ONC201.\n\n        Known HIV-positive test on combination antiretroviral therapy.\n\n        Known history of cardiac arrhythmias including atrial fibrillation, tachyarrhythmias or\n        bradycardia. Receiving therapeutic agents known to prolong QT interval will be excluded.\n        History of CHF, or MI or stroke in the last 3 months will be excluded.\n\n        Active illicit drug use or diagnosis of alcoholism.\n\n        Prior bevacizumab for treatment of glioblastoma. The rationale for restricting enrollment\n        to patients who have not had prior bevacizumab therapy is that data regarding the efficacy\n        of any therapy after progression on bevacizumab therapy are lacking.\n\n        Tumors with isocitrate dehydrogenase 1 (IDH1) or IDH2 mutations as determined by\n        immunohistochemistry for the IDH1 R132H variant or by direct sequencing. IDH1/2-mutant\n        gliomas have a markedly longer overall survival rate compared to those with IDH1/2-wildtype\n        glioma (Parsons et al., 2008; Yan et al., 2009), indicating IDH1/2-mutant gliomas have a\n        distinct natural history.\n\n        Known additional malignancy that is progressing or requires active treatment within 3 years\n        of start of study drug. Exceptions include basal cell carcinoma of the skin, squamous cell\n        carcinoma of the skin, or in situ cervical cancer that has undergone potentially curative\n        therapy.\n\n        Any surgery (not including minor diagnostic procedures such as lymph node biopsy) within 2\n        weeks of baseline disease assessments; or not fully recovered from any side effects of\n        previous procedures.\n\n        Concomitant use of CYP3A4/5 inhibitors during the treatment phase of the study and within\n        72 hours prior to starting study drug administration.\n\n        Concomitant use of potent CYP3A4/5 inducers, which include enzyme inducing antiepileptic\n        drugs (EIAEDs) (see Appendix B), during the treatment phase of the study and within 2 weeks\n        prior to starting treatment.\n\n        Planned concurrent use Optuneâ„¢. Prior use of the device is allowable.\n\n        For Arm D: Evidence of leptomeningeal spread of disease.Xx_NEWLINE_xXSubject has a history of thromboembolic event within the past 4 weeks prior to enrollment.Xx_NEWLINE_xXHave had DVT or venous thromboembolism within 6 weeks of study entryXx_NEWLINE_xX4 weeks from cytotoxic agentsXx_NEWLINE_xX6 weeks from nitrosoureasXx_NEWLINE_xXPatient received nitrosureas within 6 weeks prior to the first dose.Xx_NEWLINE_xXPatient received corticosteroids within 2 weeks prior to the first dose.Xx_NEWLINE_xXPatient received plasmapheresis within 4 weeks prior to the first dose.Xx_NEWLINE_xXPatients treated with any systemic anti-cancer therapy for NSCLC within 21 days prior to randomization (6 weeks for Bevacizumab).Xx_NEWLINE_xXCoagulopathy tests will be obtained within 2 weeks of enrollmentXx_NEWLINE_xXPatients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug; all side effects from prior therapy must recover to grade 1 or less prior to starting on trialXx_NEWLINE_xXPatients who have received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXSurgical treatment or chemotherapy within three weeks of scheduled macrobead implantation or within four weeks of bevacizumab (or similar drugs), or radiation therapy within four weeks of scheduled macrobead implantationXx_NEWLINE_xXConcurrent systemic corticosteroid therapy within 4 weeks prior to randomization, except prophylactic use of steroids prior to paclitaxel administrationXx_NEWLINE_xXReceipt of any investigational medication within 4 weeks prior to randomizationXx_NEWLINE_xXMammogram within 6 weeks of diagnosisXx_NEWLINE_xXNo use of investigational agents within 4 weeks of study enrollment or use of immunosuppressive or immunomodulating agents (including intravenous immunoglobulin [IVIG]) within 8 weeks of study entry; note: use of topical, inhaled and intranasal steroid therapy is permittedXx_NEWLINE_xXRecovered from acute toxicities of other treatments (? Grade 2). All other MDS treatments discontinued at least 4 weeks prior to treatment except epoetin alpha (Procrit) 2 weeks.Xx_NEWLINE_xXMedical history of RBC transfusion dependent anemia ?4 units of RBCs during the 16 weeks prior to admin of study drug & ?2 units of RBCs over prior 8 weeks (day -56 to day 1 prior to treatment; baseline period) for documented Hgb of ? 9g/dL (during baseline). Didn't have a 56 day RBC transfusion-free period during 16 weeks prior to administration of study drug.Xx_NEWLINE_xXno current or prior use of investigational agents within 4 weeks of study entry.Xx_NEWLINE_xXReceived hematopoietic growth factors within specified limits prior to treatment (2 weeks for epoetin alpha (Procrit) & 4 weeks for darbepoetin alpha (Aranesp)).Xx_NEWLINE_xXHistory of pathologically confirmed CIN1 by colposcopically-directed punch biopsy, within 12 weeks prior to administration of first study vaccination (CIN 2/3 subjects will not be eligible);Xx_NEWLINE_xXConcurrent cancer treatment with cytoreductive therapy, radiotherapy, cytokine therapy, cytotoxic agents, targeted small molecule therapy or any investigational anticancer small molecule drugs within 2 weeks prior to the start of study treatment (except 5 weeks from last dose of nitrosourea compound) OR treatment with monoclonal antibodies within 4 weeks prior to the start of study treatment, with the following exceptions:Xx_NEWLINE_xXVaccination within 4 weeks of the first dose of study treatment is prohibited except for administration of inactivated vaccines;Xx_NEWLINE_xXPatients who have had chemotherapy or radiotherapy within 2 weeks (4 weeks for nitrosoureas or systemic mitomycin C) before the initiation of study treatmentXx_NEWLINE_xXPatients who have not recovered from adverse events (other than alopecia) due to agents administered more than 4 weeks earlier (i.e., have residual toxicities > grade 1); however, the following therapies are allowed:\r\n* Hormone-replacement therapy or oral contraceptives\r\n* Herbal therapy ? 1 week before initiation of study treatment (herbal therapy intended as anticancer therapy must be discontinued at least 1 week before initiation of study treatment)\r\n* Palliative radiotherapy for bone metastases > 2 weeks before initiation of study treatmentXx_NEWLINE_xXPatients who have signs or symptoms of infection within 2 weeks before initiation of study treatmentXx_NEWLINE_xXPatients who have had chemotherapy within 2 weeks (6 weeks for nitrosoureas or mitomycin C), anticancer antibodies within 4 weeks, radio or toxin immunoconjugates within 2 weeks, radiation therapy within 3 weeks or major surgery within 2 weeks prior to entering the study\r\n* Palliative (limited-field) radiation therapy is permitted if the patient has additional measurable lesions to assess response of therapyXx_NEWLINE_xXHas received systemic anti-cancer therapy within the 3 weeks prior to starting the trial.Xx_NEWLINE_xXUse of any investigational product within 4 weeks prior to randomizationXx_NEWLINE_xXNo non-approved investigational agents or procedures ?4 weeks of study entryXx_NEWLINE_xXUse of systemic anti-cancer therapy ? 4 weeks, or six weeks if the systemic therapy contains a nitrosourea or mitomycin C.Xx_NEWLINE_xXEnrollment and randomization within 12 weeks of initial cholecystectomyXx_NEWLINE_xXReceived treatment with an anti-EGFR for ?16 weeksXx_NEWLINE_xXPrior treatment with any of the following: allogeneic or syngeneic SCT within 16 weeks prior to randomization; or autologous SCT within 12 weeks prior to randomization.Xx_NEWLINE_xXOff calcineurin inhibitors for at least 2 weeksXx_NEWLINE_xXHave received cancer therapies including chemotherapy, radiation, biologic, or kinase inhibitors, G-CSF, or GM-CSF within 3 weeks prior ot the first scheduled dose of CMB305Xx_NEWLINE_xXOngoing or previous anti-cancer treatment within 4 weeks of study treatment start (or 6 weeks for mitomycin C, nitrosoureas and monoclonal antibodies); with exceptions.Xx_NEWLINE_xXAny radiotherapy within 3 weeks except palliative stereotactic body radiation therapy (SBRT) within 2 weeksXx_NEWLINE_xXPrior treatment with SERMs or SERDs within 5 weeks of first G1T48 doseXx_NEWLINE_xXany systemic therapy against GvHD < 2 weeks prior to study Day 1Xx_NEWLINE_xXTreatment with a therapeutic antibody targeting CD38 < 12 weeks prior to study Day 1Xx_NEWLINE_xXPatient has received any chemotherapy, surgery, radiotherapy (for therapeutic purposes), tyrosine kinase inhibitors, investigational drugs, chronic use of systemic corticosteroids or statin therapy within 2 weeks prior to the leukapheresisXx_NEWLINE_xXNitrosourea cytotoxic drug ? 6 weeksXx_NEWLINE_xXApproved BRAF and MEK inhibitors ? 3 weeksXx_NEWLINE_xXAnti-CD20 therapy within 4 weeks of enrollment;Xx_NEWLINE_xXPatients must have completed radiation therapy or major surgery >= 3 weeks, or biologic therapy or chemotherapy >= 5 half-lives or 3 weeks, whichever is shorter (6 weeks for nitrosoureas and mitomycin C) prior to entering the study; patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study and be >= 1 week from palliative radiation therapy; patients must have recovered to eligibility levels from prior toxicity or adverse events; treatment with bisphosphonates is permittedXx_NEWLINE_xXPatients must have completed any chemotherapy, radiation therapy, or biologic therapy >= 3 weeks prior to entering the study; patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study; patients must have recovered to eligibility levels from prior toxicity or adverse events; treatment with bisphosphonates is permittedXx_NEWLINE_xXLast dose of any myelosuppressive or biologic therapy was given at least 2 weeks before the start date for vorinostat on this protocolXx_NEWLINE_xXLast dose of chemotherapy must be at least 3 weeks before first dose of study treatment; there is no required washout for endocrine therapyXx_NEWLINE_xXSubjects must be >= 4 weeks beyond treatment with any chemotherapy or other investigational therapy to include hormonal, biological, or targeted agents (>= 8 weeks from previous bevacizumab treatment) at the time of first dose of study drug(s)Xx_NEWLINE_xXPatients who have received RAI within 8 weeksXx_NEWLINE_xXNo steroids for at least 2 weeks prior to enrollment, and patient must not be expected to require steroids during the study periodXx_NEWLINE_xXPrior therapeutic intervention with any of the following:\r\n* Therapeutic anticancer antibodies (rituximab, obinutuzumab) within 4 weeks\r\n* Radio- or toxin-immunoconjugates within 10 weeks\r\n* Inhibitors of PI3K (idelalisib), ibrutinib, BH3-mimetic venetoclax, lenalidomide, and other â€œtargetedâ€ therapy (including investigational BTK inhibitors and other investigational therapy) â€“ within 6 half-lives\r\n* All other chemotherapy, radiation therapy within 3 weeks prior to initiation of therapyXx_NEWLINE_xXThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within 4 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXSigns or symptoms of infection =< 2 weeks prior to registrationXx_NEWLINE_xXMay have received 1 prior biologic regimen (i.e. avastin) but not within 4 weeks of enrollmentXx_NEWLINE_xXConcomitant therapy with any of the following: interleukin-2 (IL-2), interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; other investigational therapies; all such therapies must have been discontinued > 4 weeksXx_NEWLINE_xX(Prior to treatment) Note: evaluate at least 1 week before T cell infusion. a. Adequate venous access â€“ consider peripherally inserted central catheter (PICC) or central line. b. ECOG/Zubrod performance status of â€˜0-1. c. Bi-dimensionally measurable disease by palpation on clinical exam, or radiographic imaging (X-ray, computed tomography [CT scan]). d. At least 4 weeks must have elapsed since the last chemotherapy, immunotherapy, radiotherapy or major surgery. At least 6 weeks for nitrosoureas, mitomycin C and liposomal doxorubicin. e. Toxicity related to prior therapy must either have returned to =< grade 1, baseline, or been deemed irreversible. f. Persons of reproductive potential must agree to use and utilize an adequate method of contraception throughout treatment and for at least 3 months after study drug is stopped. g. Willing and able to give informed consent.Xx_NEWLINE_xXSevere infections within 4 weeks prior to week 1, day 1, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia\r\n* Any course of oral or IV antibiotics must have been completed at least 2 weeks prior to the first dose of study medicationsXx_NEWLINE_xXBilirubin ? 1.5 x UNL ? 2 weeksXx_NEWLINE_xXPrior treatment\r\n* Current or prior treatment for this cancer with immunotherapy and/or any other investigational agents\r\n* Surgery =< 2 weeks prior to registration\r\n* Radiotherapy =< 12 weeks prior to registration\r\n* Treatment with bevacizumab or any cytotoxic chemotherapy =< 8 weeks prior to registrationXx_NEWLINE_xXTherapy for underlying malignancy within 2 weeks prior to start of study treatmentXx_NEWLINE_xXPrior chemotherapy within 3 weeks, nitrosoureas within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy or other investigational agents within 3 weeks, major surgery within 4 weeks or vaccination with live attenuated vaccines within 4 weeks of the first dose of study drug.Xx_NEWLINE_xXCancer chemotherapy within 2 weeks prior to start of daratumumab treatment (steroid or hydroxyurea can be used up to 24 hours prior to first daratumumab infusion for control of high white cell counts)Xx_NEWLINE_xXCancer immunotherapy within four weeks prior to start of daratumumab treatment (exception blinatumomab within two weeks prior)Xx_NEWLINE_xXPatient has had any systemic therapy within 2 weeks prior to initiating study drug.Xx_NEWLINE_xXNo concomitant therapy with any of the following: IL2, interferon, or other non-study immunotherapy regimens; cytotoxic chemotherapy; immunosuppressive agents; or other investigational therapies; all such therapies must have been discontinued >= 4 weeks prior to registrationXx_NEWLINE_xXA minimum of two weeks of VMS diary recording prior to SGBXx_NEWLINE_xXDisease course appropriate for therapy initiation approximately 8-12 weeks from enrollment per treating physician.Xx_NEWLINE_xXPatient who has had systemic therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study entryXx_NEWLINE_xXLast chemotherapy at least 3 weeks from initiation of study treatmentXx_NEWLINE_xXSystemic chemotherapy for the study cancer < 2 weeks prior to registrationXx_NEWLINE_xXPart 1 patients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n* 12 weeks from the completion of radiation \r\n* 6 weeks from a nitrosourea chemotherapy or mitomycin C\r\n* 3 weeks from a non-nitrosourea chemotherapy\r\n* 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n* 2 weeks from administration of a non-cytotoxic, FDA-approved agent, except bevacizumab/ vascular endothelial growth factor receptor (VEGFR) inhibitors (e.g., erlotinib, hydroxychloroquine, etc.)\r\n* 6 weeks from bevacizumab/VEGFR inhibitorsXx_NEWLINE_xXBiopsy-proven KS involving skin (with or without visceral involvement) without need for urgent cytotoxic therapy; there should be no evidence of improvement in KS in the 4 weeks immediately prior to study enrollmentXx_NEWLINE_xXPatient has received radiotherapy ? 4 weeks or limited field radiation for palliation ? 2 weeks prior to enrollment, and who has not recovered to grade 1 or better from related side effects of such therapyXx_NEWLINE_xXClinically stable CNS tumor at the time of screening untreated or without evidence of progressions for at least 4 weeks after treatment as determined by clinical examination and brain imaging (MRI or CT) during screening period and stable low dose of steroids for 2 weeks prior to initiating study treatmentXx_NEWLINE_xXTreatment with systemic immunosuppressive medication within 2 weeks prior to initiation of studyXx_NEWLINE_xXPatients must have:\r\n* Had their last fraction of local irradiation to primary tumor >= 12 weeks prior to registration\r\n* Had their last fraction of craniospinal irradiation or total body irradiation >= 12 weeks prior to registrationXx_NEWLINE_xXAntibodies or immunotherapy within 6 weeks before the first dose of study treatment.Xx_NEWLINE_xXRequires or may require treatment with high-dose systemic corticosteroids within 2 weeks of the start of intravenous pembrolizumab infusions and within 2 weeks following the first infusion of pembrolizumabXx_NEWLINE_xXMust have disease free status as determined by imaging within 4 weeks of dosingXx_NEWLINE_xXTreatment with denosumab (or other receptor activator of nuclear factor kappa-B ligand [RANKL] inhibitor) 4 weeks before the first dose and for 10 weeks after the last dose of atezolizumabXx_NEWLINE_xXThe platelet count must be > 75,000 mm^3 prior to starting every cycle of treatment with decitabine; decitabine may be delayed for up to 4 weeks between cycles (i.e. may be administered as infrequently as every (q) 8 weeks) while waiting for counts to recoverXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive anti-cancer therapy: must not have been received within 2 weeks of study entry (4 weeks if prior nitrosourea)\r\n* Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent\r\n* Radiation therapy (RT): >= 2 weeks for local palliative radiation therapy (RT) (small port); >= 6 weeks must have elapsed if prior craniospinal RT or if >= 50% radiation of pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation\r\n* Surgery: >= 2 weeks from last major surgery, including pulmonary metastasectomy, with the exclusion of a central line placement and core needle or small open biopsiesXx_NEWLINE_xXPatients must not receive any other investigational agents while on study or within four weeks prior to randomizationXx_NEWLINE_xXThe subject must have first vaccine treatment start date at least 4 weeks out but not more than 8 weeks from the last dose of concomitant temozolomide or radiotherapyXx_NEWLINE_xXPatients who have had anti-cancer therapy within 2 weeks prior to entering the studyXx_NEWLINE_xXReceipt of therapeutic oral or IV antibiotics within 2 weeks prior to the start of the study treatmentXx_NEWLINE_xXContraindication to antiangiogenic agents, including:\r\n* Serious non-healing wound, non-healing ulcer, or bone fracture\r\n* Major surgical procedure or significant traumatic injury within 4 weeks prior to initiating study treatment; other surgical procedures within 2 weeks prior to initiating study treatment\r\n* Pulmonary hemorrhage/bleeding event >= grade 2 within 12 weeks prior to initiating study treatment\r\n* Any other hemorrhage/bleeding event >= grade 3 within 12 weeks prior to initiating study treatmentXx_NEWLINE_xXGraft-Versus-Host Disease (GVHD) therapy within 6 weeks before the first dose of study drug; low dose steroids (? 10mg) allowedXx_NEWLINE_xXAny of the following prior therapies:\r\n* Chemotherapy =< 3 weeks prior to registration\r\n* Immunotherapy =< 4 weeks prior to registration\r\n* Biologic therapy =< 4 weeks prior to registration\r\n* Radiation therapy =< 3 weeks prior to registrationXx_NEWLINE_xXAll prior systemic cancer therapy (hormonal, chemotherapeutic, and immunotherapeutic) must be completed at least 4 weeks before the baseline visitXx_NEWLINE_xXARM A: Systemic anti-cancer therapy =< 4 weeks prior to registrationXx_NEWLINE_xXARM B: Systemic anti-cancer therapy =< 4 weeks prior to registrationXx_NEWLINE_xXMust be willing to implement contraception throughout study and for the 4 weeks following last viral administrationXx_NEWLINE_xXAny of the following therapies prior to pre-registration:\r\n* Chemotherapy =< 4 weeks\r\n* Immunotherapy =< 4 weeks\r\n* Biologic therapy =< 4 weeks; Note exception: prior viral and/or gene therapy are exclusion criteria\r\n* Radiotherapy =< 4 weeksXx_NEWLINE_xXAny of the following prior therapies:\r\n* Chemotherapy =< 4 weeks prior to registration\r\n* Mitomycin C/nitrosoureas =< 6 weeks prior to registration\r\n* Immunotherapy =< 4 weeks prior to registration\r\n* Biologic therapy =< 4 weeks prior to registration\r\n* Radiation therapy =< 4 weeks prior to registration\r\n* Radiation to > 25% of bone marrow \r\n* Investigational therapy or any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) =< 4 weeks prior to registration; subjects with prostate cancer will be permitted to continue hormone therapyXx_NEWLINE_xXMajor surgery < 4 weeks or radiation therapy < 2 weeks of study entry; prior palliative radiotherapy to metastatic lesion(s) is permitted, provided there is at least one measurable lesion that has not been irradiatedXx_NEWLINE_xXSubjects must have received trastuzumab in the metastatic setting and experienced disease progression on this drug; any number of prior therapies is permitted; prior therapy with other HER2 targeted agents (trastuzumab emtansine [TDM-1], pertuzumab, lapatinib) is allowed; the last dose of cytotoxic chemotherapy must have occurred >= 3 weeks prior to study registration; the last radiation therapy must have occurred >= 3 weeks prior to study registrationXx_NEWLINE_xXConcurrent somatostatin analogues are allowed provided that the dose has been stable (+/- 10 mg) for at least 8 weeksXx_NEWLINE_xXTherapy with other investigational agents within 4 weeks of treatment initiation on this trialXx_NEWLINE_xXPatients with hemoptysis in excess of 2.5 mL within 6 weeks prior to the first dose of study medicationXx_NEWLINE_xXChemotherapy or dose of other potentially myelosuppressive treatment within 3 weeks prior to Screening (6 weeks for nitrosoureas or mitomycin C)Xx_NEWLINE_xXRecent therapeutic intervention including a) prior nitrosoureas or mitomycin C; prior radio- or toxin-immunoconjugates within 6 weeks; b) therapeutic anticancer antibodies (including rituximab, ofatumumab and obinituzumab) within 4 weeks; and c) all other chemotherapy or radiation therapy within 2 weeks prior to initiation of study drugXx_NEWLINE_xXOff all other treatments for MDS for at least 2 weeks prior to Screening.Xx_NEWLINE_xXAny anti-cancer therapy or investigational agents =< 4 weeks prior to registrationXx_NEWLINE_xXHistory of diverticulitis or pancreatitis within 12 weeks of registrationXx_NEWLINE_xXAt least 12 weeks from completion of radiation therapy except if there is unequivocal evidence for tumor recurrence in which case at least 4 weeksXx_NEWLINE_xX4 weeks from prior cytotoxic therapyXx_NEWLINE_xX4 weeks from prior experimental drugXx_NEWLINE_xX6 weeks from nitrosoureasXx_NEWLINE_xX3 weeks from procarbazineXx_NEWLINE_xXTreatment with Enzyme-Inducing Anti-Epileptic Drugs within 2 weeks prior to Day 1Xx_NEWLINE_xXAny of the following prior therapies:\r\n* Chemotherapy =< 4 weeks prior to registration\r\n* Mitomycin C/nitrosoureas =< 6 weeks prior to registration\r\n* Immunotherapy =< 4 weeks prior to registration\r\n* Biologic therapy =< 4 weeks prior to registration\r\n* Radiation therapy =< 4 weeks prior to registration\r\n* Radiation to > 25% of bone marrowXx_NEWLINE_xXThe subject must have discontinued any endocrine therapy for at least 2 weeks before the first dose of study treatment; in the cases of fulvestrant and leuprolide, these must be discontinued for at least 4 weeks before the first dose of study treatmentXx_NEWLINE_xXThe subject has received systemic chemotherapy (including investigational agents) within 4 weeks, or biological agents (antibodies, immune modulators, cytokines, or vaccines) within 6 weeks, or hormonal anticancer therapy within 2 weeks before the first dose of study treatment (within 4 weeks in the case of fulvestrant) (vaccines, such as flu shot or, pneumovax are not exclusions)Xx_NEWLINE_xXPatients must not have received chemotherapy within 4 weeks, pegfilgrastim (PEG-G-CSF) (Neulasta) within 4 weeks or filgrastim (G-CSF) (Neupogen) within 2 weeks prior to enrollmentXx_NEWLINE_xXAny of the following therapies:\r\n* Chemotherapy =< 4 weeks prior to registration (6 wks for nitrosourea-based chemotherapy)\r\n* Immunotherapy =< 4 weeks prior to registration\r\n* Biologic therapy =< 4 weeks prior to registration\r\n* Bevacizumab =< 12 weeks prior to registration\r\n* Non-cytotoxic antitumor drugs, i.e., small molecule cell cycle inhibitors =< 2 weeks prior to registration\r\n* Radiation therapy =< 6 weeks prior to registration\r\n* Any viral or gene therapy prior to registrationXx_NEWLINE_xXRecent (i.e., ? 6 weeks) history of abdominal surgery or peritonitisXx_NEWLINE_xXChemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatmentXx_NEWLINE_xXDiethylstilbestrol, estrogens, saw palmetto, or other preparations that are known to have possible endocrine effects on prostate cancer that have been started within the past 8 weeks, as they may affect PSA levels or response; these are allowed if the patient has been on a stable dose for at least 8 weeks prior to cycle 1 day 1 (C1D1)Xx_NEWLINE_xXPatients must be enrolled within 56 weeks following completion of therapyXx_NEWLINE_xX-  Subjects who have received any prior chemotherapy, radiotherapy, biologic/targeted\n             anti-cancer therapy or surgery within 4 weeks (6 weeks for monoclonal antibodies,\n             radioactive monoclonal antibodies or any radio- or toxin- immunoconjugates) before\n             the first study drug administration and have not recovered (to AEs <  Grade 2) from\n             the toxic effects from any prior therapyXx_NEWLINE_xXPrior â€œsystemicâ€ radiopharmaceuticals (strontium, samarium, radium 223 dichloride) must be completed >= 8 weeks prior to enrollmentXx_NEWLINE_xXPatients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n* 12 weeks from the completion of radiation \r\n* 6 weeks from a nitrosourea chemotherapy\r\n* 3 weeks from a non-nitrosourea chemotherapy\r\n* 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n* 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., erlotinib, hydroxychloroquine, etc.)Xx_NEWLINE_xXTreatment with an investigational small molecule less than 2 weeks before the first dose of CPI-0610Xx_NEWLINE_xXSubjects who have received systemic anticancer therapy within 3 weeks before the start of study treatment; mitomycin C or nitrosoureas must be excluded within 6 weeks before the start of study treatmentXx_NEWLINE_xXHistory and physical examination including weight, performance status, and body surface area within 8 weeks prior to study registrationXx_NEWLINE_xXPatient who has received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered to grade 1 or better from related side effects of such therapy (except alopecia)Xx_NEWLINE_xXPatients who have received oral or IV chemotherapy or targeted anticancer therapy =< 2 weeks (4 weeks for nitrosourea, antibodies or mitomycin-C) prior to study enrollment; steroids used for anti-cancer properties must be tapered to 10 mg or less of prednisone (or equivalent) for at least 2 weeks prior to initiating therapyXx_NEWLINE_xXPatients must have received standard treatment appropriate for their tumor type\r\n* Myelosuppressive chemotherapy: patients with solid tumors must not have received myelosuppressive chemotherapy within 3 weeks of enrollment onto this study (6 weeks if prior nitrosourea)\r\n* Hematopoietic growth factors: at least 14 days must have elapsed after receiving pegfilgrastim and least 7 days must have elapsed since the completion of therapy with a non-pegylated growth factor\r\n* Biologic (anti-neoplastic agent): at least 7 days must have elapsed since completion of therapy with a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period prior to enrollment must be extended beyond the time during which adverse events are known to occur\r\n* Monoclonal antibodies: at least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy: >= 2 weeks must have elapsed since local palliative external beam radiation therapy (XRT) (small port); >= 6 weeks must have elapsed since treatment with therapeutic doses of MIBG; >= 3 months must have elapsed if prior craniospinal XRT was received, if >= 50% of the pelvis was irradiated, or if total body irradiation (TBI) was received; >= 6 weeks must have elapsed if other substantial bone marrow irradiation was given\r\n* Stem cell transplant or rescue without TBI: no evidence of active graft vs. host disease and >= 2 months must have elapsed since transplantXx_NEWLINE_xXTherapy must begin between 21 days (3 weeks) and 42 days (6 weeks) after the most recent brain tumor surgery (resection or biopsy)Xx_NEWLINE_xXPatients must be at least 3 weeks from prior thoracotomy (if performed)Xx_NEWLINE_xXPrior chemotherapy within the last 3 weeks (last 6 weeks for nitrosoureas/mitomycin)Xx_NEWLINE_xXPatients must be >= 3 weeks from last chemotherapy or radiation (6 weeks for nitrosoureas or mitomycin)Xx_NEWLINE_xXPatient has not recovered from any toxicity of prior therapies; an interval of \r\n* At least 6 weeks must have elapsed since taking a nitrosourea-containing chemotherapy regimen\r\n* At least 4 weeks since completing a non-nitrosourea-containing cytotoxic chemotherapy regimen (except temozolomide: only an interval of 23 days is required from the last does administered when patient has been recently treated with the standard temozolomide regimen of daily for 5 days, repeated every 28 days)\r\n* At least 2 weeks from taking the last dose of targeted agent\r\n* At least 4 weeks from the last dose of bevacizumabXx_NEWLINE_xXPatients must not be on any other systemic therapy within the following intervals before study enrollment:\r\n* 1 week after stereotactic radiosurgery of the brain or comparable technology\r\n* 4 weeks after cytotoxic chemotherapy or external beam radiation therapy\r\n* 6 weeks after chemotherapy regimens including BCNU (carmustine) or mitomycin C\r\n* Patients who experience melanoma progression (by Response Evaluation Criteria in Solid Tumors [RECIST] 1.1 criteria) while on or after treatment with programmed cell death 1 (PD-1) or PD ligand-1 (PDL-1) antibody may enroll on this study\r\n** NOTE: Patients must be off PD-1/PDL- antibody for at least 2 weeks to assess for delayed toxicity before being enrolled and receiving INCB024360; patients who are enrolled 2 weeks and up to 6 weeks after the last dose of PD-/PDL-1 antibody will enroll in cohort B and receive 100 mg BID of INCB024360; patients enrolled beyond the 6 week period after failing anti-PD-1/PDL-1 will be enrolled in cohort A; cohort A patients will receive 300 mg BID of INCB024360; patients must not have active grade 2 autoimmune toxicities attributed to these antibodies at study entry\r\n* 8 weeks after ipilimumab, other cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody or other immunologically active antibody\r\n** NOTE: Patients receiving prior CTLA-4, anti-PD1 antibody or other immunologic therapy must show evidence of normal pituitary function at baseline and must not have active grade 2 autoimmune toxicities attributed to these antibodies at study entryXx_NEWLINE_xXIpilimumab or other immunologically active therapy within 8 weeks of enrollment; NOTE: patients who experience melanoma progression (by RECIST 1.1 criteria) while on or after treatment with PD-1 or PDL-1 antibody may enroll on this studyXx_NEWLINE_xXReceiving another experimental drug within 4 weeks before initiation of conditioning (day -6)Xx_NEWLINE_xXPrior systemic therapies allowed, except for those treatments directed toward, or with activity against, c-Met or vascular endothelial growth factor/receptor (VEGF/R), and the chemotherapy agents temozolomide and dacarbazine; prior treatment must have been no earlier than 3 weeks prior to starting treatment with cabozantinib with exceptions noted below and the following: at least 4 weeks since prior hepatic infusion or at least 2 weeks since radiation therapyXx_NEWLINE_xXNo cytotoxic chemotherapy including investigational cytotoxic chemotherapy or biologic agents (e.g., cytokines or antibodies) within the last 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatment; at least 6 weeks must have elapsed if the last regimen included an anti-cytotoxic T-lymphocyte antigen 4 (CTLA4) antibody; patients must have experienced disease progression on their prior therapy in the opinion of the treating investigatorXx_NEWLINE_xXNo hemoptysis of >= 0.5 teaspoon (2.5 mL) of red blood within 12 weeks before the first dose of study treatmentXx_NEWLINE_xXNo signs indicative of pulmonary hemorrhage within 12 weeks before the first dose of study treatmentXx_NEWLINE_xXPatients must not receive any other investigational agents during the period on study or the four weeks prior to entryXx_NEWLINE_xXPrior treatment with any investigational drug within the preceding 4 weeks prior to starting study drugXx_NEWLINE_xXPatients who have received immunotherapy of any type within the past 4 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXAll of the above inclusion criteria must occur within 8 weeks prior to patient registration, with the exception of pathologic assessment of the mediastinum and biopsy to confirm NSCLC, which can be done within 12 weeks of patient registrationXx_NEWLINE_xXPatients must be at least 4 weeks from any prior systemic therapy (6 weeks for nitrosoureas or mitomycin C), surgery or radiationXx_NEWLINE_xXRecent prior therapy:\r\n* Systemic chemotherapy =< 2 weeks (6 weeks for nitrosoureas) or radiation therapy =< 3 weeks prior to apheresis; exceptions: \r\n** There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such; \r\n** Subjects receiving hydroxyurea may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis; \r\n** Patients who relapse while receiving standard ALL maintenance chemotherapy will not be required to have a waiting period before entry onto this study provided they meet all other eligibility criteria; \r\n** Subjects receiving steroid therapy at physiologic replacement doses only are allowed provided there has been no increase in dose for at least 2 weeks prior to starting apheresis; \r\n** For radiation therapy: radiation therapy must have been completed at least 3 weeks prior to enrollment, with the exception that there is no time restriction if the volume of bone marrow treated is less than 10% and also the subject has measurable/evaluable disease outside the radiation portXx_NEWLINE_xXNo change in systemic immunosuppressive therapy (type or intensity level) within 2 weeks prior to enrollmentXx_NEWLINE_xXUse of clobetasol ointment intra-orally at any time during the last 6 weeks periodXx_NEWLINE_xXHistory/physical examination, including documentation of weight, within 2 weeks prior to registrationXx_NEWLINE_xXPatient must have recovered from toxicity of prior chemotherapy, molecularly targeted agents and/or radiotherapy; patient may not have received chemotherapy in the prior 4 weeks (6 weeks for nitrosoureas or mitomycin C); patients may have not received a molecularly targeted agent within the past 4 weeks or 5 half lives (which ever is less); patients may not have received radiotherapy in the prior 3 weeksXx_NEWLINE_xXPatients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPatients who have received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXAny exogenous hormone therapy must be completed 4 weeks prior to registrationXx_NEWLINE_xXPatients with prior investigational therapies within 4 weeks before treatment with\n             APC-100Xx_NEWLINE_xXNo chemotherapy within 4 weeks of first vaccine administrationXx_NEWLINE_xXNo targeted therapy within 2 weeks of first vaccine administrationXx_NEWLINE_xXNo immunomodulatory therapy within 2 weeks of first vaccine administrationXx_NEWLINE_xXDuring Screening period, no steroid therapy within 4 weeks of first vaccine administrationXx_NEWLINE_xXHistory and physical examination within 6 weeks of registrationXx_NEWLINE_xXPrior investigational anti-cancer therapy within 4 weeks prior to day 1Xx_NEWLINE_xXInclusion Criteria:\n\n          1. Subjects must have a histologically confirmed diagnosis of glioblastoma multiforme or\n             gliosarcoma;\n\n          2. Measurable disease by RANO criteria;\n\n          3. Disease progression or recurrence following standard of care treatment with\n             temozolomide and radiation;\n\n          4. An interval of at least 4 weeks between prior surgical resection and study\n             enrollment;\n\n          5. An interval of at least 12 weeks between prior radiotherapy or at least 4 weeks from\n             prior chemotherapy, and enrollment in this protocol;\n\n          6. Recovered to Grade 1 or less from the toxic effects of any earlier intervention;\n\n          7. Karnofsky performance status > 60%\n\n        Exclusion Criteria:\n\n          1. Prior anti-angiogenic therapy including VEGF sequestering agents (ie bevacizumab,\n             aflibercept, etc) or VEGFR inhibitors (cediranib, pazopanib, sunitinib, sorafenib,\n             etc);\n\n          2. Prior stereotactic radiotherapy;\n\n          3. Active infection;\n\n          4. Evidence of CNS haemorrhage CTCAE grade 2 or above on baseline MRI;\n\n          5. Subjects who suffered from an acute cardiac event within the last 12 months;\n\n          6. Subjects with active vascular disease, either myocardial or peripheral;\n\n          7. Subjects with proliferative and/or vascular retinopathy;\n\n          8. Subjects with known active second malignancy;Xx_NEWLINE_xXInclusion Criteria:\n\n          1. Subjects must have a histologically confirmed diagnosis of glioblastoma multiforme or\n             gliosarcoma;\n\n          2. Measurable disease by RANO criteria;\n\n          3. Disease progression or recurrence following standard of care treatment with\n             temozolomide and radiation;\n\n          4. An interval of at least 4 weeks between prior surgical resection and study\n             enrollment;\n\n          5. An interval of at least 12 weeks between prior radiotherapy or at least 4 weeks from\n             prior chemotherapy, and enrollment in this protocol;\n\n          6. Recovered to Grade 1 or less from the toxic effects of any earlier intervention;\n\n          7. Karnofsky performance status > 60%\n\n        Exclusion Criteria:\n\n          1. Prior anti-angiogenic therapy including VEGF sequestering agents (ie bevacizumab,\n             aflibercept, etc) or VEGFR inhibitors (cediranib, pazopanib, sunitinib, sorafenib,\n             etc);\n\n          2. Prior stereotactic radiotherapy;\n\n          3. Active infection;\n\n          4. Evidence of CNS haemorrhage CTCAE grade 2 or above on baseline MRI;\n\n          5. Subjects who suffered from an acute cardiac event within the last 12 months;\n\n          6. Subjects with active vascular disease, either myocardial or peripheral;\n\n          7. Subjects with proliferative and/or vascular retinopathy;\n\n          8. Subjects with known active second malignancy;Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: Must not have received within 3 weeks of entry onto this study (6 weeks if prior nitrosourea)\r\n* Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy with a biologic agent; at least 3 weeks for biologic agents with a long half life, such as antibodies\r\n* External beam radiation therapy (XRT): Must not have received craniospinal radiotherapy within 24 weeks prior to study entry; the tumor designated as â€œmeasurableâ€ for protocol purposes must not have received radiation within 12 weeks prior to study entry); focal radiation to areas of symptomatic metastatic disease must not be given within 14 days of study entry\r\n* Stem cell transplant (SCT): For autologous SCT, >= 3 months must have elapsed prior to study entry\r\n* Study specific limitations on prior therapy:\r\n** Patients must not have previously received bevacizumab, irinotecan, temozolomide or other anti-vascular endothelial growth factor (VEGF) inhibitor\r\n** Patients must not be taking enzyme-inducing antiepileptic medicines within 1 week of study entryXx_NEWLINE_xXPrior systemic radiation therapy must have been completed at least 4 weeks before study drug administration; prior focal radiotherapy completed at least 2 weeks before study drug administration; no radiopharmaceuticals (strontium, samarium) within 8 weeks before study drug administrationXx_NEWLINE_xXCompleted nitrosourea treatment at least 6 weeks before administration of any study drugXx_NEWLINE_xXPrior surgery that required general anesthesia must be completed at least 4 weeks before study drug administration; surgery requiring local/epidural anesthesia must be completed at least 72 hours before study drug administration and subjects should be recoveredXx_NEWLINE_xXPrior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) must have been completed at least 4 weeks before study drug administration, and all adverse events have either returned to baseline or stabilized\r\n* For the fourth cohort, ipilimumab at 3 mg/kg must have been completed not less than 4 weeks prior to initiation of BMS-936558; ipilimumab at 10 mg/kg must have been completed not less than 6 weeks prior to initiation of BMS-936558\r\n* All drug related toxicities must have resolved to grade 1 or less, and patients must be off steroids for at least 3 weeks\r\n* Patients in the fourth cohort who required infliximab or other immune suppressants including mycophenolic acid will be excluded\r\n* For the fifth cohort, ipilimumab at 3 mg/kg or 10 mg/kg must have been completed not less than 8 weeks prior to initiation of BMS-936558; all drug related toxicities must have resolved to grade 1 or less, and patients must be off steroids for at least 2 weeks and any other immune suppressant such as mycophenoloc acid or infliximab for at least 3 weeks\r\n* Patients in the fifth cohort who experienced grade 3-4,neurologic or ophthalmologic side effects or any other grade 4 side effect other than liver, pancreatic, gastrointestinal (GI), endocrine, pulmonary or skin related will be excludedXx_NEWLINE_xXPrior systemic radiation therapy must have been completed at least 4 weeks before study drug administration\r\n* Prior focal radiotherapy completed at least 2 weeks before study drug administration\r\n* No radiopharmaceuticals (strontium, samarium) within 8 weeks before study drug administrationXx_NEWLINE_xXCompleted nitrosourea treatment at least 6 weeks before administration of any study drugXx_NEWLINE_xXPrior surgery that required general anesthesia must be completed at least 2 weeks before study drug administration\r\n* Surgery requiring local/epidural anesthesia must be completed at least 72 hours before study drug administration and subjects should be recoveredXx_NEWLINE_xXPrior chemotherapy (except PLD in Dose Escalation Cohorts only) or any investigational agent within 3 weeks prior to registrationXx_NEWLINE_xXElectrocardiogram (EKG) within 8 weeks of registrationXx_NEWLINE_xXCytotoxic chemotherapy, steroids or monoclonal antibody (Mab) within 3 weeks of enrollment, except anti-Tac Mab (i.e. daclizumab) which cannot be used within 12 weeks of enrollment; hydroxyurea is considered different from cytotoxic chemotherapy and may be used up to the day before enrollment providing it is not increased during the week prior to enrollment and that the patientâ€™s disease burden is not decreasing during that timeXx_NEWLINE_xXPatients must be at least 4 weeks from previous chemotherapy; 6 weeks from nitrosoureasXx_NEWLINE_xXNo anti-CD25 monoclonal antibody therapy within 12 weeks of enrollmentXx_NEWLINE_xXOff all myelofibrosis (MF)-directed therapy including investigational agents for at least 2 weeks prior to study enrollment and recovered from all toxicities; patient who has been on stable dose of ruxolitinib and has received ruxolitinib =< 6 months prior to the study entry will be considered potentially eligible for the study with the caveat that there is no evidence of loss of response (> 5 cm increase in spleen size from the nadir)Xx_NEWLINE_xXIntravesical therapy within 8 weeks prior to beginning study treatment with the exception of:Xx_NEWLINE_xXprevious intravesical BCG therapy, which can be given at least 5 weeks before the diagnostic biopsy required for entry into the studyXx_NEWLINE_xXPatients must be enrolled within 6 weeks of primary surgery or within 6 weeks after diagnosis of recurrent diseaseXx_NEWLINE_xXPatients must be enrolled between 8 to 20 weeks post OLTXx_NEWLINE_xXChemotherapy: nitrosoureas (At least 6 weeks since last dose of nitrosoureas prior to first dose of tazemetostat)Xx_NEWLINE_xXImmunotherapy (e.g., tumor vaccine) At least 6 weeks since last dose of immunotherapy agent(s) prior to first dose of tazemetostat)Xx_NEWLINE_xXFor advanced disease, interleukin-2 at any dose and/or IFN-? (any formulation, no washout required); MEK and BRAF inhibitors: washout for at least 4 weeks prior to the start of dosing in this studyXx_NEWLINE_xXMultiple bone metastases within 12 weeks prior to study drugXx_NEWLINE_xXTreatment with approved anti-cancer therapy (with the exception of abiraterone) within 3 weeks of study drug. Abiraterone must not be administered within 2 weeks prior to initiation of study treatmentXx_NEWLINE_xXOther monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or T-cell or other cell-based therapies: 4 weeks (2 weeks with documented disease progression)Xx_NEWLINE_xXAnticancer treatment within 4 weeks of study drug or 2 weeks if patient experienced disease progression on prior treatmentXx_NEWLINE_xXHigh-grade Ta papillary disease based on a biopsy within 8 weeks of the initial dose of study treatment. If multiple bladder biopsies are required to confirm eligibility, the last bladder biopsy to the initial dose of study treatment must be within 8 weeks. This diagnosis must be confirmed by the independent central pathology reviewer prior to subject enrollment. A subject with persistent T1 disease on the second (i.e., restaging) TURBT may be enrolled in this study only if the investigator documents the subject declines cystectomy.Xx_NEWLINE_xXCohort 3: Subjects with high-grade Ta or any grade T1 papillary disease (without CIS) whose disease is determined to be refractory or relapsed within 6 months of the last dose of adequate BCG treatment. For eligibility and cohort assignment, 6 months is defined as 30 weeks i.e., 26 weeks (6 months) plus an additional 4 weeks to accommodate scheduling variations and for diagnostic work-up and 11 months is defined as 50 weeks i.e., 48 weeks (11 months) plus an additional 2 weeks to accommodate scheduling variations and for diagnostic work-up. For subjects enrolling in Cohort 2: The investigator documents he/she would not treat the subject with additional BCG at the time of study entry.Xx_NEWLINE_xXUse of any monoclonal based therapies within 2-4 weeks prior to the first dose of study treatment.Xx_NEWLINE_xXBRAF/MEK inhibitors within 2 weeks prior to the first dose of study treatment.Xx_NEWLINE_xXSystemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or radiopharmaceuticals (strontium, samarium) within 8 weeks prior to the first dose of study treatment.Xx_NEWLINE_xXPatient may already have initiated adjuvant endocrine therapy (ET) at the time of randomization, but randomization must take place within 52 weeks of date of initial histological diagnosis of breast cancer and within 12 weeks of initiating ETXx_NEWLINE_xXPrior chemotherapy or targeted small molecule therapy within 2 weeks prior to study Day 1 or prior radiation therapy within 4 weeks prior to study Day 1.Xx_NEWLINE_xXPeripheral edema requiring medical intervention within 2 weeks prior to study day 1.Xx_NEWLINE_xXAt least 4 weeks since any previous treatment for cancerXx_NEWLINE_xXRecovery from effects of recent surgery, radiotherapy, or chemotherapy:\r\n* Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])\r\n* Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration\r\n* Any other prior therapy directed at the malignant tumor, including chemotherapy, biological/targeted and immunologic agents (including small molecules and murine monoclonal antibodies), must be discontinued at least three weeks prior to registration; chimeric or human or humanized monoclonal antibodies (including bevacizumab) or vascular endothelial growth factor [VEGF] receptor fusion proteins (including VEGF tartrate-resistant acid phosphatase [TRAP]/aflibercept) must be discontinued for at least 8 weeks prior to registration\r\n* At least 4 weeks must have elapsed since the patient underwent any major surgery (e.g., major: laparotomy, laparoscopy, thoracotomy, video assisted thorascopic surgery [VATS]; minor: central venous access catheter placement, ureteral stent placement or exchange, paracentesis, thoracentesis)Xx_NEWLINE_xXHistory of hemoptysis in excess of 2.5 mL (1/2 teaspoon) within 8 weeks prior to first dose of pazopanibXx_NEWLINE_xXInvestigational therapy within 4 weeks prior to CMB305 dosingXx_NEWLINE_xXOther cancer therapies, including chemotherapy, radiation, biologics or kinase inhibitors within 3 weeks prior to the first scheduled dosing.Xx_NEWLINE_xXMonoclonal antibody (mAb) for direct anti-neoplastic treatment within 4 weeksXx_NEWLINE_xXAllogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CTL019 infusionXx_NEWLINE_xXPatients who have received chemotherapy within 3 weeks prior to the initiation of study treatment, or endocrine therapy within 2 weeks prior to the initiation of study treatment; if patients are already on trastuzumab, this medication may be continuedXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to first dosing.Xx_NEWLINE_xXPatient must not have history of hemoptysis in excess of 2.5 mL (1/2 teaspoon) within 8 weeks prior to randomizationXx_NEWLINE_xXHas had prior anti-myeloma therapy within 2 weeks prior to study Day 1Xx_NEWLINE_xXImmunosuppression: Any immunosuppressive medication must be stopped ? 4 weeks prior to enrollmentXx_NEWLINE_xXAntiproliferative therapies other than lymphodepleting chemotherapy within two weeks of infusionXx_NEWLINE_xXHave received radiation therapy within 4 weeks (?4 weeks) prior to randomization or has not recovered from toxic effects of the treatment that was given >4 weeks prior to randomization.Xx_NEWLINE_xXInvestigational therapy within 3 weeks prior to CMB305 dosingXx_NEWLINE_xXCancer therapies, including chemotherapy, radiation, biologics or kinase inhibitors, G-CSF or GM-CSF within 3 weeks prior to the first scheduled CMB305 dosingXx_NEWLINE_xXAt least 2 weeks from end of chemotherapy with resolution of neutropenia to above levelXx_NEWLINE_xXAt least 4 weeks from end of monoclonal antibody therapyXx_NEWLINE_xXAt least 2 weeks from end of targeted therapyXx_NEWLINE_xXPatients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugsXx_NEWLINE_xXThe last dose of trastuzumab must have been given >2 weeks and ?1 year (365 days) from enrollmentXx_NEWLINE_xXRecent hemoptysis (>= 1/2 teaspoon of red blood within 8 weeks before first dose of pazopanib)Xx_NEWLINE_xXCytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXOral endocrine therapy </= 2 weeks before study treatmentXx_NEWLINE_xXTreatment with biologic therapy </= 3 weeks before study treatmentXx_NEWLINE_xXParticipant must have received ruxolitinib therapy for at least 24 weeks and be currently on a stable dose of >= 10 mg BID of ruxolitinib for >= 8 weeks prior to the 1st dose of navitoclax, ECOG of 0,1, or 2.Xx_NEWLINE_xXSevere infection within 4 weeks prior to initiation of study treatmentXx_NEWLINE_xXHas undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years, has received a live vaccine within 30 days of planned start of study therapy, has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1, received a monoclonal antibody within 4 weeks prior to study Day 1 or has not recovered from adverse events due to a previously administered agentXx_NEWLINE_xXPatients must have received neoadjuvant chemotherapy of at least 16 weeks. This period must include 6 weeks of a taxane -containing neoadjuvant therapy (Exception: For patients with progressive disease that occurred after at least 6 weeks of taxane-containing neoadjuvant treatment, a total treatment period of less than 16 weeks is also eligible).Xx_NEWLINE_xXLess than 16 weeks interval since the date of final surgery or less than 10 weeks from completing radiotherapy (whichever occurs last) at date of randomization.Xx_NEWLINE_xX10 weeks or more have passed since completion of radiotherapy at day of randomization and 16 weeks interval since the date of final surgery have passed.Xx_NEWLINE_xXVaccination within 2 weeks of enrollment (except for annual flu vaccine).Xx_NEWLINE_xXREGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have completed chemoradiotherapy per protocol and at least four weeks but no more than six weeks must have elapsed from the last day of induction therapy (the last day of radiation)Xx_NEWLINE_xXPrior exposure to bevacizumab or other VEGF- or VEGF-receptor-targeted agent within 8 weeks of study start.Xx_NEWLINE_xXReceipt of any anticancer therapy within 4 weeks prior to the first dose of MEDI1873; in the case of mAbs, 6 weeks prior to the first dose of MEDI1873Xx_NEWLINE_xXBefore the first dose of study medication: a) Has received prior systemic cytotoxic chemotherapy for metastatic disease, b) Has received antineoplastic biological therapy (e.g., erlotinib, crizotinib, cetuximab), c) Had major surgery (<3 weeks prior to first dose)Xx_NEWLINE_xXHospitalization within 2 weeks prior to screeningXx_NEWLINE_xXPrior monoclonal antibody treatment within 4 weeks before study Day 1Xx_NEWLINE_xXAllogeneic cellular therapy: Any donor lymphocyte infusions (DLI) must be completed > 6 weeks prior to CTL019 infusionXx_NEWLINE_xXSevere infection within 4 weeks prior to D1 of C1Xx_NEWLINE_xXAny therapeutic antibody within 4 weeks of first dose of study drugs.Xx_NEWLINE_xXInvestigational therapy within 3 weeks prior to LV305 dosing.Xx_NEWLINE_xXWash out periods prior to Day 1 of Cycle 1: At least three weeks since the last chemotherapy (six weeks in some particular cases) and At least four weeks since the last radiotherapy (RT) > 30 Gy) and At least one week since the last hormonal therapy and At least two weeks since the last biological/investigational therapyXx_NEWLINE_xXChemotherapy: nitrosoureas At least 6 weeksXx_NEWLINE_xXAt least 12 weeks for craniospinal, ?50% radiation of pelvis, or total body irradiation prior to first dose of study drugXx_NEWLINE_xXHas hemoptysis within 6 weeks prior to randomization.Xx_NEWLINE_xXUse of hydroxyurea within 2 weeks prior to obtaining the screening hematology sample and prior to first dose of IP.Xx_NEWLINE_xXUse of hydroxyurea within 2 weeks prior to obtaining the screening hematology sample and prior to first dose of IP.Xx_NEWLINE_xXEvidence of active infection within 2 weeks prior to first dose of study treatment.Xx_NEWLINE_xXSubject received treatment with 5-? reductase inhibitors (finasteride, dutasteride) within 4 weeks prior to day 1.Xx_NEWLINE_xXSubject received treatment with estrogens, cyprotoerone acetate or androgens within 4 weeks prior to day 1.Xx_NEWLINE_xXSubject received treatment with herbal medications that have known hormonal antiprostate cancer activity and/or are known to decrease PSA levels within 4 weeks prior to day 1.Xx_NEWLINE_xXSubject received bisphosphonates or denosumab within 2 weeks prior to day 1 unless administered at stable dose or to treat diagnosed osteoporosisXx_NEWLINE_xXHas had prior anti-myeloma therapy within 2 weeks prior to study Day 1Xx_NEWLINE_xXFirst day of dosing with tesevatinib is less than 2 weeks from the last treatment of cytotoxic chemotherapy, biological therapy, or immunotherapy, and less than 6 weeks for nitrosoureas and mitomycin C. Surgical procedures must have been performed at least 2 weeks prior to the start of study treatment. Subjects must have recovered from the reversible effects of prior lung cancer treatments, including surgery and radiation therapy (excluding alopecia)Xx_NEWLINE_xXLocoregional therapy for hepatocellular carcinoma (HCC) must be completed at least 4 weeks prior to the baseline scanXx_NEWLINE_xXAny cancer therapy in the last 3 weeks or limited palliative radiation <2 weeksXx_NEWLINE_xXTreatment with chemotherapy (other than high-dose chemotherapy as described above) or differentiation therapy (such as retinoic acid) or immunotherapy (such as anti-GD2 antibody treatment) within 3 weeks prior to initiation of study drug or, if treatment included nitrosoureas, within 6 weeks prior to initiation of study drugXx_NEWLINE_xXTreatment with investigational therapy (with the exception of cancer therapies as described above) within 4 weeks prior to initiation of study drugXx_NEWLINE_xXCancer therapies, including chemotherapy, radiation (non-study regimen related), biologics or kinase inhibitors, G-CSF or GM-CSF within 4 weeks prior to the first scheduled G100 doseXx_NEWLINE_xXInvestigational therapy within 4 weeks prior to G100 dosingXx_NEWLINE_xXInclusion Criteria:\n\n          -  Definitive diagnosis of unresectable locally advanced or metastatic RCC with\n             clear-cell histology and/or a component of sarcomatoid carcinoma, with no prior\n             treatment in the metastatic setting\n\n          -  Evaluable Memorial Sloan Kettering Cancer Center risk score\n\n          -  Measurable disease, as defined by RECIST v1.1\n\n          -  Karnofsky performance status greater than or equal to 70%\n\n          -  Adequate hematologic and end-organ function prior to randomization\n\n        Exclusion Criteria:\n\n        Disease-Specific Exclusions:\n\n          -  Radiotherapy for RCC within 14 days prior to treatment\n\n          -  Active central nervous system disease\n\n          -  Uncontrolled pleural effusion, pericardial effusion, or ascites\n\n          -  Uncontrolled hypercalcemia\n\n          -  Any other malignancies within 5 years except for low-risk prostate cancer or those\n             with negligible risk of metastasis or death\n\n        General Medical Exclusions:\n\n          -  Life expectancy less than 12 weeks\n\n          -  Participation in another experimental drug study within 4 weeks prior to treatment\n\n          -  Pregnant or lactating women\n\n          -  Known hypersensitivity to any component of atezolizumab or other study medication\n\n          -  History of autoimmune disease except controlled, treated hypothyroidism or type I\n             diabetes mellitus\n\n          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced\n             pneumonitis, or idiopathic pneumonitis\n\n          -  Positive human immunodeficiency virus test\n\n          -  Active or chronic hepatitis B or C\n\n          -  Severe infections within 4 weeks prior to treatment\n\n          -  Exposure to oral or IV antibiotics within 2 weeks prior to treatment\n\n          -  Live attenuated vaccines within 4 weeks prior to treatment, 28 days prior to\n             randomization, during treatment, or within 5 months following last dose of\n             atezolizumab\n\n          -  Significant cardiovascular disease\n\n          -  Prior allogeneic stem cell or solid organ transplantation\n\n        Exclusion Criteria Related to Medications:\n\n          -  Prior treatment with cluster of differentiation 137 agonists, anti-cytotoxic\n             T-lymphocyte associated protein-4, anti-programmed death (PD)-1, or anti-PD-L1\n             therapeutic antibody or pathway-targeting agents\n\n          -  Treatment with immunostimulatory agents for non-malignant conditions within 6 weeks or\n             immunosuppressive agents within 2 weeks prior to treatment\n\n        Bevacizumab- and Sunitinib-Specific Exclusions:\n\n          -  History of hypertensive crisis or hypertensive encephalopathy\n\n          -  Baseline electrocardiogram showing corrected QT interval greater than 460 millisecondsXx_NEWLINE_xXAt least 2 weeks must have elapsed from the use of any other endocrine therapyXx_NEWLINE_xXAt least 3 weeks must have elapsed from the use of any chemotherapyXx_NEWLINE_xXNone of the following therapies are allowed prior to registration:\r\n* Chemotherapy =< 2 weeks\r\n* Immunotherapy =< 2 weeks\r\n* Biologic therapy =< 2 weeks\r\n* Hormonal therapy =< 2 weeks\r\n* Monoclonal antibodies =< 2 weeks\r\n* Radiation therapy =< 2 weeks\r\n* Anti-Her-2 or other â€œtargetedâ€ (e.g. mammalian target of rapamycin [mTOR]) therapy =< 2 weeks\r\n** NOTE : Any toxicities derived from these therapies must be =< grade 2 prior to starting study therapyXx_NEWLINE_xXInclusion Criteria:\n\n        Among other criteria, patients must meet all of the following conditions to be eligible for\n        the study:\n\n          -  Unresectable, histologically-confirmed advanced (Stage III or Stage IV) melanoma\n\n          -  Disease progression during or after the last anticancer therapy received. For Cohort\n             3, progression must have occurred during the PD-1 targeted CPI (checkpoint inhibitor)\n             treatment and the investigator has deemed it appropriate to continue treatment with\n             the PD-1 targeted CPI beyond confirmed disease progression\n\n          -  No more than one prior chemotherapy-containing regimen for advanced disease.\n\n          -  Prior treatments received must include at least one CPI inhibitor (e.g., anti-CTLA-4,\n             PD-1-, PD-L1-targeted immunotherapy) and for patients with a BRAF mutation at least\n             one BRAF- or MEK-targeted therapy, unless patients are not candidates for, or refused,\n             these therapies. For cohort 3, prior treatment received must include a PD-1 targeted\n             CPI administered during the most recent disease progression and for patients with BRAF\n             mutation at least one BRAF- or MEK-targeted therapy when appropriate\n\n          -  The study site will submit paraffin-embedded tumor tissue obtained from the patient\n             for gpNMB analysis. Patients may require a biopsy if recent tumor tissue is not\n             available. Patients in cohort 2 and 3 must submit a recently obtained biopsy of the\n             skin fold for gpNMB analysis. Patients in Cohort 4 will submit a tumor tissue sample\n             while on study.\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1\n\n          -  Adequate bone marrow, liver and renal function.\n\n        Exclusion Criteria:\n\n        Among other criteria, patients who meet any of the following conditions are NOT eligible\n        for the study:\n\n          -  Previously received glembatumumab vedotin (CR011-vcMMAE, CDX-011) or other\n             MMAE-containing agents\n\n          -  Treatment with the following therapies before the planned start of study treatment:\n\n               1. BRAF or MEK inhibitors within 2 weeks\n\n               2. Monoclonal based therapies within 4 weeks except for the PD-1 targeted checkpoint\n                  inhibitor in cohort 3\n\n               3. Immunotherapy (tumor vaccine, cytokine, or growth factor given to control the\n                  cancer) within 2 weeks\n\n               4. Chemotherapy within 21 days or at least 5 half-lives (whichever is longer)\n\n               5. Investigational therapy within 2 weeks (or at least 5 half-lives, whichever is\n                  longer)\n\n          -  Patients with ocular melanoma\n\n          -  Neuropathy that is moderate (Grade 2) or worse.\n\n          -  Cancer that has spread to the brain or spine will be discussed with the study sponsor\n             and may exclude patients from the trial.\n\n          -  History of another cancer except:\n\n               1. Patients with adequately treated and cured non-melanoma skin cancer or in situ\n                  cancer\n\n               2. Patients with any other cancer from which the patient has been disease-free for ?\n                  3 years\n\n          -  Significant cardiovascular disease\n\n          -  Previously received varlilumab or any other anti-CD27 mAb (Cohort 2 only)\n\n          -  Active systemic infection requiring treatment\n\n          -  Treatment with immunosuppressive medications within 4 weeks or corticosteroids within\n             two weeks\n\n          -  Patients with interstitial lung disease (Cohort 3 only)\n\n          -  Patients with active diverticulitis (Cohort 3 only)\n\n          -  Any non-study vaccination within 4 weeks, or influenza vaccine within 2 weeks, prior\n             to CDX-301 dosing (Cohort 4 only)Xx_NEWLINE_xXPatients receiving any systemic chemotherapy within 3 weeks prior to first dose of study treatmentXx_NEWLINE_xXPrior treatment (chemotherapy [chemo], radiation, hormone, and immune therapies) must be completed > 4 weeks prior to randomization (> 6 weeks prior to randomization for nitrosoureas, mitomycin C, and checkpoint inhibitors)Xx_NEWLINE_xXPrior use of any monoclonal antibody, radio-immuno-conjugate or antibody drug conjugate within 4 weeks before study startXx_NEWLINE_xXApplies only for patients without the deletion 5q 31.1; patients must have failed treatment with an erythropoietic growth factor, or have a low probability of response to rhu-erythropoietin; patients with low probability of response to rhu-erythropoietin or prior erythropoietin failures are defined as follows:\r\n* Prior erythropoietin failure-requires a minimum trial of >= 40,000 units epoetin alfa/week x 8 weeks or equivalent dose of darbepoetin alfa for 8 weeks with failure to achieve transfusion independence in dependent patients or a failure to achieve a >= 2 g rise in hemoglobin sustained for >= 4 weeks in non-transfusion dependent patients\r\n* Low erythropoietin response profile-rhu-erythropoietin and epoetin alfa-naÃ¯ve patients receiving >= 2U packed (p)RBC/month for a minimum of 8 weeks, and serum erythropoietin > 500 mU/mL in the 8 weeks prior to randomization for a hemoglobin < 9.5 g/dLXx_NEWLINE_xXPatients must not have used cytotoxic chemotherapeutic agents or experimental agents (agents that are not commercially available) for the treatment of MDS within 8 weeks of randomizationXx_NEWLINE_xXPrior experimental (non-Food and Drug Administration [FDA] approved) therapies and immunotherapies are allowed; patients must not have received these therapies for 4 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of these therapiesXx_NEWLINE_xXRadiation therapy within 4 weeks prior to start of study treatment (palliative radiotherapy to bone lesions allowed up to 2 weeks prior to study treatment start).Xx_NEWLINE_xXPatients must be at least 3 weeks from prior thoracotomy (if performed); if prior thoracotomy then measurable disease on imaging must be presentXx_NEWLINE_xXSUB-PROTOCOL AIM A: Any of the following treatments:\r\n* Chemotherapy within 4 weeks before treatment with nab-rapamycin\r\n* Hormonal therapy within 4 weeks before treatment with nab-rapamycin (with the exception of leuprolide, degarelix, or goserelin)\r\n* Immunotherapy within 4 weeks before treatment with nab-rapamycin\r\n* Radiotherapy within 4 weeks before treatment with nab-rapamycin \r\n* Treatment with nitrosoureas, mitomycin, or extensive radiotherapy within 6 weeks before treatment with nab-rapamycin\r\n* Immunosuppressive agents within 3 weeks before treatment with nab-rapamycin (except corticosteroids used as antiemetics)\r\n* Use of prior mTOR pathway inhibitor therapyXx_NEWLINE_xXSubject who has had cytotoxic chemotherapy within 3 weeks prior to leukapheresis; immune therapy or biological therapy within 4 weeks prior to leukapheresis; corticosteroids or any other immunosuppressive therapy within 2 weeks prior to leukapheresis; tyrosine kinase inhibitor (TKI) (e.g. erlotinib, gefitinib) and any other anti-cancer treatment within 1 week prior to leukapheresis.Xx_NEWLINE_xXIf taking hormonal therapy, use should be stable (no changes within 4 weeks prior to the cryoablation procedure)Xx_NEWLINE_xXReceipt of any investigational medication within 4 weeks prior to enrollmentXx_NEWLINE_xXPrior treatment will be permitted including surgery (>= 4 weeks), cytotoxic chemotherapy (maximum of 2 prior regimens); radiation, interferon, targeted growth factors (>= 4 weeks); and prior treatment with octreotide, will be allowedXx_NEWLINE_xXCompletely removed melanoma by surgery performed within 12 weeks of randomizationXx_NEWLINE_xXAt least 4 weeks from surgical resection and 12 weeks from end of radiotherapy prior to enrollment in this study, unless relapse is confirmed by tumor biopsy or new lesion outside of radiation field, or if there are two MRIs confirming progressive disease that are 8 weeks apart.Xx_NEWLINE_xXChemotherapy administered within 4 weeks (except 6 weeks for nitrosoureas, 12 weeks for an implanted nitrosoureas wafer, and 1 week from metronomic chemotherapy, like daily temozolomide and etoposide) prior to Day 1 of study treatment, unless the subject has recovered from all expected toxicities from the chemotherapy.Xx_NEWLINE_xXSubjects must have received their last chemotherapy, non-anti-VEGF biologic, or investigational therapy at least 4 weeks prior to enrollment, 6 weeks if the last regimen included BCNU or mitomycin C, and 8 weeks if the last regimen was an anti-VEGF therapyXx_NEWLINE_xXNo prior systemic therapy for CLL or SLL including chemotherapy or immunotherapy (e.g., monoclonal antibody-based therapy), radiation therapy, within 4 weeks of enrollment; no prior carmustine (BCNU) or mitomycin C within 6 weeks of enrollment; no radioimmunotherapy within a year of enrollment; no corticosteroids administered within 2 weeks prior to study entry, except for maintenance therapy (=< prednisone 20 mg daily or equivalent) for a non-malignant diseaseXx_NEWLINE_xXNo oral or intravenous corticosteroid use within 2 weeks prior to study entryXx_NEWLINE_xXChemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatmentXx_NEWLINE_xXCurrently enrolled in study CCL09101E, or YM387-II-02, or successfully completed 24 weeks of study GS-US-352-1672Xx_NEWLINE_xXHgb < 100 g/L, have received ? 2 units PRBC in the 12 weeks prior to study entry, and be intolerant of or had inadequate response to ruxolitinib;Xx_NEWLINE_xXAt least four weeks must have elapsed between the last dose of any MF- directed drug treatments for myelofibrosis (including investigational therapies) and study enrollment;Xx_NEWLINE_xXPrevious cytotoxic therapies, including cytotoxic investigational agents, for multiple myeloma within 3 weeks (6 weeks for nitrosoureas) prior to start of study treatment. Biologic, novel therapy (including investigational agents in this class) or corticosteroids within 2 weeks prior to patient registration. Patient has side effects of the previous therapy > grade 1 or previous baseline.Xx_NEWLINE_xXEXCLUSION FOR TREATMENT: Recent prior therapy: systemic chemotherapy less than 2 weeks prior to infusion or apheresis (6 weeks for clofarabine or nitrosoureas for apheresis) or radiation therapy less than or equal to 3 weeks prior to apheresis; exceptions:\r\n* There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such\r\n* Subjects receiving hydroxyurea or oral maintenance chemotherapy may be enrolled provided there has been no increase in dose for at least 2 weeks prior to starting apheresis or treatment\r\n* Subjects receiving steroid therapy at physiologic replacement doses only are allowed provided there has been no increase in dose for at least 2 weeks prior to starting apheresis or treatment\r\n* Subjects must have recovered from the acute side effects of their prior therapy, such that eligibility criteria are met; cytopenias deemed to be disease-related and not therapy-related are exempt from this exclusionXx_NEWLINE_xXTreatment with cytotoxic or biologic agents within the 4 weeks prior to beginning treatment on this study (6 weeks for mitomycin or nitrosoureas); at least 4 weeks must have elapsed from any prior surgery, radiation, hormonal or other drug therapy for their cancerXx_NEWLINE_xXPrior chemotherapy or targeted small molecule therapy within 2 weeks before administration of study treatment.Xx_NEWLINE_xXPrior systemic radiation therapy must have been completed at least 4 weeks before study drug administration; prior focal radiotherapy completed at least 2 weeks before study drug administration; no radiopharmaceuticals (strontium, samarium) within 8 weeks before study drug administrationXx_NEWLINE_xXCompleted nitrosourea treatment at least 6 weeks before administration of any study drugXx_NEWLINE_xXPrior surgery that required general anesthesia must be completed at least 4 weeks before study drug administration; surgery requiring local/epidural anesthesia must be completed at least 72 hours before study drug administration and subjects should be recoveredXx_NEWLINE_xXHave received prior treatment with monoclonal antibodies within 6 weeks of first dose of Day 1;Xx_NEWLINE_xXProhibited treatments and/or therapies\r\n* Chronic use of immunosuppressants and/or systemic corticosteroids (used in the management of cancer or non-cancer-related illnesses); however, use of corticosteroids is allowed for the treatment of immune related adverse events (irAEs), or adrenal insufficiency\r\n* Any non-oncology vaccine therapy used for prevention of infectious diseases within 4 weeks prior to first dose of ipilimumab/nivolumab\r\n* Prior treatment with a CD137 agonist, ipilimumab or other CTLA4 inhibitor\r\n* Prior investigational agents within 2 weeks prior to first dose of ipilimumab/nivolumab\r\n* Prior therapy with any anti-cancer agents including chemotherapy, adjuvant chemotherapy, immunosuppressive agents, surgery or radiotherapy within 2 weeks prior to first dose of ipilimumab/nivolumabXx_NEWLINE_xXActive hemoptysis (bright red blood of at least 2.5 mL ie, half teaspoon) within 3 weeks prior to the first dose of study drug.Xx_NEWLINE_xXWithin 3 weeks prior to the first dose of CDX-0158 of any biologic treatment or IV chemotherapy.Xx_NEWLINE_xXInactivated vaccines should precede the initiation of any study regimen and/or standard adjuvant therapy by at least 2 weeks, but preferably 4 weeks or longerXx_NEWLINE_xXWas treated for at least 24 weeks with MK-3475 before discontinuing therapyXx_NEWLINE_xXPrior immunotherapy will be permitted; however, any prior immunotherapy must be discontinued at least 2 weeks before peptide vaccine administration; non-immunologic therapy may be continuedXx_NEWLINE_xXAppropriate for study entry based on the following diagnostic workup:\r\n* History/physical examination within 28 days prior to registration\r\n* Imaging of target lesion(s) within 28 days prior to registration\r\n* Further protocol-specific assessments:\r\n** Recovery from effects of recent surgery, radiotherapy or chemotherapy\r\n** Free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])\r\n** Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration\r\n** Any other prior therapy directed at the malignant tumor including chemotherapy, targeted agents, immunologic agents, and any investigational agents, must be discontinued at least 4 weeks prior to registration (6 weeks for nitrosoureas or mitomycin C) \r\n** Any prior radiation therapy must be completed at least 4 weeks prior to registration\r\n** At least 4 weeks must have elapsed since major surgeryXx_NEWLINE_xXAny chemotherapy within 3 weeks of the first dose of AZD1775, except hormonal therapy in the refractory cohort.Xx_NEWLINE_xXAny anti-cancer therapy within 3 weeks of study drugXx_NEWLINE_xXTherapy for underlying malignancy within 2 weeks prior to start of study treatment:Xx_NEWLINE_xXReceived FOLFOX within 6 weeks before starting regorafenibXx_NEWLINE_xXAchievement of SD or PR after a minimum of 12 weeks of pre-study first- or second-line standard chemotherapyXx_NEWLINE_xXSevere infection within 4 weeks prior to randomizationXx_NEWLINE_xXHave adequate organ reserve as determined by laboratory test results obtained within 2 weeks prior to Study Day 1 as indicated below:Xx_NEWLINE_xXPatients must be screened for HBV. Patients who are either HBsAg positive or HBV-DNA positive must be willing and able to take antiviral therapy 1-2 weeks prior to 1st dose of EGF816 treatment and continue on antiviral therapy for at least 4 weeks after the last dose of EGF816.Xx_NEWLINE_xXHas discontinued antiandrogens (bicalutamide, nilutamide) >6 weeks and enzalutamide >4 weeks prior to Day 1 of trial treatmentXx_NEWLINE_xXChemotherapy or other investigational anticancer therapeutic drugs in the two weeks prior to study entry; in the event of rapidly proliferative disease, however, the use of hydroxyurea is permitted up to 24 hours before study entry in coreXx_NEWLINE_xXPatient has received chemotherapy, targeted anticancer therapy, pelvic and/or para-aortic radiotherapy or has had major surgery =< 4 weeks (6 weeks for nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXExpected survival > 12 weeks at the time of screeningXx_NEWLINE_xXReceived prior systemic cytotoxic chemotherapy, biological therapy, major surgery within 3 weeks of first dose of study drug; received thoracic radiation therapy of > 30 gray (Gy) within 6 months of first dose of study drugXx_NEWLINE_xXPrior treatment with bevacizumab within twelve weeks before the first infusion.Xx_NEWLINE_xXPrior systemic cytotoxic chemotherapy, antineoplastic biological therapy (e.g., cetuximab), major surgery within 3 weeks of the first dose of study drug; received thoracic radiation therapy of >30 Gy within 6 months of the first dose of study drug; received prior tyrosine kinase inhibitor therapy or completed palliative radiotherapy within 7 days of the first dose of study drugXx_NEWLINE_xXPatients must be > 4 weeks and < 12 weeks post-surgery at time of study registrationXx_NEWLINE_xXCurrent or past use of investigational agents within 4 weeks of study enrollmentXx_NEWLINE_xXPlatelet transfusion independent for at least 4 weeks prior to enrollmentXx_NEWLINE_xXSurvival expectation of 12 weeks or longer after starting study drugXx_NEWLINE_xXSystemic anticancer therapy within 3 weeks of study entry, except for nitrosoureas or mitomycin C (6 weeks).Xx_NEWLINE_xXThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within 3 weeks, or nitrosoureas or mitomycin within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXSubjects with any of the following MEDICATIONS within 4 weeks prior to randomization:Xx_NEWLINE_xXNo chemotherapy, radiation, biologics or immunotherapy within 2 weeks prior to registration (6 weeks if last received carmustine [BCNU] or mitomycin C)Xx_NEWLINE_xXSubjects who have received investigational drugs =< 4 weeks prior to registrationXx_NEWLINE_xXPatients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agentXx_NEWLINE_xXSubject has received treatment with any monoclonal antibodies within 4 weeks prior to first dose of study therapyXx_NEWLINE_xXReceived anti-CD30 antibody-based therapy within the previous 4 weeksXx_NEWLINE_xXAdministration of subunit or killed vaccines, such as influenza or pneumococcal vaccine, within two weeks prior to study treatment (day-1) and throughout the study; EXCEPTION - Vaccination for influenza is permitted between week 12 through week 16 and after week 20Xx_NEWLINE_xXAny of the following prior therapies: \r\n* Chemotherapy =< 4 weeks prior to registration\r\n* Mitomycin C/nitrosoureas =< 6 weeks prior to registration\r\n* Immunotherapy =< 4 weeks prior to registration\r\n* Biologic therapy =< 4 weeks prior to registrationXx_NEWLINE_xXOther experimental drugs =< 4 weeks prior to registrationXx_NEWLINE_xXOral or intravenous iodinated contrast administration =< 6 weeks prior to registrationXx_NEWLINE_xXCurrent use of or use =< 2 weeks prior to registration of exogenous corticosteroids; patients clinically proven to require maintenance steroids will be allowed on the study provided that there has been no change in the corticosteroid dose =< 6 weeks prior to registrationXx_NEWLINE_xXBicalutamide (Casodex) and nilutamide discontinued < 6 weeks prior to registrationXx_NEWLINE_xXParticipant has participated in clinical trials of experimental agents within 4 weeks prior to randomizationXx_NEWLINE_xXCorticosteroids given with antineoplastic intent within 7 days, or chemotherapy given with antineoplastic intent, targeted therapy, or radiation therapy within 3 weeks, or antibody-based therapy within 4 weeks of the start of study drugXx_NEWLINE_xXThe patient must not have required a paracentesis within the preceding 4 weeks nor be projected to require a paracentesis within the next 8 weeks.Xx_NEWLINE_xXSystemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity and washout period is 6 weeks; prior immunotherapy - washout is 4 weeksXx_NEWLINE_xXExposure to any IP during the last 4 weeks prior to enrollment.Xx_NEWLINE_xXRecent cancer-directed therapies: Radiotherapy (RT) within 4 weeks, chemotherapy or other systemic anti-cancer therapy within 4 weeks, or prior anti-angiogenic treatment (e.g., bevacizumab) within 6 weeks prior to starting treatmentXx_NEWLINE_xXHormone replacement therapy of any type, megestrol acetate, or raloxifene within four weeks prior to first study treatmentXx_NEWLINE_xXReceived chemotherapy or biologic therapy =< 3 weeks prior to the start of neratinibXx_NEWLINE_xXHave received an antibody therapy within 3 weeksXx_NEWLINE_xXAny drug used for GVHD within 4 weeks prior to enrollmentXx_NEWLINE_xXa) Prior treatment with a hypomethylating agent (example [eg], azacitidine, decitabine); b) Prior treatment with lenalidomide; c) Has received an erythropoiesis-stimulating agent (ESA) or any chemotherapy, immunomodulatory, or immunosuppressive therapy within 4 weeks prior to study entry (8 weeks for long-acting ESAs)Xx_NEWLINE_xXSystemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For cytotoxic or immunotherapy agents that can present with major delayed toxicity (eg, anti-CTLA-4), 4 weeks is indicated as washout periodXx_NEWLINE_xXMonoclonal antibody, radioimmunoconjugate, antibody-drug conjugate, chemotherapy, or other investigational anti-cancer agent within 4 weeks prior to study drugXx_NEWLINE_xXSystemic immunosuppressive medication within 2 weeks prior to study drugXx_NEWLINE_xXConcurrent treatment with estrogens or progestins; patients must stop these drugs at least two weeks prior to study entryXx_NEWLINE_xXPatients must be >= 2 weeks (minimum) to 4 weeks (preferred) from prior myelosuppressive chemotherapy (primarily lenalidomide) to facilitate mobilizationXx_NEWLINE_xXSubjects who have received prior CEA, MUC1, and/or brachyury-targeted immunotherapy (vaccine) are eligible for this trial if this treatment was discontinued at least 4 weeks prior to enrollmentXx_NEWLINE_xXReceipt of any other investigational agents within 4 weeks preceding the start of study treatmentXx_NEWLINE_xXAt least 4 weeks from last chemotherapy or bevacizumab (AvastinÂ®) therapy (6 weeks for nitrosourea or mitomycin C), or for chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity, at least 2 weeks from last dose.Xx_NEWLINE_xXAt least 4 weeks must have elapsed since the last chemotherapy, targeted therapy, immunotherapy, radiotherapy, liver-directed therapy, or major surgery. At least 6 weeks for nitrosoureas, mitomycin C and liposomal doxorubicin. If started before T-cell administration, ipilimumab infusions must be least 21 days apart.Xx_NEWLINE_xXReceipt of any investigational medication within 4 weeks prior to enrollmentXx_NEWLINE_xXPatients must be off all other anti-tumor therapies (including immunologic agents) for at least four weeks prior to study registration. Patients on hormonal agents require a washout for 10 days.Xx_NEWLINE_xXNo systemic therapy for RRP for four weeks prior to treatmentXx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXChemo-, hormone-, radio-(except for brain and extremities) or immunotherapy or therapy with monoclonal antibodies or small tyrosine kinase inhibitors within the past 4 weeks prior to treatment with the trial drug.Xx_NEWLINE_xXFor participants previously treated with first generation anti-androgens (ie, flutamide, nilutamide, or bicalutamide), discontinuation of flutamide or nilutamide therapy must occur greater than (>) 4 weeks (>6 weeks for bicalutamide) prior to start of study drug with no evidence of an anti-androgen withdrawal response (no decline in serum PSA)Xx_NEWLINE_xXPrevious chemotherapy and/or investigational agents are allowed if completed > 4 weeks prior to study entry (> 6 weeks if last regimen contained bis-chloroethyl nitrosourea [BCNU] or mitomycin C); for patients who received systemic therapy prior to study entry, there must be documented progression of measurable disease since receiving systemic therapy prior to study entryXx_NEWLINE_xXStable supplement usage for > 2 weeks prior to starting and agrees not to change while on this studyXx_NEWLINE_xXAllowed prior therapies include:\r\n* Surgery (major surgery at least more than four weeks prior to baseline assessment)\r\n* Locoregional therapy such as: chemoembolization, radio-embolization, radiofrequency ablation, radiotherapy as long as there is progressive measurable disease outside the area of locoregional therapy or there is progression in the previously treated areas\r\n* Any number of previous lines of systemic therapy; last treatment before enrollment must have occurred more than 4 weeks for chemotherapy, 6 weeks for antibodies or more than 5 half-lives of prior tyrosine kinase inhibitors (TKIs) or small moleculesXx_NEWLINE_xXPrior antitumor therapy within 2 weeks of enrollment (with the exception of somatostatin analogs)Xx_NEWLINE_xXAt the time of enrollment, patients must be ? 4 weeks since all of the following treatments (and recovered from the toxicity of prior treatment to <= Grade 1, exclusive of alopecia): major surgery; radiotherapy; chemotherapy (note: must be ? 6 weeks since therapy if treated with a nitrosourea, mitomycin, or monoclonal antibodies such as bevacizumab); immunotherapy; Biotherapy/targeted therapies.Xx_NEWLINE_xXUse of investigational agents within 4 weeks prior to study enrollment (within 6 weeks if the treatment was with a long-acting agent such as a monoclonal antibody).Xx_NEWLINE_xXSigns or symptoms of severe infection (sepsis) within 2 weeks prior to treatment startXx_NEWLINE_xXReceipt of any investigational medication within 2 weeks prior to enrollmentXx_NEWLINE_xXPatients may have had prior chemotherapy or immunotherapy or radiation therapy; all prior therapies must be stopped 4 weeks prior to first dose of study treatment, with the exception of patients who have received ipilimumab, which must be stopped 6 weeks prior to first dose of study treatment; patients are prohibited from receiving live vaccines within 30 days prior to first dose of study treatmentXx_NEWLINE_xXNew systemic immune suppressive agent added for the treatment of chronic GVHD within 2 weeks prior to enrollmentXx_NEWLINE_xXTreatment with a non-Food and Drug Administration (FDA) approved drug in the previous 4 weeksXx_NEWLINE_xXPrior systemic cytotoxic chemotherapies and/or novel immunotherapy treatments for MCC are allowed. A wash-out period of 2 weeks prior to aNK treatment will be required.Xx_NEWLINE_xXPatients with expected survival < 12 weeksXx_NEWLINE_xXPrior monoclonal antibody within 4 weeks prior to study Day 1 or chemotherapy, targeted small molecular therapy, or radiation therapy within 2 weeks prior to study Day 1Xx_NEWLINE_xXInvestigational compound within 4 weeks of enrollmentXx_NEWLINE_xXThe participant has undergone chest irradiation within 2 weeks prior to receiving study treatment.Xx_NEWLINE_xXStarted less than 12 weeks prior to randomisation AND Prostate Specific Antigen (PSA) is stable or falling. The 12 weeks starts from whichever of the following occurs earliest: first dose of oral anti- androgen, LHRHA, or surgical castration.Xx_NEWLINE_xXOther concurrent chemotherapy, immunotherapy, radiotherapy, any ancillary therapy considered investigational (utilized for a non-Food and Drug Administration [FDA]-approved indication and in the context of a research investigation) or receiving any other investigational agent which would be considered as a treatment for the primary neoplasm:\r\n* Chemotherapy =< 3 weeks of registration\r\n* Nitrosoureas or mitomycin C =< 6 weeks of registration\r\n* Small molecule cell cycle inhibitors =< 2 weeks prior to registration\r\n* Immunotherapy =< 6 weeks prior to registration\r\n* Monoclonal antibodies =< 3 half-lives prior to registration\r\n* Radiation therapy\r\n** Last fraction of craniospinal irradiation or total body irradiation =< 3 months prior to registration or last fraction of focal irradiation to symptomatic metastatic sites =< 4 weeks prior to registration\r\n* Growth factors\r\n** Colony forming growth factors < 2 weeks prior to registration (i.e., filgrastim, sargramostim, erythropoietin)\r\n** Neulasta < 2 weeks prior to registrationXx_NEWLINE_xXRecovery from effects of recent surgery, radiotherapy, or chemotherapy:\r\n* Patients should be free of active infection requiring antibiotics (with the exception of uncomplicated urinary tract infection [UTI])\r\n* Any hormonal therapy directed at the malignant tumor must be discontinued at least two weeks prior to registration; continuation of hormone replacement therapy is permitted\r\n* Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted and immunologic agents, must be discontinued at least two weeks prior to registration and at least 3 weeks before day 1 on trialXx_NEWLINE_xXSteroid dose increased in the most recent two weeksXx_NEWLINE_xXRequirement of permanent or frequent (i.e., once per week) external drainages within two weeks prior to randomizationXx_NEWLINE_xXA sufficient interval must have elapsed between the last dose of prior anti-cancer therapy (including cytotoxic and biological therapies and major surgery) and enrollment: a) cytotoxic or targeted chemotherapy: greater than or equal to the duration of the cycle of the most recent treatment regimen (a minimum of 3 weeks for all regimens, except 6 weeks for nitrosoureas and mitomycin-C); b) biologic therapy (e.g., antibodies): greater than or equal to 4 weeksXx_NEWLINE_xXPresence of hepatic encephalopathy within 4 weeks of 1st doseXx_NEWLINE_xXPatients that have received systemic treatments within four weeks prior to the beginning of treatmentXx_NEWLINE_xXAny chemotherapy must have been completed 4 weeks prior to enrollmentXx_NEWLINE_xXStable prescription of analgesic regimen during the 2 weeks prior to randomization.Xx_NEWLINE_xXFollowing prior treatments are not eligible:\r\n* Use of any investigational agent within 30 days preceding enrollment\r\n* Treatment with cytotoxic chemotherapy within previous 4 weeks\r\n* Failure to achieve =< grade 2 adverse events (AE) resolution from cytotoxic chemotherapy administered more than 4 weeks previous (however, ongoing neuropathy is permitted)\r\n* Received systemic therapy with radionuclides (e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or Ra-223 dichloride) for the treatment of bony metastasesXx_NEWLINE_xXAny infection requiring antibiotic or anti-viral treatment within 4 weeks of screeningXx_NEWLINE_xXReceived any chemotherapeutic or targeted agent (approved or investigational) for NSCLC within 2 weeks of initiation of pacritinib (with the exception of erlotinib)Xx_NEWLINE_xXPrevious radiation, hormonal therapy, and/or surgery must have been discontinued or completed at least 2 weeks prior to treatment in this study and adverse effects must have resolved; lymph node or other diagnostic biopsies within 2 weeks are not considered exclusionaryXx_NEWLINE_xXStable dose of corticosteroids for 4 weeks prior to enrollment; exception permitted with overall principal investigator (PI) approvalXx_NEWLINE_xXExposure to any new immunosuppressive medication in the 4 weeks prior to enrollmentXx_NEWLINE_xXExtra-corporeal photopheresis (ECP) or rituximab therapy within 4 weeks prior to enrollmentXx_NEWLINE_xXOther investigational drugs within 4 weeks prior to enrollment, unless cleared by the Principal InvestigatorXx_NEWLINE_xXPrior investigational agents =< 4 weeks prior to registrationXx_NEWLINE_xXPrior therapy or surgery (3 to 10 weeks depending type)Xx_NEWLINE_xXAny of the following prior therapies with interval since most recent treatment:\r\n* Chemotherapy =< 4 weeks prior to registration\r\n* Biologic or immunologic therapy =< 4 weeks prior to registration\r\n* Radiation therapy =< 4 weeks prior to registrationXx_NEWLINE_xXNo limit is placed on the number of prior therapies; prior treatment with irinotecan or eribulin is allowed, although patients must not have received co-administration of eribulin and irinotecan and must not have had disease progression while receiving either eribulin or irinotecan; patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Must not have received within three weeks of start date of this protocol chemotherapy; six weeks is required after administration of nitrosourea agents\r\n* At least 7 days since the completion of therapy with a growth factor or at least 14 days for a long-acting growth factor (e.g. pegfilgrastim)\r\n* At least 7 days or 3 half-lives since the completion of therapy with a biologic agent, whichever is longer; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are expected to occur; the duration of this interval must be discussed with the principal investigator (PI) of the study\r\n* At least 6 weeks since the completion of any type of immunotherapy (e.g. tumor vaccines)\r\n* At least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiotherapy: >= 2 weeks for local palliative radiotherapy (XRT) (small port); >= 6 months must have elapsed if prior total body irradiation (TBI), craniospinal XRT; >= 3 months must have elapsed if >= 50% radiation of pelvis; >= 6 weeks must have elapsed if therapeutic doses of metaiodobenzylguanidine (MIBG) or other substantial bone marrow (BM) irradiation was given\r\n* Allogeneic and autologous hematopoietic stem cell transplant (HSCT) will be allowed, if there is no evidence of active graft vs. host disease and >= 2 months must have elapsed since infusion; patients must not be on systemic immunosuppressionXx_NEWLINE_xXStable dose of glucocorticoids for 4 weeks prior to enrollmentXx_NEWLINE_xXOther investigational drugs within 4 weeks prior to enrollment, unless cleared by the principal investigator; previous fixed-dose IL-2 therapy that was discontinued prior to 4 weeks is permittedXx_NEWLINE_xXPatients must have >= 4 weeks since prior chemotherapy or radiation (>= 6 weeks for nitrosoureas or mitomycin C)Xx_NEWLINE_xXAny approved anti-cancer therapy within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXPatient who has received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered to grade 1 or better from related side effects of such therapy (except alopecia)Xx_NEWLINE_xXPatient who has had systemic therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to study entryXx_NEWLINE_xXDiabetics on insulin or antihyperglycemics must be on a stable dose (i.e., no titrations within the last 2 weeks) at the time of study entryXx_NEWLINE_xXPrior systemic treatment with an azole drug within four weeks of screening visitXx_NEWLINE_xXPrior nitrosourea or mitomycin C =< 6 weeks prior to registrationXx_NEWLINE_xXUse of investigational agents or concurrent anti-cancer treatment within the last 4 weeks of registrationXx_NEWLINE_xXIn the opinion of the invesgator likely to complete ? 8 weeks of treatment.Xx_NEWLINE_xXPatients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade 1 before starting the trialXx_NEWLINE_xXPatients who have received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXAt least 4 weeks must have elapsed since the last surgery and 2 weeks must have elapsed since radiotherapyXx_NEWLINE_xXDiabetics on insulin or antihyperglycemics must be on a stable dose (i.e., no titrations within the last 2 weeks) at the time of study entryXx_NEWLINE_xXPatients enrolled in other clinical trials must have received their last treatment at least 6 weeks prior to enrollmentXx_NEWLINE_xXNo experimental intravesical therapy within 6 weeks of study entryXx_NEWLINE_xXParticipation in an investigational anti-cancer study within 3 weeks prior to day -7 (beginning of loading phase)Xx_NEWLINE_xXPatients who have received chemotherapy or radiation therapy to > 30% of marrow bearing bone within < 2 weeks or experimental agent/therapy within 4 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapiesXx_NEWLINE_xXRadioimmunotherapy within 4 weeks before first dose of study drugXx_NEWLINE_xXAnti Graft-Versus-Host Disease (GVHD) therapy within 12 weeks before the first dose of study drugXx_NEWLINE_xXOther investigational agents =< 4 weeks prior to registration/ randomizationXx_NEWLINE_xXAny immunotherapy within 4 weeks of first dose of study drug.Xx_NEWLINE_xXPrior treatment: no previous cytotoxic chemotherapy within 4 weeks prior to initiation of therapy; (this does not include immunomodulatory drugs [IMIDs], proteasome inhibitors, monoclonal antibodies or steroids)Xx_NEWLINE_xXSubjects must be entered no more than 12 weeks postoperativelyXx_NEWLINE_xXParticipation in an investigational anti-cancer study within 3 weeks prior to initiation of therapyXx_NEWLINE_xXPersistent fever (> 24 hours) documented by repeated measurement =< 4 weeks prior to registrationXx_NEWLINE_xXAny approved anti-cancer therapy within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXDose-escalation: prior treatment with abiraterone acetate; at least 4 weeks must have elapsed from the last dose of abiraterone acetateXx_NEWLINE_xXAt least 12 weeks must have elapsed from the use of strontium-89, radium-223 or any investigational or approved immunotherapy (e.g., Provenge) prior to starting study drugXx_NEWLINE_xXNo cytotoxic chemotherapy within 2 weeks of starting study treatmentXx_NEWLINE_xXIf receiving myelofibrosis therapy, must be on a stable dose of the same regimen for at least 2 weeks prior to screen date and through the screening periodXx_NEWLINE_xXMyelosuppressive chemotherapy: must not have received within 4 weeks of entry onto this studyXx_NEWLINE_xXCholangitis that required treatment or intervention within 4 weeks of study enrollmentXx_NEWLINE_xXAt least 8 weeks must have elapsed from the use of strontium-89, radium-223, samarium-153, or immunotherapy (e.g., Provenge) prior to beginning protocol therapyXx_NEWLINE_xXAt least 4 weeks must have elapsed from the use of any investigational agent prior to beginning protocol therapy\r\n* Note: prior treatment with phosphatidylinositol 3 kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway inhibitors prohibitedXx_NEWLINE_xXPatients may have been treated with cytotoxic, biologic (antibody), immune or experimental therapy, tyrosine kinase inhibitors, hormone inhibitors or nonsteroidal anti-inflammatory drugs (NSAIDs) provided this has been completed at least 4 weeks prior to registration (6 weeks for mitomycin and nitrosoureas) and recovered from any therapy related toxicity to less than CTCAE grade 2Xx_NEWLINE_xXAT THE TIME OF INFUSION: Off investigational therapy for 4 weeks prior to study entryXx_NEWLINE_xXPrior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks (12 weeks for measurable sites of central nervous system [CNS] disease) prior to study Day 1 or not recovered from adverse events due to a previously administered agentXx_NEWLINE_xXPatients who have received oral or IV chemotherapy, targeted anticancer therapy or radiation therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to study enrollmentXx_NEWLINE_xXBlood transfusion or erythropoietin stimulating agents prior 4 weeks of screening and during the whole screening period before randomizationXx_NEWLINE_xXAt least 3 weeks since prior biologics or investigational agentsXx_NEWLINE_xXPatients must be off radiation therapy or chemotherapy 4 weeks (6 weeks for nitrosoureas or mitomycin C) of starting induction chemotherapyXx_NEWLINE_xXAny immunotherapy within 4 weeks of first dose of study drug.Xx_NEWLINE_xXParticipants may have had any number of previous hormonal therapies (antiandrogens including enzalutamide, estrogens, finasteride, dutasteride, ketoconazole) provided these were discontinued >= 4 weeks before starting the trial; prior therapy with steroids is allowed though these must be discontinued >= 2 weeks before starting the trial; inhaled, topical, and intra-articular steroids are allowedXx_NEWLINE_xXMyelosuppressive chemotherapy: Must not have received within 3 weeks (6 weeks if prior nitrosourea)Xx_NEWLINE_xXReceived an anti-CLL monoclonal antibody within 8 weeks prior to the first dose of study drugXx_NEWLINE_xXOther investigational therapy (not included above) within 3 weeks of randomizationXx_NEWLINE_xXRadiation therapy within 3 weeks before first dose. Radioimmunotherapy within 8 weeks before first dose.Xx_NEWLINE_xXAutologous SCT within 8 weeks and allogeneic SCT within 16 weeks prior to initiation of study treatment. Patients with prior allogeneic SCT should not have evidence of moderate-to-severe graft-versus-host disease (as defined in Filipovich 2005).Xx_NEWLINE_xXPatient was treated with trastuzumab or other antibody based therapy within three weeks of starting study treatment or with chemotherapy or hormonal cancer therapy within two weeks of starting study treatment.Xx_NEWLINE_xXAlemtuzumab treatment within 8 weeks of HSCT admissionXx_NEWLINE_xXPatients must be on a stable concomitant medication regimen, defined as no changes in medication or in dose within 2 weeks prior to start of olaparib dosing, except for bisphosphonates, denosumab and corticosteroids, which should be stable for at least 4 weeks prior to start of olaparib dosing.Xx_NEWLINE_xXLast dose of chemotherapy or experimental therapy more than 4 weeks (6 weeks in the case of nitrosourea) prior to enrollment date; 2 weeks if the last therapy was received as part of a â€œphase 0â€ or â€œexploratory investigational new drug (IND)â€ trial; last surgery more than 4 weeks prior to enrollment; core biopsies or fine need aspiration (FNA) will not require any waiting periodXx_NEWLINE_xXPatients must be at least 4 weeks from last radiation dose; patients must be at least 4 weeks from last chemotherapy, targeted therapy, or biologic therapy (exception allowed for a 2 week washout for patients who were on chemotherapy at less than a standard of care dose, as long as all other eligibility criteria are met); patients must be at least 4 weeks from last surgical procedure and recovered from all post-operative complicationsXx_NEWLINE_xXMyelosuppressive chemotherapy:\r\n* Subjects must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration or at least six (6) weeks if nitrosoureaXx_NEWLINE_xXRecent hemoptysis (>= 1/2 teaspoon [2.5 mL]) of red blood within 8 weeks before first dose of study drugXx_NEWLINE_xXPatients who have received wide field radiotherapy ? 4 weeks or limited field radiation for palliation < 2 weeks prior to screening or who have not recovered adequately from side effects of such therapy.Xx_NEWLINE_xXGranulocytes >= 1500/mm^3 within 4 weeks of enrollmentXx_NEWLINE_xXHaving smoked at least 1 cigarette within 4 weeks of study enrollmentXx_NEWLINE_xXPatient who has had chemotherapy, or biological cancer therapy within 2 weeks prior to the first dose of study drug; patient who has had radiation within 2 weeks prior to the first dose of study drugXx_NEWLINE_xXPatients must have completed any chemotherapy, radiation therapy, biologic therapy, or major surgery >= 4 weeks prior to enrollment (6 weeks for nitrosoureas or mitomycin C); patients must be >= 2 weeks since any prior administration of a study drug in a phase 0 or equivalent study, at the discretion of the principal investigator; patients must have recovered to eligibility levels from prior toxicity or adverse events; patients with bone metastases or hypercalcemia on intravenous (IV) bisphosphonate treatment prior to study entry may continue this treatmentXx_NEWLINE_xXWillingness to discontinue any cytotoxic chemotherapeutic agents, immunotherapy and biologic therapy at least 2 weeks prior to the start of RT.Xx_NEWLINE_xXStable dose of non-corticosteroid immunosuppressants for the 2 weeks prior to first dose of AMG 592.Xx_NEWLINE_xXVaccination within 4 weeks prior to the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXFludarabine within 4 weeks prior to leukapheresisXx_NEWLINE_xXPrior anti-cancer therapy within 4 weeks prior to study enrollment. Prior radiation therapy within 2 weeks prior to enrollment. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed 2 days prior to study enrollment and no clinically significant toxicities are expected (eg, mucositis, esophagitis).Xx_NEWLINE_xXVaccination within 4 weeks of study enrollment and while on trial is prohibited except for administration of inactivated vaccines.Xx_NEWLINE_xXPrevious systemic anti-cancer therapy must have been discontinued at least 3 weeks prior to treatment in this study; if there is progression of disease on that therapy and all adverse effects have resolved to grade 1 or baseline, in which case 2 weeks is acceptableXx_NEWLINE_xXNo treatment with any of the following for prostate cancer within 4 weeks prior to enrollment:\r\n* Hormonal therapy (e.g., androgen receptor [AR] antagonists, 5 alpha reductase inhibitors, estrogens); Note: treatment with bicalutamide and nilutamide within 4 weeks prior to enrollment is not allowed; treatment with flutamide within 4 weeks prior to enrollment is not allowed; treatment with all other gonadotropin-releasing hormone (GnRH) analogues or antagonists is allowed\r\n* Chemotherapy\r\n* Biologic therapy\r\n* Investigational therapy\r\n* ImmunotherapyXx_NEWLINE_xXNo use of herbal products that may decrease PSA levels within 4 weeks prior to enrollmentXx_NEWLINE_xXMaintain castrate levels of testosterone within 4 weeks prior to randomization and throughout the studyXx_NEWLINE_xXAt least 4 weeks must have elapsed from the use of 5-alpha reductase inhibitors, estrogens, and any other anti-cancer therapy prior to randomizationXx_NEWLINE_xXChemotherapy (approved or investigational) within 3 weeks prior to signing consentXx_NEWLINE_xXAntibody therapy within 6 weeks prior to signing consentXx_NEWLINE_xXA minimum of 2 weeks elapsed off of antiandrogen therapy prior to start of study drug (i.e. flutamide, nilutamide, bicalutamide)Xx_NEWLINE_xXA minimum of 4 weeks elapsed off of sipuleucel-T prior to start of study drugXx_NEWLINE_xXHemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drugXx_NEWLINE_xXAny prior chemotherapy, immunotherapy or targeted therapy must have been completed at least 2 weeks prior to start of this protocol and all side effects (except alopecia, lymphopenia and hyperglycemia) resolved to grade 1 or less; any prior radiation must have been completed at least 2 weeks prior to start of therapyXx_NEWLINE_xXAny prior chemotherapy, immunotherapy or targeted therapy must have been completed at least 4 weeks prior to start of this protocol and all side effects (except alopecia, lymphopenia and hyperglycemia) resolved to grade 1 or less; any prior radiation must have been completed at least 2 weeks prior to start of therapyXx_NEWLINE_xXMore than 2 seizures over the last 4 weeks prior to study entryXx_NEWLINE_xXPatient must be registered/randomized to Step 2 within a maximum of 7 weeks following surgeryXx_NEWLINE_xXPatients must have completed WBRT > 12 weeks prior to enrollment to limit cases of pseudoprogression; however if new lesions are noted < 12 weeks but > 4 weeks prior to enrollment, those patients are eligibleXx_NEWLINE_xXPatients must have discontinued active immunotherapy (interleukin [IL]-2, interferon, cytotoxic T-lymphocyte antigen 4 [CTLA-4], etc.) or chemotherapy at least 4 weeks prior to entering the study and oral targeted therapy at least 2 weeks prior to entering the study and have recovered from adverse events due to those agents; patients must not receive any other investigational anticancer therapy during the period on study or the four weeks prior to entry, with the exception of vaccinesXx_NEWLINE_xXOther than ongoing ADT, prior treatment with other hormonal agents such as antiandrogens or ketoconazole must have been stopped at least two weeks prior to enrollmentXx_NEWLINE_xXPrior chemotherapy, cancer immunosuppressive therapy, or other investigational agents within 4 weeks before first dose of study drug.Xx_NEWLINE_xXPatients taking a cholesterol-lowering agent must be on a single medication and on a stable dose for at least 4 weeksXx_NEWLINE_xXAnti-tumor therapy (i.e. chemotherapeutics or investigational agents or immunotherapy) within 4 weeks prior to enrollmentXx_NEWLINE_xXSurvival expectation of 12 weeks or longer after starting study drug.Xx_NEWLINE_xXActive hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks before the first dose of study drug.Xx_NEWLINE_xXPrevious anti-cancer chemotherapy, immunotherapy or investigational agents < 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the first day of study defined treatment; palliative radiation < 2 weeks, biological therapy within 2 weeks, hormonal therapy within 1 week prior to day 1 cycle 1Xx_NEWLINE_xXPatients must be randomized within 8 weeks of their last dose of chemotherapyXx_NEWLINE_xXAt the time of registration, patient must be at least 2 weeks from prior vincristine, 3 weeks from prior procarbazine, and 4 weeks from other prior cytotoxic chemotherapyXx_NEWLINE_xXAnti-neoplastic treatment less than 4 weeks prior to enrollment, with the exception of hydroxyureaXx_NEWLINE_xXPatients must be randomized within 8 weeks of their last dose of chemotherapyXx_NEWLINE_xXPrior treatment (somatostatin analogs excepted) must be completed at least 2 weeks prior to registration; in addition, prior treatment (somatostatin analogs excepted) must be completed at least 4 weeks prior to initiation of study drug; treatment-related toxicities must have improved to =< grade 1 prior to registration, with the exception of alopeciaXx_NEWLINE_xXPatients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXSurgery or irradiation ? 4 weeks prior to randomizationXx_NEWLINE_xXPatients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXImmunotherapy/standard myeloma therapy within 2 weeks; prior stem cell transplant (SCT) therapy (autologous SCT within the prior 8 weeks; allogeneic SCT within the prior 16 weeks)Xx_NEWLINE_xXRecent hemoptysis (>= Â½ teaspoon of red blood within 8 weeks before first dose of study drug)Xx_NEWLINE_xXGrade 3 or 4 hemoptysis or hemorrhage within 4 weeks prior to study entryXx_NEWLINE_xXRapidly progressing cancer likely to require palliative systemic intervention within 8 weeks after study entryXx_NEWLINE_xXPrior everolimus and/or sunitinib therapy is allowed, so long as it was discontinued >= 4 weeks prior to randomizationXx_NEWLINE_xXConcurrent somatostatin analogues are allowed provided that the patient \r\n* Has been on a stable dose (+/- 10mg) for 8 weeks and \r\n* Has documented disease progression on that doseXx_NEWLINE_xXPrior radiation therapy must be completed > 4 weeks prior to enrollment and the patient must have recovered from all toxicity. Prior radiopharmaceuticals (strontium, samarium) must be completed ? 8 weeks prior to enrollment.Xx_NEWLINE_xXSubjects may not initiate a new form of cancer therapy, non-steroidal or steroid anti-inflammatory agents, or antibiotics during the study period or for 4 weeks prior to the start of study agentsXx_NEWLINE_xXPatients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade 1 before starting the trialXx_NEWLINE_xXPatients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) =< 2 weeks (or =< 3 weeks for a monoclonal antibody) prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPatients who have received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPatients must be off all other anti-tumor therapies (including immunologic or hormonal agents) for at least four weeks prior to study registrationXx_NEWLINE_xXObtained within 2 weeks from study entry: Hemoglobin A1c (HgBA1c) =< 8%Xx_NEWLINE_xXUse of 5-alpha reductase antagonist (i.e. finasteride, dutasteride) within 6 weeks prior to randomizationXx_NEWLINE_xXUse of antiandrogen (e.g. flutamide, nilutamide, bicalutamide) within 6 weeks prior to randomizationXx_NEWLINE_xXPatient has failed to recover from any prior surgery within 4 weeks of study entryXx_NEWLINE_xXPatients who have received androgen ablative therapy for less than 8 weeks immediately prior to initiation of study drug are eligible provided they had only PSA evidence of progression (as defined above) with no visible metastases by CT-scan and bone scan (within 6 weeks) prior to starting androgen ablationXx_NEWLINE_xXAny radiotherapy or immunotherapy within the last 3 weeks (limited palliative radiation is allowed >= 2 weeks); chemotherapy regimens with delayed toxicity within the last 4 weeks (or within the last 6 weeks for prior nitrosourea or mitomycin C); chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeksXx_NEWLINE_xXAny radiotherapy or immunotherapy within the last 21 days (limited palliative radiation is allowed >= 2 weeks); chemotherapy regimens with delayed toxicity within the last 4 weeks; chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeksXx_NEWLINE_xXThe patient has received any investigational agents within 4 weeks prior to their first dose of sorafenibXx_NEWLINE_xXPatients must be ? 4 weeks since major surgery, chemotherapy (6-weeks if they were treated with a nitrosourea or mitomycin) or biotherapy/target therapies and ? 2 weeks since radiotherapy.Xx_NEWLINE_xXSorafenib treatment within 2 weeks of randomization.Xx_NEWLINE_xXCompletion of preoperative systemic chemotherapy and HER2-directed treatment consisting of at least 6 cycles of chemotherapy with a total duration of at least 16 weeks, including at least 9 weeks of trastuzumab and at least 9 weeks of taxane-based therapyXx_NEWLINE_xXAn interval of no more than 12 weeks between the date of surgery and the date of randomizationXx_NEWLINE_xXAny surgery (including diagnostic laparoscopy and/or biliary +/- duodenal palliative bypass for inoperable PC) within the 2 weeks prior to day 1 of study protocolXx_NEWLINE_xXPatients with washout period < 6 weeks from the last dose of ipilimumab or other immunotherapy.Xx_NEWLINE_xXPrevious systemic anti-cancer therapy must have been discontinued at least 3 weeks prior to treatment in this study; if there is progression of disease on that therapy and all adverse effects have resolved to grade 1 or baseline, in which case 2 weeks is acceptableXx_NEWLINE_xXPrevious radiation, hormonal therapy, and surgery must have been discontinued or completed at least 2 weeks prior to treatment in this study and adverse effects must have resolved; lymph node or other diagnostic biopsy within 2 weeks is not considered exclusionaryXx_NEWLINE_xXExpected survival > 12 weeksXx_NEWLINE_xXPatient has failed to recover from any prior surgery within 4 weeks of study entryXx_NEWLINE_xXPatient has had any treatment specific for tumor control within 3 weeks of dosing with investigational drugs and cytotoxic agents, or within 2 weeks of cytotoxic agent given weekly, or within 6 weeks of nitrosoureas or mitomycin C, or within 5 half-lives of biological targeted agentsXx_NEWLINE_xXCurrently taking hormone replacement therapy (local or systemic) (patients must discontinue for 2 weeks in order to be eligible prior to study enrollment)Xx_NEWLINE_xXUse of any standard/experimental anti-lymphoma drug therapy, including steroids, within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; prior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapyXx_NEWLINE_xXPatients who have been treated with radioactive iodine within 24 weeks prior to study enrollment (radioactive iodine within 24 weeks will be allowed if negative post-treatment scan or progressive disease defined by RECIST 1.1)Xx_NEWLINE_xXPatient must not experience hemoptysis in excess of 2.5 mL within 8 weeks prior to the first dose of pazopanibXx_NEWLINE_xXTreatment with any known therapeutic or experimental therapy within 4 weeks prior to enrollment, or currently participating in any other interventional clinical studyXx_NEWLINE_xXHave had chemotherapy (including purine analogs, rituximab, and other investigational agents) within six weeks prior to entering the studyXx_NEWLINE_xXTreatment with non-steroidal oral antiandrogens within 4 weeks of enrollmentXx_NEWLINE_xXPrior radiation therapy within 3 weeks and radionuclide therapy within 8 weeks of enrollmentXx_NEWLINE_xXTreatment with anti arrhythmia therapy for ventricular arrhythmia < 4 weeks prior to enrollmentXx_NEWLINE_xXTreatment with CoumadinÂ® or other anti-coagulant therapy (except aspirin) < 4 weeks prior to enrollmentXx_NEWLINE_xXLess than 3 weeks elapsed since prior exposure to chemotherapyXx_NEWLINE_xXThe following amounts of time must have elapsed prior to entry on study:\r\n* 2 weeks from local radiation therapy (XRT)\r\n* 8 weeks from prior craniospinal or if > 50% of the pelvis has been irradiated\r\n* 6 weeks must have elapsed if other bone marrow radiation has occurredXx_NEWLINE_xXTreatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1Xx_NEWLINE_xXAdministration of any therapy for MDS (conventional or investigational) must be completed by 2 weeks prior to of the first dose of study drug; in the event of rapidly proliferative disease use of hydroxyurea is permitted until 24 hours before the start of study treatment. Toxicities associated with prior MDS therapy must have recovered to grade 1 or less prior to start of treatment.Xx_NEWLINE_xXChemotherapy within 3 weeks prior to screening are excluded (other than hydroxyurea at stable doses and will be discontinued 24 hours prior to starting study drug)Xx_NEWLINE_xXTreatment with antiandrogens (e.g., bicalutamide, flutamide, or nilutamide) within 4 weeks of enrollment (day 1 visit)Xx_NEWLINE_xXIf taking systemic therapy for cGvHD at the time of enrollment, must be on a stable or tapering schedule in the preceding 4 weeks (extracorporeal photopheresis has to be stopped at least by 4 weeks before enrollment)Xx_NEWLINE_xXThe patient has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas or mitomycin within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXSurgically rendered free of disease no more than 12 weeks before randomization.Xx_NEWLINE_xXCohort 3: Patients with recurrent WHO grade 2 glioma may have received prior external beam radiotherapy and/or chemotherapy; patients with stable WHO grade 2 glioma must have had prior chemotherapy (at least one cycle of temozolomide or procarbazine, lomustine, and vincristine [PCV]-based chemotherapy); with regard to the prior therapy in Cohort 3, patients may have had treatment for no more than 2 prior relapses; relapse is defined as progression following initial therapy (i.e. radiation +/- chemo if that was used as initial therapy) or observation of stable disease; the intent therefore is that patients may have had 3 prior therapies (initial therapy and treatment for 2 relapses); if the patient had a surgical resection for relapsed disease, and no anti-cancer therapy was instituted for up to 12 weeks, and the patient undergoes another surgical resection, this is considered as 1 relapse\r\n* In Cohort 3 with recurrence, tumor recurrence is defined by the increase of maximum tumor diameter, based on the axial and/or coronal T2 or FLAIR MR images; increase of tumor size can be based on comparison with previous scans performed up to prior 3 years to allow assessment of slow-growth of the tumor\r\n* In Cohort 3, patients must have recovered from the toxic effects of prior therapy: 4 weeks from any investigational agent, 4 weeks from prior cytotoxic therapy and/or at least two weeks from vincristine, 4 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count); any questions related to the definition of non-cytotoxic agents should be directed to the Principal Investigator; with regard to previous RT, there must be at least 6 months from the completion of RT (or radiosurgery)Xx_NEWLINE_xXClinically stable and off corticosteroids for at least 4 weeks prior to study enrollmentXx_NEWLINE_xXPatients must have documented radiologic or clinical progressive disease following at least one prior anti-VEGF regimen administered either as a single agent or in combination with other agents for at least 8 weeks; the prior anti-VEGF treatment regimen must have included bevacizumab, pazopanib, sorafenib or sunitinib administered not more than 12 weeks before study entry; Note: enrollment not more than 8 weeks after the last dose of anti-VEGF therapy is encouraged; nevertheless, intercurrent therapy with an mTOR inhibitor (everolimus or temsirolimus) will be allowed if progression on that treatment is observed within 12 weeks of the prior anti-VEGF therapyXx_NEWLINE_xXNo chemotherapy or immunotherapy for a minimum of three weeks prior to study enrollmentXx_NEWLINE_xXLast dose of cytotoxic chemotherapy must have been at least 4 weeks (6 weeks for nitrosoureas) prior to catheter placement; patients are eligible if they received bevacizumab or other anti-vascular endothelial growth factor (VEGF) therapies, although the most recent dose must be at least 6 weeks prior to catheter placementXx_NEWLINE_xXMyelosuppressive chemotherapy: interval >= 6 weeks and >= 4 weeks from last dose of nitrosourea and other chemotherapy drugs before study enrollment, respectively; however, interval must be >= 1 week from last dose of oral etoposide and other drugs administered at low doses (metronomic regimen) before study enrollmentXx_NEWLINE_xXInterval >= 4 weeks and =< 8 weeks from the completion of radiochemotherapyXx_NEWLINE_xXUse previously of intra-articular treatment within 4 weeks prior dosing.Xx_NEWLINE_xXWilling to schedule definitive resection of DCIS 2-5 weeks after study enrollmentXx_NEWLINE_xXBrain metastases (except if all known lesions were previously treated with surgery or stereotactic radiosurgery and lesions, if still present, are confirmed stable for >= 12 weeks prior to randomisation or if no longer present are confirmed no evidence of disease for >= 12 weeks, and are asymptomatic with no corticosteroid requirements for >= 4 weeks prior to randomisation, and no enzyme inducing anticonvulsants for >= 4 weeks prior to randomisationXx_NEWLINE_xXTreatment with trastuzumab, bevacizumab or other targeted therapies within the past 2 weeksXx_NEWLINE_xXHemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks of registrationXx_NEWLINE_xXGrade 3 infection within 2 weeks of first dose romidepsin plus ICE.Xx_NEWLINE_xXThe participant has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/ mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXPatients may have had any number of prior therapies; at least 3 weeks must have elapsed since the last dose of systemic therapy; at least 6 weeks must have elapsed if the last regimen included BCNU or mitomycin C; at least 6 weeks must have elapsed if the last regimen included an anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA4) antibody; patients must have experienced disease progression on their prior therapy in the opinion of the treating investigatorXx_NEWLINE_xXInvestigational or biologic therapies within 3 weeks of C1D1Xx_NEWLINE_xXPrior peripheral ASCT within 12 weeks of C1D1Xx_NEWLINE_xXOral retinoid therapy for any indication within 3 weeks of study entryXx_NEWLINE_xXCorticosteroid therapy within 3 weeks or immunosuppressive chemotherapy or any antibody-directed or immunoglobulin-based immune therapy (e.g., immunoglobulin replacement, other monoclonal antibody therapies) within 12 weeks of first dose of study drugXx_NEWLINE_xXPatients on Octreotide LAR at a fixed dose of 20 mg or 30 mg at 3-4 weeks intervals for at least 12 weeks prior to randomization in the study.Xx_NEWLINE_xXPatients must have progressive disease based on RECIST Criteria, Version 1.1 while receiving an uninterrupted fixed dose of Octreotide LAR (20-30 mg/3-4 weeks). Disease progression must be centrally confirmed. In order to make the assessment, two CT (or MRI) scans are required. The oldest scan must not be older than 3 years from the date of randomization. The most recent scan must not be older than 4 weeks from the date of randomization. Both scans must be obtained while the patient is receiving the same fixed dose of Octreotide LAR (20-30 mg/3-4 weeks) with the following exceptions; 1) it is acceptable if the oldest scan is obtained within 12 weeks of the patient receiving a fixed dose regimen of Octreotide LAR (20-30 mg/3-4 weeks); AND 2) it is acceptable for either scan to be obtained before or during the time a patient receiving a fixed dose of Octreotide LAR has switched to an equivalent dose of short acting Octreotide for up to 6 weeks in order to obtain an OctreoScanÂ®, provided the patient returns to the Octreotide LAR fixed dose after the OctreoScanÂ® has been obtained.Xx_NEWLINE_xXTreatment with >30 mg Octreotide LAR at 3-4 weeks intervals within 12 weeks prior to randomization in the study.Xx_NEWLINE_xXAny surgery, radioembolization, chemoembolization, chemotherapy and radiofrequency ablation within 12 weeks prior to randomization in the study.Xx_NEWLINE_xXInterferons, Everolimus (mTOR-inhibitors) or other systemic therapies within 4 weeks prior to randomization in the study.Xx_NEWLINE_xXprior immunotherapy, or prior investigational agents should be washed out 4 weeks before apheresis and must be completed 4 weeks prior to pre-infusion lymphodepletive chemotherapy.Xx_NEWLINE_xXmonoclonal antibody therapy must be completed at least 6 weeks prior to pre-infusion lymphodepletive chemotherapyXx_NEWLINE_xXAll previous cytotoxic chemotherapy, monoclonal antibody therapy, immune therapy should be washed out 3 weeks before apheresis and must be completed at least 3 weeks prior to pre-infusion lymphodepletive chemotherapy.Xx_NEWLINE_xXSystemic corticosteroid or other immunosuppressive therapy should be washed out 2 weeks before apheresis and must be completed at least 2 weeks prior to pre-infusion lymphodepletive chemotherapyXx_NEWLINE_xXAn investigational drug administered for the diagnosis of seminoma given concurrently or within four weeks of the first fraction of proton therapy administrationXx_NEWLINE_xXPatients must have recovered (to Common Toxicity Criteria [CTC] version [v.]4.0 =< grade 1 unless indicated below) from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study, with the exception of alopecia, weight changes and grade I or II lymphopenia\r\n* Myelosuppressive chemotherapy: must not have received within 3 weeks of entry onto this study (6 weeks if prior nitrosourea or mitomycin-C)\r\n* Biologic (anti-neoplastic agent): at least 7 days after the last dose of a biologic agent; for agents that have known adverse events occurring beyond 7 days after administration, this period must be extended beyond the time during which adverse events are known to occur\r\n* Immunotherapy: at least 42 days after the completion of any type of immunotherapy, e.g. tumor vaccines\r\n* Monoclonal antibodies: at least 3 half-lives of the antibody after the last dose of a monoclonal antibody\r\n* Radiation therapy (RT): patients must have had their last fraction of craniospinal RT >= 6 months prior to study entry and their last fraction of focal RT >= 4 weeks prior to study entry; if the lesion used for on-study criteria is in the radiation field, there must be evidence of tumor progression after radiation therapy was completed\r\n* Study specific limitations on prior therapy:\r\n** Patients who have received thalidomide are eligible if all acute thalidomide-related toxicity has resolved\r\n** Patients must not have received lenalidomide previouslyXx_NEWLINE_xXPatient has failed to recover from any prior surgery within 4 weeks of study entryXx_NEWLINE_xXThe use of the 5-alpha-reductase inhibitor dutasteride and systemic steroids must be discontinued within 4 weeks of degarelix injection for Cohort 1, 2, and 4, and within 4 weeks of surgery for Cohort 3Xx_NEWLINE_xXPrior sunitinib and everolimus will be permitted; a wash-out period of 2 weeks is required prior to first dose on this studyXx_NEWLINE_xXConcurrent somatostatin analogues are allowed provided that patients 1) have been on stable doses x 8 weeks and 2) have documented disease progression on that doseXx_NEWLINE_xXHistory of gastrointestinal perforation within 12 months of randomization, except for gastrointestinal (GI) perforation related to a primary colorectal tumor that has subsequently been fully resected; subjects would be eligible if >= 4 weeks have elapsed from the time of surgery to start date of chemotherapy on protocol and >= 6 weeks have elapsed from time of surgery to first dose of bevacizumab; the subject must have recovered from the effects of the surgery (e.g. wound is healed, no active infection, no drains, etc.)Xx_NEWLINE_xXSubjects who have had cytotoxic chemotherapy or treatment with monoclonal antibodies within 4 weeks (6 weeks for nitrosoureas or mitomycin C), radiotherapy within 3 weeks, or other molecular targeted therapies (including tyrosine kinase inhibitors within 2 weeks prior to entering the study)Xx_NEWLINE_xXIf a patient enters the trial on androgen suppression therapy (AST) that consists of both an LHRH agonist and an oral antiandrogen, both agents should be continued throughout the study; if an antiandrogen is stopped prior to study entry, it should be stopped 4 weeks before for nilutamide and flutamide and 6 weeks before for bicalutamide to ensure that a withdrawal phenomenon does not interfere with interpretation of efficacy resultsXx_NEWLINE_xXMore than two seizures over the last 4 weeks prior to study entryXx_NEWLINE_xXTwo weeks must have elapsed since administration of previous chemotherapyXx_NEWLINE_xXAt least 2 weeks must have elapsed since the completion of therapy with a monoclonal antibody; seven days must have elapsed since the last dose of retinoidsXx_NEWLINE_xXPatients who have not recovered from the toxic effects of prior chemotherapy and/or radiation therapy will be excluded; guidelines for this recovery period are dependent upon the specific therapeutic agent being used:\r\n* Patients may not have received chemotherapy or bevacizumab =< 4 weeks (except for nitrosourea [6 weeks] or metronomic dosed chemotherapy such as daily etoposide or cyclophosphamide [1 week]) prior to starting the study drug unless patients have recovered from side effects of such therapy\r\n* Patients may not have received immunotherapy =< 4 weeks prior to starting the study drug unless patients have recovered from side effects of such therapy\r\n* Patients may not be less than 12 weeks from radiation therapy, unless progressive disease outside of the radiation field or 2 progressive scans at least 4 weeks apart or histopathologic confirmation\r\n* Patients must have completed all standard of care treatments, including surgical procedure, and radiation therapy (at least 59 Gy)\r\n** If the MGMT promoter in their tumor is known to be unmethylated, patients are not mandated to have received chemotherapy prior to participating in this trial\r\n** If the MGMT promoter in their tumor is known to be methylated or the MGMT promoter status is unknown at the time of screening, patients must have received at least one chemotherapy regimen prior to participating in this trialXx_NEWLINE_xXPatients on greater than 4 mg per day of dexamethasone within the 2 weeks prior to admission for PVSRIPO infusionXx_NEWLINE_xXTreatment with other FAP directed drug therapy (including sulindac or celecoxib, fish oil) within 12 weeks of study enrollment.Xx_NEWLINE_xXSystemic chemotherapy within 2 weeks prior to study entry (signing consent form)Xx_NEWLINE_xXThe first dose of study treatment must be at least three weeks since prior chemotherapy, including sunitinib or everolimusXx_NEWLINE_xXPatients who have received either immunotherapy within =< 8 weeks; chemotherapy within =< 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapiesXx_NEWLINE_xXRadioimmunotherapy (i.e. Zevalin) within 8 weeks of enrollmentXx_NEWLINE_xXPrior treatment with anti-CD20 monoclonal antibody or alemtuzumab within 4 weeks prior to start of therapyXx_NEWLINE_xXAny non-oncology vaccine therapy used for prevention of infectious diseases for up to 4 weeks before or after any dose of ipilimumabXx_NEWLINE_xXHistory of hemoptysis in excess of 2.5 mL (1/2 teaspoon ) within 8 weeks prior to first dose of study drugXx_NEWLINE_xXNitrosurea: ? 6 weeksXx_NEWLINE_xXBiologic therapy: ? 4 weeksXx_NEWLINE_xXPatients must be registered on the study within 5 weeks of completion of concurrent chemoradiationXx_NEWLINE_xXPrevious chemotherapy, immunotherapy, and hormone therapy must be completed at least 4 weeks prior to the administration of MLN2480 and radiation must be completed at least 3 weeks prior to the administration of MLN2480; all associated toxicity must be resolved to ? Grade 1Xx_NEWLINE_xXPrior investigational agents for malignant or non-malignant disease within 4 weeks prior to Day 1Xx_NEWLINE_xXINCLUSION CRITERIA:\n\n        Phase 1b\n\n          -  Histologically confirmed diagnosis of a hematologic malignancy, excluding patients\n             with acute leukemia or MDS.\n\n          -  Relapsed after standard therapy for their malignancy and considered to be an\n             appropriate candidate for a Phase 1 clinical study by their treating physician.\n\n        Phase 2\n\n          -  Multiple myeloma with measurable disease\n\n          -  WaldenstrÃ¶m macroglobulinemia with symptomatic relapse\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2.\n\n        Ethical/Other\n\n          -  Patients must sign a written informed consent form in accordance with federal, local,\n             and institutional guidelines.\n\n          -  Female patients of childbearing potential must have a negative serum or urine\n             pregnancy test and agree to use effective contraception. Male patients must use an\n             effective barrier method of contraception.\n\n        EXCLUSION CRITERIA:\n\n          -  Chemotherapy with approved or investigational anticancer therapeutics, including\n             steroid therapy intended to treat underlying malignancy, within 3 weeks prior to first\n             dose or 6 weeks for antibody therapy.\n\n          -  Radiation therapy within 3 weeks prior to first dose. Radioimmunotherapy within 8\n             weeks prior to first dose. Localized radiation therapy within 1 week prior to first\n             dose.\n\n          -  Immunotherapy within 3 weeks prior to first dose (except for antibody therapy, where 6\n             weeks is required).\n\n          -  Prior stem cell transplant (SCT) therapy (autologous SCT within the prior 8 weeks;\n             allogeneic SCT within the prior 16 weeks). Patients with prior allogeneic SCT should\n             not have evidence of moderate-to-severe graft-vs-host disease (GvHD; as defined in\n             Filipovich 2005).\n\n          -  Evidence of central nervous system (CNS) lymphoma.\n\n          -  Prior treatment with carfilzomib unless in the phase 2.\n\n          -  Major surgery within 3 weeks prior to first dose.\n\n          -  Symptomatic Congestive heart failure, ischemia, conduction abnormalities, or\n             myocardial infarction within 6 months.\n\n          -  Acute active infection requiring systemic antibiotics, antivirals, or antifungals.\n\n          -  Known or suspected human immunodeficiency virus (HIV) infection or patients who are\n             HIV seropositive.\n\n          -  Active hepatitis A, B, or C infection.\n\n          -  Significant neuropathy (Grade 3, Grade 4, or Grade 2 with pain) at the time of the\n             first dose.\n\n          -  Patients with pleural effusions requiring routine thoracentesis or ascites requiring\n             routine paracentesis.\n\n          -  History of previous clinically significant GI bleed in the last 6 months prior to\n             first dose.\n\n          -  Female patients who are pregnant or lactating.Xx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy including but not limited to: \r\n* An interval of >= 4 weeks (28 days) from prior cytotoxic therapy except 6 weeks from nitrosoureas\r\n* An interval of >= 1 week (7 days) from any non-cytotoxic agents\r\n* An interval of >= 3 months from the completion of radiation therapyXx_NEWLINE_xXInclusion Criteria:\n\n        Phase I ONLY:\n\n          -  Advanced, metastatic solid tumor that has progressed after standard therapy, or is a\n             tumor type resistant to therapy, and for which bevacizumab is clinically appropriate.\n\n          -  Patient may have measurable disease or non-measureable disease as defined by RECIST\n             v1.1 criteria\n\n        Phase II ONLY:\n\n          -  Progressive GBM after treatment with surgical resection (if possible) and 1st line\n             radiation/chemotherapy.\n\n          -  No previous treatment with a PI3K inhibitor. Previous treatment with bevacizumab as a\n             component of first-line therapy is allowed.\n\n          -  At least one measurable or evaluable lesion definable by MRI scan. Disease must be\n             measurable by RANO criteria.\n\n          -  Archival tumor tissue available for correlative testing.\n\n        ALL PATIENTS:\n\n          -  Patient must be ? 4 weeks from administration of last dose of cancer therapy\n             (including radiation therapy, biologic therapy, hormonal therapy, or chemotherapy).\n             Patients who receive a small molecule targeted therapy as part of their first line\n             treatment regimen must be ? 4 weeks or ? 5 half lives from administration of last\n             dose, whichever is shorter. The patient must have recovered from or come to a new\n             chronic or stable baseline from all treatment-related toxicities.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n\n          -  Life expectancy of ? 3 months.\n\n          -  Adequate hematologic, hepatic, and renal function.\n\n        Exclusion Criteria:\n\n          -  Patients with diarrhea ? grade 2.\n\n          -  Patients with uncontrolled type I or type II diabetes mellitus, defined as a fasting\n             plasma glucose ?120 mg/dL.\n\n          -  Patients who have received prior treatment with a P13K inhibitor.\n\n          -  Treatment with therapeutic doses of coumarin-type anticoagulants (maximum daily dose\n             of 1 mg allowed for port line patency permitted).\n\n          -  Patient has active cardiac disease including any of the following:\n\n               -  Left ventricular ejection fraction (LVEF) < 50% as determined by Multiple Grated\n                  acquisition (MUGA) scan or echocardiogram (ECHO)\n\n               -  QTc > 480 msec on screening ECG (using the QTcF formula)\n\n               -  Angina pectoris that requires the use of anti-anginal medication\n\n               -  Ventricular arrhythmias except for benign premature ventricular contractions\n\n               -  Supraventricular and nodal arrhythmias requiring a pacemaker or not controlled\n                  with medication\n\n               -  Conduction abnormality requiring a pacemaker\n\n               -  Valvular disease with documented compromise in cardiac function\n\n               -  Symptomatic pericarditis\n\n          -  Patients who are currently receiving treatment with medication with a known risk to\n             prolong the QT interval or inducing Torsades de Pointes and the treatment cannot\n             either be discontinued or switched to a different medication prior to starting study\n             drug.\n\n          -  Patients with clinical history of hemoptysis or hematemesis (defined as having bright\n             red blood of Â½ teaspoon or more per episode) ?1 month prior to study enrollment.\n\n          -  Patients with any history of a bleeding diathesis or coagulopathy (in the absence of\n             therapeutic anticoagulation)\n\n          -  Patients who have received chemotherapy or targeted anticancer therapy ? 4 weeks (6\n             weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must\n             recover to a grade 1 before starting the trial.\n\n          -  Patients who have received any continuous or intermittent small molecule therapeutics\n             (excluding monoclonal antibodies) ? 5 effective half lives prior to starting study\n             drug or who have not recovered from side effects of such therapy.\n\n          -  Patients who have been treated with any hematopoietic colony-stimulating factors (e.g.\n             G-CSF, GM-CSF) ? 2 weeks prior to starting study drug. Erythropoietin or darbepoetin\n             therapy, if initiated at least 2 weeks prior to enrollment may be continued.\n\n          -  Major surgical procedure, open biopsy, intracranial biopsy, ventriculoperitoneal shunt\n             or significant traumatic injury ? 28 days prior to entry.Xx_NEWLINE_xXPrior experimental systemic therapies must have been completed greater than 2 weeks prior to study entryXx_NEWLINE_xXSubject has received a monoclonal antibody for anti-neoplastic intent within 8 weeks prior to the first dose of study drug.Xx_NEWLINE_xXRecovered from side effects that might interfere with the protocol therapy and:\r\n* >= 4 weeks must have elapsed from last radiation treatment to time of study entry\r\n* >= 4 weeks must have elapsed from the last chemotherapy administration to time of study entry\r\n* >= 8 weeks from the last immunotherapeutic agent administered to time of study entryXx_NEWLINE_xXInterval >= 4 weeks between open brain biopsy and initiation of protocol-based therapyXx_NEWLINE_xXPatients who have received chemotherapy within </= 2 weeks by time of cycle 1 day 1 of therapy on trial ; or radiation therapy to > 30% of marrow-bearing bone within 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies.Xx_NEWLINE_xXBrain metastases permitted in Arms C and D if:\r\n* CNS-directed treatment has been given\r\n** >= 4 weeks interval between whole brain radiation therapy and initiation of protocol-based therapy\r\n** >= 2 weeks interval between stereotactic radiosurgery or gamma knife (or equivalent) and initiation of protocol-based therapy\r\n* CNS disease has been clinically and radiographically stable for at least 4 weeks\r\n* In Arm C, if patient on glucocorticoids, must be on stable (4 weeks) dose of no more than 2 mg/day of dexamethasone or equivalent\r\n* In Arms B and D, no steroids are allowedXx_NEWLINE_xXTime since the last dose of prior therapy to treat underlying malignancy:\r\n* Cytotoxic chemotherapy or endocrine therapy: >= the duration of the most recent cycle of the previous regimen (with a minimum of 3 weeks for all, except 6 weeks for nitrosourea, mitomycin-C)\r\n*Biologic therapy (e.g., antibodies): >= 4 weeks\r\n* >= 5 X half-life of a small molecule therapeutic\r\n* >= 4 weeks interval between whole brain radiation therapy and initiation of protocol-based therapy for ARM C or D patient with stable brain metastases\r\n* >= 2 weeks interval between stereotactic radiosurgery (SRS) or gamma knife (or equivalent) and initiation of protocol-based therapy for ARM C or D patient with stable brain metastases\r\n* Patients enrolled in ARM C may remain on trastuzumab without a washout period\r\n* Patients enrolled in ARM D may remain on lapatinib without a washout periodXx_NEWLINE_xXReceived wide field radiotherapy =< 4 weeks, or SRS or gamma knife for brain metastasis =< 2 weeks or limited field radiation for palliation =< 2 weeks prior to starting either BYL719 or BKM120 or have not recovered from side effects of such therapyXx_NEWLINE_xXPatients must have recovered to at least eligibility levels following any display of adverse events and/or toxicity due to prior chemotherapy or biologic therapy; they must not have had hormonal therapy, chemotherapy or biologic therapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C, or 7-hydroxystaurosporin [UCN-01]); patients must be >= 2 weeks since any prior administration of study drug in a phase 0 study (also referred to as an â€œearly phase I studyâ€ or â€œpre-phase I studyâ€ where a sub-therapeutic dose of drug is administered) at the principal investigator's (PIâ€™s) discretion; patients must be >= 4 weeks since any prior radiation or major surgery; however, patients receiving bisphosphonates or therapeutic anticoagulation are eligible for this trialXx_NEWLINE_xXAny other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted (non-cytotoxic) agents and immunologic agents, must be discontinued at least three weeks prior to registrationXx_NEWLINE_xXAny prior therapy for lymphoma within the previous 2 weeks for standard treatments and within 4 weeks for experimental therapies unless the patient has recovered from the nadir of the previous treatment to a level that meets the inclusion criteriaXx_NEWLINE_xXTreatment with radiotherapy within the past 4 weeks or radiopharmaceutical therapy (strontium, samarium) within the past 8 weeksXx_NEWLINE_xXFor Parts A, B, and D: have discontinued sorafenib for at least 2 weeksXx_NEWLINE_xXDate of randomization must be within 32 weeks of initiation of optimal systemic therapyXx_NEWLINE_xXPatients must have adequate organ function to undergo local therapy 4 weeks +/ - 2 weeks prior to randomization per investigator discretion and institutional guidelinesXx_NEWLINE_xXHypertension must be well controlled on stable doses of medication for at least two weeks prior to enrollmentXx_NEWLINE_xXCompletion of at least 4 cycles of a rituximab-containing, anthracycline-based combination chemotherapy regimen no sooner than 3 weeks and no longer than 8 weeks prior to the start of radiation therapyXx_NEWLINE_xXHemoptysis within 6 weeks of first dose of study drugXx_NEWLINE_xXEXPANSION COHORT ONLY: Hemoptysis within 6 weeks of first dose of study drugXx_NEWLINE_xXHave not received anti-cancer therapy for at least 2 weeks prior to study entry, with the exception of low dose ara-C (LDAC) given as subcutaneous injections (no less than 15 days prior), hydroxyurea or anagrelide (no less than 24 hours prior), TKI (no less than 5 days prior), and interferon (no less than 2 weeks prior)Xx_NEWLINE_xXPatients must begin temozolomide chemotherapy no sooner than 2 weeks and no later than 6 weeks from the diagnostic surgery; patients must begin bevacizumab no sooner than 4 weeks and no later than 6 weeks from the surgeryXx_NEWLINE_xXPrior anti-tumor therapy within 2 weeksXx_NEWLINE_xXLive vaccination within 4 weeks of the first dose of avelumabXx_NEWLINE_xXAny type of systemic therapy (chemotherapy or experimental drugs) within 2 weeks of starting treatment on protocol except for a EGFR TKIXx_NEWLINE_xXFor patients previously treated with first generation anti-androgens (i.e., flutamide, nilutamide, or bicalutamide), discontinuation of flutamide or nilutamide therapy must occur >4 weeks (>6 weeks for bicalutamide) prior to start of study drug with no evidence of an anti-androgen withdrawal response (i.e., no decline in serum PSA).Xx_NEWLINE_xXFor patients previously treated with other agents approved for the treatment of prostate cancer (5-? reductase inhibitors, estrogens, others), discontinuation of therapy must have occurred ?4 weeks prior to start of study drug.Xx_NEWLINE_xXFor patients receiving bone-loss prevention treatment (e.g., bisphosphonates or denosumab), the patient must be on stable dose ?4 weeks prior to start of study drug.Xx_NEWLINE_xXChemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 3 weeks prior to first administration of study treatmentXx_NEWLINE_xXcomplete abstinence from intercourse from 2 weeks prior to administration of the 1st dose of study agent and 6 months after the last dose of study agent; orXx_NEWLINE_xXSubjects may begin cediranib and olaparib at least 3 weeks after their last dose of chemotherapy or hormonal therapy, assuming they are otherwise eligibleXx_NEWLINE_xXInterval of at least 2 weeks from any prior neurosurgical resection (1 week for intracranial biopsy) to start of study drug; and patient must have adequate wound healingXx_NEWLINE_xXReceiving therapy for chronic GVHD for more than 16 weeks.Xx_NEWLINE_xXPatients must be off all \statin\ drugs for ?2 weeks prior to initiation of therapy.Xx_NEWLINE_xXHave received prior cancer or other investigational therapy within 2 weeks prior to the first administration of study drugXx_NEWLINE_xXSystemic cytotoxic therapy within 3 weeks of treatmentXx_NEWLINE_xXSpecific anti-cancer therapy within 3 weeks of study startXx_NEWLINE_xXAutologous SCT within 12 weeks prior to study entry (Arms A and D only)Xx_NEWLINE_xXAny prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least six weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an â€œearly phase I studyâ€ or â€œpre-phase I studyâ€ where a sub-therapeutic dose of drug is administered) at the PIâ€™s discretion, and should have recovered to eligibility levels from any toxicitiesXx_NEWLINE_xXAny prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least 6 weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients must be >= 2 weeks since any investigational agent administered as part of a phase 0 study (also referred to as an â€œearly phase I studyâ€ or â€œpre-phase I studyâ€ where a sub-therapeutic dose of drug is administered) at the principal investigator's (PIâ€™s) discretion, and should have recovered to eligibility levels from any toxicitiesXx_NEWLINE_xXKS therapy other than HAART within 3 weeksXx_NEWLINE_xXSevere or life-threatening infection within 2 weeks of entry onto the studyXx_NEWLINE_xXHemoptysis within 4 weeksXx_NEWLINE_xXPrevious bevacizumab within 6 weeks prior to enrollmentXx_NEWLINE_xXCytotoxic chemotherapy =< 3 weeks, or biologic or novel targeted therapies =< 2 weeks, or corticosteroids =< 2 weeks, prior to registration; patients may be receiving chronic corticosteroids if they are being given for disorders other than myelomaXx_NEWLINE_xXMust have completed last cycle of second-line induction no less than 8 weeks (56 days) and no greater than 20 weeks (140 days) prior to randomization.Xx_NEWLINE_xXPatients must be on a stable or decreasing dose of steroids for at least two weeks prior to randomizationXx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy to < grade 2 non hematological or grade 2 or lesser hematological toxicity per CTC ver 4 (except deep vein thrombosis): 4 weeks from prior cytotoxic therapy and/or at least two weeks from vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, cis-retinoic acid, etc. (radiosensitizer does not count). Patients who receive anticancer agents for non-therapeutic purposes unrelated to this studyXx_NEWLINE_xXAny myeloma directed therapy within 12 weeks of registration including plasmapheresis or transfusionXx_NEWLINE_xXPatients who have received cranial or spinal irradiation less than 3 weeks prior to the start of this protocolXx_NEWLINE_xXLast dose of prior chemotherapy received less than 4 weeks prior to randomizationXx_NEWLINE_xXASCT within 4 weeks (i.e., ASCT is allowed if it occurred before enrollment in Study NEOD001-201 or after completion of Study NEOD001-201 if it was at least 4 weeks before Month 1-Day 1 of this study)Xx_NEWLINE_xXAny experimental imaging agent directed at amyloid within 2 weeksXx_NEWLINE_xXAntileukemia or experimental treatment within 4 weeks of study drug (other than hydroxyurea or 6-mercaptopurine)Xx_NEWLINE_xXSystemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or radiopharmaceuticals (strontium, samarium) within 8 weeks prior to the first dose of study treatment.Xx_NEWLINE_xXAny investigational treatments for any condition within 4 weeks prior to the start of study treatment.Xx_NEWLINE_xXDiscontinuation of all cytotoxic chemotherapy and anti-CD20 antibody therapy for ? 4 weeks, alemtuzumab for ? 8 weeks, targeted therapy for ? 2 weeks, and investigational therapy for ? 3 weeks before enrollment (Phase 1b) or randomization (Phase 2). For individuals with relapsed CLL most recently treated with B-cell receptor (BCR) pathway inhibitors who, in the opinion of the investigator, will not tolerate waiting 3 weeks, a washout period of > 5 half-lives is allowed. If on a systemic corticosteroid, the dose must be stable for the previous 4 weeks.Xx_NEWLINE_xXPrior anti-tumor therapy including (all times measured prior to start of study drug): nitrosoureas within 6 weeks, chemotherapy within 3 weeks, therapeutic antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy within 2 weeks, investigational agents within 3 weeks, unless antibody this should be within 4 weeksXx_NEWLINE_xXPreviously received an EGFR-directed monoclonal antibody within the past 4 weeks.Xx_NEWLINE_xXMust be willing to implement contraception throughout study and for the 8 weeks following last study drug administration.Xx_NEWLINE_xXAny of the following prior therapy: Chemotherapy ? 3 weeks prior to registration. Biologic therapy ? 4 weeks prior to registration. Radiation therapy ? 3 weeks prior to registrationXx_NEWLINE_xXAt least 3 weeks post any treatments/therapies at the time of first dose.Xx_NEWLINE_xXAllogeneic cellular therapy: Donor lymphocyte infusions (DLI) are prohibited within 4 weeks prior to leukapheresisXx_NEWLINE_xXGVHD therapies: Any drug used for GVHD within 4 weeks prior to leukapheresisXx_NEWLINE_xXNo more than 3 prior lines of chemotherapy; prior therapy with doxorubicin is permitted but no more than lifetime cumulative dose of 150 mg/m^2; at least 3 weeks since prior chemotherapy or radiotherapy, at least 6 weeks if the last regimen included bis-chloroethylnitrosourea (BCNU) or mitomycin CXx_NEWLINE_xXRefusal to use adequate contraception for fertile patients (females and males) for 12 weeks after the last dose of rociletinib and 2 weeks after the last dose of erlotinibXx_NEWLINE_xXReceived major surgery, radiotherapy, or immunotherapy within 4 weeks of GSK2879552 administration. Chemotherapy regimens with delayed toxicity within the last four weeks (six weeks for prior nitrosourea or mitomycin C). Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity or palliative radiation to a limited area within the last two weeks.Xx_NEWLINE_xXAt least 6 weeks must have elapsed since administration of nitrosureas.Xx_NEWLINE_xXPatients must be >= 4 weeks from cytotoxic chemotherapy, except >= 6 weeks for mitomycin C or nitrosoureas, and >= 8 weeks from prior 7-hydroxystaurosporine (UCN01); >= 4 weeks from monoclonal antibody therapy (cetuximab, bevacizumab); >= 4 weeks from prior experimental therapy; >= 2 weeks from radiation or hormonal therapy; >= 2 weeks from sorafenib, sunitinib or temsirolimus treatment; patients with prostate cancer may continue ongoing luteinizing hormone-releasing hormone (LhRH) agonist therapy; patients with bone metastases or hypercalcemia who began intravenous bisphosphonate treatment prior to study entry may continue this treatment while on studyXx_NEWLINE_xXConventional cytotoxic chemotherapy: ?4 weeks (? 6 weeks for nitrosoureas and mitomycin-C)Xx_NEWLINE_xXBiologic therapy (e.g., antibodies): ?4 weeksXx_NEWLINE_xXMinimum of 12 weeks from the first dose of antiCTLA-4 and 6 weeks from the last doseXx_NEWLINE_xXInvestigational drug other than NEOD001 within 4 weeksXx_NEWLINE_xXHistory/physical examination with digital rectal examination of the prostate within 8 weeks prior to registrationXx_NEWLINE_xXProgression within 6 weeks following their last dose of anti-EGFR therapyXx_NEWLINE_xXAt least three weeks from any non-anti-EGFR therapy prior to start of study treatment; any number of prior therapies is permittedXx_NEWLINE_xXSubject does not require steroids or does not require escalating doses of steroids for at least 2 weeks prior to the first dose of study drug.Xx_NEWLINE_xXChemotherapy must have been completed at least 4 weeks prior to initiation of study medicationXx_NEWLINE_xXWashout periods for prior therapy are as follows\r\n* Bevacizumab â€“ last dose must be >= 6 weeks prior to day 1 of study treatment\r\n* Targeted therapy â€“ last dose must be >= 5 half-lives prior to initiation of day 1 of study treatment\r\n* Other chemotherapy, immunotherapy, or radiotherapy â€“ last dose must be =< 3 weeks prior to day 1 of study treatmentXx_NEWLINE_xXSubjects who have received systemic antitumor therapy within 4 weeks or radiotherapy to target lesions within 3 weeks before the first dose of study drug, which is longerXx_NEWLINE_xXSignificant co-morbidities within 4 weeks prior to enrollmentXx_NEWLINE_xXIn the absence of rapidly progressing disease and after discussion with the Principal Investigator (PI), the interval from prior treatment to time of IMGN901 administration will be at least 2 weeks or at least 5 half-lives for cytotoxic/noncytotoxic agents; for prior monoclonal antibody therapy the interval from prior monoclonal antibody treatment to time of IMGN901 administration will be at least 2 weeks; the use of chemotherapeutic or anti-leukemic agents other than hydroxyurea is not permitted during the study with the exception of intrathecal (IT) therapy for patients with controlled central nervous system (CNS) leukemia at the discretion of the PI; hydroxyurea is allowed prior to the initiation of IMGN901 and during the first 3 cycles, either prior to or concomitantly with IMGN901 administration initially to control leukocytosisXx_NEWLINE_xXTreatment with any known non-marketed drug substance or experimental therapy within 4 weeks prior to enrollment, or currently participating in any other interventional clinical study for NHL or any other illness (except observational and registry trials)Xx_NEWLINE_xXBRAF/MEK inhibitors within 2 weeks prior to first dose of study treatment.Xx_NEWLINE_xXMonoclonal based therapies within 4 weeks and all other immunotherapy within 2 weeks prior to first dose of study treatment.Xx_NEWLINE_xXSystemic radiation therapy within 4 weeks, focal radiotherapy within 2 weeks and radiopharmaceuticals (strontium, samarium) within 8 weeks prior to first dose of study treatment.Xx_NEWLINE_xXIf patients have been treated with anti-VEGF agents, such as bevacizumab, last dose must be >= 4 weeksXx_NEWLINE_xXSystemic radiation therapy within 4 weeks, prior focal radiotherapy within 2 weeks, or radiopharmaceuticals (strontium, samarium) within 8 weeks prior to the first dose of study treatment.Xx_NEWLINE_xXAbility to participate in the clinical study for a minimum of at least 2 cycles (6 weeks).Xx_NEWLINE_xXAll prior chemotherapy completed at least three weeks before study treatmentXx_NEWLINE_xXInclusion Criteria:\n\n          1. Male or female patients, > 18 years of age (in Singapore > 21 years or > 18 years with\n             consent of guardian).\n\n          2. Patients with documented (histologically- or cytologically-proven) HCC, with at least\n             1 measureable lesion > 10 mm (excluding bone metastases). If the measurable lesion(s)\n             is in the liver, it either should not have been treated previously with loco-regional\n             therapy, or there must be demonstrated progression of the lesion following previous\n             loco-regional therapy.\n\n          3. Patients with Barcelona Clinic Liver Cancer (BCLC) stage B or C HCC not amenable to\n             surgical intervention due to either medical contraindications or non-resectability of\n             the tumor.\n\n          4. Patients who are either refractory to or intolerant of sorafenib despite dose\n             reduction and best supportive care, or patients who do not have access to sorafenib or\n             other suitable therapy for HCC.\n\n          5. Patients with underlying hepatic cirrhosis must have a current cirrhosis status of\n             Child-Pugh Class A (i.e., score of 5-6) without encephalopathy.\n\n          6. Phase 1b MTD Biopsy Cohort: Patients with primary or metastatic tumor site(s)\n             considered safely accessible for biopsy and consenting to undergo pre- and post-dosing\n             tumor biopsies.\n\n          7. Patients with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or\n             1, and an anticipated life expectancy of ? 3 months.\n\n          8. Patients, both male and female, who are either not of childbearing potential or who\n             agree to use a medically effective method of contraception during the study and for 3\n             months after the last dose of study drug.\n\n          9. Patients with the ability to understand and give written informed consent for\n             participation in this trial, including all evaluations and procedures as specified by\n             this protocol.\n\n        Exclusion Criteria (Patients):\n\n          1. Women who are pregnant or lactating; women of child-bearing potential (WOCBP), and\n             fertile men with a WOCBP-partner not using and not willing to use a medically\n             effective method of contraception.\n\n          2. Patients with known central nervous system (CNS) or leptomeningeal metastases not\n             controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS\n             involvement for which treatment is required.\n\n          3. Patients with mixed histology cholangiocarcinoma and HCC, or fibrolamellar variant\n             HCC.\n\n          4. Patients with any of the following hematologic abnormalities at baseline:\n\n               -  Hemoglobin < 8.5 g/dL\n\n               -  Absolute neutrophil count < 1,500 per mm3\n\n               -  Platelet count < 75,000 per mm\n\n          5. Patients with any of the following serum chemistry abnormalities at baseline:\n\n               -  Total bilirubin > 1.5 Ã— the upper limit of normal (ULN) for the institution\n\n               -  AST or ALT > 5 Ã— the ULN for the institution\n\n               -  Serum creatinine > 1.5 Ã— the ULN for the institution\n\n          6. Patients with the following coagulation parameter abnormality at baseline:\n\n               -  INR > 1.7 Ã— ULN for the institution\n\n          7. Patients with:\n\n               -  A history of deep vein thrombosis (DVT) or pulmonary embolism (PE), within 6\n                  months prior to first study drug administration; patients receiving systemic\n                  anti-coagulation for prophylactic or therapeutic reasons\n\n               -  Active uncontrolled bleeding or a known bleeding diathesis\n\n          8. Patients with:\n\n               -  Esophageal or gastric variceal bleeding within 2 months prior to first study drug\n                  administration; patients with a history of variceal bleeding between 2 and 12\n                  months prior to first study drug administration should have undergone adequate\n                  treatment and be considered clinically stable in the opinion of the investigator\n\n               -  A history of symptomatic ascites requiring paracentesis within the past 3 months\n                  or any encephalopathy requiring hospitalization or medication within the past 3\n                  months\n\n               -  Portal-caval shunts\n\n          9. Patients with a significant cardiovascular disease or condition, including:\n\n               -  Congestive heart failure currently requiring therapy\n\n               -  Need for antiarrhythmic medical therapy for a ventricular arrhythmia\n\n               -  Severe conduction disturbance (i.e., 3rd degree heart block)\n\n               -  Angina pectoris requiring therapy\n\n               -  Known left ventricular ejection fraction (LVEF) < 50% by MUGA or echocardiogram\n\n               -  QTc interval > 450 msec in males, or > 470 msec in females\n\n               -  Uncontrolled systemic hypertension (per the Investigator's discretion)\n\n               -  Class III or IV cardiovascular disease according to the New York Heart\n                  Association (NYHA) Functional Criteria\n\n               -  Myocardial infarction within 6 months prior to first study drug administration\n\n         10. Patients with a known or suspected hypersensitivity to any of the components of lipid\n             nanoparticle-formulated DCR-MYC; patients with a known sensitivity to cremophor (found\n             with paclitaxel and other formulations).\n\n         11. Patients with an estimated daily alcohol intake greater than 80 g/day.\n\n         12. Patients having undergone previous organ transplantation (e.g., liver transplantation)\n             requiring immunosuppression; patients on long-term immunosuppressive therapy.\n\n         13. Patients with a known history of human immunodeficiency virus (HIV) seropositivity.\n\n         14. Patients with any other serious/active/uncontrolled infection, with the exception of\n             chronic hepatitis B virus (HBV) or chronic hepatitis C virus (HCV) infection; any\n             infection requiring parenteral antibiotics, or unexplained fever > 38ÂºC within 2 weeks\n             prior to first study drug administration.\n\n         15. Patients with inadequate recovery from an acute toxicity associated with any prior\n             antineoplastic therapy.\n\n         16. Patients with inadequate recovery from any previous surgical procedure, or patients\n             having undergone any major surgical procedure within 4 weeks prior to first study drug\n             administration.\n\n         17. Patients with an active second malignancy or history of another malignancy within the\n             last 3 years, with the exception of:\n\n               -  Treated, non-melanoma skin cancers\n\n               -  Treated CIS of the breast or cervix\n\n               -  Controlled, superficial carcinoma of the bladder\n\n               -  T1a or b carcinoma of the prostate treated according to local standard of care,\n                  with prostate specific antigen (PSA) within normal limits (wnl)\n\n         18. Patients with any other life-threatening illness, significant organ system\n             dysfunction, or clinically significant laboratory abnormality, which, in the opinion\n             of the Investigator, would either compromise the patient's safety or interfere with\n             evaluation of the safety of the study drug.\n\n         19. Patients with a psychiatric disorder or altered mental status that would preclude\n             understanding of the informed consent process and/or completion of the necessary\n             study-related evaluations.\n\n         20. Patients with the inability or with foreseeable incapacity, in the opinion of the\n             Investigator, to comply with the protocol requirements, including the ability to\n             attend all visits and undergo all assessments.\n\n        Exclusion Criteria (Treatments):\n\n          1. Phase 1b: Greater than 3 prior systemic anti-cancer chemotherapies or targeted agents\n             for HCC; prior loco-regional treatment, including transcatheter arterial\n             chemo-embolization (TACE), is allowed.\n\n          2. Phase 2: greater than 1 prior systemic anti-cancer chemotherapy or targeted agent for\n             HCC; prior loco-regional treatment, including TACE, is allowed.\n\n          3. Sorafenib therapy within 2 weeks prior to first study drug administration and during\n             study.\n\n          4. Any other antineoplastic agent (standard or experimental) within 4 weeks; monoclonal\n             antibody therapy, nitrosoureas, and nitrogen mustard within 6 weeks prior to first\n             study drug administration and during study.\n\n          5. Loco-regional therapy including TACE or radioembolization within 6 weeks prior to\n             first study drug administration and during study.\n\n          6. Radiotherapy within 4 weeks prior to first study drug administration and during study.\n\n          7. Therapy with sofosbuvir for HCV within 6 weeks prior to first study drug\n             administration and during study.\n\n          8. Herbal preparations, or related non-prescription preparations/supplements containing\n             herbal ingredients, aimed at treating the underlying malignancy within 2 weeks prior\n             to first study drug administration and during study.\n\n          9. Systemic hormonal therapy within 2 weeks prior to first study drug administration and\n             during study.\n\n         10. Any other investigational treatments during study. This includes participation in any\n             medical device or therapeutic intervention clinical trial.\n\n         11. Prophylactic use of hematopoietic growth factors within 1 week prior to first study\n             drug administration and during Cycle 1 of study; thereafter prophylactic use of growth\n             factors is allowed as clinically indicated.Xx_NEWLINE_xXPatients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug must recover to a grade 1 before starting the trialXx_NEWLINE_xXPatients who have received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPatients who have received wide field radiotherapy =< 4 weeks or limited field radiation for palliation =< 2 weeks prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPatients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C, and 1 week for hormone therapy) prior to starting study drug or who have not recovered from side effects of such therapyXx_NEWLINE_xXPrior chemotherapy within 3 weeks, nitrosoureas (carmustine) within 6 weeks, therapeutic anticancer antibodies within 4 weeks, radio- or toxin-immunoconjugates within 10 weeks, radiation therapy within 3 weeks, or major surgery within 2 weeks of first dose of study drugXx_NEWLINE_xXSubjects who are receiving concomitant corticosteroids must be on a stable or decreasing dose for at least 4 weeks prior to first dose of study treatment and off all anticonvulsants for at least 4 weeks prior to study entry.Xx_NEWLINE_xXInterval of at least 3 weeks after biopsy or open surgery and able to begin study treatment.Xx_NEWLINE_xXMust be at least 4 weeks since treatment with standard or investigational chemotherapy, biochemotherapy, surgery, radiation, cytokine therapy, and 8 weeks since any monoclonal antibodies or immunotherapy, and recovered from any clinically significant toxicity experienced during treatmentXx_NEWLINE_xXPatients with washout period < 6 weeks from the last dose of ipilimumab or other immunotherapyXx_NEWLINE_xXPrior local therapy within 2 weeks (for both phases I and II) or prior systemic therapy within 4 weeks of starting protocol treatmentXx_NEWLINE_xXPatients who have received cancer immunotherapy of any type within the past 2 weeks prior to initiation of CPI-613 treatmentXx_NEWLINE_xXPatients who have received systemic steroids within 4 weeks prior to starting study treatmentXx_NEWLINE_xXTherapy with samarium-153, strontium-89, or radium-223 within 8 weeks prior to first dose of study drug.Xx_NEWLINE_xXThere should be no evidence for improvement in KS in the 3 months prior to study enrollment, unless there is also evidence for progression of KS in the 4 weeks immediately prior to enrollmentXx_NEWLINE_xXA cluster of differentiation (CD)4+ lymphocyte count > 50/mcL will be required within 2 weeks of study participationXx_NEWLINE_xX? 2 weeks elapsed from the completion of previous treatment regimen and must have recovered or be at a new stable baseline from any related toxicitiesXx_NEWLINE_xXThree or more weeks have elapsed from the completion of previous treatment regimen and subjects must have recovered or be at a new stable baseline from any related toxicities.Xx_NEWLINE_xXBisphosphonates and denosumab are permitted, if on a stable dose for >= 4 weeksXx_NEWLINE_xXAll studies required for evaluation will be performed within 8 weeks of Photofrin administrationXx_NEWLINE_xXReceiving any cancer therapy within 2 weeks of first dose (including surgery, and/or tumor embolization) Note: the following are allowed: Corticosteroids to control systemic or local symptoms, up to a dose of 10 mg prednisone or equivalent daily and stable for at least 7 days prior to enrollment. Subjects with prostate cancer may remain on GnRH agonists. Other hormonal therapies (e.g., bicalutamide, abiraterone and enzlutimide) for prostate cancer must be stopped 4 weeks prior to enrolment. Note: the following are NOT allowed: Chemotherapy regimens with delayed toxicity within the last 3 weeks. Nitrogen mustards, Melphalan, Monoclonal antibody or Nitrosourea within the last 6 weeks.Xx_NEWLINE_xXHemoptysis in excess of 2.5 mL (or one half teaspoon) within 8 weeks prior to first dose of study drugXx_NEWLINE_xXAt least 1-4 weeks since prior myelofibrosis therapy, including any erythropoietic or thrombopoietic agentXx_NEWLINE_xX1st progression of GBM on bevacizumab-containing regimen or within 8 weeks of discontinuing bevacizumab. In either case, must have received a minimum of 8 weeks (4 infusions) of bevacizumab.Xx_NEWLINE_xXAt least 12 weeks from completion of radiation therapy except if there is unequivocal evidence for tumor recurrence in which case at least 4 weeksXx_NEWLINE_xX4 weeks from prior cytotoxic therapyXx_NEWLINE_xX4 weeks from prior experimental drugXx_NEWLINE_xX6 weeks from nitrosoureasXx_NEWLINE_xX3 weeks from procarbazineXx_NEWLINE_xXTreatment with Enzyme-Inducing Anti-Epileptic Drugs within 2 weeks prior to Day 1Xx_NEWLINE_xXUse of any standard/experimental anti-lymphoma drug therapy, including steroids, within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g. donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; prior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapyXx_NEWLINE_xXImaging evaluations necessary to establish eligibility for study entry must be done within three (3) weeks prior to registration; all other evaluations necessary to establish eligibility for study entry must be done within two (2) weeks prior to registration; in the event that the patientâ€™s condition deteriorates (performance score < 60) within 48 hours prior to the injection the patient is no longer eligible to receive HSV1716 injectionXx_NEWLINE_xXPatients must have received their last dose of known myelosuppressive anticancer chemotherapy at least three (3) weeks prior to study registration or at least six (6) weeks if nitrosoureaXx_NEWLINE_xX-  Subjects with Philadelphia negative B-precursor ALL, with any of the following:\n\n               -  refractory to primary induction therapy or refractory to salvage therapy,\n\n               -  in untreated first relapse with first remission duration <12 months\n\n               -  in untreated second or greater relapse\n\n               -  relapse at any time after allogeneic HSCT\n\n          -  Subject has received intensive combination chemotherapy for the treatment of ALL for\n             initial treatment or subsequent salvage therapy.\n\n          -  Greater than 5% blasts in the bone marrow\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status ? 2\n\n        Exclusion Criteria\n\n          -  Malignancy other than ALL within 5 years before blinatumomab treatment, except for\n             adequately treated selected cancers without evidence of disease\n\n          -  Diagnosis of Burkitt's leukemia according to World Health Organization classification,\n             or human immunodeficiency virus (HIV), Hepatitis B or C, or other clinically\n             significant disorder\n\n          -  Current relevant central nervous system (CNS) pathology or known or suspected CNS\n             involvement\n\n          -  Isolated extramedullary disease\n\n          -  Current autoimmune disease or history of autoimmune disease with potential CNS\n             involvement\n\n          -  Autologous HSCT within 6 weeks or allogeneic HSCT within 12 weeks before blinatumomab\n             treatment, or eligibility for allogeneic HSCT at the time of enrollment\n\n          -  Active acute grade 2 to 4 graft versus host disease (GvHD) according to Glucksberg et\n             al (1974) criteria that required systemic treatment to prevent or treat GvHD 2 weeks\n             before blinatumomab treatment\n\n          -  Known exclusion criteria to investigator choice of SOC chemotherapy (per package\n             insert)\n\n          -  Cancer chemotherapy or radiotherapy with 2 weeks, or immunotherapy (included CD19\n             therapy) within 4 weeks of protocol-specified therapy\n\n          -  Abnormal laboratory values (alanine or aspartate transaminase [ALT or AST] or alkaline\n             phosphatase [ALP] ? 5 Ã— upper limit of normal [ULN]; total bilirubin or creatinine ?\n             1.5 Ã— ULN), or calculated creatinine clearance < 60 mL/min.Xx_NEWLINE_xXSubject's pain-related medication regimen is stable 4 weeks prior to the baseline evaluationXx_NEWLINE_xXCompleted their last dose of chemotherapy or had their last cancer surgery more than 10 weeks, whichever came later, prior to randomization.Xx_NEWLINE_xXPrior local therapy within 2 weeks of starting the study treatmentXx_NEWLINE_xXMyelosuppressive chemotherapy: patients must not have received myelosuppressive chemotherapy within 3 weeks of enrollment (6 weeks if prior nitrosourea)Xx_NEWLINE_xXMonoclonal antibodies: at least 4 weeks must have elapsed since prior therapy that included a monoclonal antibodyXx_NEWLINE_xX5. Received last dose of prior chemotherapy within ? 6 weeks of first dose of VS-6063.Xx_NEWLINE_xXThe last dose of previous therapy targeting RET kinase must be given at least 4 weeks prior to the first dose of ponatinibXx_NEWLINE_xXA minimum of 4 weeks must have elapsed since the administration of all other investigational agentsXx_NEWLINE_xXPatients must have stable use of hormonal therapy for two weeks prior to cryoablation procedure)Xx_NEWLINE_xXHemoptysis of red blood in excess of 2.5 mL (or one half teaspoon) within 8 weeks of first dose of study drug.Xx_NEWLINE_xXStable steroid dose in past 4 weeksXx_NEWLINE_xXNo chemotherapy, RT, donor lymphocyte infusion (DLI) or biologic therapy for lymphoma at least 4 weeks prior to scheduled treatmentXx_NEWLINE_xXThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (eg, cytokines or antibodies) within 3 weeks, or nitrosoureas/ mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXPatient must be willing to undergo surgery at MUSC within 4-8 weeks of completing chemoradiationXx_NEWLINE_xXHave completed treatment greater than 4 weeks prior to enrollment.Xx_NEWLINE_xXPatients must have no residual neurologic symptoms while taking no steroids, a stable or decreasing dose of steroids, or a stable dose of anti-seizure medication for the 2 weeks prior to enrollment.Xx_NEWLINE_xXPatients with nasal NK lymphoma who received local RT less than 4 weeks prior to randomization.Xx_NEWLINE_xXHepatitis B (HBV)-positive serology and is receiving interferon therapy or has liver function test results outside the parameters of study inclusion criteria. Other antiviral therapies are permitted if at a stable dose for at least 4 weeks.Xx_NEWLINE_xXHave received experimental therapy within 2 weeks of enrollmentXx_NEWLINE_xXPatients must have recovered and healed from the effects of any prior surgery, must have received prior chemotherapy at least 2 weeks prior to dosing with adequate recovery of white blood cell (WBC) and platelet counts, and at least 12 weeks must have elapsed from the completion of radiotherapy, unless there are new lesions appearing on imaging within this 12 weeks frameXx_NEWLINE_xXCompleted prior chemotherapy a minimum of 4 weeks previously (6 weeks for BCNU and/or mitomycin C), 4 weeks for prior immune therapy, 6 weeks for antibodies to checkpoints CTLA4, PD1, PDL1, etc, and 2 weeks for targeted agents (i.e. inhibitors of MEK, BRAF, Akt, PI3K, mTORC1/2) or localized radiation therapy; all treatment related toxicity must have resolved to grade 2 or less or to a baseline level as wellXx_NEWLINE_xXThere should be no evidence for improvement in KS in the 3 months prior to study enrollment, unless there is evidence for progression of KS in the 4 weeks immediately prior to study enrollmentXx_NEWLINE_xXSubjects who have received investigational agents must wait at least 4 weeksXx_NEWLINE_xXSigns or symptoms of infection within 2 weeks prior to the first dose of study treatmentXx_NEWLINE_xXTreatment with any approved anti-cancer therapy within 3 weeks prior to the first dose of study treatmentXx_NEWLINE_xXAny other prior therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to registrationXx_NEWLINE_xXHas had within the 4 weeks prior to initiation of study drug, or is expected to have during the study period, surgery requiring general anesthesia.Xx_NEWLINE_xXBevacizumab within 4 weeks.Xx_NEWLINE_xXOther chemotherapy (e.g., mitomycin-C, nitrosourea) or immunotherapy (e.g., antibody, cytokine) within 4 weeksXx_NEWLINE_xXHas, within 2 weeks prior to Day 1, received a medication prohibited based on CYP3A4 interactionXx_NEWLINE_xXCompletion of at least 3 months, but no more than 6 months of standard induction chemotherapy for LAPC, which may include FOLFIRINOX or gemcitabine and nab-paclitaxel, preferably within 2-4 weeks but no longer than 8 weeksXx_NEWLINE_xXPatients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n* 12 weeks from the completion of radiation\r\n* 6 weeks from a nitrosourea chemotherapy\r\n* 3 weeks from a non-nitrosourea chemotherapy\r\n* 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n* 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., erlotinib, hydroxychloroquine, etc.)\r\n* 4 weeks from prior antiangiogenesis therapy (approved or investigational) (e.g., bevacizumab, aflibercept, ramucirumab, cediranib, cabozantinib, etc.)Xx_NEWLINE_xXPatients must have completed last chemotherapy >= 3 weeks or radiotherapy >= 2 weeks prior to receiving study drugsXx_NEWLINE_xXThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 3 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXNo chemotherapy within 4 weeks prior to study treatment administration; nitrosoureas and mitomycin C are not allowed within 6 weeks prior to initiation of study treatmentXx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy: 4 weeks from prior cytotoxic therapy and/or at least two weeks from vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count). Any questions related to the definition of non-cytotoxic agents should be directed to the Study Chair.Xx_NEWLINE_xXPatients who have received either immunotherapy within =< 8 weeks; chemotherapy within =< 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapiesXx_NEWLINE_xXNo more than 12 weeks must have elapsed from hysterectomy.Xx_NEWLINE_xXNo radiation, major surgery, chemotherapy or biologic therapy within 4 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin C); >= 2 weeks since any prior administration of study drug in an exploratory investigational new drug (IND)/phase 0 study (also referred to as an â€œearly phase I studyâ€ or â€œpre-phase I studyâ€ where a subtherapeutic dose of drug is administered) at the principal investigator (PI)â€™s discretion; patients must have recovered to at least eligibility levels due to adverse events and/or toxicity of prior chemotherapy or biologic therapyXx_NEWLINE_xXAt least 2 weeks must have elapsed since the last anti-leukemia treatment (with the exception of hydroxyurea) before first dose in this study.Xx_NEWLINE_xXConcurrent or previous anti-cancer chemotherapy, immunotherapy or investigational agents < 3 weeks, or palliative radiation < 2 weeks prior to the first day of study treatment. Patients who receive gamma knife radiosurgery for brain metastases or whole brain radiation are eligible if gamma knife radiosurgery was performed > 2 weeks before treatment is started or whole brain radiation was performed > 4 weeks before treatment is started, and are clinically stable.Xx_NEWLINE_xX< 6 weeks for mitomycin-C or nitrosoureasXx_NEWLINE_xXLess than 4 weeks since prior treatment; or 2 weeks if patient experienced disease progression on the prior treatmentXx_NEWLINE_xXSchedule can accommodate both of the following: 2 doses of mirvetuximab soravtansine administered 3 weeks apart and surgery within 9 weeks of last dose of NACXx_NEWLINE_xXTreatment with any investigational drug within 6 weeks of first dose of mirvetuximab soravtansineXx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this study (4 weeks if prior nitrosourea)\r\n* Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent\r\n* Radiation therapy (RT): >= 2 weeks for local palliative RT (small port); >= 6 months must have elapsed if prior craniospinal RT or if >= 50% radiation of pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiation\r\n* Monoclonal antibodies: must not have received any monoclonal based therapies within 4 weeks, and all other immunotherapy (tumor vaccine, cytokine, or growth factor given to control the cancer) within 2 weeks, prior to study enrollmentXx_NEWLINE_xXUse of any approved anti-cancer therapy within 3 weeks prior to treatmentXx_NEWLINE_xXTreatment with immunostimulatory agents within 4 weeks or immunosuppressive agents within 2 weeks prior to randomizationXx_NEWLINE_xXSystemic investigational drug of any kind within 6 weeks of AVB-620 administrationXx_NEWLINE_xXParticipant has not taken immunosuppressive medications for at least 2 weeksXx_NEWLINE_xXRadiographic progression, defined by RECIST v.1.1, after the last cancer treatment and within 12 weeks prior to enrollment, compared with scans within 1 year of enrollment.Xx_NEWLINE_xXSystemic antineoplastic therapy or any experimental therapy within 3 weeks before the first dose of study drug (6 weeks for prior nitrosoureas, bevacizumab, or mitomycin C)Xx_NEWLINE_xXReceived chemotherapy regimens with delayed toxicity within the last four weeks (six weeks for prior nitrosourea or mitomycin C). Received chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last two weeks.Xx_NEWLINE_xXReceipt of any investigational treatment within 4 weeks of scheduled dosing day 1.Xx_NEWLINE_xXReceipt of cytotoxic chemotherapy within 3 weeks (6 weeks for nitrosoureas and mitomycin C) of scheduled dosing day 1.Xx_NEWLINE_xXPrior treatment with any investigational product within the past 4 weeksXx_NEWLINE_xXPrior therapy with nitrosoureas or mitomycin within 6 weeks prior to the first dose of TKM-080301.Xx_NEWLINE_xXHas had surgery requiring general anesthesia within 4 weeks of starting the study.Xx_NEWLINE_xXOral kinase inhibitors approved by local regulatory authorities may be used within 2 weeks prior to initiation of DLYE5953A, provided that any clinically relevant drug-related toxicity has completely resolved and prior approval is obtained from the Medical MonitorXx_NEWLINE_xXSubjects on metformin for any reason during the preceding 4 weeksXx_NEWLINE_xXParticipant must have recovered from the acute side effects of all prior anti-cancer therapy, and:\r\n* At least 2 weeks have elapsed since prior systemic cytotoxic chemotherapy (except intrathecal chemotherapy, and/or low dose maintenance therapy such as vincristine, mercaptopurine, methotrexate or glucocorticoids), and\r\n* At least 4 weeks have elapsed since treatment with an investigational agent or antibody-based therapy, if applicable, and\r\n* If the participant received a prior allogeneic hematopoietic stem cell transplant (HSCT), at least 3 months have elapsed and there is no evidence of active graft-versus-host disease (GVHD), participant has discontinued immunosuppression, and there is no history of veno-occlusive diseaseXx_NEWLINE_xXLess than four weeks since last monoclonal antibody-containing therapyXx_NEWLINE_xXPatients must not have received myelosuppressive therapy within 2 weeks of enrollment onto this study (6 weeks if prior nitrosourea)Xx_NEWLINE_xXWashout from any prior biologic or targeted therapy at least 4 weeks or five times the T1/2 (whichever is shorter) prior to C1D1Xx_NEWLINE_xXWashout from prior hormonal therapy of at least 2 weeks prior to C1D1Xx_NEWLINE_xXDiscontinuation of all other therapies for treatment of iNHL ? 3 weeks before Visit 2Xx_NEWLINE_xXOther investigational agents within 4 weeks prior to study treatment, except for subjects with anaplastic/undifferentiated thyroid cancer who may be enrolled immediately of discontinuation of previous therapyXx_NEWLINE_xXPrior surgery that required general anesthesia must be completed at least 4 weeks before study drug administration. Surgery requiring local/epidural anesthesia must be completed at least 72 hours before study drug administration.Xx_NEWLINE_xXBrain metastases or spinal cord compression, unless treatment was completed at least 4 weeks before study entry, and stable without steroid treatment for at least 4 weeksXx_NEWLINE_xXRequired screening laboratory data (within 2 weeks prior to administration of study drug) as shown in study protocol.Xx_NEWLINE_xXPrior treatment with bevacizumab within twelve weeks before the first infusion.Xx_NEWLINE_xXOral treatment with antimicrobial therapy starting less than two weeks prior to first dose.Xx_NEWLINE_xXOff all myelofibrosis-related investigational or standard agents (except for ruxolitinib) for at least 4 weeks prior to study enrollment and recovered from all toxicities; if patient is already on ruxolitinib for a minimum of 16 weeks prior to study enrollment, patient can proceed to mobilization and collectionXx_NEWLINE_xXSubject has had chemotherapy within 4 weeks prior to the first study dose.Xx_NEWLINE_xXIndividuals must have been on a stable dose of ruxolitinib for at least 4 weeks prior to study entryXx_NEWLINE_xXRadiotherapy (except for palliative reasons), chemotherapy, endocrine therapy, or immunotherapy during the previous 3 weeks (4 weeks for investigational medicinal products and 6 weeks for nitrosoureas and Mitomycin-C) before treatment.Xx_NEWLINE_xXPrior AR targeted therapy (abiraterone acetate or enzalutamide) must be stopped at least 2 weeks before study treatment.Xx_NEWLINE_xXCompleted 24 weeks of treatment in Protocol 8400-401Xx_NEWLINE_xXAll patients must have an electrocardiogram (ECG) within 2 weeks of starting conditioningXx_NEWLINE_xXPrior chemotherapy completed at least 3 weeks prior to study enrollmentXx_NEWLINE_xXMore than 4 weeks must have elapsed since any prior systemic therapy at the time the patient receives the preparative regimen; note: patients may have undergone minor surgical procedures within the past 3 weeks, as long as all toxicities have recovered to grade 1 or less or as specified in the eligibility criteriaXx_NEWLINE_xXReceived any chemotherapeutic or targeted agent for metastatic colorectal cancer within two weeks of initiation of study drugXx_NEWLINE_xXPatients who have received chemotherapy, biological agents or investigational therapy within 4 weeks prior to entering the studyXx_NEWLINE_xXPatients who have received any hormonal therapy directed at the malignancy within 2 weeks prior to entering the studyXx_NEWLINE_xXHas received treatment with focal radiotherapy within 2 weeks, or radiopharmaceuticals (e.g., strontium, samarium) within 8 weeks of receiving cyclophosphamide on Day -3Xx_NEWLINE_xXAdministration of any other vaccine ? 4 weeks of receiving cyclophosphamide on Day -3Xx_NEWLINE_xXRadiotherapy < or = 4 weeks or limited field radiation for palliation < or = 2 weeks prior to starting with the investigational product.Xx_NEWLINE_xXMust have completed any systemic therapy at least one week prior to planned start of SBRT (two weeks preferred), and must have no plans to initiate systemic therapy for at least one week following end of SBRT (two weeks preferred)Xx_NEWLINE_xXHas had surgery requiring general anesthesia within 4 weeks of starting the studyXx_NEWLINE_xXSubjects must have the following minimum wash-out and adverse event (AE) recovery period from previous treatments without treatment between documentation of relapse/progression and enrollment of specifically:\r\n* >= 2 weeks for local radiation therapy\r\n* >= 4 weeks for systemic cytotoxic anticancer agents, anticancer investigational agents that are not defined as immunotherapy, or for tumor-targeting monoclonal antibodies (mAbs) with the exception of alemtuzumab for which the washout is at least 8 weeks\r\n* >= 15 weeks for anti-cluster of differentiation (CD)137 or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)\r\n* >= 2 weeks from resolution (i.e., =< grade 1 or at baseline) from AEs due to procedures performed or therapeutic agents administered\r\n* >= 2 weeks for retinoids, interferons, vorinostat, romidepsin, denileukin diftitox, and therapeutic doses of oral corticosteroids (physiologic replacement doses of oral corticosteroids are allowed, topical corticosteroids are allowed)\r\n* >= 2 weeks for phototherapy\r\n* >= 1 week for topical therapy (including retinoid, nitrogen mustard, or imiquimod)Xx_NEWLINE_xXScreening endoscopic ultrasound if done prior to consent but within 6 weeks of expected randomization date it may be usedXx_NEWLINE_xXAbiraterone acetate; primary resistance to abiraterone will be defined as:\r\n* No PSA decline\r\n* PSA decline less than 50% after 12 weeks of abiraterone therapy\r\n* PSA progression within 12 weeks of abiraterone acetate (AA) treatment (by Prostate Cancer Working Group-2 [PCWG2] criteria), after initial response to therapy\r\n* Objective progression, by RECIST criteria for soft tissue lesions and by modified PCWG2 criteria for bone lesions within 12 weeks of starting abiraterone treatment\r\n* Unequivocal clinical progression (per the treating provider's discretion) within 12 weeks of starting abiraterone treatmentXx_NEWLINE_xXEnzalutamide; primary resistance to enzalutamide will be defined as:\r\n* No PSA decline\r\n* PSA decline less than 50% after 12 weeks of enzalutamide therapy\r\n* PSA progression within 12 weeks of enzalutamide treatment (by PCWG2 criteria), after initial response to therapy\r\n* Objective progression, by RECIST criteria for soft tissue lesions and by modified PCWG2 criteria for bone lesions within 12 weeks of starting enzalutamide treatment\r\n* Unequivocal clinical progression (per the treating provider's discretion) within 12 weeks of starting enzalutamide treatmentXx_NEWLINE_xXOther second-generation investigational anti-androgen/androgen-receptor targeted therapies, including apalutamide (ARN-509); primary resistance will be defined as:\r\n* No PSA decline\r\n* PSA decline less than 50% after 12 weeks of enzalutamide therapy\r\n* PSA progression within 12 weeks of enzalutamide treatment (by PCWG2 criteria), after initial response to therapy\r\n* Objective progression, by RECIST criteria for soft tissue lesions and by modified PCWG2 criteria for bone lesions within 12 weeks of starting enzalutamide treatment\r\n* Unequivocal clinical progression (per the treating provider's discretion) within 12 weeks of starting enzalutamide treatmentXx_NEWLINE_xXCombination therapy with abiraterone, enzalutamide and/or other second- generation investigational anti-androgen/androgen-receptor targeted therapies, including ARN-509; primary resistance to combination therapy will be defined as:\r\n* No PSA decline\r\n* PSA decline less than 50% after 12 weeks of abiraterone and enzalutamide therapy\r\n* PSA progression within 12 weeks of abiraterone and enzalutamide treatment (by PCWG2 criteria), after initial response to therapy\r\n* Objective progression, by RECIST criteria for soft tissue lesions and by modified PCWG2 criteria for bone lesions within 12 weeks of starting abiraterone and enzalutamide treatment\r\n* Unequivocal clinical progression (per the treating providerâ€™s discretion) within 12 weeks of starting abiraterone and enzalutamide treatmentXx_NEWLINE_xXChemotherapy, biological therapy or investigational agents (except EGFR TKIs) within 4 weeksXx_NEWLINE_xXAny conventional molecularly targeted therapy within 2 weeks or, chemotherapy or radiotherapy within 2 weeks (local) or 4 weeks (systemic) prior to entering the study.Xx_NEWLINE_xXPatient has received chemotherapy or anticancer therapy ? 4 weeks (6 weeks for nitrosourea, monoclonal antibodies or mitomycin-C) prior to starting study drug.Xx_NEWLINE_xXPatients must have recovered (grade 1 or baseline) from any clinically significant toxicity associated with prior therapy; typically, this is 3â€“4 weeks for patients who most recently received cytotoxic therapy, except for the nitrosoureas and mitomycin C, for which 6 weeks is needed for recoveryXx_NEWLINE_xXAble to initiate study treatment at least 2 weeks but no more than 4 weeks after completion of salvage therapyXx_NEWLINE_xXAny type of systemic therapy (chemotherapy or experimental drugs) within 3 weeks of starting treatment on protocol except for erlotinib or other EGFR TKIXx_NEWLINE_xXPersistent diarrhea (>= Grade 2) lasting greater than (>) 3 days within 2 weeks before the first dose of study treatment.Xx_NEWLINE_xXLocal-regional therapy within 4 weeks before Day 1Xx_NEWLINE_xXPatients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\r\n* Myelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this study (6 weeks if prior nitrosourea)\r\n* Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with a biologic agent\r\n* Bisphosphonates: at least 4 weeks since the completion of therapy with a bisphosphonate\r\n* Monoclonal antibodies: at least 3 half-lives must have elapsed since prior therapy that included a monoclonal antibody\r\n* Radiation therapy (RT): >= 2 weeks (wks) for local palliative RT (small port); >= 6 months must have elapsed if prior craniospinal RT or if >= 50% radiation of pelvis; >= 6 weeks must have elapsed if other substantial bone marrow (BM) radiationXx_NEWLINE_xXNo chemotherapy or investigational agent for at least 3 weeks prior to the start of SL-701, with at least 6 weeks of elapsed time from last dose of nitrosoureas.Xx_NEWLINE_xXFollowing treatment-free period prior to enrollment to the study: i)Surgery: 4 weeks for major surgery (e.g., laparotomy and thoracotomy); 2 weeks for less extensive surgery (e.g., colostomy) ii)Radiation: 4 weeks (2 weeks for palliative irradiation to bone metastases [except for pelvic irradiation], and brain metastasis) iii) Chemotherapy (including systemic treatment with anticancer therapy and retinoid therapy): 3 weeks (6 weeks for nitrosourea antineoplastic agent and mitomycin C) iv) Antibody-based therapy: 4 weeks v) Small molecule targeted agents: If myelosuppression is not expected, 2 weeks or 5 half-lives, whichever is longer; otherwise, 3 weeks vi) Hormonal treatment: 3 weeks. Previous and concurrent use of hormone replacement therapy, the use of gonadotropin-releasing hormone modulators for prostate cancer, and the use of somatostatin analogs for neuroendocrine tumors are permitted if such therapy has not been changed within 8 weeks before study drug treatment. vii) Pleurodesis: 2 weeksXx_NEWLINE_xXAll patients must be off previous chemo- and/or radiotherapy for at least three (3) weeks prior to entrance into the study and have recovered from any toxic effects induced by such treatment(s); no nitrosourea type drug or ipilumimab treatments are permitted within the last six (6) weeks prior to enrollment. No major surgery within 14 days of enrollment. Patients may continue to receive anti-estrogen/steroid therapy that has been initiated at least eight weeks prior to enrollment in the study.Xx_NEWLINE_xXPatient has discontinued all corticosteroids for that indication for at least 2 weeks;Xx_NEWLINE_xXHepatic radiation, chemoembolization, and radiofrequency ablation < 4 weeks prior to study day 1.Xx_NEWLINE_xXInterferon therapy < 4 weeks prior to study day 1.Xx_NEWLINE_xXPeripheral edema ? grade 2 within 2 weeks prior to study day 1.Xx_NEWLINE_xXwithin 3 weeks prior to the first dose of KTN3379, orXx_NEWLINE_xXPatients who are taking simvastatin or lovastatin. Patients should be switched to alternative therapies a minimum of 2 weeks before starting study drugXx_NEWLINE_xXHas the subject received cytotoxic chemotherapy within the past 3 weeks (6 weeks for nitrosoureas) of the planned date of vector injection?Xx_NEWLINE_xXDoes the subject have, or has the subject had, within the past 4 weeks any infection requiring antibiotic, antifungal or antiviral therapy?Xx_NEWLINE_xXcompleted all treatment and follow-up through at least 12 weeksXx_NEWLINE_xXAdministration of any vaccine ? 4 weeks prior to first maintenance or retreatment cohort dose of ONT-10 with the exception of influenza, pneumococcus, and TdapXx_NEWLINE_xXCoronary angioplasty or stenting within the past 12 weeksXx_NEWLINE_xXStopped tobacco use for 4 weeks prior to day 1 and during the studyXx_NEWLINE_xXPrevious anti-cancer therapy for malignancy within 4 weeks (6 weeks for the nitrosoureas or mitomycin C) before day 1Xx_NEWLINE_xXTreatment with antiarrythmic drugs and any medication known to cause QTc prolongation within 4 weeks before screening and during the studyXx_NEWLINE_xXTreatment with any anti-cancer therapy within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXTreatment with any anti-cancer therapy within 3 weeks prior to initiation of study treatmentXx_NEWLINE_xXAt least three weeks since the last prior therapy, at least four weeks since completion of any prior radiotherapyXx_NEWLINE_xXSignificant cancer-related weight loss (?10%)within four weeks prior to treatment startXx_NEWLINE_xXAdequate recovery from prior systemic or local melanoma therapy; no systemic anticancer therapy in the 4 weeks and no ipilimumab in the 6 weeks from planned vemurafenib administration; no radiation therapy in 2 weeks prior to date plan to initiate vemurafenib treatment and no surgery in 3 weeks prior to date of planned vemurafenib administrationXx_NEWLINE_xXTreatment with radiotherapy, chemotherapy or investigational therapy within 1 month (or 5 half lifes for cytotoxics) prior to study entry (6 weeks for nitrosoureas or Mitomycin C).Xx_NEWLINE_xXHigh-dose chemotherapy within 4 weeks of study drugXx_NEWLINE_xXAny of the following prior therapies:\r\n* Chemotherapy =< 4 weeks prior to registration\r\n* Mitomycin C/nitrosoureas =< 6 weeks prior to registration\r\n* Immunotherapy =< 4 weeks prior to registration\r\n* Biologic therapy =< 4 weeks prior to registration\r\n* Radiation therapy =< 4 weeks prior to registration\r\n* Radiation to > 25% of bone marrow prior to registrationXx_NEWLINE_xXReceipt of any biological therapy within 6 weeks of the first dose of GSK3052230Xx_NEWLINE_xXPresence or history of hemoptysis (>1/2 teaspoon of red blood) 2 weeks prior to the first dose of GSK3052230Xx_NEWLINE_xXThe subject has received cytotoxic chemotherapy (including investigational cytotoxic chemotherapy) or biologic agents (e.g., cytokines or antibodies) within 2 weeks, or nitrosoureas/mitomycin C within 6 weeks before the first dose of study treatmentXx_NEWLINE_xXPersistent diarrhea (greater than Grade 2) lasting > 3 days within 2 weeks before the first dose of study treatmentXx_NEWLINE_xXUse of a first-generation anti-androgen such as bicalutamide within 6 weeks of study drug dosing, or flutamide within 4 weeks of study dosingXx_NEWLINE_xXAdministration of conventional chemotherapy within 2 weeks of enrollment date. In the event that subjects have received chemotherapy > 2 weeks from the date of enrollment, they may be included provided they have recovered from the associated non-hematological toxicities to ? grade 1.Xx_NEWLINE_xXAnti-cancer therapy (including conventional cytotoxic chemotherapy and/or biological therapy) and radiotherapy must be completed and any associated toxicities resolved to </= Grade 1 levels or baseline levels and at least 2 weeks must have elapsed before enrollment. Treatment with monoclonal antibodies must be completed at least 14 days before entry. Must have completed immunosuppressive medications or vaccinations before enrollment.Xx_NEWLINE_xXReceipt of any prior cytotoxic chemotherapy for ALK-positive NSCLC within 4 weeks prior to Day 1. Patients who received crizotinib or any other tyrosine kinase inhibitors need to have a minimum 2-week washout period before the first doseXx_NEWLINE_xXUse of medications or herbal supplements which are known to potentially lower serum PSA within 6 weeks of day 1 of protocol therapyXx_NEWLINE_xXSystemic anticancer treatment (including biologic therapy/antibodies) within 2 weeks before first dose of study treatment (6 weeks for nitrosourea, mitomycin, and monoclonal antibodies).Xx_NEWLINE_xXAsymptomatic with no corticosteroid requirements for >= 4 weeks prior to randomization, ANDXx_NEWLINE_xXNo enzyme inducing anticonvulsants for >= 4 weeks prior to randomizationXx_NEWLINE_xXChemo-, immune-, or hormone-therapy within 5 elimination half life times or 4 weeks prior to randomization, whichever is the shorter. Radiotherapy (including pre- or post-operative brachytherapy) within 4 weeks prior to randomization.Xx_NEWLINE_xXDiscontinued prior systemic treatment or any investigational drug for at least 2 weeks (14 days) or for at least 3 weeks for IV anti-cancer drugs, prior to the study randomizationXx_NEWLINE_xXTreatment less than two weeks prior to enrollment with other systemic experimental therapies or antineoplastic agents, with the exception of hydroxyurea and intrathecal chemotherapeutic agentsXx_NEWLINE_xXRituximab within six weeksXx_NEWLINE_xXPatients who have received prior anti-CTLA4 or anti-PD1 therapy less than 8 weeks prior to enrollmentXx_NEWLINE_xXPatients who have received prior biologic agents less than 4 weeks prior to enrollmentXx_NEWLINE_xXPatients who have received prior interferon or IL-2 therapy less than 4 weeks prior to enrollmentXx_NEWLINE_xXPrior treatment with bortezomib (Velcade) is acceptable with a wash-out of 2 weeksXx_NEWLINE_xXReceived radiation therapy, surgery, or chemotherapy within 2 weeks prior to study entry (6 weeks for nitrosoureas or Mitomycin C)Xx_NEWLINE_xXReceived bisphosphonates (e.g., etidronate, clodronate, tiludronate, pamidronate, neridronate, olpadronate, alendronate, ibandronate, risedronate, zoledronate) within 2 weeks prior to study entryXx_NEWLINE_xXPrior treatment with a Smoothened inhibitor Systemic anticancer treatment within 2 weeks before first dose of study treatment (6 weeks for nitrosourea, mitomycin, and monoclonal antibodies).Xx_NEWLINE_xXChemotherapy, targeted therapies, radiotherapy, immunotherapy, or treatment with an investigational anticancer agent within 2 weeks or at least 5 half-lives of the drug, whichever is longer and up to a maximum of 4 weeks (in the case of nitrosoureas and mitomycin C within 6 weeks) before the first administration of study drug. Localized radiation therapy and ongoing luteinizing hormone-releasing hormone (LHRH) agonists, bisphosphonates and denosumab, are permittedXx_NEWLINE_xXChemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drugXx_NEWLINE_xXPatients who have received the last administration of nitrosourea or mitomycin-C =< 6 weeks prior to starting study drug, or who have side effects (except alopecia, lymphopenia and hyperglycemia) that have not resolved to NCI CTCAE grade 1or lessXx_NEWLINE_xXPatients who have received either immunotherapy within =< 8 weeks; chemotherapy within =< 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapiesXx_NEWLINE_xXTreatment with androgen receptor antagonists (bicalutamide, flutamide, nilutamide), 5-? reductase inhibitors (finasteride, dutasteride), estrogens, chemotherapy, or biologic therapy within 4 weeks of Day 1 visitXx_NEWLINE_xXRadiation therapy within 3 weeks (if single fraction of radiotherapy within 2 weeks) of Day 1 visit, or radionuclide therapy within 8 weeks of Day 1Xx_NEWLINE_xXLast dose of bevacizumab >= 2 weeks prior to registration (Phase I); note: for the phase II study only, prior exposure to bevacizumab is not allowedXx_NEWLINE_xXCompletion of radiation therapy >= 12 weeks prior to registration and prior chemotherapy >= 4 weeks prior to registration (>= 6 weeks from nitrosourea-containing regimens)Xx_NEWLINE_xXPrior treatment with one to three lines of systemic chemotherapy for locally advanced or metastatic disease and two weeks from any previous anticancer therapy including biologics and recovered from expected toxicity; at least 4 weeks from major surgery and recovered; at least 3 weeks from radiation affecting more than 25% of bone marrow and recovered; and 2 weeks from other palliative radiation and recovered. No more than 450 mg/m2 cumulative dose of doxorubicin is allowed.Xx_NEWLINE_xXChemotherapy or other systemic cancer therapy within 4 weeks of initial study treatment (6 weeks for nitrosoureas or mitomycin), or regional chemotherapy (limb infusion or perfusion) within 12 weeks of initial study treatmentXx_NEWLINE_xXImmunotherapy for cancer within 4 weeks of initial study treatmentXx_NEWLINE_xXAnti-tumor vaccine therapy within 6 weeks of initial study treatment.Xx_NEWLINE_xXHave had a loco-regional procedure for the treatment of hepatocellular carcinoma (such as a percutaneous, trans-arterial, or radio-ablative procedure) less than 4 weeks prior to beginning protocol therapy. Protocol therapy may begin a minimum of 4 weeks after such a procedure provided the following criteria are met:Xx_NEWLINE_xXMost recent enzalutamide dose received is 160 mg once daily with no change in dose for at least 2 weeks prior to Screening.Xx_NEWLINE_xXTreatment with any known non-marketed drug substance or experimental therapy within 4 weeks prior to enrollment, or currently participating in any other interventional clinical study for NHL or any other illness (except observational, prevention, and/or registry trials)Xx_NEWLINE_xXAnti-platelet drugs within 4 weeks prior to the first dose of study drug. Anti-platelet drugs are defined as any agent or combination of agents with clinically proven anti-thrombotic activity administered by any route with the purpose of affecting blood clotting ability of the subject.Xx_NEWLINE_xXRecovery from effects of recent surgery, radiotherapy, or chemotherapy\r\n* At least 4 weeks out from their last dose of radiation therapy\r\n* At least 4 weeks post-operative (op) from any major surgical procedure\r\n* At least 3 weeks out from their last dose of chemotherapy and/or biologic/targeted therapyXx_NEWLINE_xXPatients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n* 12 weeks from the completion of radiation \r\n* 6 weeks from a nitrosourea chemotherapy\r\n* 3 weeks from a non-nitrosourea chemotherapy\r\n* 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n* 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g., Tarceva, hydroxychloroquine, bevacizumab, etc.)Xx_NEWLINE_xXNo limit to prior therapies with last anti-cancer treatment >= 2 weeks from initiation of WBRT; please note: there is no washout period required for trastuzumab and pertuzumabXx_NEWLINE_xXHad chemotherapy or radiotherapy within 3 weeks (or 6 weeks for nitrosoureas or mitomycin C) prior to administration of the first dose of study treatment.Xx_NEWLINE_xXAny prior therapy must have been completed >= 4 weeks prior to enrollment on protocol and the participant must have recovered to eligibility levels from prior toxicity; patients should be at least 6 weeks out from nitrosoureas and mitomycin C; prior radiation should have been completed >= 4 weeks prior to study enrollment and all associated toxicities resolved to eligibility levels; patients who have had prior monoclonal antibody therapy must have completed that therapy at least 3 half-lives of the antibody or 6 weeks ago; patients who have received more than a cumulative dose of 350 mg/m^2 of doxorubicin may be enrolled at the discretion of the coordinating center principal investigator (PI) after consultation with a cardiologist and if screening echocardiogram is normalXx_NEWLINE_xXHistory and physical examination, including neurologic examination, within 2 weeks prior to registrationXx_NEWLINE_xXRT must be administered within 12 weeks of definitive surgery if the patient is not treated with chemotherapy; if adjuvant chemotherapy is given, RT must begin within 2-8 weeks after the last doseXx_NEWLINE_xXPrior treatment with immune checkpoint inhibitors, immunomodulatory monoclonal antibody (mAbs), and/or mAb-derived therapies is allowed provided that at least 6 weeks (Phase 1a) or 3 weeks (Phase 1b) have elapsed between the last dose and the proposed Cycle 1, Day 1, with the exceptions as specified in protocol Dose-Exploration/Expansion Cohorts in Phase 1b:Xx_NEWLINE_xXTreatment with any chemotherapy or investigational agents within 4 weeks of the start of study treatment; subjects must have recovered from toxicities of prior therapyXx_NEWLINE_xXNo prior use of EGFR tyrosine kinase inhibitors or monoclonal antibodies; all other prior treatments are allowed if >= 4 weeks since treatment completed, including chemotherapy (systemic or intraperitoneal), radiation therapy, and/or surgery; there is no limit on the number of previous treatments allowedXx_NEWLINE_xXPatients who have taken part in an experimental drug study within 4 weeks of initiating treatment with LDE225Xx_NEWLINE_xXUse of ketoconazole, itraconazole, ritonavir, cyclosporine, carbamazepine, phenytoin, phenobarbital within 2 weeks prior to and while on study therapyXx_NEWLINE_xXOnly patients who are expected to survive at least 6 weeks will be eligible for this studyXx_NEWLINE_xXAt least 6 weeks must have elapsed since prior systemic mitomycin CXx_NEWLINE_xXAt least 8 weeks must have elapsed since any dose of Strontium-89Xx_NEWLINE_xXAt least 4 weeks must have elapsed since prior Sm-153 lexidronam (Quadrametâ„¢)Xx_NEWLINE_xXRadioembolization within 8 weeks of day 1 dosing of sorafenibXx_NEWLINE_xXReceived nitrogen mustard agents, melphalan, or BCNU therapy within 6 weeks prior to the first study doseXx_NEWLINE_xXAt least 4 weeks from last chemotherapy or bevacizumab (Avastin) therapy (6 weeks for nitrosourea or mitomycin C), or for chemotherapy regimes given continuously or on a weekly basis with limited potential for delayed toxicity, at least 2 weeks from last dose.Xx_NEWLINE_xXActive severe personality disorders (defined according to DSM-IV). Note: for patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous 6 weeks prior to start of study drug.Xx_NEWLINE_xXAnti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of the first dose of ARQ 092 (within 2 weeks for orally administered drugs)Xx_NEWLINE_xXReceived prior cancer or other investigational therapy within 2 weeks prior to the first administration of study drug;Xx_NEWLINE_xXPatients must not have received systemic therapy for RCC within four weeks prior to registrationXx_NEWLINE_xXAn interval of at least 6 weeks between prior surgical resection, 4 weeks from the end of prior radiotherapyXx_NEWLINE_xXAn interval of at least 3 months from the completion of most recent radiation therapy; at least 4 weeks from a non-nitrosourea chemotherapy regimen and at least 6 weeks from a nitrosourea containing regimenXx_NEWLINE_xXHave had their last administration of study treatment (siltuximab or placebo) less than 6 weeks (window of plus 2 weeks) prior to first doseXx_NEWLINE_xXHave adequate clinical laboratory parameters within 2 weeks prior to the first dose of siltuximab for this studyXx_NEWLINE_xXRandomization within 4 weeks of progression of diseaseXx_NEWLINE_xXHemoptysis in excess of 2.5 mL within 8 weeks of first dose of study drug.Xx_NEWLINE_xXInclusion Criteria:\n\n          -  Must have evidence of c-MET dysregulation from either local data or the results of\n             molecular pre-screening evaluations.\n\n          -  Confirmed diagnosis of a solid tumor.\n\n          -  Measureable lesion.\n\n          -  Refractory to currently available treatment or no therapies available.\n\n          -  18 years or older.\n\n          -  ECOG performance status of 0, 1, or 2.\n\n          -  Obtained written informed consent.\n\n        Additional inclusion criteria for NSCLC patients EGFRwt with high c-MET expression:\n\n          -  Written documentation of EGFRwt NSCLC.\n\n          -  Written documentation of c-MET positivity.\n\n          -  Patients should not have received more than three prior lines of antineoplastic\n             therapy for NSCLC.\n\n          -  Presence of at least one measurable lesion as determined by modified RECIST version\n             1.1\n\n        Exclusion Criteria:\n\n        HCC with liver dysfunction greater than Child-Pugh A. Previous treatment with a c-MET\n        inhibitor or HGF-targeting therapy. Symptomatic CNS metastases that are neurologically\n        unstable or requiring increasing doses of steroids to control their CNS disease.\n\n        Any CNS deficits. For patients with GBM, CNS symptoms grade 2 or greater. Subjects with\n        significant or uncontrolled cardiovascular disease (eg, uncontrolled hypertension,\n        peripheral vascular disease, congestive heart failure, cardiac arrhythmia, or acute\n        coronary syndrome) within 6 months of starting study treatment or heart attack within 12\n        months of starting study treatment.\n\n        Receiving anti-epileptic drugs that are known to be strong inducers of CYP3A4. Prior or\n        current anti-angiogenic therapy for patients with GBM. Radiation therapy within ? 4 weeks\n        (< 12 for GBM) prior to the first dose of study drug or limited field radiotherapy within ?\n        2 weeks (< 12 weeks GBM) prior to the start of study treatment. Any persistent side effect\n        of prior radiotherapy must be resolved to ? Grade 1 prior to the first dose of study drug.\n\n        Additional exclusion criteria for NSCLC patients EGFRwt with high c-MET expression:\n\n          -  Patients who have received more than three prior lines of antineoplastic therapies\n\n          -  Any unresolved toxicity (CTCAE grade > 1) from previous anti-cancer therapy or\n             radiotherapy, except alopecia\n\n          -  Patients have received anti-cancer therapies within the following time frames prior to\n             the first dose of study treatment:\n\n               -  Conventional cytotoxic chemotherapy: ?4 weeks (?6 weeks for nitrosoureas and\n                  mitomycin-C)\n\n               -  Biologic therapy (e.g., antibodies): ?4 weeks\n\n               -  Non-cytotoxic small molecule therapeutics: ?5 half-lives or ?2 weeks (whichever\n                  is longer)\n\n               -  Other investigational agents: ?4 weeks\n\n               -  Radiation therapy (palliative setting is allowed.): ?4 weeks\n\n               -  Major surgery: ?2 weeks\n\n        Other protocol-defined inclusion/exclusion criteria may apply.Xx_NEWLINE_xXPatients who have received chemotherapy or targeted anticancer therapy =< 4 weeks (6 weeks for nitrosourea, antibodies or mitomycin-C) prior to starting study drug or who have not recovered from side effects of such therapy (except alopecia)Xx_NEWLINE_xXTreatment with anti CD 20 therapy within 4 weeks, or alemtuzumab within 8 weeks, or any cytotoxic antileukemia therapy within 2 weeks, Ibrutinib or Idelalisib within 1 week prior to the first administration of the trial drug.Xx_NEWLINE_xXTreatment with another investigational drug within the past four weeks before start of therapy or concomitantly with this trial.Xx_NEWLINE_xXPrior use of monoclonal antibody (other than anti CD20) within 3 months prior to randomization. Chemotherapy or other systemic lymphoma therapy within 4 weeks of study entry.Xx_NEWLINE_xXPresence of brain metastases, unless the patient has received adequate treatment at least 4 weeks prior to randomization, and is stable, asymptomatic, and off steroids for at least 4 weeks prior to randomization;Xx_NEWLINE_xX4-12 weeks since completion of combined modality therapyXx_NEWLINE_xXA cluster of differentiation (CD) 4 count > 100/mcL will be required within 2 weeks of study participationXx_NEWLINE_xXLast dose of chemotherapy or experimental therapy more than 4 weeks (6 weeks in the case of nitrosourea) prior to enrollment date; unless the last therapy consisted of an oral agent whose average half life is known to be less than 48 hours in which case only 2 weeks need to have elapsed; regardless of the therapy, any toxicity greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 from previous anti-cancer therapy must have been resolvedXx_NEWLINE_xXCytotoxic chemotherapy: ? the duration of the cycle of the most recent treatment regimen (a minimum of 2 weeks for all regimens, except 6 weeks for nitrosoureas and mitomycin-C).Xx_NEWLINE_xXBiologic therapy (e.g., antibodies): ? 4 weeks.Xx_NEWLINE_xXHas completed any prior hormonal therapy ? 2 weeks prior to randomizationXx_NEWLINE_xXHas received investigational therapy within 2 weeks prior to randomizationXx_NEWLINE_xXHas received bevacizumab within 4 weeks prior to randomizationXx_NEWLINE_xXPatients must have fully recovered from the effects of any prior surgery, chemotherapy or radiation therapy; a minimum time period of 3 weeks should elapse between the completion of radiation therapy for recurrent/metastatic disease and enrollment in the study; a minimum of 4 weeks should elapse between the completion of chemotherapy or any experimental therapy and enrollment in the study; a minimum of 4 weeks should elapse between prior major surgery (such as open biopsy or significant traumatic injury) and enrollment in the study; a minimum of 2 weeks should elapse between prior minor surgical procedures (such as chemotherapy infusion port placement or core visceral organ biopsy) and enrollment in the studyXx_NEWLINE_xXTreatment with investigational parenteral anti-influenza drugs (IV peramivir, IV zanamivir or IV oseltamivir) in the 4 weeks prior to Baseline.Xx_NEWLINE_xXAll previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study; a minimum of 6 weeks treatment break is required in case of nitrosoureas or mitomycin CXx_NEWLINE_xXLess than (<) 4 weeks since the last anti-tumor therapy prior to Day 1 of study treatmentXx_NEWLINE_xXPatients who have received either immunotherapy within =< 8 weeks; chemotherapy within =< 3 weeks; or radiation therapy to > 30% of marrow-bearing bone within =< 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapiesXx_NEWLINE_xXHas undergone chest irradiation within 12 weeks prior to randomization (except palliative irradiation of bone lesions)Xx_NEWLINE_xXcytotoxic therapy within the past 4 weeks (6 weeks for BCNU/CCNU)Xx_NEWLINE_xXany infection requiring antibiotic, anticoagulant, or antiplatelet agents within the past 4 weeksXx_NEWLINE_xXHemoptysis within 6 weeks of first dose of study drugXx_NEWLINE_xXChemotherapy or investigational agent within 3 weeks prior to randomization or antibody therapy within 6 weeks prior to randomizationXx_NEWLINE_xXPart D: Prior exposure to BRAF inhibitors. A washout period of 6 weeks is required for ipilimumab.Xx_NEWLINE_xXThe first ASCI administration should be given within one year after the last chemotherapy administration. All screening procedures should be completed within seven weeks before the first ASCI administration.Xx_NEWLINE_xXINCLUSION CRITERIA:\n\n          -  Age: >/= 18\n\n          -  Diagnosis:\n\n               -  Histologically confirmed recurrent, locally advanced unresectable or metastatic\n                  adenocarcinoma of the pancreas who have progressed after front line chemotherapy,\n                  OR\n\n               -  Histologically confirmed metastatic colorectal adenocarcinoma who have progressed\n                  after at least 2 standard chemotherapy regimens.\n\n          -  Tumor sections must stain >/= 20% positive for NPC-1C antibody/antigen target\n\n          -  Measurable disease (by RECIST)\n\n          -  Karnofsky performance status of >/= 50%\n\n          -  Laboratory Function (within 21 days of receiving first dose of study drug):\n\n               -  Hemoglobin > 8.5 g/dL, or on stable doses (hematocrit stable within 1 gram and\n                  dose stable for one month) of erythropoietin or similar medication.\n\n               -  Absolute neutrophil count (ANC) >/= 1,500/mm3\n\n               -  Platelets >/= 50,000/mm3\n\n               -  Total bilirubin </= 2.0 mg/dL\n\n               -  ALT and AST </= 2.5 times the ULN, or, if the patient has liver metastases, </= 5\n                  times the ULN\n\n               -  Creatinine </= ULN\n\n          -  Voluntary written informed consent before performance of any study-related procedure\n             that is not part of normal medical care.\n\n          -  Expected to be able to remain on a study protocol for at least 8 weeks.\n\n          -  Is post-menopausal, surgically sterilized, or willing to use acceptable methods of\n             birth control for the duration of the study. Male subject agrees to use an acceptable\n             barrier method for contraception during the study.\n\n        EXCLUSION CRITERIA:\n\n          -  Has history of disseminated or uncontrolled brain metastases or central nervous system\n             disease.\n\n          -  Ascites with abdominal distention.\n\n          -  Mechanical, non-reversible reason for not being able to eat, or have a likelihood of\n             developing malignant bowel obstruction during the course of the induction phase of\n             treatment; subjects with uncomplicated J-tubes will not be excluded.\n\n          -  Any major surgery within four weeks of enrollment.\n\n          -  Uncontrolled concomitant illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac\n             arrhythmia.\n\n          -  Has another serious medical illness, including a second malignancy, or psychiatric\n             illness that could, in the Investigator's opinion, potentially interfere with the\n             completion of treatment according to this protocol.\n\n          -  Pregnant or breast-feeding.\n\n          -  Any chemotherapeutic agents or corticosteroids within 2 weeks of study entry or\n             biologic treatment within 4 weeks of study entry.\n\n          -  Use of any high risk medications that prolong the QT/QTc interval.\n\n          -  History of allergic reaction to Erbitux greater than grade 1.\n\n          -  Uncontrolled diabetes.\n\n          -  Prior history of a documented hemolytic event.\n\n          -  Receiving warfarin.Xx_NEWLINE_xXPatients must not have received any cytotoxic therapy, immunotherapy, antitumor vaccines or monoclonal antibodies in the 4 weeks prior to the start of the studyXx_NEWLINE_xXAny prior chemotherapy therapy is allowed in this protocol; no more than 2 prior cytotoxic chemotherapy regimens are allowed for eligibility; non-myelotoxic therapies such as sunitinib and sorafenib or everolimus are not considered \cytotoxic chemotherapies\; patients must be >= 4 weeks from prior radiation or cytotoxic chemotherapy, except >= 6 weeks for mitomycin C and nitrosoureas; >= 2 weeks from hormonal therapy; >= 4 weeks from prior experimental therapy; >= 4 weeks from monoclonal antibody therapy (cetuximab, bevacizumab), >= 2 weeks from sorafenib, sunitinib or temsirolimus and >= 8 weeks from prior 7-hydroxystaurosporine (UCN01) treatment; patients with prostate cancer may continue ongoing luteinizing hormone-releasing hormone (LHRH) agonist therapy; patients with bone metastases or hypercalcemia who began intravenous bisphosphonate treatment prior to study entry may continue this treatmentXx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy: 4 weeks from prior cytotoxic therapy and/or at least 2 weeks from vincristine, 6 weeks from nitrosoureas, 3 weeks from procarbazine administration, and 1 week for non-cytotoxic agents, e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, etc. (radiosensitizer does not count), 4 weeks for experimental biologic agents (epidermal growth factor receptor [EGFR] inhibitors, etc) and 7 weeks from Gliadel implantationXx_NEWLINE_xXPatients must have recovered from the toxic effects of prior therapy:\r\n - 4 weeks from any investigational agent\r\n - 4 weeks from prior cytotoxic therapy (except 6 weeks from nitrosoureas, 3 weeks from procarbazine, 3 weeks from vincristine)\r\n - 3 weeks for non-cytotoxic or biologic agents e.g., interferon, tamoxifen, thalidomide, cis-retinoic acid, tarceva, etc; note a 3-week washout is required for prior treatment with bevacizumabXx_NEWLINE_xXChemotherapy, hormone therapy, immunotherapy with monoclonal antibodies, treatment with tyrosine kinase inhibitors, or radiotherapy (except for treatment of extremities) within the past four weeks prior to treatment with the trial drug, i.e., the minimum time elapsed since the last anticancer therapy and the first administration of BIBF 1120 must be four weeksXx_NEWLINE_xXSignificant weight loss (> 10 %) within the past 6 weeks prior to treatment in the present trialXx_NEWLINE_xXChemotherapy: Must not have received myelosuppressive chemotherapy within 3 weeks prior to study entry (6 weeks if prior nitrosourea)Xx_NEWLINE_xXPrior therapy: patients must have fully recovered from the acute toxic effects of all prior therapy prior to enrolling on study\r\n* Myelosuppressive chemotherapy: must not have received myelosuppressive therapy within 2 weeks prior to study entry (4 weeks if nitrosourea)\r\n* Biologic (anti-neoplastic agent): at least 7 days since the completion of therapy with biologic agent, including retinoic acid; participants receiving Intravenous Immunoglobulin (IVIG) are eligible; however, participant must not receive IVIG during the 4 days of antibody infusion\r\n* Radiation therapy: at least 2 weeks since prior local radiation therapy at the time of study entry\r\n* Growth factors: must not have received hematopoietic growth factors (filgrastim [G-CSF], sargramostim [GM-CSF]) for at least 1 week prior to study entry\r\n* Investigational agent: must not have received investigational agent within 14 days of study entry\r\n* Immune therapy: must not have received immunosuppressive (including glucocorticoids), immunostimulatory or any immunomodulatory treatment within 2 weeks of study entry; steroid\r\ncontaining inhalers, steroid replacement for adrenal insufficiency and steroid premedication for prevention of transfusion or imaging contrast-agent related allergic reaction will be permittedXx_NEWLINE_xXTreatment with nitrosoureas, such as carmustine (BiCNU), nitrogen mustard agents, or melphalan, within 6 weeks of first dose of elotuzumab.Xx_NEWLINE_xXInclusion criteria:\n\n        Phase I Part:\n\n          1. Histologically-confirmed WHO Grade III or IV malignant glioma that is recurrent after\n             prior chemoradiotherapy. Patients with prior low-grade glioma are eligible if\n             histologic assessment demonstrates transformation to WHO Grade III or IV malignant\n             glioma.\n\n          2. Age at least 18 years at entry\n\n          3. KPS at least 60%\n\n          4. Patients must have recovered from previous surgery and chemotherapy.\n\n          5. Written informed consent that is consistent with local law and ICH-GCP guidelines.\n\n        Phase II Part:\n\n          1. Histologically-confirmed WHO Grade IV malignant glioma at first episode of recurrence\n             after prior combined chemoradiotherapy. Patients with prior low-grade glioma are\n             eligible if histologic assessment demonstrates transformation to WHO Grade IV\n             malignant glioma and if prior treatment included temozolomide chemotherapy and\n             radiotherapy.\n\n          2. Bi-dimensionally measurable disease with a minimum measurement of 1 cm (10 mm) in one\n             diameter on Gd MRI performed within 14 days prior to first treatment (Day 1).\n\n          3. Age at least 18 years at entry\n\n          4. KPS at least 70%\n\n          5. Patients must have recovered from previous surgery and chemotherapy.\n\n          6. Written informed consent that is consistent with local law and ICH-GCP guidelines.\n\n          7. Patients receiving corticosteroids have to receive a stable or decreasing dose for at\n             least 14 days before start of study treatment.\n\n        Exclusion criteria:\n\n        Phase I and Phase II Parts:\n\n          1. Less than 12 weeks between radiotherapy and start of study treatment, unless new\n             enhancing lesion outside of radiation field or radiologically progressive on two\n             consecutive MRI scans at least four weeks apart or biopsy-proven recurrence.\n\n          2. Less than two weeks from surgical resection (one week from prior stereotactic biopsy)\n             or major surgical procedure.\n\n          3. Less than two weeks after previous chemotherapy (6 weeks from nitrosureas).\n\n          4. Treatment with other investigational drugs; participation in another clinical study\n             within the past 2 weeks before start of therapy or concomitantly with this study.\n\n          5. Progressive disease or toxicity =CTCAEv3 Grade 3 to protracted temozolomide dosing\n             (defined as temozolomide administered more than 5 days/28 day cycle).\n\n          6. Active infectious disease requiring intravenous therapy.\n\n          7. Known human immunodeficiency virus (HIV) infection or chronic Hepatitis B or C.\n\n          8. Gastrointestinal disorders that may interfere with the absorption of the study drug or\n             chronic diarrhea.\n\n          9. Serious illness or concomitant non-oncological disease considered by the investigator\n             to be incompatible with the protocol.\n\n         10. Patient is <3 years free of another primary malignancy except: if the other primary\n             malignancy is either not currently clinically significant or does not require active\n             intervention (such as a basal cell skin cancer or a cervical carcinoma in situ).\n             Existence of any other malignant disease is not allowed.\n\n         11. Cardiac left ventricular function with resting ejection fraction <50%.\n\n         12. Absolute neutrophil count (ANC) less than 1500/mm3.\n\n         13. Platelet count less than 100,000/mm3.\n\n         14. Bilirubin greater than 1.5 x upper limit of institutional norm.\n\n         15. Aspartate amino transferase (AST) greater than 3 x upper limit of institutional norm.\n\n         16. Serum creatinine greater than 1.5 x upper limit of institutional norm.\n\n         17. Patients who are sexually active and unwilling to use a medically acceptable method of\n             contraception.\n\n         18. Pregnancy or breast-feeding.\n\n         19. Patients unable to comply with the protocol.\n\n         20. Known pre-existing interstitial lung disease (ILD).\n\n        Phase I part only:\n\n        1. Less than four weeks from prior treatment with bevacizumab.\n\n        Phase II Part only:\n\n          1. Prior EGFR-directed therapy.\n\n          2. Prior bevacizumab therapy.\n\n          3. Patients presenting with second or higher number of episodes of recurrence.\n\n          4. Requirement of treatment with any of the prohibited concomitant medications listed in\n             Section 4.2.2 (Restrictions regarding concomitant treatment).Xx_NEWLINE_xXHas completed study 3200K1-4000-WW, including 2 weeks of therapy and completion of all post baseline efficacy, safety, and health outcomes assessments.Xx_NEWLINE_xXImmunotherapy, radiotherapy, or chemotherapy ? 2 weeks prior to enrollment. (? 6 weeks for nitrosoureas, mitomycin-C, and liposomal doxorubicin, and ? 6 weeks from prior antibody therapy).Xx_NEWLINE_xXAntiviral treatment for influenza in 2 weeks prior to randomizationXx_NEWLINE_xXIntravesical chemo- or biologic therapy within 6 weeks of first treatmentXx_NEWLINE_xXMinimum 3 weeks since prior systematic treatment or phototherapyXx_NEWLINE_xXPatient may already have initiated adjuvant endocrine therapy (ET) at the time of randomization, but randomization must take place within 52 weeks of date of initial histological diagnosis of breast cancer and within 12 weeks of initiating ETXx_NEWLINE_xXPrior biologic or immunologic therapy =< 4 weeks prior to study entryXx_NEWLINE_xXChemotherapy, radiation therapy, or immunotherapy within 4 weeks prior to first dosing of study drug (6 weeks for nitrosoureas); concomitant hormonal therapies for breast cancers are allowedXx_NEWLINE_xXPatients must have completed prior (non-excluded) anti-cancer therapy (including surgery or chemotherapy or hepatic embolization/chemoembolization or radioactive isotopes i.e. yttrium 90) at least 4 weeks prior to day 1Xx_NEWLINE_xXPatients must be off myeloproliferative neoplasm (MPN) directed therapy, such as Janus kinase (JAK)-inhibitors, for at least 2 weeks prior to administration of the study drug; NOTE: This does not include supportive transfusion, or hydroxyurea; these must be stopped prior to first day of treatment, but no wash â€“out period is requiredXx_NEWLINE_xXPatients who are on any prohibited medication; they have to be have a wash-out period of at least 2 weeks prior to registration, in order to be eligible for the studyXx_NEWLINE_xXPatients who received anti-cancer therapy prior to the first dose of WNT974 within the following time frames:\r\n* Biological therapy with a prolonged half-life (e.g., monoclonal antibodies) within 4 weeks\r\n* Cytotoxic agents associated with delayed hematologic recovery (e.g., nitrosourea or mitomycin-C) within 6 weeks\r\n* Other systemic anti-cancer agents within 3 weeks\r\n* Radiotherapy within 2 weeksXx_NEWLINE_xXPatients with a history of more than two weeks treatment with immuno-suppressants (including systemic corticosteroids), cytotoxic chemotherapy within one month prior to initial screening, or who receive such medications during the screening period, or who are anticipated to require such medications during the course of the studyXx_NEWLINE_xXRecent hemoptysis (>= Â½ teaspoon of red blood within 8 weeks before first dose of study drug)Xx_NEWLINE_xXPrior treatment:\r\n* Patients must not have received chemotherapy, radiation or surgical resection of malignancy within 3 weeks prior to the start of study drug; however, if they have received nitrosourea or mitomycin C then they should not be enrolled in the study until 6 weeks after therapy was last received\r\n* No limitations to number of prior therapies\r\n* Prior therapy with other ALK inhibitor investigational agents with the exception of crizotinib (i.e., prior treatment with crizotinib is allowed)Xx_NEWLINE_xXRecent hemoptysis (>= half teaspoon of red blood within 8 weeks before first dose of study drug)Xx_NEWLINE_xXInability to start study treatment within 12 weeks following the completion of curative intent therapy for rectal adenocarcinomaXx_NEWLINE_xXThe biopsy confirming diagnosis can be up to 12 weeks prior to registration as long as there is no intervening therapy; note: if patient has had lymphoma treatment since previous biopsy, a biopsy should be repeatedXx_NEWLINE_xXAll patients must have an electrocardiogram (ECG) within 2 weeks of starting conditioningXx_NEWLINE_xXSystemic anticancer treatments (including chemotherapy and biologics) less than 3 weeks prior to T cell therapy; locally directed therapy (e.g. radiation) 2 weeks prior to cell infusionXx_NEWLINE_xXPrevious anti-cancer chemotherapy, immunotherapy or investigational agents < 4 weeks, or palliative radiation < 2 weeks prior to the first day of study treatment, or who have not recovered to grade 1 or better from related side effects of such therapy (except alopecia); patients who receive gamma knife radiosurgery for brain metastases are eligible if procedure was performed > 2 weeks before treatment is started, is clinically stable and has been on stable low dose corticosteroid treatment (e.g., dexamethasone 2 mg/day, prednisolone 12 mg/day for at least 14 days before start of study treatment are eligible); ongoing hormonal therapies (luteinizing hormone-releasing hormone [LHRH] antagonists, megestrol) are allowedXx_NEWLINE_xXExperimental therapy within 4 weeks prior to first dose of study drugXx_NEWLINE_xXAll previous therapies must have been discontinued at least 4 weeks prior to initiation of the administration of this studyâ€™s drugsXx_NEWLINE_xXHave received chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to initiating administration of the study drugsXx_NEWLINE_xXNo methadone within 4 weeks prior to registrationXx_NEWLINE_xXPatients must have used opioid medication(s) for pain at some time in the 4 weeks prior to registration; current use of opioids (at the time of registration) and/or later during the course of the study is permitted but not requiredXx_NEWLINE_xXSurgery must be scheduled no sooner than 10 days after randomization and no more than twelve weeks after randomizationXx_NEWLINE_xXNo systemic therapy within 2 weeks prior to registration or plan for systemic therapy within the first 8 weeks after study registrationXx_NEWLINE_xXCurrent oral steroid use > 2 weeks prior to registrationXx_NEWLINE_xXOther investigational therapy received within 8 weeks prior to screening visitXx_NEWLINE_xXWithin one month (+/- 1 month) of starting chemotherapy or within two weeks (+/- 2 weeks) of starting radiation therapy (may be prior to or after starting treatment)Xx_NEWLINE_xXReceived an investigational therapy within the 4 weeks prior to registration, or is scheduled to receive one during the treatment periodXx_NEWLINE_xXReceived a new anti-cancer agent within 4 weeks prior to registrationXx_NEWLINE_xXHistologically confirmed breast cancer for which chemotherapy with AC (doxorubicin plus cyclophosphamide) is being utilized in the neoadjuvant or adjuvant setting (AC may be administered every 2 or 3 weeks, and may be preceded by or followed by paclitaxel planned to be given at 80 mg/m^2 weekly or 175 mg/m^2 every 2-3 weeks, per standard treatment plan) OR metastatic prostate adenocarcinoma for which docetaxel will be administered (between 60 mg/m^2 to 75 mg/m^2 every 3 weeks)Xx_NEWLINE_xXSevere anemia (hemoglobin < 8 g/L) not corrected prior to study enrollment (bloodwork is not required if patient did not have chemotherapy within past 2 weeks).Xx_NEWLINE_xXExpected to undergo therapeutic thoracentesis in the next 2 weeks.Xx_NEWLINE_xXDue to receive at least 6 weeks (for aim 1 and 2) or 12 weeks (for aim 3) of CTX at enrollmentXx_NEWLINE_xXPrevious androgen blockade (e.g. antiandrogens) given for greater than 2 weeks in the last 3 months; anti-androgens used during the initiation of ADT to avoid a flare phenomenon are acceptable for up to 4 weeksXx_NEWLINE_xXChemotherapy treatment schedule < 12 weeksXx_NEWLINE_xXBefore starting study treatment, patients must have recovered from toxic effects of prior therapies (except for residual alopecia or grade 2 peripheral neuropathy) and at least 3 weeks must have elapsed since any prior signaling pathway modulators, (e.g., EGFR, FGFR, or other tyrosine kinase inhibitors), at least 3 weeks must have elapsed since temozolomide, 4 weeks must have elapsed since carboplatin or cisplatin, and at least 6 weeks from nitrosoureas (e.g., carmustine [BCNU], lomustine [CCNU]); in general, at least 4 weeks must have elapsed from any other anticancer therapy (e.g. bevacizumab)Xx_NEWLINE_xXAny previous treatment for vulvar HSIL within 4 weeks prior to screening;Xx_NEWLINE_xXSystemic anticancer treatment (including investigational agents) less than 3 weeks before the first dose of study treatment (<=4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell engager agents; <=8 weeks for cell-based therapy or anti-tumor vaccine).Xx_NEWLINE_xXSubjects must have the following minimum wash-out from previous treatments and without treatment between documentation of relapse/progression and enrollment:\r\n* >= 2 weeks for local radiation therapy\r\n* >= 8 weeks for low dose (12 Gy or less) total skin electron beam therapy (TSEBT)\r\n* >= 4 weeks for systemic cytotoxic anticancer agents, anticancer investigational agents that are not defined as immunotherapy, or for tumor-targeting monoclonal antibodies (mAbs) with the exception of alemtuzumab for which the washout is at least 16 weeks\r\n* >= 15 weeks for anti-CD137 or anti-CTLA-4 (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)\r\n* >= 2 weeks from resolution (i.e., < grade 1 or at baseline) from adverse event (AE)s due to procedures performed or therapeutic agents administered\r\n* >= 2 weeks for retinoids, interferons, vorinostat, romidepsin and denileukin diftitox\r\n* >= 4 weeks for doses of systemic corticosteroidsgreater than 10 mg/day of prednisone or equivalent; patients who are on physiologic doses of corticosteroids (prednisone equivalent 10 mg/day or less) may participate, however, they must be on a stable dose for at least 4 weeks before enrollment; patients who are on low or moderate potency topical corticosteroids may participate if they are on a stable dose for at least 4 weeks before enrollment; inhaled corticosteroids are acceptable; local injections of corticosteroids are acceptable; all corticosteroids will be reported as concomitant medications\r\n* >= 2 weeks for phototherapy\r\n* >= 1 week for topical therapy (including retinoid, nitrogen mustard, or imiquimod)Xx_NEWLINE_xXExogenous sex steroid use within 4 weeks prior to core needle biopsyXx_NEWLINE_xXVaccination within 4 weeks of the first dose of avelumab and while on trial is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXPrevious treatment with immunotherapy within 8 weeks of starting study medication, chemotherapy, radiotherapy, molecular-targeted therapy, or biological therapies (including HER2 directed therapies) within 4 weeks of starting study medication, or hormone therapy within 2 weeks of starting study medication.Xx_NEWLINE_xXUse of any investigational drug within the past 4 weeks before start of study medication or concomitantly with this study except for investigational immune-stimulatory therapy (e.g. checkpoint-regulator targeted treatment). The minimum washout period should be 8 weeks before starting the study medication.Xx_NEWLINE_xXReceipt of any type of small molecule kinase inhibitor (including investigational kinase inhibitors) within 2 weeks of enrollment or receipt of any anti-cancer therapy (including investigational therapy, monoclonal antibodies, cytokine therapy) within 4 weeks of enrollmentXx_NEWLINE_xXUse of plaquenil must be discontinued two weeks prior to first study treatmentXx_NEWLINE_xXRecent history of allergen desensitization therapy within 4 weeks of starting study treatment.Xx_NEWLINE_xXWill not start treatment for at least 2 weeks ANDXx_NEWLINE_xXAre engaged in shift work or travel across more than three time zones within 2 weeks prior to studyXx_NEWLINE_xXSubject has participated in another clinical study for systemic therapy within 6 weeks of baseline.Xx_NEWLINE_xXPHASE 1 & 2: Identified at least two weeks prior to their scheduled surgery dateXx_NEWLINE_xXAnticipated to undergo pancreatectomy in >= 6 weeks from enrollmentXx_NEWLINE_xXSubjects on metformin for any reason during the preceding 4 weeksXx_NEWLINE_xXChronic nausea over the past 4 weeksXx_NEWLINE_xXPatient should describe fatigue as being present for a minimum of 2 weeks prior to screeningXx_NEWLINE_xXAny anemia treatment within 4 weeks before inclusion (oral iron, IV iron, or erythropoiesis-stimulating agents), or transfusion of packed red blood cells (PRBCs) in 2 weeksXx_NEWLINE_xXDiagnosis of metastatic cancer no greater than 6 weeks prior to expected study enrollmentXx_NEWLINE_xXIf patient is taking systemic therapy for cGVHD at the time of enrollment, they must be on a stable or tapering doses in the preceding 4 weeksXx_NEWLINE_xXPhase II: Patients with MBC who\r\n* Have been diagnosed with leptomeningeal disease in the past eight weeks\r\n* Have diagnosed with progressive brain metastases after initial radiation therapy in the past eight weeks\r\n* Have been diagnosed brain metastases and began whole brain radiation therapy in the past eight weeks\r\n* Have an unplanned hospital admission and be discharged within the past eight weeks\r\n* Have been diagnosed with triple negative breast cancer and started second-line therapy within the past eight weeks\r\n* Have received at least three different therapy regimens within a twelve month period and began the third-line therapy regimen within the past eight weeks\r\n* Have HER2+ disease and started third-line therapy in the past eight weeks; or\r\n* Have estrogen receptor positive (ER+) disease and started third line chemotherapy in the past eight weeks\r\n* Have begun a treatment clinical trial in the past eight weeksXx_NEWLINE_xXWilling to participate in yoga therapy for twelve weeks if randomized to intervention groupXx_NEWLINE_xXUnwilling to participate in yoga therapy for twelve weeks if randomized to intervention groupXx_NEWLINE_xXCompleted primary treatment (surgery, chemotherapy, and/or radiation) at minimum 6-8 weeks before the first group meeting, and maximum 24 months before the first group meeting, which approximates the â€˜re-entryâ€™ phase of cancer survivorship.Xx_NEWLINE_xXThe presence of fatigue for at least 2 weeksXx_NEWLINE_xXRecent esophageal, gastric or bowel surgery (within 3 weeks of study enrollment)Xx_NEWLINE_xXUnable to start nintedanib/placebo treatment between 4 - 6 weeks after completing the last dose of thoracic radiationXx_NEWLINE_xXUse of finasteride or dutasteride within 3 weeks or 6 months, respectively, of study entryXx_NEWLINE_xXConcomitant medication as follows:\r\n* Subjects treated with gabapentin or other anticonvulsant for neuropathic pain will be required to taper the medication and discontinue for at least 2 weeks prior to study initiation\r\n* Patients on antidepressant treatment for pain or depression (tricyclic antidepressants [TCAs], selective serotonin reuptake inhibitor [SSRI], serotoninâ€“norepinephrine reuptake inhibitors [SNRIs] etc.) will be allowed to continue their medications provided they have been on a stable dose for at least 4 weeks before study initiation; no dose regimen changes of antidepressants will be allowed during the study period\r\n* Patients on around-the clock opioid treatment (including tramadol) will be allowed to continue their medication provided they have been on a stable dose for at least 4 weeks before study initiation; the maximum allowed dose of opioid will be equivalent to 60 mg oral morphine sulfate; patients with higher doses will be required to taper down their opioid dose to maximum 60mg oral morphine equivalent, and continue on stable dose for 4 weeks before enrollment in the study; pro re nata (PRN) short-acting opioids for painful CIPN treatment will not be allowed; patients receiving PRN short-acting opioids (with or without acetaminophen) for pain other than CIPN will be allowed up to 4 daily doses, with daily recording of analgesic consumption\r\n* Treatment with nonsteroidal anti-inflammatory drug (NSAIDs) will be discontinued at least 2 weeks before study initiation; however, low-dose aspirin (=< 325 mg/day) will be allowedXx_NEWLINE_xXWithin 2 weeks prior to study enrollment the patient must be on a stable dose of medications for management of chemotherapy-induced peripheral neuropathy (CIPN) symptoms; for at least 2 weeks prior to enrollment stable dose is defined as: \r\n* No change in drug class \r\n* Increases or decreases that are less than or equal to 20% of the total dosage; all drug classes are allowedXx_NEWLINE_xXHave at least 6 weeks of cancer treatment (e.g. chemotherapy or biologics such as Herceptin) remainingXx_NEWLINE_xXUse of any exogenous estrogen within the preceding four weeksXx_NEWLINE_xXOn stable doses of any supplements or medications for six weeks prior to enrollment on the studyXx_NEWLINE_xXPlanning on starting or stopping any chronic supplements or medications within six weeks prior to or throughout the study periodXx_NEWLINE_xXAcupuncture treatment in the preceding 4 weeks prior to day 1Xx_NEWLINE_xXIf on medication for anxiety, stable dose of medications for management of anxiety symptoms for at least six weeks prior to enrollment with no plans to change meditations in the subsequent four weeks. Increases or decreases allowed within drug class, but changing drug class will make patient in-evaluableXx_NEWLINE_xXHistory/physical examination within 2 weeks prior to registrationXx_NEWLINE_xXOn AI therapy for at least 4 weeksXx_NEWLINE_xXPatients who have had chemotherapy within three (3) weeks or radiation within four (4) weeks; patients may not receive additional chemotherapeutic agents while on this studyXx_NEWLINE_xXAble to commit to LOFT training 2 times/week for 4 weeksXx_NEWLINE_xXSubjects who have unknown transfusion history for at least the 12 weeks prior to screeningXx_NEWLINE_xXPersistent genitourinary symptoms causing discomfort for more than 2 weeks prior to the visit with the physicianXx_NEWLINE_xXUse of probiotics =< 2 weeks prior to registrationXx_NEWLINE_xXWithin the first 3 weeks of initiation of a new type of therapyXx_NEWLINE_xXSubjects on metformin for any reason during the preceding 4 weeksXx_NEWLINE_xXPatients should describe fatigue as being present for a minimum of 2 weeksXx_NEWLINE_xXPATIENT: Informed of diagnosis of incurable disease within the previous 8 weeksXx_NEWLINE_xXNo history of untreated narrow angle glaucoma within 6 weeks prior to registrationXx_NEWLINE_xXNo untreated urinary retention within 6 weeks prior to registrationXx_NEWLINE_xXNo cryotherapy for prophylactic mucosal protection within 6 weeks prior to registrationXx_NEWLINE_xXUse of any vaccines against infectious diseases (e.g. varicella, pneumococcus) within 4 weeks of initiation of study treatment.Xx_NEWLINE_xXTreatment with chemotherapy or biologic therapy within 3 weeks, except for hydroxyurea, which must be discontinued prior to treatment on studyXx_NEWLINE_xXPatients who have received chemotherapy within 3 weeks of first fenretinide treatment, or who have received investigational drugs within 6 weeks of first fenretinide treatment. Patients must have otherwise recovered from toxicities of prior therapy.Xx_NEWLINE_xXPatients who have had chemotherapy or other systemic therapy or radiotherapy, or those who have not recovered from adverse events due to prior administered agents as follows:\r\n* Chemotherapy < 3 weeks prior to registration\r\n* Hormone therapy < 2 weeks prior to registration\r\n* Targeted therapy (other than below) < 2 weeks prior to registration (e.g., tyrosine kinase inhibitors)\r\n* Trastuzumab < 6 weeks prior to registration\r\n* Bevacizumab < 6 weeks prior to registration\r\n* Nitrosoureas/mitomycin C < 6 weeks prior to registration\r\n* Radiotherapy < 3 weeks prior to registration (NOTE: a previously irradiated lesion may not be used as a target lesion unless there is evidence of post-radiation progression)\r\n* Surgery < 3 weeks prior to registration\r\n* Other approved or investigational agents < 3 weeks prior to registration unless otherwise noted by the protocol chair\r\n* Patients who have received prior epigenetic (e.g., histone deacetylase [HDAC] inhibitors such as entinostat, panobinostat, vorinostat, romidepsin or demethylating agents such as 5-azacitidine or decitabine) immunomodulatory or other checkpoint inhibitors should only be considered after discussion with the protocol chair\r\n* Those who have not recovered from acute adverse events to grade < 2 or baseline due to agents administered, with exception of alopecia, unless approved by the protocol chairXx_NEWLINE_xXHave received prior treatment with monoclonal antibodies within 6 weeks of first dose of Day 1;Xx_NEWLINE_xXSevere infection within 4 weeks prior to randomizationXx_NEWLINE_xXPatients who have been on opioid therapy for the last 4 weeks or moreXx_NEWLINE_xXStable dose of corticosteroids for 2 weeks prior to enrollmentXx_NEWLINE_xXExposure to any new immunosuppressive medication in the 4 weeks prior to enrollmentXx_NEWLINE_xXInitiation of extracorporeal pheresis (ECP) therapy within 4 weeks prior to enrollmentXx_NEWLINE_xXStable dose of glucocorticoids for 4 weeks prior to enrollmentXx_NEWLINE_xXLow-dose IL-2 therapy in the 4 weeks priorXx_NEWLINE_xXOther investigational drugs within 4 weeks prior to enrollment, unless cleared by the principal investigatorXx_NEWLINE_xXSevere anemia (hemoglobin [Hb] < 7g/L) not corrected prior to study enrollment (bloodwork is not required if patient did not have recent chemotherapy within the last 2 weeks)Xx_NEWLINE_xXPatients who have taken melatonin within the past two weeksXx_NEWLINE_xXRegularly used cognitive behavioral therapy in the last 6 weeksXx_NEWLINE_xXHistory of Guillain-Barre within 6 weeks of previous influenza vaccinationXx_NEWLINE_xXHistologically proven stage 0-III invasive carcinoma of the breast\r\n* Patientâ€™s must have completed primary surgical resection at least 2 weeks prior to enrollment, radiation at least 2 weeks prior to enrollment and/or cytotoxic chemotherapy at least 6 weeks prior to enrollment in the studyXx_NEWLINE_xXInitiation of hormone therapy < 4 weeks prior to enrollment in the studyXx_NEWLINE_xXAn expected hospital stay of 3-4 weeks or longerXx_NEWLINE_xXThe subject is a current smoker (has smoked within 4 weeks prior to surgery)Xx_NEWLINE_xXExposure to any new immunosuppressive medication in the 4 weeks prior to enrollmentXx_NEWLINE_xXInitiation of extracorporeal pheresis (ECP) therapy within 4 weeks prior to enrollmentXx_NEWLINE_xXPatients must be receiving stable or increasing doses of morphine for 1-2 weeks prior to registration for protocol therapy; NOTE: switching patient from current pain regimen to morphine equivalent for at least 1-2 weeks prior to registration for protocol therapy is requiredXx_NEWLINE_xXUse of muscle relaxant medications such as cyclobenzaprine within four weeks of enrollment and during course of the study, unless the regimen of muscle relaxants is stable for 4 weeks prior to enrollment and does not change for the duration of the studyXx_NEWLINE_xXStable use of hormonal therapy (no changes within 4 weeks prior to the cryoablation procedure)Xx_NEWLINE_xXStable use of pain medications (no changes within 2 weeks prior to the cryoablation procedure)Xx_NEWLINE_xXSubject has not started any new systemic immunosuppressive therapies within 2 weeks prior to enrollmentXx_NEWLINE_xXTuberculosis requiring treatment within the past 3 years; all patients must have a negative quantiferon test within 4 weeks prior to starting study drugXx_NEWLINE_xXUse of probiotics =< 2 weeks prior to registrationXx_NEWLINE_xXCurrent routine mammogram has been/will be performed more than 8 weeks prior to scheduled screening ultrasoundXx_NEWLINE_xXThis disease assessment is required for eligibility and preferably should be done within 2 weeks prior to enrollment, but must be done within a maximum of 4 weeks before enrollment.Xx_NEWLINE_xXUse of any other investigational agents =< 12 weeks prior to pre-registrationXx_NEWLINE_xXWillingness to discontinue smoking during the study two weeks prior to beginning the study and willingness to not smoke while taking study medicationXx_NEWLINE_xXUse of metformin, insulin, steroids or prescription weight loss or anti-psychotic drugs within the prior 3 weeksXx_NEWLINE_xXEXCLUSION CRITERIA (PRIOR TO IBRUTINIB ADMINISTRATION): Chemotherapy =< 21 days prior to first administration of study treatment and/or monoclonal antibody =< 6 weeks prior to first administration of study treatmentXx_NEWLINE_xXWillingness to be randomized to an immediate or delayed (by 8 weeks) start dateXx_NEWLINE_xXUse of metformin, insulin, steroids or weight loss or anti-psychotic drugs within the prior 3 weeksXx_NEWLINE_xXUse of investigational drugs within 3 weeks of signing consent or foreseen use during the studyXx_NEWLINE_xXUse of chemotherapy, trastuzumab, or pertuzumab within the past 3 weeksXx_NEWLINE_xXReceived a negative mammography screening result in the previous four weeksXx_NEWLINE_xXMedications:\r\n* Current anticoagulant use (must discontinue for 3 weeks prior to fine needle aspirate [FNA])\r\n* Taking systemic hormones within two months (eight weeks) prior to screening RPFNA\r\n* Taken tamoxifen, raloxifene, or an aromatase inhibitor within the past 6 months\r\n* Participation on any chemoprevention trial within 6 monthsXx_NEWLINE_xXReceived any investigational agents or received any tumor vaccines within the previous six weeks prior to cell infusionXx_NEWLINE_xXReceived anti-CD30 antibody-based therapy within the previous 4 weeks prior to cell infusionXx_NEWLINE_xXPatients with steroid refractory cGVHD cannot have prior exposure to any new immunosuppressive medication in the preceding 2 weeks prior to enrollmentXx_NEWLINE_xXStudy entry must be within 12 weeks of last surgery (breast or axilla) or last chemotherapy (if applicable)Xx_NEWLINE_xXScreening visit 2 must occur within 8 weeks prior to administration of the first dose of Polyphenon EXx_NEWLINE_xXAny oral steroid use within 2 weeks of testingXx_NEWLINE_xXStable hormone status for 8 weeks prior to aspiration and willing to maintain same status while on study; this means no change in an oral or non-oral hormonal contraceptive within the past 8 weeks prior to RPFNAXx_NEWLINE_xXHave changed type of hormonal contraception during the previous 8 weeksXx_NEWLINE_xXRegular use of NSAIDs =< 6 weeks prior to randomization, defined as a frequency of 7 consecutive days (1 week) for > 3 weeks (Exception: low dose aspirin [81 mg] for those subjects who are chronic users of aspirin prior to the beginning of the study)Xx_NEWLINE_xX3. Administration of any vaccine within 4 weeks of the first study treatmentXx_NEWLINE_xXAdministration of any vaccine within 8 weeks of enrollment and within 4 weeks for flu vaccine.Xx_NEWLINE_xXAny use of oral corticosteroids =< 12 weeks prior to registration/randomizationXx_NEWLINE_xXNo prior chemotherapy regimen; prior isotope therapy with strontium-89, samarium or radium-223 (RAD223) should be completed at least three months (12 weeks) prior to treatment startXx_NEWLINE_xXPatients must have recovered from severe toxicity of prior therapy; the following intervals from previous treatments are required to be eligible:\r\n* 12 weeks from the completion of radiation \r\n* 6 weeks from a nitrosourea chemotherapy or mitomycin C\r\n* 3 weeks from a non-nitrosourea chemotherapy\r\n* 4 weeks from any investigational (not Food and Drug Administration [FDA]-approved) agents \r\n* 2 weeks from administration of a non-cytotoxic, FDA-approved agent except bevacizumab/vascular endothelial growth factor receptor (VEGFR) inhibitors (e.g., erlotinib, hydroxychloroquine, etc.)\r\n* 6 weeks from bevacizumab/VEGFR inhibitorsXx_NEWLINE_xXNitrosoureas: 6 weeksXx_NEWLINE_xXOther cytotoxic agents: 4 weeksXx_NEWLINE_xXAnti-angiogenic agents including bevacizumab: 4 weeksXx_NEWLINE_xXTargeted agents including small-molecule tyrosine kinase inhibitors: 2 weeksXx_NEWLINE_xXPrior experimental (non-Food and Drug Administration [FDA] approved) therapies and immunotherapies are allowed; patients must not have received these therapies for 3 weeks prior to the initiation of study treatment and must have full recovery from any acute effects of these therapiesXx_NEWLINE_xXAll previous cytotoxic chemotherapy, monoclonal antibody therapy, or immune therapy must be washed out 3 weeks before apheresis and must be completed at least 3 weeks prior to pre-infusion lymphodepletive chemotherapy.Xx_NEWLINE_xXSystemic corticosteroid or other immunosuppressive therapy should be washed out 2 weeks before apheresis and must be completed at least 2 weeks prior to pre-infusion lymphodepletive chemotherapy.Xx_NEWLINE_xXCompleted definitive local therapy and have scans, 10?12 weeks after completion of definitive local therapy confirming either Complete Response (CR), Partial Response (PR), or Stable Disease (SD). If salvage neck dissection or salvage laryngectomy is not performed, patients must initiate study treatment within 4 weeks of the screening scans and within 16 weeks after completion of the definitive local therapy. If salvage neck dissection or salvage laryngectomy is performed, patients must initiate study treatment within 4 weeks of screening scans and within 20 weeks after completion of definitive local therapy.Xx_NEWLINE_xXSubject has been receiving ruxolitinib therapy for intermediate or high-risk myelofibrosis for >6 months prior to enrollment with no more than 1 dose reduction of ruxolitinib in the 2-8 weeks prior to enrollment and a stable daily dose ?5 mg twice daily (BID) >2 months prior to enrollment.Xx_NEWLINE_xXTargeted agents, including small-molecular tyrosine kinase inhibitors: 2 weeksXx_NEWLINE_xXOther cytotoxic agents: 3 weeksXx_NEWLINE_xXNitrosoureas: 6 weeksXx_NEWLINE_xXMonoclonal antibody immunotherapies (eg, PD-1, CTLA-4): 6 weeksXx_NEWLINE_xXCranio-spinal radiation ? 12 weeks NOTE: Subjects in Arm 2 (ie, with DIPG) must be ? 2 weeks and ? 10 weeks after standard focal radiotherapy (dose of 5400 to 5960 cGy and maximum dexamethasone of 1 mg/m2/day)Xx_NEWLINE_xXGVHD therapies within 4 weeks of leukapheresis and JCAR017 administration.Xx_NEWLINE_xXZero CPD for past 4 weeksXx_NEWLINE_xXAgree to participate in the study and be available for 6 weeks of treatment and 6 months of follow-upXx_NEWLINE_xXUse anti?platelet agents within two weeks of anticipated sigmoidoscopyXx_NEWLINE_xXUse of anti?coagulants within two weeks of anticipated sigmoidoscopyXx_NEWLINE_xXNo limit to prior therapies with last anti-cancer treatment >= 2 weeks from initiation of WBRT; please note: there is no washout period required for trastuzumab, pertuzumab for patients who have developed new parenchymal brain metastases while on these agentsXx_NEWLINE_xXPatient must not have undergone therapy with any VEGF monoclonal antibodies in the last twelve weeks; patient must not be receiving any small molecule anti-VEGF drug within previous 4 weeksXx_NEWLINE_xXSubject who have received ferumoxytol within 3 weeks of study entryXx_NEWLINE_xXPatients with positive findings on prior imaging within the past 4 weeks are eligibleXx_NEWLINE_xXAny therapy directed at the malignant tumor, including immunologic agents, must be discontinued at least three weeks prior to registrationXx_NEWLINE_xXSubject who have received ferumoxytol within 3 weeks of study entryXx_NEWLINE_xXSubject who have received ferumoxytol within 4 weeks of study entryXx_NEWLINE_xXPrior systemic chemotherapy within 2 weeks of planed anti-PD1 treatment.Xx_NEWLINE_xXHas not received Dex or another corticosteroid in over 4 weeks prior to enrollmentXx_NEWLINE_xXCytotoxic chemotherapy within 4 weeks prior to study enrollmentXx_NEWLINE_xXSystemic radioisotope therapy within 24 weeks prior to study enrollmentXx_NEWLINE_xXTreatment with Sandostatin long-acting release (LAR) within 4 weeks, subcutaneous (SQ) Octreotide within 12 hours, or Lanreotide injection within 8 weeks of Ga-68 DOTATOC PET/CT (+/-5%)Xx_NEWLINE_xXAt least 4 weeks after most recent prostate biopsyXx_NEWLINE_xXPrior radiation therapy or chemotherapy within 2 weeks prior to study radiotracer administration (washout is one half-life of the drug or 2 weeks, whichever is longest)Xx_NEWLINE_xXPrior radiation therapy, chemotherapy, or androgen-deprivation therapy within 2 weeks prior to study radiotracer administration (washout is one half-life of the drug or 2 weeks, whichever is longest)Xx_NEWLINE_xXPatient must not have hemoptysis within 6 weeks of first dose of study drugXx_NEWLINE_xXAn interval of > 6 weeks between the biopsy and MRSIXx_NEWLINE_xXPatients must have been off tamoxifen or other estrogen receptor blocking agents for at least 6 weeks and off chemotherapy for 3 weeks for the initial baseline FESXx_NEWLINE_xXUse of tamoxifen, Faslodex, diethylstilbestrol (DES) or any other ER blocking agent < 6 weeks or chemotherapy < 3 weeks prior to imaging scanXx_NEWLINE_xXChemotherapy (taxanes) or Radium-223 alpha-particle treatment within the last 6 weeks prior to imagingXx_NEWLINE_xXSubjects who have had a needle biopsy of the suspicious area within the last 6 weeksXx_NEWLINE_xXPatient must not have had myelosuppressive chemotherapy =< 3 weeks prior to entry onto this study (or 6 weeks if prior nitrosourea)Xx_NEWLINE_xXMonoclonal based therapies within 4 weeks (excluding cetuximab) and all other immunotherapy within 2 weeks prior to first dose of study treatment.Xx_NEWLINE_xXSubjects must have the following laboratory values at screening within 2 weeks of the first dose of investigational agents:Xx_NEWLINE_xXRadiation, chemotherapy, or immunotherapy or any other anticancer therapy (including investigational therapies) ? 2 weeks prior to C1D1. Localized radiation to a single site at least 1 week before C1D1 is permitted. Glucocorticoids within 2 weeks of C1D1 are permitted. Patients on long-term glucocorticoids during Screening do not require a washout period but must be able to tolerate the specified dexamethasone dose in this study.Xx_NEWLINE_xXMost recent laboratory values (within 2 weeks prior to Week 1 Day 1 (W1D1)) before study entry meet the following standards:Xx_NEWLINE_xXBilirubin =< 1.5 x ULN, completed within 2 weeks prior to start of protocol therapyXx_NEWLINE_xXPatient who has received vaccination within 4 weeks of the first dose of avelumab and while on trials is prohibited except for administration of inactivated vaccinesXx_NEWLINE_xXTreatment with systemic chemotherapy or investigational therapy within 4 weeks of first study drug administration; other agents (e.g., biologics) within 2 weeks; radiation within 2 weeks; patients receiving 131I-MIBG therapy must wait 6 weeks prior to the initiation of study drug administration; corticosteroids (? 0.2 mg/kg/day prednisone or equivalent) or other immune suppressive drugs within the 2 weeks prior to the initiation of study drug administration.Xx_NEWLINE_xXActive hemoptysis (bright red blood > 1 teaspoon on more than one occasion) =< 3 weeks prior to registrationXx_NEWLINE_xXHas had hormonal cancer therapy (e.g., tamoxifen, leuprolide). within 4 weeks prior to the first dose of study treatmentXx_NEWLINE_xXSubject has had no use of investigational agents, with the exception of FLT3 inhibiting agents during induction and/or consolidation therapy, within the prior 4 weeks.Xx_NEWLINE_xXUreteral stint present or removed within six weeksXx_NEWLINE_xXSubjects agree to be contacted 4-6 weeks after each study visitXx_NEWLINE_xXPre-imaging radiological scans/studies must be performed approximately 16 weeks prior to study entry; but not less than 24 hours priorXx_NEWLINE_xXProstate biopsy within 4 weeks prior to study entryXx_NEWLINE_xXRequired imaging studies obtained within four weeks prior to registrationXx_NEWLINE_xXProgressive disease manifest (within 6 weeks of screening) by eitherXx_NEWLINE_xXIn patients who will receive bortezomib for imaging purposes only:\r\n* Total bilirubin < 1.5 x upper limit of normal obtained within 2 weeks prior to registration\r\n* Platelet count >= 70,000/mm^3 obtained within 2 weeks prior to registration\r\n* No pre-existing peripheral neuropathy greater than grade 1Xx_NEWLINE_xXExpected lifespan of 12 weeks or lessXx_NEWLINE_xXParticipants who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for bevacizumab) of liver resectionXx_NEWLINE_xXEXCLUSION CRITERIA - FOR NORMAL HEALTHY FEMALE COHORT: Use of regular medications within 2 weeks prior study enrollment or use of any medications within one week prior to study enrollment, except oral contraceptives or cases which, based on drug's or metabolite's half-life, complete elimination can be assumedXx_NEWLINE_xXNeed to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical stagingXx_NEWLINE_xXWilling to be seen at baseline, 6 weeks, 12 weeks, and 16 weeks for the study time pointsXx_NEWLINE_xXMust have been off metformin for at least 2 weeks prior to starting IFN gammaXx_NEWLINE_xXWilling to avoid cruciferous vegetable intake during the study period (2 weeks)Xx_NEWLINE_xXPrior chemotherapy within 2 weeks; prior immunotherapy or biologic therapy within 4 weeks; prior radiation therapy within 3 weeksXx_NEWLINE_xXWash-out periods: at least three weeks since the last anticancer therapy, including radiation therapy (RT) in more than 35% of the bone marrow; at least three weeks since the last biological/investigational therapy [excluding monoclonal antibodies (MAbs)]; at least four weeks since the last MAb-containing therapy; and at least six weeks since nitrosoureas and mitomycin C (systemic). In the case of hormonesensitive breast cancer progressing while on hormone therapy, the latter must be either stopped up to one week before or continued without changes during the trial.Xx_NEWLINE_xXThe patient has received chemotherapy or radiotherapy within 4 weeks or has received nitrosoureas or mitomycin C within 6 weeks prior to the first dose of study drug.Xx_NEWLINE_xXTreatment with other investigational agents (defined as not used in accordance with the approved indication) within 4 weeks of Day 1Xx_NEWLINE_xXNo chemotherapy within 2 weeks of first dose of SGI-110 (minimum of 6 weeks for nitrosoureas and 8 weeks for bone marrow transplantation) with the exception of hydroxyurea which will be allowed during course 1 of treatment.Xx_NEWLINE_xXSystemic anticancer treatment (including investigational agents) less than 3 weeks before the first dose of study treatment (<=4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell engager agent; <=8 weeks for cell-based therapy or anti-tumor vaccine).Xx_NEWLINE_xXLast dose of anti-CD20 antibody therapy must have been >4 weeks before the first dose of XmAb13676Xx_NEWLINE_xXAt least 4 weeks since any previous treatment for cancerXx_NEWLINE_xXFor Concomitant Treatment: Prior tumor resection or biopsy up to 8 weeks prior to first MRZ doseXx_NEWLINE_xXPatients who have had chemotherapy or other systemic therapy or radiotherapy, or those who have not recovered from adverse events due to prior administered agents as follows: chemotherapy, radiotherapy or surgery =< 3 weeks prior to entering the study, targeted therapy (e.g., TKI) =< 1 week prior to entering the study; autologous HSCT =< 6 weeks prior to entering the study; investigational drug or immunotherapy (e.g. rituximab) =< 4 weeks prior to entering the study; prophylactic intrathecal chemotherapy within one week of enrollment allowed; patients will be allowed to receive cytoreduction with hydroxyurea, 6-mercaptopurine, corticosteroids (dexamethasone, prednisone or similar) or cyclophosphamide provided that it is discontinued at least 24 hours prior to the initiation of study treatment; pre-phase treatment with dexamethasone 10 mg/m^2 (maximum total 24 mg per day) for up to 5 days is required for patients with bone marrow blasts more than 50%, peripheral blood blasts of 15,000/uL or higher, or elevated lactate dehydrogenase suggesting rapidly progressing disease as per investigatorâ€™s assessment; pre-phase treatment must be stopped at least 24 hours prior to the initiation of blinatumomabXx_NEWLINE_xXLeukapheresis ? 2 weeks prior to starting CC-90009.Xx_NEWLINE_xXSystemic anticancer treatment including investigational agents or radiotherapy <2 weeks before the first dose of study treatment (<4 weeks for antibody-based therapy including unconjugated antibody, antibody-drug conjugate, and bi-specific T-cell engager agents; <=8 weeks for cell-based therapy or antitumor vaccine) or have not recovered from acute toxic effects from prior chemotherapy and radiotherapy.Xx_NEWLINE_xXPrior local intravesical chemotherapy or immunotherapy is allowed if completed at least 4 weeks prior to the initiation of study treatmentXx_NEWLINE_xXSevere infections within 4 weeks before randomization or therapeutic oral or IV antibiotics within 2 weeks before randomizationXx_NEWLINE_xXComplete initial work up earlier than 12 weeks prior to subject registrationXx_NEWLINE_xXOff dexamethasone treatment for ?4 weeks before the first dose of study drug.Xx_NEWLINE_xXClinical laboratory values as specified below within 4 weeks before the first dose of study drug:Xx_NEWLINE_xXGlioma patients must have completed chemoradiotherapy at least 12 weeks prior to screening and their baseline scanXx_NEWLINE_xXTreatment with investigational or approved anti-cancer drugs within 4 weeks before the start of BAY1436032 treatment and during the study (glioma patients must have completed chemoradiotherapy at least 12 weeks prior to screening and their baseline scan; see inclusion criteria #2)Xx_NEWLINE_xXActive hemoptysis (bright red blood of at least 0.5 teaspoon) within 3 weeks prior to the first dose of study drug.Xx_NEWLINE_xXCancer treatment within the past 3 weeksXx_NEWLINE_xXExpected survival of at least 12 weeks after dosing.Xx_NEWLINE_xXPatients who have received prior systemic anticancer therapy ? 3 weeks prior to study start (6 weeks for nitrosourea, antibodies, or mitomycin-C)Xx_NEWLINE_xX